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ABSTRACT
Macromolecules have been investigated extensively as carriers of drugs for site- 
specific drug delivery. The specialised structure of tumours leads to selective 
accumulation of some polymers. Attachment of chelated paramagnetic ions to water- 
soluble polymers enhances the relaxivity of the ions; this effect, coupled with tumour 
tropism, makes macromolecular MRI contrast agents highly attractive.
The principal mode of uptake of macromolecules into cells is pinocytosis. Their fate is 
to be transported to lysosomes. If the polymer is non-degradable by the lysosomal 
enzymes, it will remain in the body indefinitely. Enzymically degradable polymers, 
therefore, represent interesting opportunities for the design of macromolecular pro- 
drugs and imaging agents.
A series of peptide-based monomers have been prepared using Boc- and Z-protected 
amino acid active esters in standard solution phase couplings. All have a sequence 
inverting unit (ethane-1,2-diamine) to present secondary amines at the C and N 
termini. Both potentially degradable and non-degradable peptide monomers have been 
synthesised, the former containing the sequence GlyPheLeuGly. A number also 
incorporate one or more side-chain functionalised amino acids to allow attachment of 
the potential magnetic resonance contrast agent chlorotetraphenylporphyrinato- 
manganese (III).
An efficient preparation of a,o-diglycidyl ethers of polyethylene glycols) has been 
developed to provide suitable bis-electrophiles for co-polymerisation with the a ,o - 
bis-nucleophilic peptide monomers. Preliminary investigations of these polymerisation 
reactions have indicated formation of small molecular weight polymers. In one case 
using the l,9-bis(sarcosylamide) of nonane-1,9-diamine as a model for the peptide, 
1 : 1 macrocycles were formed. Early studies of metallation of porphyrins indicated 
insertion of manganese (III).
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ACCUMULATION OF MACROMOLECULES IN TUMOUR 
TISSUES
“I did as physicians do when they, in order to 
make a medicament for the benefit of the liver, 
add sugar, honey or some other sweet stuff, 
because the liver likes sweet things. And due to 
this preference for the sweet, the liver attracts the
sweet and the medicament with it. The same is
done with every organ which needs a medicament: 
the drug is mixed with something the organ 
naturally is inclined to.” 1
1.1 Introduction
The dream of site-specific drug delivery has existed for many years, as can be seen 
from this 14th Century quotation, but has still to reach a reality in the treatment of 
many diseases, especially cancer. Paul Ehrlich, first proposed the modem form of site- 
specific drug delivery, with the ‘magic bullet’ approach; the targeting of drugs to cells 
via receptors2,3.
The most simple methods of site-specific drug delivery involve either direct treatment 
of diseases of the nasal, vaginal and anal passages or implantation of solid devices to 
the affected area, allowing controlled release of a drug. Both these approaches are
unsuitable for the treatment of most forms of cancer, as the tumour is often
inaccessible and / or difiuse.
1
More recently, a general approach to site-specific drug delivery using carriers has 
been investigated. These carriers protect the drug from degradation prior to 
interaction with the target cells but, more importantly, protect the body from the toxic 
effects of the drug 4 By incorporation of targeting moieties to interact with cellular 
receptors, site-specific drug delivery can be achieved. Many potential carriers have 
been investigated including red blood cells 3’4, low density lipoprotein (LDL) 4 and 
antibodies 5. Limited success has been achieved with these carriers; they are, on the 
whole, difficult to manipulate and characterise. More useful approaches based on 
synthetic polymers and lipids have been more widely investigated2,6
Liposomes are formed from polar phospholipids which, in contact with water, form 
concentric lipid bilayers. The aqueous core thus formed can be used to carry water- 
soluble drugs, whereas hydrophobic drugs can be incorporated into the lipid. 
Liposomes are very versatile and, by careful choice of lipid, the size, number of 
lamellae, charge and stability can be altered 4. These modifications provide variations 
in the pharmacokinetics of the liposomes and allow targeting to organs 6. 
Investigators have also incorporated specific targeting residues such as sugars to 
evaluate the possibility of specific drug targeting 2 However, despite such attempts, 
because of their size most liposomes are taken up by the particle recognition systems 
of reticulo-endothelial cells. Thus, at present, few liposomal medicines are available. 
However, a liposomal formulation of the antifungal drug amphotericin B is available, 
which shows reduced toxicity, thus allowing increased dosages1.
Another approach to site-specific drug delivery is the use of microspheres or 
nanoparticles 8. These are small polymer particles which either encapsulate a drug or 
contain drug in the matrix. Again, because of their size, they are prone to capture by 
the reticulo-endothelial system, although targeting moieties can be incorporated. By 
appropriate choice of the polymer, it is possible to provide a system that only 
degrades in the desired region and hence selectively releases drug. This targeting can 
be achieved on two levels, either to a specific area of the body (for example, the use 
of polymers which degrade in the anaerobic conditions of the colon), or within a cell 
(for example, by using acid-sensitive linkages).
2
The most useful approach to site-specific drug delivery is that of macromolecular pro- 
drugs. These were first proposed by Ringsdorf in 1975 6,9 and an idealised model of 
such a system is shown in Figure 1.1 By attaching a drug of low molecular weight to a 
macromolecule, two main effects can be achieved: firstly, a controlled release system 
and, secondly, a targeted system. The macromolecule itself should be non-toxic and 
non-immunogenic and should be easily manipulated for chemical reactivity 2 
Originally, the macromolecules used were naturally occurring, for example DNA 10, 
albumin 11 and dextran 12. However, synthetic polymers, which have been previously 
used as plasma expanders, are now more commonly used 2. Targeting groups can be 
easily attached to the polymer and these can either increase non-specific cellular 
interactions 13, or exploit receptor interactions to elicit a specific effect 14 Drug 





Drug  M u g  Drug
Figure 1.1
Attachment of a drug to a macromolecule is of particular interest as a therapy for 
cancer. Macromolecules are known to accumulate within solid tumours, giving a first 
level of targeting 17. This accumulation can be enhanced by incorporation of specific 
targeting groups. Once a drug is attached to a macromolecule, it can no longer enter a 
cell by diffusion and must enter by endocytosis which is often enhanced in tumour 
cells 2 Furthermore, once access to the cell is limited to endocytosis, 
‘lysosomotrophic drugs’ can be produced where release of drug only occurs within 
the lysosomes, thereby conferring a high level of targeting 10.
3
1.2 Uptake of macromolecules into tissues
Many investigators, have demonstrated an increased uptake of macromolecules into 
tumour cells 18’19’20 Originally, this was thought to be due to an increase in the rate of 
constitutive pinocytosis in tumour cells 18. However, more recent studies have 
suggested that the increased uptake may be due to an “Enhanced Permeation and 
Retention Effect” (EPR effect)17.
Matsumura and Maeda 17 investigated the accumulation in tumours of a series of 
radioactive macromolecules and Evans’ blue, a dye. The uptake of a range of 
polymers of molecular weight 12,000 Da to 150,000 Da was investigated in tumour 
bearing mice with respect to the plasma clearance time and the time to reach a fixed 
gradient (5:1) between the tumour and plasma. Macromolecules of above 16,000 Da 
accumulated in the tumours, all reaching the desired ratio. However, it was apparent 
from the data that the ideal range for the macromolecules was between 15,000 Da and 
70,000 Da.
The investigators proposed that the accumulation was due to four properties of 
tumour tissues; increased angiogenesis, enhanced vascular permeability, little 
macromolecular recovery via post capillary venules and lack of functioning lymphatic 
systems 17.
1.2.1 Angiogenesis in Tumours
The rate of angiogenesis in some tumour tissues is greatly increased 19,20. Tumour 
growth is dependent on the development of a new functioning vascular system. To 
achieve this increased growth, tumours secrete a range of angiogenic factors, such as 
the polypeptide angiogenin17,21. These factors either act directly on the dividing cells 
or stimulate the realise of endothelial growth factors from other cells. The increased 
number of blood vessels can be easily demonstrated using angiography17
4
1.2.2 Enhanced Vascular Permeability
1.2.2.1 Capillary Types
There are three main types of endothelial capillaries; continuous, fenestrated and 
sinusoidal \  In all of these, the endothelial cells are similar. Each cell has approximate 
dimensions of 20-40 pm long, 10-15 pm wide and 0.1-0.5 pm thick 22. These form a 
single layer above a basement membrane and are covered by a layer of 
glucosoaminoglycans 22 However, in each organ, the endothelium is highly 
distinctive 22
The three types of endothelium are illustrated in Figure 1.2 . Continuous capillaries 
are seen in normal connective tissue and the blood brain barrier 22. They are the least 
permeable to all molecules but especially to macromolecules, having tight junctions 
between the cells of approximately 2 nm. Post-capillary venules are a slightly modified 
type of continuous capillaries. Here the junctions are larger (=6 nm), allowing easier 
passage of some molecules 19.
Fenestrated capillaries have an intact basement membrane, but in some places have 
large interendothelial junctions of 40-60 nm (fenestrae). The fenestrations can be 
open, as in the case of the glomerulus, or closed by thin diaphragms 19’22. These 
capillaries are mainly found in the kidney, endocrine and exocrine glands. They are 
also found in some tumours 19
Sinusoidal capillaries are found in only a few organs, most notably the liver and 
spleen, and in some tumours. These capillaries allow easy access of molecules to the 
interstitium, as they often exhibit a lack of, or a discontinuous, basement membrane 
and large interendothelial spaces (150 nm) 19.
5
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Fenestrated Capillaries
Figure 1.2 : Types o f  Capillary
1.2.2.2 Transport o f  molecules across capillary endothelium
Five types o f  molecular movement through endothelia have been described
1. Simple diffusion o f  the molecule across the cell
2. Lateral diffusion o f  the molecule in the cell membrane allowing transport around 
the cell and across the barrier
3. Through inter-endothelial cell junctions
4. Through endothelial gaps i.e. fenestrae o f  sinusoids
5. Vesicular transport
6
The first two types can be discounted when considering the transport of 
macromolecules, although they are the main methods of transport for small solutes. 
All of the other types are involved in the transport of macromolecules. The majority 
of transport is thought to be based on the formation of water filled pores at the 
endothelial junctions 22. The role of vesicles in transport is more widely disputed 19,22 
Vesicular transport can take two forms; the uptake of a macromolecule into a vesicle 
followed by transport across the cytoplasm and release, or linkage of vesicles to form 
a transient pore across the cell. The importance of the first method is questionable; 
some workers have suggested it to be the major method of transport of 
macromolecules, whereas other feel its role is minimal. The latter hypothesis is 
supported by the observations of no change in the rate of transport at reduced 
temperature where vesicular transport is known to be abolished 19,22
The transport of macromolecules can be affected by both their size and charge. 
Measurement of the glomerular filtration rate, an example of endothelial transport, has 
demonstrated that the hydrodynamic radius of a macromolecule is a more accurate 
description of the tendency to be transported than is molecular weight 1?. Hence, it 
has been proposed that albumin, a natural macromolecule, has a small radius, due to 
strong hydrogen bonding, and therefore a large renal threshold, whereas a 
hydrophobic synthetic polymer with few intramolecular bonds, such as HPMA, shows 
lower renal thresholds19
The charge of a macromolecule can also affect transport across endothelial cells. The 
endothelial surface exhibits a small negative charge and experiments with albumin 
have shown that cationic albumin is three times more permeable than neutral 
albumin19.
1.2.2.3 Tumour Endothelium
Most tumours are epithelial and have vasculature distinct from that of normal tissue. 
The endothelium, in all but a few cases, is continuous having tight endothelial 
junctions and an intact basement membrane, unlike inflammatory tissue. However, as
7
accumulation of macromolecules occurs, the endothelium must be more permeable 
than normal continuous endothelium 19
In a very few tumours, angiogenesis is altered and the new blood vessels produced are 
composed of only endothelial cells, whereas most vessels also contain pericytes. 
Pericytes are thought to be involved in the maturation of vessels and it has been 
postulated that lack of pericytes can lead to incomplete basement membranes. This 
alteration in basement membrane could lead to a non-specific ‘leakiness’ of cells, 
allowing accumulation of macromolecules19
However, in the majority of cases, no morphological differences in the blood vessels 
can be observed. This has lead to the hypothesis that tumour cells secrete factors 
which alter the permeability of endothelium to macromolecules 19
Senger et al. 23 have investigated the uptake of labelled human serum albumin and 
colloidal carbon in tumour bearing guinea pigs. Accumulation was demonstrated in 
the regions around the tumour and within the tumour. Analysis of the ascitic fluid 
from the animals and tissue culture experiments allowed the isolation of a protein 
which has been called the vascular permeability mediator (VPM). The isolated factor 
caused increased permeability in cutaneous tissues without causing endothelial cell 
damage 19. This protein of between 34,000 and 42,000 Da has been isolated from a 
range of tumour cells 24. These workers have suggested that this factor is released to 
allow the passage of fibrin into the interstitium to enable coagulation, which is 
beneficial to tumour growth and angiogenesis25.
A second factor, bradykinin, has also been investigated as a promoter of tumour 
permeability 26. Increased concentrations of both bradykinin and Hyp3-bradykinin have 
been found in numerous tumour types including stomach, pancreatic and ovarian 
cancer 20,26 Bradykinin is known to have both permeability and pain-inducing 
properties but it also is involved in the activation of phospholipase-A2, leading to the 
formation of another permeability factor, prostaglandin E2 .
8
Other permeability factors have been investigated. Obvious candidates are the 
leukotrienes, which have been found in increased levels in most inflamed tissue but 
not, as yet, in tumour cells. Other potential permeability enhancers include, tumour 
necrosis factor, platelet derived growth factor, serotonin, interleukin 2 and 
leukokinin20,26
1.2.3 Macromolecular Recycling
Once molecules are present in the interstitium, they can be taken into cells of the 
organ or passed back into the blood stream. Small molecules generally pass easily into 
the blood stream via the post capillary venules, as described earlier. The endothelial 
cells of these contain slightly enlarged interendothelial junctions. However, these 
spaces are too small for the passage of macromolecules 19
Natural macromolecules 19’20,24,26 pass into lymph capillaries. These vessels are formed 
from capillaries but have very large endothelial spaces. These capillaries form a 
separate circulation allowing the movement of macromolecules away from an organ. 
The macromolecules are eventually passed from the lymphatic system into the 
thoracic duct which empties into the blood stream via the sub-clavian vein 17,19
Macromolecules of lipid nature are particularly attracted into the lymphatic system. 
Experiments 20 involving Lipiodol, an iodinated derivative of poppy seed oil, have 
shown that it is selectively taken into lymphatics and ‘recycled’ via the lymphatic 
system. When Lipiodol was injected into a tumour-feeding artery 76\ however, it 
accumulated in the tumour. This suggests that tumours have little lymphatic 
drainage27. This has been confirmed by imaging experiments which have shown 
decreased lymphatic development in tumours 17,19 Macromolecules in tumour tissues 
can therefore only escape by slowly diffusing through the tumour mass to the surface 
where they can be recovered by the well-developed lymphatic system of surrounding 
organs. This transport is minimal, as macromolecules are too large to diffuse easily. 
This results in accumulation of the macromolecule and the formation of a depot of 
‘drug’ 19
9
This combination of enhanced permeability and lack of lymphatic drainage results in 
an highly effective “passive” targeting of macromolecules and hence macromolecular 
pro-drugs to tumour cells. The more specific ‘active* targeting of cells to particular 
cell lines will be considered later.
1.2.4. Enhancement of the Enhanced Permeability and Retention Effect
Following the identification of the EPR effect, Maeda 20,26 has investigated ways of 
manipulating the properties which lead to enhanced uptake, to allow even more 
effective chemotherapy using macromolecular pro-drugs.
1.2.4.1 Enhancement of Vascular Permeability
As discussed earlier, bradykinin, exhibits an effect on the vascular permeability either 
directly or through prostaglandin^ 26 It is formed by the action of kallikrien on 
kininogen and is continually broken down by kinase I and II enzymes (Figure 1.3). 
Inhibition of kinase I and II enzymes will lead to increased levels of bradykinin and 
hence to increased vascular permeability. These enzymes are inhibited by inhibitors of 
angiotensin converting enzymes (A.C.E.), for example, captopril and enalapril 20. 
Concurrent administration of an inhibitor with a macromolecule would lead to 
enhanced uptake of the macromolecule into the tumour, whilst normal tissue would 
remain unaffected as the kinin cascade would not be in operation. Investigations on 
the uptake of labelled albumin into a mouse ascitic tumour in the presence of such an 















In a few tumours, this exploitation could prove disastrous as macromolecular influx 
also results in fluid accumulation which can be difficult to control. In this case, the 
administration of soy-bean trypsin inhibitor, which halts the cascade, would be more 
beneficial20.
1.2.4.2 Enhancing Vascular Variations
As discussed earlier, many tumours have a hypervasculature allowing increased blood 
flow to the tumour. These blood vessels have been shown to be unaffected by 
angiotensin II. This is thought to be due to a lack of contractile smooth muscle in the 
blood vessels rather than lack of receptors for angiotensin I I 26. Thus, if a hypotensive 
state was to be produced in a patient, the junctions between the endothelium would be 
tightened and less passage of macromolecules would occur. However, in tumour 
vasculature, the vessels would remain as normal, allowing passage of 
macromolecules26.
Clinical data have been produced using this method with small molecules. Both an 
increased regression of tumour size and improved response rate was demonstrated 26. 
It is thought that with small molecules once the hypertension wears off, back flow of 
the molecules can occur, this would not be the case with macromolecules. Thus, 
studies with macromolecules 24 have shown a two fold concentration enhancement in 
tumours six hours after the hypotensive event as well as decreased levels in the bone
11
marrow. Unfortunately, this approach is of little value in naturally hypertensive 
patients.
1.3 Uptake of Macromolecules into Tumour Cells
Small solutes are easily taken into cells, via passive diffusion or through the action of 
specific porters for certain substrates such as glucose and amino acids 28. 
Macromolecules, however, cannot enter a cell by such a route because of their size. 
Natural macromolecules such as proteins, polysaccharides and polynucleotides are 
taken into the cell by endocytosis. Synthetic macromolecules also follow this route 28.
Endocytosis can be considered to be of two types; pinocytosis or phagocytosis. 
Phagocytosis or ‘eating* occurs only in specialised cells such as macrophages29 and is 
the uptake of particles larger than 10-20 pm in diameter. It is of major interest in the 
immune system, as it is involved in the uptake and destruction of bacteria 29. This 
process is of minor importance when considering soluble macromolecular pro-drugs 
but can be significant in approaches to drug targeting using liposomes and 
microparticles. Both types of endocytosis follow the same essential steps and these 
will be described in respect to pinocytosis.
1.3.1 Pinocytosis
Whereas phagocytosis occurs only in response to an event 30, pinocytosis is a 
constitutive phenomenon in all mammalian cells 29. It has been likened to drinking as it 
involves the continual uptake of extracellular fluid. Pinocytosis is also known as fluid 
phase endocytosis.
The initial endocytic event in pinocytosis is the formation of an invagination in the 
plasma membrane. A vesicle (a pinosome) is then formed encapsulating extracellular 
fluid. This then buds away from the cell surface into the cytoplasm. The pinosome 
then fuses with other pinosomes without release of the contents. This agglomeration 
of pinosomes then fuses with a lysosome (a vesicle from the Golgi Apparatus) to form
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a secondary lysosome. Within the secondary lysosome, degradation of 
macromolecules occurs and small molecules are released into the cytoplasm. The 
secondary lysosome then forms both a residual body, which contains non-degradable 
material and remains in the cell for its lifetime, and vesicles which can fuse with the 
cell surface allowing exocytosis of the contents 3’17’28,30. This is expressed 
diagramatically in Figure 1.4.
Each cell has a basic rate of pinocytosis which can be measured by the use of 
polymers, such as inulin, polyvinylpyrrolidone (PVP)30 or hydroxypropylmethacryl- 
amide (HPMA)31,32 which show no specific adsorption to the cell surface. In this case, 
uptake by fluid phase pinocytosis is directly related to the concentration of the ‘probe’ 
in the medium. The rate of uptake is expressed as the Endocytic Index - “the volume 
of the culture medium which is captured in a defined number of cells in a defined 
time” 33. This allows comparisons to be made on the uptake of various 
macromolecules and on the differing rates of uptake in different cell lines. The 
Endocytic Index also allows the measurement of three other types of pinocytosis, 
non-specific adsorptive pinocytosis, receptor mediated pinocytosis and ‘piggy back’ 
endocytosis33.
1.3.2 Adsorptive Pinocytosis
Measurement of the Endocytic Index for some macromolecules shows an increase 
over the model polymers 33. Two hypotheses for this event have been put forward 
Firstly, the macromolecule is taken up by fluid phase pinocytosis but exerts a 
pharmacological effect on the cell leading to an increased rate of constitutive 
pinocytosis. This hypothesis can be refuted easily by measuring the rate of uptake of a 
fluid phase ‘probe’ in the presence of the test macromolecule. If the rate of uptake of 
the ‘probe’ is unaltered, the test macromolecule cannot have been taken up by fluid 
phase pinocytosis33.
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Figure 1.4 : Endocytic Pathways
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The second hypothesis is more likely, that the macromolecule is internalised faster due 
to adsorptive endocytosis, that is a direct interaction with the cell surface resulting in 
the formation of a pinosome. However, it is possible that adherence can occur without 
pinosome formation and internalisation. This must be considered before the measured 
Endocytic Index can be taken as the true value. This can be easily examined by the 
administration of an inhibitor of endocytosis, such as 2,4-dinitrophenol33.
There are two types of adsorptive pinocytosis; non-specific - due to changes in 
hydrophobicity or charge, and receptor mediated pinocytosis - where specific 
interactions between receptor and substrate occur30.
1.3.2.1 Receptor Mediated Pinocytosis
The interaction of a ligand with a receptor leads to a slightly altered pinocytic 
pathway (Figure 1.4). Firstly, the ligand binds to receptor sites which are spread over 
the surface of the cell. Clustering of the receptors then occurs on the cell surface in 
areas called coated pits. These areas have on their interior surface a protein called 
clathrin. It was thought that these pits then ‘bud’ off to form coated vesicles which 
then pass the ligand for degradation whilst allowing the recycling of the receptor- 
clathrin complex to the cell surface via a recycling endosome. More recently, it has 
been suggested that that the clathrin does not enter the pinosome and uncoated 
vesicles containing receptor and ligand (receptosomes) are passed into the cell for 
processing 30,34\
1.3.3 ‘Piggy Back’ Endocytosis
‘Piggy Back* pinocytosis is the enhanced uptake of one molecule due to its binding to 
another molecule 35. It is the process which is exploited by all macromolecular pro- 
drugs, the binding of a small molecule to a macromolecule restricts its uptake to 
endocytosis and leads to reduced non target interactions 10. An early example of the 
use of ‘piggy back pinocytosis’ to elicit a therapeutic effect was demonstrated by 
Trouet et al. 2,6 Ethidium bromide is active against Trypanosoma cruzi in vitro but is
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inactive in vivo. In host organisms, the parasite lives within lysosomes where it is 
unharmed by lysosomal enzymes. It is protected from ethidium bromide, since this is a 
small molecule which passes into cells by diffusion and cannot pass into lysosomes. 
Attachment of ethidium bromide to DNA results in death of the parasite as the 
conjugate is taken up by pinocytosis and can act within the lysosome .
This process can be used to explain many early results that suggested an enhanced 
uptake of a macromolecule due to an increase in the rate of formation of pinosomes. 
For example, the uptake of colloidal radioactive gold was enhanced in the presence of 
poly (L-lysine). This is more likely to be due to association and the macromolecule 
being taken up by non-specific adsorptive pinocytosis than an increased rate of 
formation of pinosomes35.
1.3.4. Factors affecting rate and type of pinocytic uptake
1.3.4.1 Hydrophobicity and Charge
Early experimental work 33 demonstrated an increased rate of uptake of denatured 
bovine serum albumin over untreated albumin in rat yolk sacs. As the rate of 
formation of pinosomes was unchanged, these results were attributed to an increased 
affinity for the cell surface, leading to an increase in non-specific adsorptive 
pinocytosis. This increase was dependent on the extent of denaturation but was 
unaffected by the method of denaturation. The researchers believed that this increase 
was due to either the unmasking of hydrophobic groups or the masking of charged 
residues 33. With other denatured proteins such as insulin the rates were either 
unaffected by the process or showed decreased binding. Thus it was proposed that 
binding sites for both hydrophobic regions and charged regions exist in yolk sacs33. 
Polypeptides are very difficult to study as each amino acid can exert an effect on the 
binding capabilities. Experiments with model polymers, however, give more reliable 
data on cell surface interactions. As has been mentioned earlier, both PVP and HPMA 
have no affinity for the cell surface and are taken up by fluid phase pinocytosis, hence 
they are good models for investigating the effect of hydrophobic groups33.
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Duncan et al 13 have demonstrated in vitro that the incorporation of tyrosinamide 
residues onto (HPMA) leads to an increased uptake in rat yolk sacs. The effect was 
dependent on the molar percentage of the hydrophobic moiety, the highest percentage 
incorporation (15.4 mol %), resulting in a 10 fold increase in the Endocytic Index. 
Interestingly the effect is not seen below a threshold level of 10 mol % and the 
authors suggest that this is due to a requirement for hydrophobic domains before non­
specific binding occurs. Similar results have been reported using the polymer 
poly(a,P-(N-2-hydroxyethyl))-D,L-aspartamide (PHEA) 36,37,38,39 Incorporation of a 
tyramine derivative at a range of concentrations between 1.2 and 21.9 mol % resulted 
in enhanced uptake above a threshold value of 10 mol %. The increase was verified to 
be due to a non-specific interaction as if both PHEA and PVP were administered no 
increase in the rate of uptake of PVP could be measured.
Obviously, pinocytosis can only be enhanced if the hydrophobic moieties are exposed 
and therefore available for interactions with the cell surface 35. Studies 6,40 on a block 
co-polymer of poly(ethylene glycol) (PEG) and poly (L-lysine) (6:3) substituted with 
highly hydrophobic palmitoyl derivatives demonstrated no increase in uptake of the 
co-polymer over that of PEG alone. This initially seems surprising. However, further 
evaluation of the co-polymer revealed that, in solution, the polymer forms a micelle in 
which the hydrophobic groups are in the core and the less hydrophobic PEG is 
exposed to the cell surface. It should be noted that PEG alone does show an increased 
uptake in comparison with PVP, demonstrating a degree of hydrophobic non-specific 
interactions.
The effect of charge is more complex, both anionic and cationic polymers exhibit 
adsorptive pinocytosis characteristics. Co-polymerisation of a vinylamine with PVP 
(8 mol %) results in a cationic polymer. This has an increased pinocytic uptake in both 
rat macrophages and yolk sac41. Equally, the anionic polymer, DIVEMA pyran-co- 
polymer, is taken up by a non-specific adsorptive process 28.
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1.3.4.2 Size and Molecular Weight
The effect of size and molecular weight on macromolecular uptake is more properly 
defined as the effect of the hydrodynamic radius of the polymer. This is affected by 
the ability of the polymer to form intra-molecular hydrogen or van der Waal’s 
interactions. The size of the pinocytic vesicles is the main barrier to uptake and varies 
according to cell type. Ease of access to the cell surface also requires consideration19.
Studies on both HPMA35 and PVP 41 have shown the uptake to be size-dependent in 
the rat yolk sac. Co-polymers of PVP and vinylamine of molecular weight 120,000 Da 
were taken up slowly in comparison to those of molecular weight 46,000 Da. In 
comparisons using rat macrophages, uptake of the larger polymer was more efficient.
1.3.4.3 Specific Receptor Interactions
All the modifications above result in an increase in non-specific interactions; however, 
many cells also possess receptors for particular substrates on the cell surface. These 
receptors allow internalisation and formation of pinosome. Processing allows the 
recycling of the receptor for further binding and release of the desired substrate into 
the cell30. Thus, these receptor-substrate interactions can be exploited to allow the 
delivery of macromolecules to specific cell lines. Such receptor-substrate interactions 
include; carbohydrate-lectin, antibody-antigen and hormone-receptor interactions.
1.3.4.3.1 Lectins
The area of lectin-mediated drug delivery has been widely explored 3,42 Many cells 
express lectins on their surface and most are limited to one cell type 3. Substrates for 
lectins are, however more, diverse, although many do show structural similarities. In 
vivo, lectins bind complex oligosaccharides. Therefore, it is possible for one lectin to 
bind two structurally different sugars in different areas of the binding sites 3’42. An 
example of this is the ‘P’-selectin on endothelial cells which binds the oligosaccharide 
Lewis x which contains both galactose and fructose. Polymers containing either
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galactose or fructose can also bind to the lectin 3. As lectins bind oligosaccharides, it 
has been suggested recently that triantennary targeting ligands should be attached 
rather than single sugar molecules. Experiments with the asialoglycoprotein that binds 
N-acetyllactosamine have shown that binding of an oligosaccharide containing three 
N-acetyllactosamine antennae is higher than those containing one or tw o3,42
1.3.4.3.1.1 Hepatocyte asialoglycoprotein
This asialoglycoprotein is expressed in many but not all hepatocytes. The receptor is 
present on the venous face of hepatocytes, allowing for interactions with blood-borne 
substrates. The receptor consists of at least two sub-units each capable of binding one 
galactose residue, raising the possibility of multi-ligand binding 42
Hepatocytes are valuable target cells for many diseases such as hepatitis 34 The 
potential of targeting to hepatoma cells, however, is low. Most tumours in the liver 
are either primary hepatomas or secondary metastases of breast or colo-rectal cancer. 
The metastases comprise modified cells from the region of the primary tumour, so do 
not contain the asailoglycoprotein 42. In primary tumours, expression of the 
asialoglycoprotein is sometimes retained but appears to be cell line dependent. The 
degree of expression is also often reduced. This suggests that organ specific delivery 
is possible but that tumour cell specific delivery is unlikely34,42,43.
The asialoglycoprotein has been investigated using a number of polymers bearing 
galactose residues both in vitro and in vivo. Vansteenkiste 44 investigated the 
distribution of dextran containing one (6 mol%) or three D-galactose residues 
(8.5 mol %) in vivo in mice. Thirty minutes after injection, the triantennary dextran 
displayed the highest uptake into liver (71%). The polymer containing only one 
residue and the unmodified dextran accumulated less (43 % and 16 % respectively). 
The increase in the uptake of the triantennary containing polymer could be due to 
better binding, but other workers 42 have suggested that the effect is due to the larger 
mol percentage of galactose residues. Another possibility is that the polymer is being 
picked up by a different receptor, the Kupffer cell ‘galactose particle* receptor3,42.
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HPMA co-polymers bearing galactose have been evaluated in both rats and 
mice14,31,45,46,47. The kinetics of the galactose substituted polymers demonstrated a 
more rapid clearance from blood and an increased uptake into the liver. In studies in 
vitro using the HepG2 cell line, a human tumour cell line known to express the 
asialoglycoprotein receptor, a seven fold increase in uptake was observed using the 
galactose-containing polymer31.
1.3.4.3.1.2 Fucose Receptor on L1210 Leukaemia Cells
Of major interest in drug targeting is the fucose receptor on L1210 mouse leukaemia 
cells3,42 This has been investigated by Ulbrich et al. 48 A conjugate of HPMA bearing 
the cytotoxic drug sarcolysin was further derivatised by the inclusion of fiicosylamine. 
The fucosylamine derivative caused greater cytotoxicity in vitro than did the 
underivatised polymer48.
A second HPMA co-polymer bearing daunomycin and fucosylamine has also been 
tested both in L1210 and CCRF cells (a human leukaemia cell line which does not 
have fucose receptors). Inclusion of fucosylamine enhanced the inhibitory effect of 
daunomycin in L1210 cells but not in CCRF cells. Similar polymers containing 
galactosamine rather than fucosylamine were no more effective than underivatised 
polymers 49. These polymers have also been investigated in vivo in DBA2 mice 
inoculated interperitoneally with LI210. In this situation, incorporation of the 
carbohydrate gave no significant advantage on day 1 after inoculation. After 3 days, 
however, the fucosylamine-containing HPMA was more effective than those polymers 
without. It has been suggested that this may be due to the increased number of fucose 
receptors arising from rapid proliferation of the tumour cells 46.
Studies in vivo using HPMA bearing fucosylamine and adriamycin gave similar 
results. Again, the conjugates containing fucosylamine were more effective than those 
without, especially at low doses. Unfortunately, an increased liver concentration of 
these polymers was seen, along with targeting to the tumour. This may be due to
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other cells having fucose-recognising receptors, such as hepatocytes and 
macrophages50
Interestingly, attempts to increase cellular interactions using triantennary ligands 51 
have been unsuccessful, although this may have been due to a lack of flexibility in the 
spacer employed.
1.3.4.3.1.3 Macrophage Receptor for Mannose
Macrophages are not an obvious target cell for chemotherapy. However, delivery of a 
macrophage-activating agent such as N-acetylmuramyl dipeptide (MDP) to the 
macrophages could result in increased phagocytic activity against tumour cells and 
metastatic cells in particular 3. Many sugars interact with this receptor but are of two 
main classes, one based on D-mannose and one on L-galactose42
Studies involving both glucosamine and mannosamine HPMA glycoconjugates 
demonstrate little change in kinetics at low levels of substitution 42 More highly 
substituted polymers were accumulated in the liver, possibly owing to interactions 
with Kupffer cells52. Derriers et a l3 investigated poly-L-lysine bearing both MDP and 
mannose-related sugars and were able to demonstrate activity in activating 
macrophages.
All of the studies performed so far, demonstrate the potential of lectin-targeting in 
enhancing chemotherapy. However, more investigation of the lectins expressed by 
tumour cells is required before such targeting becomes a clinical reality.
1.3.4.3.2. Antibodies
Over the past few decades, much interest has been focused on exploiting the specific 
antibody-antigen interaction as a means of targeting drugs to particular cells 2 This 
approach, however, has been beset with difficulties such as immunogenicity 53. More 
importantly, the realisation that tumours are formed from more than one type of cell
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and thus display more than one type of hapten, has led to a reduced interest in 
antibody targeting 54 Using only one antibody conjugate would not allow interactions 
with every tumour cell.
Despite these problems, a number of macromolecular conjugates have been developed
7 53and tested . Much interest has focused on antibodies to the transferrin receptor 
This receptor is present on most proliferating cells but is expressed in high numbers 
on tumour cells 55. Studies in vitro using the monoclonal antibody B3/25 attached to 
HPMA demonstrated one of the main difficulties in using antibodies. The conjugate 
was no more actively internalised than one containing non-specific IgG, showing that 
conjugation had eliminated the specificity of the antibody52
Other workers56’57,5859,60 have looked at targeting o f  co-polymers bearing anti-Thy 1.2 
antibodies which interact with Thy 1.2 alloantigens on mouse splenic cells. From these 
studies it became apparent that the binding method used was of great importance in 
retaining activity60. The targeting of HPMA co-polymers to colorectal cancer has also 
been investigated using Fab* fragments of specific antibodies61.
An alternative approach was investigated by Shen et al 62 They developed a 
conjugate of poly-D-lysine where the antibody was bound via the Fab’ regions to 
expose only the Fc region. As many cells exhibit Fc receptors, the polymer can act as 
a hapten for interactions. Many tumour cells show Fc receptors including a few which 
are derived from cells which do not have this receptor type. This last type are of 
particular interest in drug targeting. The polymer was taken up more effectively than 
with non targeted polymers in Fc-positive cells but, as expected, showed no 
enhancement in Fc-negative cells.
1.3.4.3.3 Hormonal targets
A further consideration is the use of hormone receptor interactions to promote 
internalisation and drug targeting. The melanocyte stimulating hormone receptor 
(a-MSH receptor) is of interest, as this receptor is expressed by the majority of
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melanocytes in malignant melanoma 63. Malignant melanoma is a cancer which is 
difficult to treat, often leading to hepatic and brain metastases 63. O’Hare et al 63*64’65 
have used HPMA co-polymers bearing doxorubicin and MSH to asses hormonal 
targeting. Effective targeting of the polymer was demonstrated both in vitro, in 
B16F10 cells, a cell line which exhibits a-MSH receptors, and in vivo, in mice 
inoculated with B16F10. Binding of the hormone, to the polymer, through its N- 
terminus, did not affect activity. This is not surprising as the receptor binding site of 
this 13 amino acid peptide is the region between the sixth and tenth residues which are 
unaffected by conjugation to the polymer. Although these results are promising, 
workers have recently shown that that receptors for MSH are expressed in other cell 
lines, particularly in the brain, which may limit the therapeutic opportunities for these 
conjugates66,67.
1.4 Lysosomal Degradation
Once a drug molecule is only able to pass into a cell by endocytosis, as in the case of a 
macromolecular pro-drug, the final destination of that macromolecule is pre­
determined to be the lysosome.
Lysosomes are the organelles of cells responsible for digestion and are found in 
almost all mammalian cells 28. The lysosomal membrane is impermeable to 
macromolecules and most initial products of digestion such as oligosaccharides. 
However, it is freely permeable to single units such as amino acids, monosaccharides 
and mononucleotides 28. The lysosomal membrane also contains specific porters for 
some amino acids to allow rapid transport of the degradation products to the 
cytoplasm68.
Lysosomes exhibit unique characteristics in terms of pH and enzyme activity. 
Lysosomal pH is slightly acidic, usually about pH 5.5, in comparison to serum34 This 
is an important consideration as the drug delivered should not be acid sensitive. 
Lysosomes contain over 50 digestive enzymes, the majority of which are hydrolytic in 
nature. They allow the cleavage of all common natural inter-monomer bonds such as
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peptidyl, glycosyl and phosphate linkages 54. One family of enzymes found in 
lysosomes are of particular interest, the cathepsins. The thiol-proteinases, cathepsin B,
H, and L are involved in peptide cleavage as are the non-thiol dependent cathepsin C, 
a peptidyldipeptidase, and cathepsin D, an endopeptidase15,69
These characteristics of lysosomes afford the means of selective release of active drug 
from its macromolecular carrier within the cell, conferring the highest level of 
targeting of drugs. Release of the drug can be achieved by exploiting the acidic pH of 
lysosomes, the specific and high level enzyme activity or the reductive properties of 
the endosomal pathway3.
Many workers have shown that release of a drug from a macromolecule is better 
achieved by incorporating a spacer unit between the macromolecule and drug 16 
Otherwise, the macromolecule itself must be degradable, a possibility which will be 
discussed in Chapter 2. The ideal properties of the linkage are that it should render the 
drug inactive, that it should be stable in serum and be readily broken down in 
lysosomes. Both covalent and non-covalent linkages are acceptable. However, a non- 
covalent linkage, although easier to form, is unlikely to be as stable in serum as is a 
covalent linkage 10.
I.4.1 pH sensitive Linkages
Shen 70 first explored the potential of acid labile spacers in 1981 using a cisaconityl 
acid spacer between daunomycin and poly(D-lysine) . Conjugates bearing this linkage 
demonstrated 90% growth inhibition in WEHI-5 cells, whereas polymers with N- 
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A  further example o f  acid labile spacers are those based on p-benzylthiocarbamoyl 
moiety (Schem e 1.1) 71. In slightly acidic conditions, as in a lysosom e, this spacer 
undergoes an Edman cyclisation, resulting in release o f  daunomycin (Schem e 1.1). 
This is only achieved if  the amino acid used is acidic, such as aspartic acid. Studies 
comparing the side arm attached to aspartic acid or leucine demonstrated the 
suitability o f  the linkage. With aspartic acid, no drug release was seen in serum over 
the three w eeks o f  the study, but at pH 5 and pH 4 release w as afforded. The leucine 
derivative did not undergo cyclisation to form a thiazolinone at pH 7.4 or pH 5 and 
only a small amount o f  release w as seen at pH 4 71.
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M ore recently, Shen 72 has suggested that acid-labile drug arms are relatively 
unsuitable as the difference in pH between serum and lysosom es is not large enough
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to provide totally site-specific degradation. In a novel approach, he has investigated 
the potential of non-covalent acid-sensitive linkages. The receptor-substrate 
complexes on the surface of cells are robust but are easily broken down in lysosomes. 
This is due to a conformational change in the receptor at the lower pH resulting in a 
decreased binding affinity for the substrate. Shen has developed a polymer poly 
(glutaminylhistamine-glutamate) (PHG) which forms a pH-dependent complex with 
poly(lysine). Release of poly(lysine)-methotrexate from PHG was demonstrated in 
lysosomes 72. Obviously, further work is required on this approach before it can be 
utilised.
1.4.2 Disulphide linkages
The degradation of proteins is often achieved by the reductive cleavage of disulphide 
bonds and it is thought that this reaction is the first step in the degradation of insulin. 
The actual location of this reaction is unknown, but it is believed that it occurs early 
on in the endosomal pathway, as shown by studies on diphtheria toxin. Diphtheria 
toxin consists of two sub-units A and B linked via a disulphide bond. Release of the
active B portion is afforded by cleavage of the bond, but as this portion of the toxin is
* 16 62 acid-sensitive, this cleavage and release must occur before reaching the lysosome ' •
Shen et al 16,62 have investigated disulphide bonds for the release of methotrexate 
from poly-D-Lysine. Poly-D-lysine is an ideal choice o f polymer as it is not degraded 
by lysosomes and any drug release must result from cleavage of the disulphide bond. 
The conjugate was effective in both normal and methotrexate-deficient cells and was 
unaffected by leupeptin or decreased glutathione levels; however, its activity was 
abolished by 2-mercaptoethanol. These results demonstrate that cleavage does not 
occur on the cell surface, is independent of enzymes and acidic pH and is not a non- 
enzymatic glutathione reaction. This confirms the view that the reduction occurs in 
pinosomes prior to fusion with the pre-lysosome.
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More recently, Bonfils et a l73 have used disulphide bonds to link oligonucleotides to 
mannosylated proteins. These conjugates were stable in incubation with serum but 
rapidly released the nucleotide within cells.
1.4.3 Lysosomal Enzymes
Most interest in the development of spacers has been focused on amino acid 
sequences which are specific to lysosomal degradation by enzymes. One of the earliest 
examples of this approach dates from 1954. Jatzkewitz employed a dipeptide 
sequence GlyLeu to attach mescaline to poly(vinylpyrrolidone-co-acrylic acid). This 
increased the biological half life of mescaline from a few hours to seventeen days 54,74
The specificity of lysosomal enzymes can be described using the method of Schechter 
and Berger 75. The substrate specificity of many enzymes is now known enabling the 
design of spacers for testing. Two major research groups have investigated the action 
of lysosomal enzymes in the context of macromolecular pro-drugs : Duncan and 
Kopecek et al and Trouet et al.
1.4.3.1 Work of Duncan and Kopecek
1.4.3.1.1 Model studies on chymotrypsin
Initially macromolecular pro-drugs based on HPMA were synthesised to contain 
peptide sequences with known specificity for chymotrypsin to investigate the effect of 
the macromolecule, the length of spacer, and the stereospecificity of the amino acids 
of the spacer on enzyme specificity. The suitability of the sequence was measured by 
the release of a drug model - 4-nitroaniline75.
The binding site of chymotrypsin displays a preference for an amino acid which can 
act as a hydrogen bond donator in the Pi position, one able to form van der Waal’s 
interactions with lie" at P 2  and hydrophobic amino acids at P 4  75. These specificities 
were retained, where the peptide bond to be cleaved was between a macromolecule
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and a drug molecule, revealing major differences in the release o f  drug from spacers 
o f  the same length 75.
With smaller spacers, for exam ple those with only tw o  amino acids, substrate 
specificity was o f  little importance. In this case, the polymer backbone will occupy  
som e o f  the binding site, so decreasing the strength o f  binding. The degradation was 
also affected, not surprisingly, by the inclusion o f  unnatural D  amino acids such as D - 
Phe and D-Ala. In these cases degradation was greatly decreased 15,76.
The effect o f  the macrom olecule on enzym e action has been further investigated using 
PVP and PEG 77,78. Conjugates w ere synthesised with the same peptide sequences as 
previously produced for H PM A  and the degradation rates w ere measured. The same 
relative degradability o f  the sequences w as seen in all three series; however the rates 
o f  degradation o f  a sequence varied considerably. The highest rates o f  release w ere 
seen in the PEG  series in that even a one amino acid spacer was degradable It is 
thought that this may be due to enhanced interactions betw een PEG and the enzyme 
PEG is a linear polymer with the ability to  form hydrogen bonds. Ulbrich e t a l 78 have 
proposed possible interactions between PEG and the enzym e binding site (Figure 1.6).
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A higher rate o f  degradation was also evident with PVP, although this w as not as 
impressive as that o f  PEG 77 This is likely to be due to an interaction o f  the cationic 
chymotrypsin with the negatively charged polymer. These studies also provided  
evidence that increased levels o f  substitution lead to decreases in degradability. This is 
likely to be caused by decreased enzym e accessibility and suggests that there may be 
an optimum level o f  side chain incorporation77
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1.4.3.1.2 Experiments using cathepsins
Based on this early work, attempts were made to design peptide linkages which are 
substrates for particular lysosomal cathepsins 15. Studies were performed using a wide 
variety of single enzymes and mixed lysosomal extracts 15,54,48,69,79 but the most 
promising results were achieved in studies on cathepsin D. Cathepsin D is an 
endopeptidase with specificity for the bond between hydrophobic amino acids 15. On 
the whole it has little activity with low molecular weight substrates, however, 
GlyPheLeuGlyPhe is a known substrate. Three sequences were prepared, 
GlyPheLeuGlyPhe, GlyGlyPheLeuGlyPhe and GlyPheLeuGly, and all degraded easily 
in a mixture of lysosomal enzymes. The first two sequences yielded Phe-NAp. This is 
not ideal, since release of unmodified drug would ensure target activity whereas 
amino acid conjugates may prove to be inactive. In the final sequence, however, linear 
release of unmodified drug was achieved. Interestingly, although this sequence was 
designed for degradation by cathepsin D it also fits the substrate conditions for 
cathepsin L activity i.e. hydrophobic amino acids in positions P2 and P 3  and is 
degraded on incubation with cathepsin B 69,80 Analysis of the degradation events 
showed that the terminal NAp bond was cleaved first to reveal a tetrapeptide which 
was further broken down to release LeuGly; the final amino acids GlyPhe were not 
cleaved from the polymer15.
These studies 69 provided GlyPheLeuGly as a front line candidate for a lysosomally 
degradable sequence. The stability of HPMA co-polymers bearing this sequence in 
serum was determined. Serum contains a wide range of enzymes including a small 
amount of lysosomal enzymes which have leaked from cells, although most of the 
enzymes have trypsin-like activity i.e. they cleave bonds following Arg and Lys. The 
co-polymer was not degraded in serum and so was further evaluated80.
Macromolecular pro-drugs were then prepared incorporating this sequence or the 
sequence GlyGly which is not degraded by lysosomal enzymes. Numerous drugs 
including daunomycin, adriamycin 81,82, sarcolysin 48, melphalan 83 and
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doxorubicin 63,84,85, have been attached to this sequence and in all cases the 
degradability of GlyPheLeuGly is maintained in lysosomes whilst being minimal in 
serum. It has also been shown, by the activity of the conjugates, to be degraded in the 
lysosomes of many cell lines including B16F 10-melanoma cells 63’85, LI210-mouse 
leukaemia cells 46'49’50’81, Walker’s sarcoma cells 83,84 and the HepG2-hepatoma cell 
line31.
However, there are some problems which occur with this sequence. Firstly, it is 
slightly hydrophobic, and in sufficient quantities, could alter the nature of the 
macromolecule. This would be especially problematic if a hydrophobic drug were then 
to be attached 86. Also, in some systems, release of free drug molecules is not 
achieved, only amino acid derivatives being released. This is probably due to the 
macromolecule used e.g. PHEG 87 and its interactions with the enzyme. Nevertheless 
as has been mentioned earlier, amino acid pro-drugs could be exported from the 
lysosome and result in lack of activity88.
1.4.4 Work of Trouet et a l
Originally Trouet investigated macromolecular drug delivery using DNA as a carrier 
molecule. DNA is biodegradable so no spacer moiety was required to afford drug 
release89. However, the limitations of DNA as a carrier (Chapter 2) led to the use of 
albumin 90. Release of the drug from albumin was not achieved from a direct linkage 
therefore spacer units were investigated. Following experiments with small amino acid 
pro-drugs, the ideal bond for release of daunomycin was found to be one between 
leucine and the drug and the ideal sequence for enzyme specificity to be AlaLeu 91,92 
Pro-drugs were then synthesised with one of three linkages AlaLeu, LeuAlaLeu, and 
AlaLeuAlaLeu 90 Studies in vitro showed release to be highest from the tri-and 
tetrapeptide sequences and these conjugates were active in studies in vivo. The 
conjugates were stable in serum for 24 hours and this, in combination with the high 
lysosomal degradability, has lead to this sequence being used in a variety of
90situations .
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De Mare et al 87 have developed spacer sequences based on AlaLeu to attach 
mitomycin C (MMC) to PHEG. Two sequences were sensitive to lysosomal 
hydrolysis GlyPheAlaLeu and AlaLeuAlaLeu resulting in release of MMC although 
some LeuMMC was also released. The sequence GlyGlyGlyLeu has also been used as 
a linker between PGA and adriamycin but, again, some amino acid derivatives are 
produced suggesting that the sequence has low substrate specificity86.
The results from both research groups suggest that enzymatically degradable spacers 
provide the greatest selectivity in degradation and hence the greatest potential for 
targeted drug delivery. At this time, one macromolecular pro-drug incorporating the 
amino acid sequence GlyPheLeuGly is undergoing Phase II clinical trials in humans.
1.5 Conclusion
Macromolecules accumulate in many solid tumours due to a number of inherent 
physical properties of the tissue. This accumulation can be exploited to allow 
enhanced delivery and targeting of macromolecular pro-drugs to solid tumours. 
Altering the charge or size of the macromolecule can lead to enhanced uptake into 
target cells, as can the incorporation of targeting moieties. Lysosome specific delivery 
can be achieved by preparing a conjugate which affords release of a drug, by 





When considering a macromolecular pro-drug, the major determinant of in vivo 
characteristics is the macromolecule rather than the drug or targeting moiety. The 
ideal characteristics of a macromolecule are 11,93:
1. Ease of synthesis
2. Ease of chemical modification
3. Water solubility
4. Biodegradability
5. Lack of toxicity
6. Lack of immunogenicity
However, at present, no carrier has been found which has all these characteristics. In 
this chapter, the most well known polymers are evaluated with respect to these 
criteria and previous macromolecular drug conjugates are discussed.
Both synthetic and natural macromolecules have been used as carriers. Synthetic 
polymers are considerably more versatile than non-synthetic polymers. They can be 
easily synthesised in known molecular weight fractions and modified for the 
attachment of drug molecules. They are also less toxic and immunogenic than natural 
polymers. Unfortunately, synthetic polymers are, on the whole, not degradable due to 
their carbon-carbon backbone. Thus, investigators are presently developing co­
polymers of synthetic polymers and natural amino acids, which retain the favourable 
properties of synthetic polymers whilst allowing a limited biodegradability11,93.
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2.2 DNA
DNA was one of the first macromolecular carriers investigated. It is an ideal 
lysomotrophic carrier as it is stable in serum but is degraded in the lysosome. In the 
early 1970s, Trouet et al. 10 produced complexes of daunomycin and adriamycin 
intercalated into DNA. These complexes proved effective in in vitro studies in 
leukaemia cells and in DBA2 mice inoculated with the L1210 leukaemia. Limited 
clinical trials were performed in terminal leukaemia patients whose disease was 
resistant to all forms of therapy. The complex was well tolerated and gave very 
encouraging results; in 20 cases of non-lymphoblastic leukaemia, 12 resulted in 
complete remission. Interest in DNA as a carrier has waned since then, possibly 
because of the instructional nature of DNA which may lead to unwanted side effects, 
or due to the difficulty of preparing drug conjugates 10,89
2.3 Albumin
The serum protein, albumin, has also been used as a carrier. It is attractive due to 
good biological stability, lysosomal degradability, ease of chemical substitution, low 
toxicity and with homologous albumin, low immunogenicity. Early attempts to 
produce a methotrexate derivative of albumin resulted in an inactive conjugate 11. 
Later attempts to produce a conjugate of daunomycin, attached via degradable 
spacers to albumin, resulted in therapeutic activity. The conjugates led to a 200% 
increase in life span in mice inoculated with L1210 11,20,9(\
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2.4 Polysaccharides
Many polysaccharides have been used as macromolecular carriers including cellulose 
and starch 12 However, dextran and inulin have been m ost widely investigated. 
Polysaccharides are attractive as carriers, because they are easily chemically 
derivatised and are o f  both low  toxicity and immunogenicity.
2.4.1 Dextran
Dextran (6) is the collective name for a wide range o f  polysaccharides based on a -D -  
glucose having a predominance o f  1 ,6 -a  linkages i.e. there is little chain branching 
(Figure 2.1). These polysaccharides are derived from bacteria and the actual 
com position is determined by their origin. One type is o f  particular interest in 
pharmaceutical applications and is derived from L eu co n o sto c  m esesteroides. In this 
type, 95% o f  the chain is unbranched and the remaining 5% is branched with the 
majority o f  the branches only one or tw o  residues long 12
Dextran has been used for many years in medical practice. Dextran T-70 (dextran o f  
molecular weight 70,000) is used as a plasma expander in patients suffering from  
shock or haemorrhage and dextran T -40 is used to increase blood flow  in capillaries in 
the treatment o f  vascular occlusion 12 Thus, dextran is an ideal candidate for a 
macromolecular carrier as its toxic and immunological effects are well characterised
Figure 2.1 : Dextran
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Dextrans are available in narrow molecular weight bands with low polydispersity that 
allow easy characterisation and evaluation of resulting drug conjugates. They also 
have very high water solubility, which is retained even with 20% w/w ligand
• . 04incorporation .
2.4.1.1 Activation
12The methods for activation of dextran have been reviewed excellently by Larsen 
and by Schacht 94. Dextran contains a large number of hydroxyl groups that are 
suitable for either direct conjugation with carboxylic-acid bearing drugs, such as 
aspirin or for chemical modification and activation prior to coupling with other drugs. 
There are three main methods of activation, all of which have been used in the 
preparation of macromolecular pro-drugs.
The most popular method involves the production of dextran dialdehydes by the 
action of periodic acid (Scheme 2.1). The resulting aldehydes can then react to form 
Schiff bases with drugs containing amine groups. This bond is highly unstable and can 
be stabilised by reduction with sodium borohydride. This coupling and subsequent 
reduction can be achieved in one step. Unfortunately, this reaction may also result in 
the formation of hemiacetals that reduce the degree of oxidation along the chain and 
potentially affect coupling reactions. Chemical modification of this type also greatly 
effects the structure of the carrier backbone which will effect its physiochemical 













Another attractive method is the use o f  cyanogen bromide. This leads to less 
alteration in the basic structure o f  the carrier, but does result in the introduction o f  
positive charges into the molecule (Schem e 2 .2) 12. The reaction is not well 
understood but it is thought that, along with the desired electrophile, three other 
preliminary products are produced The imidocarbonate structures are com monly 
produced in dextran activation, particularly the stable five-membered ring structure 
(13). This can then form the desired linkage when treated with an amine but can also 
form other linkages which can result in a charged dextran. Thus, this approach, 
although the chemistry is easy to perform, is o f  limited use as reliable and 














-O H  CNBr —O -C SN ll—O -C -O —





















The final method o f  activation is through the use o f  carbamate esters. Treatment o f  
dextran with 4-nitrophenyl chloroformate results in the highly active carbonate which 
couples easily with amine drugs 95. Again it is thought that som e inter-chain cross­
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2.4.1.2 Distribution in vivo
Dextran has a renal threshold o f  approximately 55,000 and fractions o f  a higher 
molecular weight undergo slow  partial depolymerisation due to the action o f  
dextranases 12 Studies with dextran T -40 demonstrate a rapid clearance from the 
bloodstream; this is thought to be due to three excretory mechanisms. The main 
fraction which is below  the glomerular filtration threshold is excreted in the urine. A  
small amount passes into the gastro-intestinal tract where it is degraded in the colon. 
Another small fraction passes across the endothelium and into the interstitium where it 
is recycled via  the lymphatics. The remaining fractions are taken up over time into 
cells o f  the reticulo-endothelial system, such as macrophages and Kupffer cells o f  the 
liver, where the polysaccharide is slowly degraded 12.
The distribution o f  dextran in  vivo  can be greatly changed by chemical modification. 
A  cationic derivative, diethylaminoethyl dextran, can be formed by treatment o f  
dextran with diethylaminoethyl chloride and an anionic form, carboxymethyl dextran, 
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Equally, incorporation o f  a spacer unit for attachment o f  a drug m olecule can result in 
the formation o f  cationic and anionic derivatives o f  dextran 93. The conjugation o f  
mitomycin C (M M C ) to cyanogen bromide-activated dextran via  a 6-aminohexanoic
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acid spacer results in a positively charged dextran molecule, whereas 6-oxyhexanoic  
acid spacers give a negatively charged polymer 1193,97 (Figure 2.3).
M M C -O X C H ^N H -C -O
nU
MMC-OCXCH^s-O
0 2 a C H 2)5
Figure 2.3
Studies on both these types o f  charged polymers reveal altered in  vivo  distributions. A  
cationic conjugate with uricase was rapidly cleared from plasma whereas an anionic 
derivative has an increased half-life. Measurements o f  hepatic uptake and urinary 
excretion gave similar results. Uricase was taken up faster when conjugated to neutral 
dextran. This rate was enhanced by conjugation to cationic dextran and reduced by 
conjugation to anionic dextran 96.
With the mitomycin C derivatives 91, studies w ere undertaken in tumour-bearing mice. 
Here the cationic derivative w as rapidly cleared whereas the anionic derivative had an 
increased blood residence time, resulting in accumulation in the tumour. These results 
suggest that intentional incorporation o f  anionic charges into a dextran 
macromolecular pro-drug would result in an enhanced delivery system.
An alternative approach to the modification o f  distribution in  vivo  is the use o f  lectins 
to target a polymer to particular cell lines. In early studies, Vansteenkiste 44 
investigated the effect o f  pendant D-galactosylated dextrans on distribution. Plasma 
clearance was higher than for non-derivatised dextran and hepatic uptake was
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increased. An interesting finding from this study was that dextrans carrying 
fluorescein thiocarbamate alone also exhibited an increased disposition in liver. Thus, 
it can be taken that the changed in vivo distribution due to changes in the carrier could 
be augmented or overridden by attachment of drug.
2.4.1.3 Biodegredation
Dextran is degraded in vivo by the action of dextranases. These enzymes are absent 
from blood but are present in the liver, kidney, spleen and parts of the gastro-intestinal 
tract. Dextranases can be either exo or endo in their action. Dextran is only degraded 
very slowly by these enzymes and large molecular weight dextrans can be captured by 
the reticulo-endothelial system before they are degraded. Thus, it is important to 
consider degradation by isolated dextranases and tritosomes of both dextran and 
dextran derivatives 12.
In initial studies, Schacht et al. 95 investigated the degradation of dextran derivatives 
in vitro by an endo dextranase. Three derivatives were assessed, a reduced dialdehyde 
dextran, formed from periodate activation and reduction, an amine derivative, formed 
by the reaction of 2-hydroxypropylamine with chloroformate-activated dextran, and a 
succinate derivative. Degradation was diminished by periodate activation and this 
reduction was proportional to the degree of activation. The other derivatives gave 
similar results suggesting that enzyme activity is affected by the degree of 
derivatisation, rather than the type of modification. The degradation of these 
macromolecules in tritosomes was also assessed. Dextran itself was slowly degraded 
and both the urethane and succinylated dextrans showed even lower degradability. 
Interestingly, the reduced dialdehyde had, in this case, a higher rate of degradation. 
This was thought to be a combined effect of both hydrolytic and lysosomal 
degradation. These workers suggested that the degradation of dextran in lysosomes is 
achieved by dextranases with both endo and exo characteristics95.
The same workers have also investigated the lysosomal degradation of dextran, 
cationic dextran dialdehyde and anionic dextran monosuccinate ester 98. Results were
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obtained for both the degradation index and degree o f  g lucose release, i.e. the extent 
of exo-dextranase activity. Liberation o f  glucose was the same for both dextran and 
the derivatives. H owever, the degradation rates o f  the derivatives were lower. This 
confirms that dextran is degraded in lysosom es by more than one enzyme. It was 
proposed that the enzyme with exo  activity w as a-glucosidase and the endo  enzyme 
was 1,6-a -D -g lu co se-6-glucanohydrolase.
Crepon et al. 99 have examined the degradation o f  dextran derivatives that bear more 
resemblance to  macromolecular pro-drugs. Carboxylic acid, benzylamide, and 
sulphonated benzylamine derivatives o f  dextran T -40 w ere prepared and degraded 
using an m io-dextranase (Figure 2.4). Incorporation o f  increasing numbers o f  
carboxylic acid groups resulted in a linear reduction in degradation. Comparison o f  
polymers derivatised with carboxylic acid groups and polymers derivatised with both 
carboxylic acids and benzylamine sulphonated groups showed the benzylamine 
sulphonated groups had a greater inhibitory effect on lability to  dextranase 










The effect o f  larger substituents has also been investigated 100. Dextrans have been  
prepared bearing pendant poly(ethylene glycol) chains which were degraded both with  
dextranase and tritosomes. All the derivatives were degraded by dextranase but the 
extent o f  degradation was substantially reduced with longer poly(ethylene glycol)
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chains. With the lysosomal enzymes, no degradation of the derivatives was seen in 36 
hours.
These results suggest that dextran is suitable as a carrier molecule, as it is not 
degraded in the blood stream where there are no dextranases, but is very slowly 
degraded in lysosomes. To afford efficient release of drug from dextran, it may be 
appropriate to use lysosomally degradable spacers.
2.4.1.4 Immunogenicity
The immunogenicity of dextran has been reviewed by Rihova and Riha 10 \  
Immunogenicity is dependent on the molecular weight of the dextran. Dextrans with 
MW 51,000 Da have very low immunogenicity whereas injection of dextran with MW 
over 90,000 Da results in the formation of antibodies over three weeks. It has also 
been shown that the immune effect depends on the dose injected, for large molecular 
weight dextrans, an immune response is induced at low doses but, at higher doses, 
tolerance is seen. The immunogenicity of dextrans is also structure-dependent, 
branched polysaccharides being more immunogenic 94.
Two main specificities of antibody are raised to dextran, one with a combining site for 
isomaltotriose and one with a larger combining site for isomaltohexose 101.
The immunogenicity of modified dextrans must also be evaluated, as this provides 
information on the macromolecular pro-drug situation. Crepon 99 evaluated the 
antibody response to a dextran T-40 derivative with 54% carboxylic acid groups and 
19.5% sulphonated benzylamine units. The polymer was injected three times over 14 
days, with or without complete Freunds’ adjuvant, into Balb/c mice. The antibody 
titre was low, even in mice treated with the adjuvant, and the conjugate can be 
considered to have low immunogenicity. Despite the low immunogenicity of dextran, 
occasional anaphylactic reactions are seen. However, the development of a pre­
immunisation technique has reduced the risk to 1 in 85,000 12.
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2.4.1.5 Macromolecular pro-drugs based on dextran
Sezaki et al. have developed pro-drugs of mitomycin C based on dextran 102. These 
workers employ hydrolysable spacer bonds, rather than lysosomally degradable bonds, 
in order to achieve release of the acid-unstable drug both within the cell and within 
the tumour mass. This could however result in the release of the drug in other regions 
of the body, with consequent toxicity.
Mitomycin C has been attached to cyanogen bromide-activated dextran thorough a 
variety of bonds 12,93,96. In a recent study 102, three spacers of varying length were 
evaluated with respect to rate of drug release and effectiveness in vivo. In vitro drug 
release rates demonstrated an increased half-life with increasing chain length, but in 
cell culture experiments growth inhibition increased as the length of the spacer 
decreased. Thus these two effects must be balanced to provide the most selectively 
active conjugate. Studies in vivo have shown that a 6-aminohexanoic acid spacer 
provides the largest increase in life-span combined with the largest therapeutic 
index 102
2.4.2 Inulin
Inulin is a vegetable-derived polysaccharide based on fructose units, which is 
terminated at one end with a sucrose unit. It has limited solubility and is degraded by 
acid. It is a small polysaccharide with MW < 10,000, and is used clinically for testing 
renal filtration rates as in a normal kidney as it is excreted rapidly without 
degradation 94.
Activation of inulin using the standard methods mentioned above proved 
unsuccessful. Periodate activation resulted in only 50% active units, due to the high 
level of formation of hemiacetals 94 An alternative activation method has been 
developed which is also suitable for the activation of dextran 103. Treatment with 
epichlorohydrin yields a 3-chloro-2-hydroxypropyl derivative which can react easily 
with amine drugs. Succinylated derivatives can also be prepared which can then be
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activated with l,r-carbonyldiim idazole 104’105 Inulin has been used to  a limited extent 
in preparing macromolecular pro-drugs, mainly as a carrier for the anti-arrhythmic 
drug, procainam ide94
2.5 Poly(amino acids)
Poly(amino acids) can be considered to be synthetic proteins. The use o f  these  
macromolecules as carriers has been explored for many years. The degradability o f  
poly amino acids is a highly attractive feature as is the ease o f  chemical modification. 
However, the use o f  many macromolecules o f  this type is restricted due to  their 
general cell toxicity. Polymers o f  most amino acids have been prepared and evaluated. 
The most popular systems are poly(glutamic acid), poly(lysine), poly(hydroxyethyl- 
glutamine) and poly(hydroxyethylaspartamide).
2.5 .1 Poly(glutamic acid)
Poly(glutamic acid) (poly(G lu)) can be easily prepared by base-initiated 
polymerisation o f  the N-carboxyanhydrides o f  L-glutamic acid y-benzyl ester (Schem e  
2.4). Deprotection reveals the desired polymer. The polymerisation reaction can be 




Although attachment o f  amine drugs to  the carboxylic acid function would appear to  
be easily achievable using standard peptide chemistry, som e workers have found
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difficulties with activation procedures. Activation with carbodiimides can result in the 
formation o f  cyclic imides, which can lead to chain scission, or inactive N - 
acylisoureas. These problems can be overcom e by using l-ethoxycarbonyl-2-ethoxy- 




The same workers have also developed an alternative coupling method for the 
attachment o f  peptide spacers to the macromolecule 86. Poly(G lu) can be activated 
using a CDI-saccharin method and then coupled with tetramethylguanidinium salts o f  
oligopeptides to  produce the spacer 86 107 (Schem e 2.5). A  stepwise incorporation o f  
amino acids is also possible using a modification o f  this method, in which the 
diimidazole can be regenerated using phenyl dichlorophosphate. With both methods, 
the drug can then be coupled to the polymer via  the EEDQ method 106,107









Complexes of poly(Glu) can also be prepared. The polymer has an inherent negative 
charge and a non-covalent complex of this and c/s-dichlorodiammineplatinum II has 
been made and evaluated as a pro-drug 108
Hoes et al have investigated poly(Glu) macromolecular pro-drugs of adriamycin with 
respect to their activity in vivo and in vitro, rate of release of drug and 
immunogenicity 86,106’107. In studies involving papain in vitro, release of adriamycin 
was achieved only when a peptide spacer was incorporated between poly(Glu) and the 
drug molecule. This is to be expected, as papain has specificity for the cleavage of 
a-amide bonds. Further studies, evaluating the effect of spacer concentration gave 
surprising results. Cleavage of the spacer is expected to be faster in polymers with a 
few spacer units, as access of the enzyme is facilitated. However, with these 
conjugates, degradation proceeded faster with polymers bearing many chains. These 
authors considered these results to be due to degradation of the peptide backbone by 
the enzyme 109
Later studies using lysosomal enzymes, tritosomes, confirmed many of these results. 
Release was obtained slowly in the direct conjugate, due to degradation of the 
polymer backbone. The release from a conjugate with a GlyGlyGlyLeu spacer was 
faster, indicating faster degradation of the spacer unit than the polymer backbone86.
Poly(Glu) is unlikely to be immunogenic. Many workers have shown that the degree 
of immune response is dependent on the number of different amino acids in the 
molecule; thus polymers of four amino acids are considerably more immunogenic than 
homopolymers 10 \  In studies of poly(Glu) in rabbit, guinea pig and man, no antibodies 
were raised to the polymer 109 These results were confirmed by studies of an 
adriamycin conjugate of poly(Glu) in mice. Antibodies were raised both to a direct 
conjugate of drug to polymer and to a conjugate incorporating GlyGlyGlyLeu, but at 
lower levels than the response to bovine gammaglobulin 86. It would be interesting to 
develop these studies further. Both adriamycin and spacer units have been shown 
previously to act as haptens. Thus the antibodies raised should be examined for cross- 
reactivity to determine whether their combining site is part of the polymer backbone.
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The cytotoxicity in vitro and in vivo of these conjugates has also been evaluated 86,106. 
Initial experiments, using both directly-bound and spacer-bound adriamycin, 
suggested that the compounds were completely devoid of activity against LI210 and 
B16 cell lines. However, carriers with a biodegradable spacer, when assessed in vivo 
in mice inoculated with B16 melanoma, gave increased survival times. Not 
surprisingly, the direct conjugate was also inactive in vivo.
2.5.2 Poly(Lysine)
Poly(L-lysine) would appear to be an ideal macromolecular carrier. It is available in a 
wide range of molecular weights, has a high number of amine groups for attachment 
of drug molecules, is biodegradable and can stimulate endocytosis due to the 
interaction of positive charges with the negatively charged cell membrane. Poly(D- 
lysine) has all these advantages except that it is not biodegradable, owing to its 
stereochemistry no.
Poly(L-lysine) was used regularly in the early years of macromolecular pro-drug 
development. It was used mainly as a carrier for methotrexate and, in these studies, 
the intracellular mechanism of pro-drug action was confirmed, as conjugates were 
active in cells without transport mechanisms for methotrexate 16,62. Poly(D-lysine) was 
also an excellent tool in the development of lysosomally degraded spacer arms. 
Release of a drug from a poly(D-Lysine) conjugate with a spacer can only occur if the 
spacer is degraded 16. More recently, however, the use of both these carriers has 
declined due to their general cytotoxicity.
Poly(L-lysine) is known to have antibacterial, antiviral and antitumour activity. These 
properties are thought to be due to interactions with the cellular membrane or parasite 
coat. Unfortunately, the charged interaction that provides these positive effects can 
also lead to toxicity as it is not tumour-cell specific. In a comprehensive study, 
Choksakulnimitr et al. 111 investigated the effect of numerous macromolecules on 
cultured bovine brain endothelial cells, a model of the blood-brain barrier, mouse
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peritoneal macrophages, a model of Kupffer cells, and rat hepatocytes. Damage to the 
cell membrane was measured by the release of lactate dehydrogenase (LDH). With 
Poly(Lys) of high molecular weight (39,880 Da), severe leakage of LDH was 
observed in all the cell lines, while with a smaller polymer (8,000 Da) release was 
reduced, especially in macrophages. It has been suggested that the flexibility of 
poly(Lys) plays a major part in the release, as many interactions can be made on the 
cell surface leading to membrane disruption. These results are particularly worrying as 
polycations have been shown to accumulate in the liver in vivo and suggest that the 
toxicity of poly(Lys) may be too high for use in macromolecular pro-drugs.
The immunogenicity of poly(Lys) is more debatable. In some animals, antibodies can 
be raised to the homopolymer but the response in a particular species is 
unpredictable 101. Furthermore, initial studies by Maurer suggested that the polymer 
was non-immunogenic in rabbits, however it has now been shown that at low levels 
immune responses do occur 112. In a recent study, the immunogenicity of poly(D-Lys) 
has been investigated in rabbits 112. Antibodies of both IgM and IgG were raised in 
response to an initial inoculation with the polymer. On a further administration, a 
booster effect was seen consisting only of IgG antibodies. The antibodies were 
isolated and were only reactive against poly(D-Lys). No activity was seen with 
monomers, suggesting that at least part of the antibody determinant is the peptide 
bond, or with poly(L-Lys) showing stereochemical specificity. These results suggest 
that both poly(L-Lys) and poly(D-Lys) are slightly immunogenic. This does not 
preclude their use in macromolecular pro-drugs but it should be noted that the 
immunogenicity is likely to be enhanced by inclusion of spacers or drug molecules.
The concerns about the toxicity of poly(Lys) have led to the development of new 
approaches to using the polymer as a drug carrier. Monsigny et a l3 have investigated 
a conjugate of poly (L-Lys) with MDP and sugar targeting moieties in which any free 
lysine e-amines have been acylated with 5-gluconolactone. This considerably reduces 
the adverse properties of the polymer whilst retaining the useful properties. Thus, the 
polymer is still degradable but is electrically neutral and has a higher water 
solubility 113,114 Immunogenicity studies have shown that antibodies are not raised to
48
this conjugate 3 and that the neutralisation of charge results in a decrease of non­
specific cell binding and toxicity.
Hudecz et al. have investigated branched polypeptides based on poly(Lys) as 
carriers 115. Branched polypeptides have been used as synthetic antigens as the 
antigenicity of amino acid polymers is increased in polymers with many different 
components 101. Thus, before branched polypeptides can be used as carriers, non- 
immunogenic structures must be found. In a large study of the toxicity of these 
carriers, it was found that inclusion of other amino acids onto a poly(L-Lys) backbone 
can reduce the toxicity to cell cultures, both rat liver and mouse spleen cells, whilst 
the positive cytotoxic effect against cervical cancer cells is maintained.
Hence, although poly(Lys) is not a suitable candidate for a drug carrier due to its high 
level of non-specific toxicity, modifications of the structure could lead to suitably non­
toxic molecules.
2.5.3 Poly(hydroxyethylglutamate)
Poly(hydroxyethylglutamate) (PHEG) is a water soluble, neutral, biodegradable and 
biocompatible polymer that has been proposed as a plasma expander. It is easily 
prepared and can be reliably activated, making it a suitable candidate as a drug carrier. 
PHEG (32) can be synthesised from poly(y-benzylglutamate) via an aminolysis 
reaction with 2-aminoethanol (Scheme 2.6) 116. Treatment with 2-aminoethanol alone 
can result in chain scission due to aminolysis reactions on the backbone amides. This 
can be avoided by the use of the catalyst, 2-hydroxypyridine. With a five-fold excess 
of the catalyst, complete conversion was achieved with minimal chain loss 117
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N H (C H 2 >20H
(27) (32)
Scheme 2.6
The single hydroxyl group can be easily activated by treatment with 4-nitrophenyl 
chloroformate. In contrast to  dextran, the desired carbonate ester is not rearranged 
and inter and intra chain cross-links do not occur. A useful property o f  this reaction is 
that the degree o f  activation is proportional to  the concentration o f  chloroformate and 
thus can be tailored for particular requirements 116 Quantitative couplings with the 
amino groups o f  both targeting moieties, such as sugars, and drugs, such as 
melphalan, can be achieved within 24 hours116
PHEG is known to be biodegradable H owever, in an extensive study, Pytela e t al. 118 
have investigated the role o f  particular enzymes in this degradation. PHEG was 
incubated with both thiol proteases, such as papain and cathepsin B which have a 
lysosomal type activity, and serine proteases, such as chymotrypsin and elastase which 
are found in blood. Interestingly, the homopolymer was resistant to degradation by 
the serine proteases and was degraded by the thiol proteases, suggesting a potential 
lysomotrophic carrier. Unfortunately, when the same workers investigated the effect 
o f  inclusion o f  a hydrophobic group on the side chain, they found that the conjugate 
w as susceptible to  serine proteases. This could mean that the selectivity o f  
degradation could be abolished by attachment o f  a drug. N ot surprisingly, the 
degradation o f  PHEG was reduced by incorporation o f  som e o f  the D-am ino acid and 
abolished in D-PHEG
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PHEG has been investigated mainly as a carrier of mitomycin C. Studies in vitro have 
demonstrated the potential of peptide spacers to afford release of the drug within 
lysosomes whilst retaining hydrolytic stability in the blood stream but the conjugates 
have not been investigated further87. Another approach in the use of PHEG is to co- 
polymerise it with other amino acids to produce macromolecules with different 
properties and biodistribution118,119
2.5.4 Poly(a,|3-(N-(2-hydroxyethyl)-D,L-aspartamide)) (PHEA)
PHEA has also been evaluated as a plasma expander and a drug carrier, although it 
has not been widely used at present. PHEA has a similar chemical reactivity to PHEG, 
thus it can be activated to the nitrophenyl carbamate and coupled to amine-containing 
molecules such as sugars 51. Coupling of carboxylic acid drug molecules can also be 
achieved by the use of reagents such as CDI 120. For other drugs such as acyclovir, 
with a hydroxyl group, the drug molecule can be pre-activated by treatment with 
succinic anhydride. A CDI coupling can then be performed between the carboxylic 
acid group of the drug derivative and the hydroxyl of the polymer. Interestingly, this 
approach also results in the inclusion of a spacer unit121.
2.6 Hydroxypropylmethacrylamide (HPMA)
Hydroxypropylmethacrylamide (33) and its co-polymers have been investigated as 
blood plasma expanders and drug carriers 122 HPMA is a synthetic vinyl polymer 
produced by radical precipitation polymerisation (Figure 2.6) 123. The homopolymer is 
non-immunogenic101 and is easily activated to allow the attachment of drug moieties, 
making it an almost ideal macromolecule. One potential limitation of the system is its 
lack of biodegradability, which restricts the use to macromolecules with a molecular 
weight of less than the glomerular filtration threshold.
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Figure 2 .6 : HPM A
2.6.1 Activation
The homopolymer is itself inert. H owever, the hydroxyl gToups can be activated to  
allow attachment o f  drugs and enzymes. One o f  the easiest methods o f  activation is to  
treat HPM A with cyanuric chloride (Schem e 2 .7) 124 The resulting active species 
reacts easily with enzymes in aqueous solution
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Hydrazide derivatives can also be prepared which, when activated to the azide, can be 
coupled to amine-containing drugs (Schem e 2 .8 ) 124
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Activation o f  the polymer can also be achieved by the use o f  cyanogen bromide 125. 
Although this reaction is versatile and can be tailored for the degree o f  reactivity 
required, it can result in inter- and intra-chain reactions. All these methods do result in 
substantial changes in the structure and charge o f  the homopolymer that may affect 
both its distribution and immunogenicity in  vivo.
An alternative approach is to use an active ester method o f  activation 126. Treatment 
o f  the homopolym er with 4-nitrophenyl chloroformate provides an active polymer. 
Aminolysis reactions with amino acids or drugs results in the restoration o f  the 
original polymer structure This is the most useful and versatile method o f  activation 
available. (Schem e 2 .9)
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Activation o f  the homopolymer is, however, not suitable for reproducible levels o f  
incorporation o f  drug. The alternative is to  use a co-polymerisation method. C o­
polymerisation o f  H PM A with derivatised methacrylamide units can be easily 
achieved. This allows a more accurate and reproducible interaction o f  reactive groups 
into the polymer whilst maintaining the majority o f  characteristics o f  the 
homopolymer. K opecek e t al. 123 have developed this approach and have used co ­
polymers o f  H PM A incorporating peptide spacers for the delivery o f  many drugs. The 
general method o f  synthesis involves the N-methacrylylation o f  an amino acid or 
dipeptide units under Schotten Baumann conditions. The a-am ino acid can then be 
activated as a nitrophenyl ester (Schem e 2 .10).
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Co-polymerisation o f  these methacrylamide derivatives with HPM A occurs via  a 
radical method involving an azo initiator such as a , a ‘-azobisisobutyronitrile (A IBN ). 
The co-polymerisation takes place rapidly at 50°C in acetone. H owever, the rate o f  
polymerisation and yield o f  polymer are reduced in comparison to preparation o f  the 
homopolymer 127 Using this method, up to 10% reactive side chains have been  
incorporated 54 (Schem e 2.11).
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Drug m olecules or targeting moieties can be easily incorporated into the polymer by 
aminolysis reactions The reactivity o f  the nitrophenyl groups on the polymer is 
considerably reduced in comparison to the monomers ow ing to steric effects 127 The 
rate o f  reaction is also dependent on the nature o f  the ester, a-am ino active esters 
react faster than o-acylam ino esters 128
With som e drugs, it is possible to produce a methacrylylated derivative that can then 
be co-polymerised. This approach has been utilised by Schacht for the anti-arrhythmic 
drug, procainamide Co-polymerisation o f  the derivative with H PM A resulted in a 
water soluble drug conjugate (Schem e 2 .12 ) 129
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2.6.2. Distribution in  vivo
Studies with iodine-labelled H PM A provide a value for the glomerular filtration 
threshold o f  45 ,000  D a 19 Polymers o f  higher molecular weights remain in the
range o f  HPM A polymers showed clearance from the blood stream to be fairly rapid 
but dependent on molecular weight. Accumulation in tissue e.g. spleen and liver, is 
only apparent with polymers o f  778,000 D a or above. Thus, most interest has been  
focussed on polymers o f  molecular weight less than 20 ,000  D a to ensure glomerular 
filtration.
As has been discussed in Chapter 1, the distribution o f  H PM A co-polym ers in vivo  
can be altered easily by the incorporation o f  non-specific hydrophobic groups 34 and 
charge or by the use o f  specific targeting residues 45,63. In tumour-bearing animals, 
conjugation o f  drugs to H PM A co-polymers results in an increased concentration o f  
the drug in tumours, suggesting that the co-polymer is tumour tropic 81,82
circulation indefinitely as they are non-degradable 52 130 Intravenous application o f  a
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2.6.3 Degradation
Obviously, due to their synthetic nature, co-polymers of HPMA cannot be degraded 
by enzymes in the blood stream or lysosome. This could lead to an unacceptable 
accumulation of the polymer within the body. Hence, with these linear polymers, the 
molecular weight must be kept below the renal threshold, potentially reducing the 
tumour tropic effect. Accumulation of the polymers can be avoided by the use of 
soluble cross-linked polymers. By careful choice of the cross-link, spacers can be 
prepared which only degrade within the lysosome i.e. after delivery of the drug. The 
resulting low molecular weight polymers can be excreted in the urine 13U32.
An example of a cross-linked HPMA co-polymer is shown in Figure 2.7 131,132 . The 
cross-linking reaction is designed to occur below the gel point in order to produce a 
soluble rather than an insoluble polymer. This reaction has to take place at low 
concentrations owing to the low solubility of the reactants. However, this could result 
in the formation of cyclised structures with the amine reacting twice with the same 
polymer chain. This can be avoided by cross-linking the polymer through short 
diamines such as ethane-1,2-diamine. This, however, could lead to decreased 
enzymatic degradability. Cyclisation can be more easily overcome by employing a 
two-step reaction. Treatment of the polymer with a large excess of the diamine will 
minimise cyclisation and maximise the formation of free amines. In a second step, the 
free amino groups can then be allowed to react with more polymer starting 
material123. Two-stage cross-linking also allows the formation of very high molecular 
weight products128.
Initially, model studies on the degradation of peptide sequences between the bis-amine 
and polymer were performed. Amino acid sequences were prepared which showed 
similar specificity as side-chains for the enzymes chymotrypsin 128’131, trypsin 133 and 
papain 134 In all cases, degradation was reduced in comparison to the same chains 
attached to the linear polymers. This could be due to either decreased access of the 
enzyme to the bond to be cleaved or to conformational constraints of the amino acid 










This decrease in degradability was especially pronounced with cross-linked polymers 
with either a two amino acid peptide sequence or a short diamine 131,134
Cross-linked polymers have been evaluated in vitro for lysosomal degradation using 
isolated cathepsin B. Degradation was again highest with long amino acid chains or 
with a long bis-amine69. In a further study, cross-linked polymers with the amino acid 
sequence GlyGlyPheTyr were degraded easily by rat lysosomal enzymes but were 
resistant to degradation in plasma. Preliminary experiments with the same polymer in 
vivo in rats confirmed degradation takes place as low molecular weight chains were 
excreted 135,136.
This approach has not been investigated further in the development of intravenous 
agents for the treatment of cancer, although HPMA cross-linked polymers formed 
above the gel point are being evaluated for colon-specific drug release 137
2.6.4 Immunogenicity
The immune response to both HPMA and co-polymers of HPMA has been thoroughly 
investigated by Rihova 101. Injection of the homopolymer does not appear to result in 
an immune response in mice as no antibody titre is measurable. Incorporation of 
peptidyl side chains, however, does result in the production of antibodies. This is a 
weak reaction, the titre is considerably lower than for a model immunogen, bovine 
gamma globulin, and the antibodies are of the weak IgM class 138. Injection of a wide 
range of doses of the co-polymers demonstrated a tolerance reaction; the antibody 
response to most co-polymers was higher for a 10 pg/kg dose than for a 100 pg/kg 
dose. The structure of the peptide also had an effect on the antibody titre but no 
structure-activity relationships could be evaluated 138.
Interestingly, using one peptide spacer at different substitution levels did not affect the 
number of antibodies raised. This suggests that the presence of only one or two 
epitopes, as in the 1 mol% conjugate, can elicit an antibody response138.
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The specificity of the antibodies has also been investigated in cross-reactivity 
reactions. These showed that the majority of antibodies formed were directed to the 
peptide sequence and therefore could not cross-react but some were raised against the 
polymer backbone, most probably against the hydroxypropyl unit. This suggests that, 
although antibodies are not raised against the homopolymer, once the entire molecule 
becomes immunogenic due to the peptide chain, antibodies are raised against all parts 
of the molecule 138. Similar results were obtained with co-polymers bearing 
adriamycin. A low antibody response were seen at all doses and was unaffected by the 
incorporation of galactosamine targeting residues 13°.
The effect of incorporation of known haptens has also been investigated. Again, the 
majority of antibodies were raised against the hapten. With this system, the effect of 
molecular weight on immunogenicity was evaluated. More antibodies were raised to 
the hapten with a co-polymer of molecular weight 200,000 Da than for one of 5,000 
Da 101.
The effect of pre-immunisation on the efficacy of a daunomycin HPMA co-polymer 
has also been evaluated. Pre-immunization can either give no effect, an adverse toxic 
affect or result in loss of activity of a drug. In this system, pre-immunization over 35 
days prior to inoculation of the mice with L1210 cells resulted in no loss of activity of
i • 139the conjugate
2.7 Poly(ethylene glycol) PEG
Poly(ethylene glycol) is a non-toxic, non-immunogenic, highly water-soluble linear 
polymer 140. It has mainly been used medically in the modification of therapeutic 
proteins. Modification of proteins with PEG leads to a decrease in the toxicity and 
immunogenicity of the protein, whilst increasing both the water solubility and plasma 
half-life 140,141,142. These properties suggest that conjugation of a drug to PEG or PEG 
co-polymers would provide an ideal non-toxic macromolecular pro-drug with 
enhanced plasma lifetime and potentially increased uptake into tumours.
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2.7.1 Activation
Much research has been directed towards the preparation o f  activated PEG  for 
attachment to proteins. The coupling reaction in this system is usually betw een PEG  
monomethyl ester and the e-amino group o f  protein lysine residues 14°. Therefore, 
most active derivatives are based on carboxylic acid-type groups. For the conjugation 
o f  drug or the formation o f  block co-polymers, amine residues may be required. These 
can be provided by treatment o f  the carboxyl-activated PEG with bis-amine or by 
direct conversion o f  PEG to PEG-amine l43>144
The activation o f  PEG by cyanuric chloride is one o f  the oldest and most widely used  
methods for protein coupling. The original method o f  Abuchowski and Davis has been 
modified by Harris 145 to enable com plete conversion within tw o hours, through the 
use o f  alkoxides (Schem e 2.13). Coupling o f  proteins using this method has been  
linked to inactivation o f  the protein 141>146? cross-linking and non-specific coupling to  












Activation using CDI (Schem e 2 .14) is effective and does not lead to cross-linking. 
However, the coupling reaction is slow  and can take up to 72 hours. This method, 
therefore, is o f  little use in co-polymerisation reactions 147
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Scheme 2.14
Treatment o f  PEG with succinic anhydride generates a carboxylic acid group which 
can then be activated via  a DCC coupling to form the N-hydroxysuccinimide ester 
(Schem e 2 .15)  146147 These derivatives react quickly with amines 148 but the resulting 
product can be unstable due to hydrolysis o f  the ester linkage147.
r i Succinic Anhydride r 1




D O C  X
Q
CH3|(>-CH 2-CH2|o -C -C H 2- a i 2- C - 0 - / ^ 3




c h 3 | o - c h 2 - c h 2 | o - c - c h 2 - c h 2 - c -  
o  o
-NHR




An alternative approach, developed by Zalipsky, allows the formation o f  a N-hydroxy- 
succinimide-activated PEG without hydrolytic instability. Treatment o f  PEG with 
phosgene follow ed by N-hydroxysuccinimide results in a stable urethane derivative 
between an amine drug and PEG (Figure 2 .8 ) 148
Figure 2 .8
These are only the main methods used. Activation and coupling have also been 
achieved by reductive amination with PEG aldehyde, by formation o f  glycidyl ethers 
with epichlorohydrin 149,150 and the formation o f  tresylates (2 ,2,2- 
trifluoroethanesulphonates) 147,151
A number o f  co-polym ers o f  PEG have been prepared for use in drug delivery. 
Zalipsky 148,152 utilised the N-hydroxysuccinimide method to prepare a co-polymer o f  
PEG and lysine with the amino acid linked through the a -  and e-amino groups 
(Schem e 2.16).  The degree o f  polymerisation could be easily altered by varying the 
reaction time and concentration o f  the reactants. A  polymer o f  molecular weight o f
170,000 D a w as achieved in a tw o hour polymerisation from PEG o f  mean molecular 
weight 2 ,000  Da. The co-polymer produced has pendant carboxylic acid groups that 




An AB Block co-polym er o f  monomethyl PEG  with poly(aspartic acid) has also been 
prepared. In this case, an amine derivative o f  PEG acts as an initiator for the N - 
carboxyanhydride polymerisation o f (3-benzyl-protected aspartic acid. 153
2.7.2 Degradation
PEG as well as being chemically inert, is not susceptible to  biodegradation. Thus, if  
high molecular weight co-polym ers are to be used for macromolecular pro-drug 
production, enzymatically degradable units must be introduced to the structure. 
Obviously, in a co-polym er o f  PEG and poly(aspartic acid), the aspartic acid unit will 
be degradable, allowing breakdown o f  the polymer 153. Unfortunately, this 
degradation w ould not be specific to  the lysosomal compartment H owever, by 
developing particular small peptide linkages, it may be possible to  produce a 
selectively degradable co-polymer.
Ulbrich et a l  78 investigated the degradability o f  PEG units linked via  diamines 
incorporating one amino acid, Phe. Three polymers w ere synthesised, one containing 
both enzymatically and hydrolytically degradable bonds (Polymer A ) and tw o  
containing enzym e-sensitive bonds (Polymers B and C) (Figure 2 .9). These workers
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were able to  demonstrate the cleavage o f  all three polymers by chymotrypsin, 
however only polymer A  w as degraded hydrolytically. With polymers B and C, the 
rate o f  degradation depended on the orientation o f  the peptide bond with respect to  
the PEG chain. In polymer B, more favourable enzyme-substrate interactions are 
provided, where PEG is in P2 to  P4 than in polymer C where these positions are 
occupied by the bis-amine Thus, the degradation o f  Polymer B is faster than Polymer 
C. These results demonstrate the ease o f  producing degradable PEG co-polym ers 78. 
H owever, before these polymers can be used as drug carriers either an amino acid 
with functionality or a modified bis amine must be introduced to allow attachment o f  a 
drug molecule.
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2.7.3 In vivo Distribution
PEG is uncharged and hydrophilic and, therefore, does not interact easily with body 
components. An example of this is the reduced uptake of microspheres into the 
reticulo-endothelial system when they are coated with PEG 153.
Studies 154 of the body distribution of PEG injected intravenously to mice show that 
the half-life is dependent on molecular weight and can vary between minutes and days. 
Urinary clearance was dependent on molecular weight and a glomerular filtration 
threshold was calculated to be 30,000 Da. Uptake by other organs was unrelated to 
the molecular weight of the polymer; appreciable accumulation was only seen in the 
kidney and liver. This accumulation was thought to be due to uptake by macrophages 
and Kupffer cells.
2.7.4. Immunogenicity and Toxicity
PEG has low toxicity. Studies in dogs have shown no toxic or cumulative effects even 
at the high dose of 90 mg/kg a day 140 Studies in rats have confirmed these results, 
administration of a 16% w/w oral dose of PEG had no adverse effects. There have 
been occasional reports of toxicity in man on oral and topical administration. 
However these reactions are not seen with intravenous application 147.
PEG is also non-immunogenic. Antibodies were not raised to PEG of molecular 
weights up to 100,000 Da in rabbits, even in the presence of complete Freund’s 
adjuvant. Investigations on the immunogenicity of PEG-protein conjugates have 
demonstrated a decrease in the antigenicity of the protein. Proteins are highly 
antigenic due to their heterogeneity. The decrease in immunogenicity, measured by 
decreased antibody titre, is thought to be due to a shielding effect of the PEG chain, 
preventing recognition of the haptens 101’140,146.
When antibodies are raised to PEG-protein conjugates, a portion of the antibodies are 
raised against the PEG chain. Injection of PEG-allergens to humans does result in the
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formation of PEG antibodies in 50% of the population but these are of the weak IgM 
type. In fact, two years after administration, no circulating antibodies to PEG can be 
seen. This response, therefore, is not thought to be of clinical significance 140
The shielding property of PEG may also prove beneficial with PEG block copolymers 
bearing drugs. Many drugs are very active haptens, so coupling with PEG co­
polymers may reduce their immunogenicity. The micellar structure formed by some 
AB block co-polymers of PEG are also highly unlikely to be immunogenic.
2.7.5 Micelles
Initial studies by Pratten et al. on block co-polymers of PEG and Poly(Lys) 
substituted with palmitoyl groups gave surprising results 40. It was expected that 
pinocytic uptake of this polymer would be high due to hydrophobic interactions 
between the palmitoyl groups and the cell surface. However, no improvement over 
PEG was seen. It was suggested that the block co-polymer forms a micellar structure 
in which the palmitoyl groups are in a central core and cannot interact with the cell 
surface.
This system was further investigated by Ringsdorf et al.y 6 with a drug moiety, an 
inactive cyclophosphamide, attached to the palmitoyl group. The drug is usually 
rapidly hydrolysed to an active derivative. However, when attached to the polymer, 
this hydrolysis was slower. The cross-linking of DNA due to the drug was evaluated 
in vivo in LI210 cells. Maximal cross-linking was achieved considerably later with the 
conjugate than with free drug. It was suggested that the drug was within a micelle 
core and was only released after cellular uptake 6.(Figure 2.10)
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M ore recently, Yokoyam a e t al. 155,156 have consciously developed a block copolymer 
pro drug system that spontaneously forms micelles in solution. The system is based on 
a co-polymer o f  PEG and poly(A sp), where drug m olecules such as adriamycin can be 
attached to the aspartic carboxylic functions. The co-polym er is easily produced. PEG  
acts as the initiator for the polymerisation o f  the aspartic unit and, following de­
protection o f  the polymer, adriamycin can be introduced via an EDC coupling 155156
Incorporation o f  a drug onto a macromolecule is usually limited by the solubility o f  
the conjugate; as the level o f  drug increases, precipitation can occur. With these block  
polymers, however, 50 mol % o f  drug can be incorporated 156457 This property is 
dependent on the solubilizing action o f  PEG, as similar incorporations cannot be 
achieved with poly(A sp) 158. Analysis o f  these co-polymers gave apparent molecular 
weights o f  over 30 ,000  Da, where the single chain molecular weight is 9 ,000 Da. This 
suggests that an aggregation process has occurred, i.e. a micelle has been formed. 
This is confirmed as these structures are broken on treatment with a surfactant153.
It has been suggested that single polymer chains exist in an equilibrium with the 
micelles and that drug release is only achieved from the single chain 158. The m icelle 
size can be altered within tight limits by altering the molecular weight o f  the PEG  
chain. However, altering either the length o f  the poly(Asp) chain or the content o f  
incorporated drug does not affect the size o f  the micelle 158.
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These systems have been extensively investigated both for their distribution in vivo 
and cytotoxicity 157 In an distribution study in vivo, the existence of micelles was 
confirmed. No urinary clearance was measured for two conjugates based on PEG
5,000 and 12,000 despite the fact that their molecular weights are below the 
glomerular filtration threshold. The conjugates remained in the blood stream for a 
prolonged period and were passively accumulated into the tumour. After 24 hours a 
concentration of 10% dose/gram of tissue was seen for the tumour, whereas for free 
drug the best concentration was 0.9%. Coupled with this, the conjugate displays 
decreased accumulation in the heart, a major organ for toxicity, in comparison to free 
drug 157’158. The activity in mice with P388 leukaemia has also been evaluated. The 
conjugates displayed increased activity and decreased toxicity when compared to the 
free drug 158.
These workers have also attached an antibody to this system and demonstrated that 
the micellar structure is lost. In this situation, the single polymer chains form an ideal 
conformational state in which the disulphide linkage to the antibody is protected by 
the aspartic acid residues 153,155. Micelle formation is only possible with block co­
polymers of an AB structure. However, it is thought that, in more complicated co­
polymers, the molecule will arrange itself into the most suitable conformational state. 
With PEG co-polymers, it is thought that the PEG will be exposed to the circulation 
and hydrophobic units will be protected, as is the case with PEG proteins153.
2.7.6 Macromolecular pro-drugs based on PEG
An interesting approach to the use of PEG as a macromolecular carrier has recently 
been proposed 159 In this case, one PEG chain is coupled to one drug molecule e.g. 
adriamycin, and one targeting group, lactose. This conjugate was active in vitro in 
both leukaemia and hepatoma cell lines. Despite this efficacy, this system cannot be 
considered ideal as a large number of conjugates would have to be delivered to the 
cell rather than one conjugate bearing many drug molecules.
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Nathan et al. 148,152 have investigated a co-polymer of PEG and lysine as a carrier for 
the antibacterials; cephradine and penicillin V. In this approach, the pendant 
carboxylic acid group of the amino acid was successfully converted to other reactive 
groups, such as amino and hydroxyl, to enable the coupling of a variety of 
compounds. Both biodegradable and non biodegradable conjugates were prepared, a 
number of which also incorporated a spacer.
2.8 Conclusion
Thus, although many macromolecules have been investigated for the preparation of 
macromolecular pro-drugs, none is ideal. At present, the system with the greatest 
potential is pro-drugs based on co-polymers of hydroxypropylmethacrylamide 
(HPMA). Macromolecular pro-drugs formed from this polymer are at present 
undergoing clinical trial. A prospect for the future is the development of 




CONTRAST AGENTS IN MAGNETIC RESONANCE IMAGING
3.1 Introduction
The majority of research on macromolecular carriers has involved the investigation of 
macromolecular pro-drugs for the treatment of cancer. However, almost any drug can 
be attached to a carrier to allow targeting or to increase blood circulation time. 
Macromolecules can also be used in the imaging of tumours and other diseases. A 
range of macromolecular contrast agents have been produced for use in magnetic 
resonance imaging (MRI). These are successful not only in the imaging of tumours 
and inflammation but as blood pool contrast agents allow investigation of perfusion 
and occlusion of the vascular system. The basis of contrast enhancement of MR 
images and contrast agents are considered in this chapter.
3.2 Magnetic Resonance Imaging (MRI)
Magnetic Resonance Imaging (MRI) is based on detecting the NMR signals of water 
protons within the body. Tissues contain varying amounts of water and this is the 
basis of contrast between organs. This is enhanced by using a gradient magnetic field. 
The protons then resonate at a different frequency depending on the position within 
the field. This allows spatial information to be combined with the resonance 
frequencies and transformed into an image of the organs within the body 160,161
When a magnetic field is applied to a proton, the induced magnetism is aligned along 
the Z axis. When a radio frequency pulse is applied, this magnetic vector moves away 
from the axis and then returns or ‘relaxes’ back to the axis. The time taken for this 
relaxation is Ti, the spin-lattice (longitudinal) relaxation time. A component of the 
magnetic field lies perpendicular to the Z axis; this is also perturbed by application of
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a pulse and relaxes back with a relaxation time T2, the spin-spin (transverse) 
relaxation time. So, in MRI, pulses are applied rapidly to prepare images that are 
based on the different relaxation rates of water protons 16°.
In some cases, in normal, non-enhanced tissue, the properties of two tissues are not 
sufficiently different to allow imaging of lesions or tumours. In these cases, a contrast 
enhancement agent can be used. These can either alter the spin density of a tissue or 
the relaxation times of the protons within the tissue. Spin density is a measure of the 
number of protons in an area. By using gases, such as CO2, and perfluorocarbons, 
which have no hydrogen atoms, the total spin density within the area can be reduced 
giving a decrease in signal intensity 160,163.
However, most interest has been focussed on altering the Ti and T2 times of tissues. 
Tissues with short Ti give brighter images than those with long Ti as the majority of 
the magnetism is aligned along the Z axis at a given time. In contrast, tissues with 
short T2 values have decreased signal intensity and are seen in images as dark areas. 
The values of Ti and T2 can be altered in vitro and in vivo by the addition of 
compounds with magnetic properties 160,162
3.2.1 Diamagnetism
Most molecules are diamagnetic; that is, they have no magnetic dipole as they contain 
no unpaired electrons. In an applied magnetic field, they do exhibit a small net 
magnetism which is aligned antiparallel to the applied field. This small local field 
exerts only a minor effect on the water protons of a tissue. Hence, addition of a 
diamagnetic ion does not result in enhanced images 164.
3.2.2. Paramagnetism
Paramagnetism occurs when an ion or molecule contains unpaired electrons. Although 
there is no net magnetism without application of an external field, once an external 
field is applied orientation of the unpaired electrons results in the formation of a
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strong local magnetic field. Paramagnetism is prevalent in transition metals, where 
there is preferential filling of the 4s level giving rise to a number of unpaired electrons 
in the 3d level, and the lanthanides. Thus Mn2+ with five unpaired electrons and Gd3+ 
with seven impaired electrons are effective paramagnetic ions 164.
If a paramagnetic ion is introduced to the body, it can interact with the proton nuclei 
of water molecules to reduce both the Ti and T2 relaxation times. The ability of the 
ion to alter the times depends upon the ease of approach of the proton to the 
paramagnetic centre and is termed relaxivity. This property depends on the magnetic 
moment of the ion which is itself related to the number of unpaired electrons. Thus 
Mn2+, Gd3+ and Fe3+ ions have high relaxivities due to their large magnetic 
moments 162
The type of interaction can be inner sphere in which a molecule of water binds directly 
to the primary co-ordination sphere of the metal ion from which it can exchange with 
the bulk water. Alternatively outer sphere interactions, where there is no direct 
binding, can occur. The relaxivity is a combination of these effects, although outer 
sphere mechanisms are only of interest with chelated ions 160
Relaxivity is also dependant on the correlation time, which is a term describing the 
likelihood of an interaction occurring between the unpaired electron and a water 
molecule. The correlation time is the sum of three correlation times; the rotational T r, 
the electron spin relaxation Ts and chemical exchange Tm 162.
1/TC = 1/Tr + 1/TS+ 1/Tm
Increasing the rotational correlation time, by slowing molecular motion of a 
paramagnetic ion can lead to increased relaxivity. This has been demonstrated by the 
attachment of paramagnetic ions to slow-tumbling protein macromolecules. Careful 
choice of paramagnetic ion can also enhance relaxivity; paramagnetic compounds 
based on Mn and Gd and nitroxides have long electron spin relaxation times and high
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relaxivity, whereas Dy has a faster electron spin relaxation time and lower 
relaxivity 162.
Paramagnetics alter both Tj and T2 . Reduction in Ti leads to an enhanced signal 
intensity, whereas reduction in T2 leads to a loss of image intensity. Thus, a balance 
must be found between these two effects to achieve contrast enhancement. At low 
field strengths, the decrease in Ti dominates the relationship and enhanced images are 
seen, at higher fields the T2 effects dominate and signal enhancement is reduced. The 
concentration of paramagnetic ions can also alter the imaging effect at high 
concentrations as T2 effects dominate. Thus, in producing images, it is important to 
alter the applied magnetic field strength to provide either Ti or T2 weighted images. 
With paramagnetic ions and chelates, the majority of images are produced with 
positive enhancement Ti weighted scans 160,161,162,164
3.2.3 Ferromagnetism
Ferromagnets are permanent magnets. This is due to a property of a group of atoms 
or molecules in a solid crystal rather than of a single ion. When an external field is 
applied, the molecules arrange to produce a magnet which remains even when the 
field is removed. However, if the size of a multidomain ferromagnet is reduced to less 
than 350 A, a single domain particle can be formed. These particles have slightly 
different properties, although they are rapidly magnetised in an external field like 
ferromagnets, when the field is removed they behave as paramagnets and do not retain 
the induced magnetism. These particles are known as superparamagnets. The most 
commonly used superparamagnetic contrast agent is based on small particles of 
magnetite, a naturally occurring iron oxide Fe3C>4 . Superparamagnetics, unlike 
paramagnetics, have a monophasic action on relaxation times. Thus Ti relaxation 
times are barely affected by the administration of a superparamagnet but T2 is greatly 
increased allowing negative enhancement images 164
Thus it is possible to design contrast enhancement agents for the imaging of disease 
states by altering the magnetic environment in particular tissues. Initially, free
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paramagnetic ions were used to produce this effect but these have now been 
developed further, with the production of metal chelates and the use of 
pharmaceutical delivery forms, to achieve excellent organ specific imaging.
3.3 Metal Ions
As early as 1948, paramagnetic ions, such as Fe3+ in ferric nitrate, were used to 
enhance the relaxivity of water protons 160 This phenomenon was exploited in gastro­
intestinal imaging, but the free ferric ions caused irritation of the gastro-intestinal 
tract. Further studies using Mn2+ enabled the imaging of myocardium in dogs. This 
cation localises in healthy myocardium but cannot be taken up into infarcted regions. 
Thus imaging of infarction was possible. These studies showed that the degree of 
relaxation enhancement was directly proportional to the concentration of 
paramagnetic ion in the organ. Although these results were promising, the free 
paramagnetic Mn2+ ion is highly toxic so cannot be used in MRI. It is taken up by 
calcium transport mechanisms in the body, resulting in cardiovascular toxicity 162
3.4 Metal Complexes
Complexes of paramagnetic ions with co-ordinate ligands have been widely tested as 
contrast enhancement agents. Although the relaxivity of most of these complexes is 
reduced in comparison to the free ion, owing to decreased inner sphere binding of 
water, the toxicity of the paramagnetic ion is also reduced. Thus a larger dose can be 
given overcoming the reduced relaxivity162. The main paramagnetic ions used in these 
systems are Gd3+, Mn2+ and Fe3+ although chromium EDTA complexes were used in 
initial studies 165,166,167,168. Both cyclic and acyclic ligands have been developed, 
although at present only one compound, an acyclic compound, is in general clinical 
use.
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3 .4.1 Acyclic Ligands
The original acyclic ligands were developed from EDTA. E D TA  has been used since 
the early 1950s as a detoxifying agent for iron overload. Since then, it has been shown  
that modification o f  the ligand structure can result in enhanced contrast in a variety o f  
tissues and coupling to targeting moieties can achieve cell line targeting162.
3.4.1.1 G d-DTPA
The dimeglume salt o f  G d-D TPA  (Figure 3 .1) has been used in the clinic for over ten 
years in the imaging o f  brain and spinal tumours M odel studies in rats 169 
demonstrated the potential o f  contrast enhancement imaging o f  radiation damage in 
the brain. These studies were rapidly advanced into human trials, where cerebral 
tumours were more accurately contrasted with oedem a and normal tissue using the
conjugate 170




Figure 3 .1 : DTPA
G d-DTPA exerts its effect in an extracellular manner and undergoes rapid renal 
clearance, it is therefore a useful contrast enhancement for the assessment o f  renal 
function. In studies in rats 169, enhancement o f  the kidney parenchyma w as achieved  
five minutes post injection and w as retained for over 90 minutes. The com plex has 
also been used in angiographic studies 171172j to  determine neurological conditions, 
vascular occlusion and atherosclerotic disease. Imaging o f  small vessels not seen  
without a contrast agent w as possible with Gd-DTPA.
Despite these promising results, G d-D TPA  is not a universal contrast agent for all 
disease states. Imaging o f  liver disease and tumours is not possible due to rapid
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exchange between the normal and diseased tissue leading to the entire region showing 
enhanced contrast173.
Targeting of a DTP A complex has however been achieved, with a radioactive chelate, 
to malignant melanoma. Two DTPA U1ln chelates were conjugated to MSH. This 
allowed targeting to the a-MSH receptors on malignant cells and gave excellent 
radiographic imaging. This technology could be easily transferred to the delivery of 
paramagnetic ions 174. Phosphonate chelates of Gd3+ have also been prepared to 
enable targeting to myocardial cells 172.
Gd-DTPA is of low toxicity. A small amount of demetallation does occur but is not
162significant and the complex is extremely safe in the normal dosage range 
However, the charged complex becomes more toxic at higher doses owing to 
increased osmolality. More recently, non-ionic complexes derived from DTPA have 
been prepared. These have comparable molar relaxivities to Gd-DTPA but reduced 
osmolality and hence can be used over a larger dosage range 175. The most commonly 
used derivative is Gd-DTPA bis(methylamide) or Gadodiamide injection 176.
34.1.2 Mn-DPDP
As Gd-DTPA cannot be used successfully in the imaging of liver carcinoma, many 
attempts have been made to prepare similar chelates which are in some way targeted 
to the liver. Manganese (II) N,N,-dipyridoxalethylenediamine-N,N,-diacetate-5,5’- 
bis(phosphate) (Mn-DPDP) (Figure 3.2) is designed to be targeted to hepatocytes 
through the pyridoxal-5’-phosphate moieties. This co-enzyme is taken up by a 
membrane transport system in hepatocytes as is the chelate 177. It is therefore possible 
to distinguish between functioning and non-functioning hepatocytes, that is, between 
normal and diseased tissues 178’179 Thus, negative contrast enhancement is achieved, 
the normal cells showing hyperintense relative to the diseased cells.
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In healthy subjects, enhancement o f  liver parenchyma was achieved after one minute 
and persisted for 30 minutes. Bile imaging was also possible after 15 minutes due to 
hepatobiliary excretion o f  the chelate 180 Few side effects were seen with this 
compound, although the majority o f  subjects did experience facial flushing
Pre-clinical studies in tumour bearing rats 177 demonstrated a small accumulation o f  
the chelate in the liver and initial images gave no contrast between normal and tumour 
tissue. After 30 minutes however, there is enhanced tumour to liver ratio, presumably 
due to decreased excretion from the tumour cells. Obviously, the degree o f  uptake o f  
the chelate by diseased cells depends on the level o f  normal hepatocyte function 
retained. Thus it is possible to  achieve differential diagnosis o f  liver tumours 178 ,81 
M etastatic liver disease and well-differentiated tumours have no uptake and thus are 
easily negatively imaged, whereas non differentiated tumours can only be visualised by 




Figure 3 .2 : DPDP
3.4 1.3 G d-BO PTA
N ew  ligands for gadolinium have also been prepared to allow liver targeting. Gd- 
BO PTA is a derivative o f  D TPA  with a benzyloxymethyl group in the backbone 
(Figure 3.3). It is intended that this should be taken up by the anionic hepatocyte 
receptor which takes up brom osulphophthalein162. This com plex has a high 
proportion o f  biliary excretion and is accumulated in liver in rats, in which organ 
normal cells can easily be imaged 173 This leads to  negative imaging o f  tumours 182’183.
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Figure 3.3 : BO PTA
3.4 .1 .4  Fe-EH PG
A  lipophilic chelate o f  iron has been produced (Figure 3 .4) 184 This is designed to be 
taken up into rat liver cells through non specific hydrophobic interactions. G ood  
localisation in the liver and bile was achieved. H ow ever, this chelate has lower 
relaxivity than other chelates and large doses are required; this is a problem as some 
toxicity has been seen 162. Studies in mice demonstrated increased signal intensity o f  
both the liver and bile in healthy animals and enhanced visualisation o f  intrahepatic 
implanted tumours and a metastatic model 185. Increasing the lipophilicity can lead to  
decreased liver uptake as the chelate binds to serum proteins, therefore, the chloro 









In the search for even more effective chelates, macrocyclic ligands have been  
produced. Although these com plexes take up paramagnetic ions slowly, they exhibit 
increased stability once the ion is bound and hence reduced risk o f  toxicity due to  
leaching. The major ligand that has been evaluated is G d-DO TA 186 (gadolinium  
tetraazacyclododecanotetraacetic acid) (Figure 3.5). This com plex has similar 
relaxivity to G d-D TPA  and similar biodistibution but is less toxic 187 188 it is also has a 
more enhanced relaxivity at low  field strengths due to the effect o f  symmetry on the 
electron relaxation time.
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Figure 3.5 DO TA
A s with D TPA, non ionic com plexes have been made such as D 0 3 A  162. 
Azaphosphonic acid derivatives have also been produced which can be either anionic, 
cationic or neutral and suitably functionalised for the attachment o f  targeting 
m oieties 161 These com plexes (Figure 3.6) are targeted to the liver and bile. 
Radiolabelled Gd com plexes o f  the tetraphosphonate (74) have been shown to  clear 
more slow ly from tumour tissue than normal tissue allowing a degree o f  specificity 161.
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Tumour targeting has also been achieved with indium-labelled NO T A  complexes. 
These com pounds accumulate in some skin cancers. H ow ever, N O T A  is not a good
Cu(II) have also been produced (Figure 3.7). Mn (III) cyclam is a highly stable 
com plex with comparable relaxivity to G d-DTPA and localises as efficiently as 
Fe-EHPG in the liver 189
3 .4.2.2 Metalloporphyrins
Metalloporphyrins are endogenous metal-binding ligands Although they are o f  
com plex chemical structure, they are o f  increasing interest owing to selective uptake 
by som e tumours 162 The selective uptake o f  porphyrins into tumour cells w as first 
noted in the 1920s. M ore recently, this property has been exploited in photodynamic 
therapy 190 Som e derivatives o f  haematoporphyrin can be localised to tumours and 
act as photosensitisers for conversion o f  triplet oxygen to cytotoxic singlet oxygen.
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Incorporation o f  a paramagnetic ion into a porphyrin could, therefore, result in a 
higher tumour concentration o f  a contrast agent. Accumulation o f  metal-bearing 
polymers in tumour cells has been demonstrated by many workers, although some 
have suggested that the tumour selectivity o f  porphyrins can be reduced by 
metallation. The mechanism by which tumour selectivity occurs remains unknown 191. 
It has been suggested that the porphyrin could be trapped in cells by enzymic 
alteration or be compartmentalised into specific regions in the cell. Alternatively, it is 
possible that the porphyrin binds to proteins or fibrous tissue, or is taken up into cells




Figure 3 7 :  N O TA
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by specific transport mechanisms. Studies on the retention of both TPPS and Mn- 
TPPS in human breast cancer cell lines confirmed that the most likely mechanism is 
selective uptake via a porter for TPPS 191.
Although porphyrins can chelate numerous metal ions, the most useful in terms of 
imaging is manganese. Gadolinium is too large an ion to form a stable complex so is 
easily leached and iron loses its paramagnetism at pH>6 when chelated into 
porphyrins 162. Manganese fits easily into the porphyrin and these complexes have 
surprisingly high relaxivities of over 10 mM‘1s'1. Although direct comparisons cannot 
be made with Mn (HI) ions as they are unstable in the circulation, this relaxivity is 
three times higher than that of MnCl2. It has been suggested that the increased 
relaxivity is due to closer interactions between the paramagnetic ion and the water 
protons or to symmetry effects 160
3.4.2.2.1 Mn-TPPS
The water-soluble tetraphenylporphyrin derivative TPPS (Figure 3.8) has been most 
widely evaluated as a paramagnetic chelating ligand. Studies in tumour-bearing 
mice 192>193’194’195’196’197 demonstrated increased uptake of the chelates into 
lymphomas, fibrosarcomas, colon carcinomas and breast cancer. In all cases, 
accumulation is seen almost immediately in the tumour; however, the best tumour : 
normal tissue ratios are achieved after approximately 48 hours when the complex has 
been excreted from normal tissues. This complex has also been used in imaging brain 
glioma m . Unlike Gd-DTPA, which perfuses out of the tumour, the porphyrin 
appears to bind tightly to the tumour cells resulting in enhancement of the tumour 
image for more than 4 days. The porphyrin complex is also highly efficient in 
distinguishing tumour from normal tissue and oedema. In this situation, it has been 
proposed that the selective uptake is through peripheral benzodiazepine receptors. 
These receptors are abundant in tumour cells but not in normal cells. The versatility of 
porphyrins suggests that there is potential, through chemical modification, of 




3 .4.2 2.2 Mn-Mesoporphyrin, Mn-Protoporphyrin IX and Mn-Haematoporphyrin
Although M n(III)TPPS can be used successfully in many situations, contrast 
enhancement betw een the organ and tumour in the liver is not achieved. This is 
probably due to  the rapid excretion o f  the com plex through the kidney and urine 199. 
Therefore, researchers have developed other synthetic porphyrins which are lipid 
soluble, in the hope that these will be excreted through the liver and bile and hence 
improve imaging o f  the liver. In a study comparing Mn-Mesoporphyrin (Figure 3.9) 
and M n-TPPS, no enhancement o f  liver tissue image w as seen with Mn-TPPS. With 
mesoporphyrin, there was significant enhancement o f  the signal intensity o f  normal 
liver parenchyma enabling contrast-enhanced images o f  both liver abscesses and 
metastatic disease within one hour. It was proposed, from radioactivity studies, that 
the mesoporphyrin derivative is taken up directly by the hepatocytes where 






Figure 3 .9 : Mesoporphyrin
Similar results have been obtained with Mn(III) haematoporphyrin. H owever, this 








Figure 3.10 : Haematoporphyrin
Mn-Protoporphyrin IX is also targeted towards the liver in rat biodistribution studies. 
H owever, although it is a very stable com plex, it has relatively low  relaxivity and is 







Figure 3 .11:  Protoporphyrin IX
M n-M esoporphyrin has also been used in the imaging o f  rat glioma models. Increased 
enhancement o f  the tumour tissue image was achieved allowing the tumour to be 
distinguished from oedema and normal tissue. As with TPPS, the enhancement was 
prolonged in comparison to G d-DTPA 184 One added advantage o f  using lipid soluble 
porphyrins is their lack o f  photosensitisation. With M n-TPPS, test animals experience 
both pigmentation o f  the skin and photosensitivity, with Mn-mesoporphyrin, these 
effects are not seen 199
3.4.2.2.3 Gd-Porphyrins
As has been mentioned, the gadolinium ion is too  large to form a stable com plex with 
the porphyrin skeleton. However, as the relaxivity o f  Gd3+ is higher there have been 
attempts to  exploit the targeting properties o f  porphyrins to  deliver Gd complexes. 
Recently, Hindre e t a l  201 developed a conjugate o f  G d-D TPA with a non-metallated 
tetraphenylporphyrin derivative The relaxivity o f  this conjugate in  vitro  was greater 
than that o f  G d-DTPA, probably owing to the increased size and hence increased 
correlation time Enhanced images o f  human adenocarcinoma implanted into mice 
were achieved after 24 hours, demonstrating an increased tumour uptake o f  the Gd 
ions due to  the tumour specificity o f  porphyrins. Similar results have been reported by 
Nakajima e t a l  202.
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An alternative approach is the use o f  modified porphyrins, known as texaphyrins, in 
which there is an expanded central region that contains five rather than four nitrogen 





3 .4.2.2.4 Indium Porphyrins
Recently a new class o f  metalated cationic porphyrins has been evaluated for targeting 
to malignant melanoma (Figure 3.13 ) 203 Although these porphyrins contained  
radioactive 1HIn, the results provide information on the potential o f  targeting 
paramagnetic ions to one o f  the most diffuse metastatic cancers. These com plexes 
gave excellent tumour localisation and tumour : blood ratios which were retained for 
over 72 hours. Interestingly, it w as also possible to see where the porphyrin localised  
within the tumour. In this case, localisation was seen in the outer growing region  







3.5 M acrom olecules
Proton relaxation enhancement can be achieved by the direct complexation o f  a 
paramagnetic ion to a macromolecule or through the attachment o f  a metal chelator to  
a macromolecule. The enhancement is due to an increase in the molar relaxivity o f  the 
complex. This effect is caused by the slow  rotation o f  the paramagnetic ion which 
leads to an increased correlation time. The degree o f  effect depends upon the rigidity 
o f  the macromolecule and its tertiary structure. Relaxivities are higher when the 
paramagnetic ion is com plexed with rigid globular protein m olecules than with more 
flexible synthetic poly(amino acids). The effect o f  the increased correlation time is 
highest at higher field strengths where there is a large increase in relaxivity 160
Both non-covalent and covalent com plexes can be prepared. Non-covalent 
com plexes, which result from a combination o f  electrostatic, van der Waals, hydrogen 
bonding and hydrophobic interactions, are more stable, through the action o f  many 
functional groups on the polymer, and exhibit higher relaxivities. In this situation, the 
metal is in equilibrium with metal in the bulk solution. On the other hand, although 
covalent attachments are attractive due to ease o f  characterisation, proteolytic
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degradation within lysosomes can lead to release of the paramagnetic ion or chelator 
resulting in toxicity 160.
Complexation of a paramagnetic ion to a macromolecule has many advantages. 
Multiple paramagnetic ions can be attached to one large carrier molecule, therefore 
the molar dose of imaging agent can be reduced and hence toxicity can be reduced. 
More importantly, the macromolecular bound agents can be used to image the blood 
pool and hence situations where vascular integrity is lost such as in tumours and 
inflamed tissue 204.
3.5.1 Non-covalent complexes
Direct complexation of Gd and Mn to proteins such as concovalin A and bovine 
serum albumin result in enhanced molar relaxivities 160 The synthetic polymer, 
poly(aspartic acid), has also been used to chelate Gd3+ ions directly. Increased 
relaxivities were demonstrated with chelates bearing below 40 ions; above this level 
the relaxivity is reduced. This is probably due to interactions between the chelated 
ions 205. Paramagnetic chelates can also be bound non-covalently to albumin. The 
hepatobiliary contrast agent Fe-EHPG has been successfully bound to albumin leading 
to a 2-3 times increase in relaxivity. The binding affinity can be enhanced by 
increasing the lipophilicity of the chelate 160
3.5.2 Covalent Complexes
3.5.2.1 Albumin
Considerably more interest has been directed towards the development of covalent 
macromolecular chelate complexes. Albumin is retained within the vascular space 
after intravascular injection. Conjugates of albumin Gd-DTPA have been used in 
studies in both rats and rabbits for imaging myocardial ischaemia 206’207. in normal
208 209rats, attachment of the chelate to albumin results in better imaging of the heart,
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liver and brain at very low doses. Subcutaneous tissue and muscle are not enhanced, 
unlike with free Gd-DTPA. In this study, 16 chelates were attached to each albumin 
molecule and a threefold increase in relaxivity of the chelate was achieved on binding. 
Albumin is a natural polymer with high dispersity. It may be immunogenic and exhibits 
cardiovascular toxicity; thus other macromolecules have also been evaluated.
3.5.2.2. Dextran
Dextran, is available in a variety of sizes, has low toxicity and can be prepared to 
contain a biodegradable bond to ensure elimination of bound chelates. Chelation of 
Gd-DTPA to dextran leads to a large increase in relaxivity which is dependent on the 
number of chelates bound210,21 \  The chelates are successful in enhancing the imaging 
of the blood pool in rats, but are not as efficient as albumin chelates. This could be 
due to the larger molecular weight of albumin or to the higher permeability of the 
capillaries to dextran. Incorporation of a biodegradable bond enabled both superior 
imaging and excretion of the chelate in comparison to the free chelate 21 \  
Interestingly, with a large increase in the molecular weight of dextran, relaxivity is 
decreased. This is thought to be due to displacement of the bound water molecules, 
from the chelate, by neighbouring hydroxyl groups due to the polymer wrapping 
around itself212.
3.5.2.3 Poly(Amino acids)
Synthetic poly(amino acids) have also been used for the formation of Gd-DTPA 
complexes. Poly(Lys)-Gd-DTPA allows enhanced images of the blood pool, 
pulmonary disease, such as oedema and embolisms, and the heart 209,213,214 Mn (HI) 
porphyrins have also been conjugated to poly(amino acids). Cross-linked polymers 
were produced through the coupling of protoporphyrin IX to a range of amino acids, 
poly(Glu) derivatised with lysine, poly(Lys), poly(Lys-co-Phe) and poly(Lys-co- 
Ala)215. All these conjugates exhibited higher relaxivities than the free porphyrin, this 
may be due to decreased porphyrin aggregation, as well as the increased rotational 
correlation time 216. Highest binding of the porphyrin was achieved with the
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poly(Glu)-based polymer, possibly owing to the incorporation of a long spacer unit. 
However, if the loading factor becomes too high, relaxivity enhancement may be lost 
due to interactions between the bound chelates. Attempts by these workers to 
produce a linear polymer, using a monofunctionalised porphyrin, resulted in an 
insoluble polymer217
3.5.2.4 Poly(ethylene glycol)
Poly(ethylene glycol) has also been used to change the relaxivity and toxicity of
paramagnetic chelates. Desferrioxamine is an effective iron chelator but can lead to
hypotensive effects on administration. A non-ionic PEG derivative has been prepared
which was non toxic and allowed enhanced imaging of the kidney and liver in dogs 
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More recently, Gd-DTPA has been attached to PEG. With polymers of MW above 
20,000 Da increased contrast enhancement of the blood pool and tumours was 
observed219.
3.5.2.5 Dendrimers
Recently it has been suggested that dendrimers or cascade polymers would be more 
effective relaxation enhancers, owing to their high rigidity and potential for binding a 
large number of ions. The first branched polymers used were based on 
polyethyleneimmine, which can directly chelate paramagnetic ions 22°. However, 
dendrimers based on Starburst ® have also been evaluated. Monodispersed chelates 
could be produced with varying numbers of chelating ligands, depending on the cycle 
of polymerisation, allowing between 11 and 170 Gd ions to be bound to the DTPA- 
dendrimer. The relaxivity of the macromolecule with 170 Gd ions bound was 
equivalent to that produced by 1074 free Gd-DTPA molecules and was over ten times 
greater than that achieved with linear polymers. Interestingly, no mass effect is seen 
with these macromolecules; increasing the mass does not lead to a decrease in 
relaxivity212 The wide variety of molecular sizes available with this system leads to a
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diverse set of applications, small complexes can be used for extravascular imaging of 
tumours and brain, whereas large complexes can be used for the imaging of 
vasculature.
3.6 Particulates
Imaging of small lesions in liver and spleen is difficult to achieve using magnetic 
resonance imaging. Although images can be enhanced using Gd-DTPA, the 
enhancement is transitory due to the fast blood and urinary clearance of the chelate 
and the lack of an active uptake mechanism 221. This can be overcome by the use of 
higher doses; however, higher and potentially unacceptable toxicity will ensue.
3.6.1 Liposomes
An alternative approach is to use either particles or liposomes containing 
paramagnetic ions or chelates. Liposomes, due to their size, are retained in 
vasculature for a prolonged time period and are removed from the circulation either 
within the lung or by the action of phagocytic cells of the reticulo-endothelial system. 
In the normal liver, liposomes can be taken up by the Kupffer cells or, if very small, 
can be taken up by hepatocytes. Hepatic tumours lack phagocytic cells and therefore 
cannot take up liposomes 222. Therefore, by preparing liposomes containing contrast 
enhancement agents, the normal tissue image can be enhanced relative to that of the 
tumour and a negative image of the tumour can be obtained.
There are three approaches to the incorporation of contrast enhancement agents into 
liposomes. Firstly, a water soluble chelate, such as Gd-DTPA, can be incorporated 
into the aqueous core of the liposome. Secondly, a lipid-soluble chelate can be 
incorporated into the pre-formed lipid bilayer. Finally, the chelate can be modified to 
prepare ampipathic derivatives which can be used, along with other lipids to form the 
bilayer 222.
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3.6.1.1 Chelates in Aqueous Core
Liposomes have been prepared in which Gd-DTPA is enclosed within the aqueous 
core 223,224,225. These liposomes have been tested for their relaxivity in vitro, and 
stability in serum and saline. Liposomes were prepared in a variety of sizes between 
50 and 400nm in diameter from egg phosphatidyl choline (EPC) 224 The relaxivity of 
the paramagnetic ion in liposomes was less than for free paramagnetic chelates and 
was highest in the smallest liposomes, which have the largest surface area : volume 
ratio. It has been postulated that relaxivity of a chelate-containing liposome is directly 
proportional to the flux of water molecules across the liposomal membrane which is 
itself related to the surface area : volume ratio. The loss of image intensity due to 
decreased relaxivity can be overcome if the agent becomes concentrated in the desired 
region. With small Gd-DTPA liposomes there is increased uptake into the liver, 
vascular space and bone marrow and the body clearance is increased to 3.5 days in 
mice. This distribution allows imaging of small hepatic metastases with dose as low as 
0.025 mmol/kg of liposome 224.
Acute and sub-acute toxicity tests have also been performed. The acute toxicity of the 
liposomal preparation is not dissimilar to that of standard chelates. However, on 
continued administration, the mice treated with the liposomes demonstrated both 
enlarged livers and spleens. It has been suggested that this effect may not be seen if 
liposomes containing Gd-DOTA, where the ion is bound more tightly, are used 224.
3.6.1.2 Chelates in Lipid Bilayer
The main disadvantage with entrapping the chelate within the aqueous core is the 
reduced relaxivity. If the paramagnetic ion could be presented to the desired cells on 
the surface of liposomes this could be overcome. Thus, a second type of liposome has 
been prepared in which the chelating ligand is derivatised to be lipid-like, allowing it 
to be incorporated into the lipid bilayer 226. The amphipathic chelate Gd-DTPA-SA 
was prepared and mixed with EPC and cholesterol to form liposomes. Maximal 
relaxivity was seen with a 33.3% incorporation of the modified ligand; in studies in
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vitro, the relaxivity of spleen and liver was increased by 110% and 66% respectively. 
Biodistribution was also evaluated, the liposomes rapidly clearing from the blood and 
accumulating in liver and spleen from which they are cleared after 11 days. No 
toxicity was seen. Following .on from this work 7X1, a second ampipathic ligand has 
been prepared which would allow more rapid clearance from the liver. Thus the ligand 
was bound to the lipid via a stearyl ester (SE) group rather than through a stearyl 
amide (SA) group. With a 33.3% incorporation comparable Ti signal enhancement 
was observed as with Gd-DTPA-SA. However although the liposomes clear as 
rapidly from the blood and accumulate in the liver, after 2 days 50% of the liposomes 
are cleared. In a further study 228, liposomes were prepared containing the derivatised 
ligand DTPA-SA, in a variety of concentrations. Gd3+, Mn2+ and Fe3+ were then 
incorporated into the chelate and the liposomes were evaluated. The Fe3+ liposomes 
were unstable on formation and could not be evaluated. The Mn2+ liposomes were 
unstable in serum; however, they accumulated rapidly in the liver and were excreted 
rapidly, allowing good quality images to be obtained. The Gd3+ liposomes, in contrast, 
were stable in plasma, were accumulated rapidly into the liver and were retained, 
allowing images to be obtained even after 24 hours.
Thus, liposomes are highly attractive for specific delivery to the liver and spleen. 
Incorporation of the ligand in either part of the liposome allows enhanced images with 
lower doses of paramagnetic ions. It has been suggested that this technology could be 
further exploited. Liposomes can be diverted from the reticulo-endothelial system by 
using large doses or very small vesicles or by ‘blocking’ the phagocytic cells by pre­
treatment with empty liposomes. These alterations would allow blood pool imaging. 
Alternatively, targeting moieties could be incorporated into the lipid bilayer to allow 
cell specific targeting 162.
3.6.2 Particles
It has also been suggested that particles can be used for the carrying of chelates. In a 
study of cross-linked starch microspheres incorporating DTPA, a variety of 
paramagnetic ions were coupled and exhibited increased relaxivity over simple
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chelates. The increase in relaxivity is possibly due to the swelling o f  the microsphere 
in water, allowing passage o f  water protons close to the paramagnetic ions 229 
M icrospheres offer potential as contrast enhancement agent carriers and deserve 
further evaluation.
3 .7 M olecular Oxygen and Nitrogen Stable Free Radicals
Other paramagnetic species, apart from metallic ions, have been evaluated as contrast 
agents 162
Molecular triplet oxygen has been used in MRI o f  the lung through inhalation. In 
these studies, signal enhancement is seen in the left oxygenated lung in comparison to  
the right lung. H owever, this alteration is insufficient to  warrant further 
investigation 230.
A more promising approach, utilising paramagnetic m olecules, is the use o f  stable free 
radicals or ‘spin labels’, particularly nitroxyl stable free radicals. Nitroxyls are labile to  
redox reactions; steric protection confers stability. Thus the moiety is relatively 
unreactive in m ost conditions and remains stable even when heated above 100°C and 





Figure 3 .14:  Piperidine Nitroxyl Stable Free Radical
These com pounds provide strong relaxation enhancement because o f  electron  
paramagnetism that is comparable to Cu2+ or Fe3+ paramagnetic ions. They produce 
decreases in both Ti and T2. H owever, these compounds offer one major advantage
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over other paramagnetics. They can be chemically modified through the R group or 
attached to targeting molecules or biomolecules to allow selectivity of action. 
Previously, these compounds have been successfully attached to drugs such as 
propranolol and steroids to study drug metabolism 230.
Nitrogen stable free radicals have mainly been used as spin probes to study 
biochemical systems using electron spin resonance spectroscopy. These studies 
demonstrate that the compounds persist for a prolonged period in biological tissues 
without electron pairing or reduction taking place by the formation of 
hydroxylamines231. They have been mainly used in MRI to asses renal function and 
identify renal abnormalities. In an early study 231, the compound TES (N-succinyl-4- 
amino-2,2,6,6-tetramethylpiperidine-l-oxyl) was used to image the kidney and asses 
renal function in animals with renal ischaemia, congestion or atrophy. The free radical 
is rapidly excreted in urine with a clearance rate equal to the glomerular filtration rate. 
This allows a transient increase in signal intensity in the kidney thus enabling increased 
determination of renal abnormalities.
Nitrogen stable free radicals have not been widely used in MRI, as little advantage is 
obtained over simple paramagnetic chelates. However, one interesting use of nitrogen 
stable free radicals is in the imaging of hypoxic tumours. These compounds can be 
used as probes of oxygen concentration, as in low oxygen reducing environments such 
as in hypoxia, the compound is reduced and the signal enhancement is lost. 230
3.8 Superparamagnetic particles
Small ferrite particles have superparamagnetic properties, that is, they are easily 
magnetised to a high magnetic moment but the magnetism is lost once the external 
magnetic field is removed 164. An example of a ferrite particle is magnetite, a natural 
compound Fe3 0 4 , found in many living organisms, which is often found in 
combination with maghaematite and haematite Fe2 0 3  164. Superparamagnetic particles 
exert effects on both Ti and T2, but the effect on T2 outweighs all other effects 
leading to a loss of signal in the affected organs 162. Magnetite particles are
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administered as polymer coated particles to allow the formation of aqueous solutions, 
and alter particle size. Although both starch and albumin have been used, the majority 
of studies have been performed on AMI-25, a commercial product, in which the iron 
oxide is coated in dextran 162.
3.8.1 Dextran-Coated Particles
Initially, studies were carried out using relatively large particles designed to be 
captured by the cells of the reticulo-endothelial system allowing imaging of the liver 
and spleen ’ . AMI-25 has been used in clinical trials for the diagnosis of liver 
cancer 234,235, cerebral vasculature 236 and cardiovascular imaging 237. Studies 235 in 15 
patients with known liver cancers demonstrated hyperintense imaging of these lesions. 
Normal liver cells, i.e. Kupffer cells, take up the particles by phagocytosis and there is 
a loss of signal in these cells and the surrounding hepatocytes giving a negative image 
of the liver. Abnormal cells loose the ability to phagocytose, so do not take up the 
contrast agent and thus appear hyperintense on the image. Although 90% of the 
particles were cleared by the liver in 1 hour, some remain circulating allowing imaging 
of other systems, particularly the heart 237 and brain 238. Clearance from the liver is 
demonstrated in humans within 24 hours of treatment 235. The breakdown of the 
particle does not lead to abnormalities or toxic effects as iron is a major constituent of 
the body.
3.8.2 Albumin Microspheres
Studies with microspheres, in which magnetite is imbedded in an albumin matrix, have 
also demonstrated enhanced imaging of hepatic tumour models in rabbits. These are 
slightly larger particles (1-5 pm) but they are still efficiently taken up by the reticulo 
endothelial system and are rapidly cleared from the blood stream. There is long term 
retention of these microspheres. However, no toxicity or immunogenicity has been 
demonstrated; after 2 months there is no evidence of hepatocellular damage or 
fibrosis239
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3.8.3 Ultrasmall Dextran Particles
Ultrasmall dextran-magnetite particles have also been developed by particle-size 
sorting of AMI-25. In normal rats, 240 over 24 hours, accumulation was higher in the 
lymph nodes, bone marrow, liver and spleen and the blood half-life was increased 
from 6 minutes for AMI-25 to 81 minutes. These particles are small enough to 
transmigrate through capillaries and thus are taken up by the lymphatics. Without 
contrast enhancement, there is a considerable overlap in the relaxivities of both normal 
and metastatic lymph tissue. However, on administration of ultrasmall particles, 
metastatic lymph tissue is visualised as hyperintense regions, in comparison to normal 
tissue, as it cannot phagocytose241.
With these developments, have come further approaches to targeting, away from the 
reticulo-endothelial system. One approach is the ferrosome, this is a small vesicle that 
contains superparamagnetic particles in the central aqueous compartment. These have 
been evaluated in the imaging of lymph nodes, pulmonary emboli, adenocarcinomas 
and hepatomas. In tumour tissue, they are taken up by the macrophages located at the 
surface of the tumour giving a rim of low signal intensity. Alternatively, the 
superparamagnetic particles can be coated in polymers with intrinsic targeting 
properties. Particles coated with arabinogalactose can be targeted to hepatocytes via 
the asialoglycoprotein. This achieves imaging of the liver with reduced doses in 
comparison to targeting to Kupffer cells 162
3.9 Conclusion
Many contrast enhancement agents have been developed for MRI. The majority are 
based on the relaxation properties of paramagnetic ions. Complexation or 
conjugation, of paramagnetic ions or small chelates of paramagnetic ions, to 
macromolecules results in an enhanced relaxivity. Thus images with greater contrast 
can be produced. This coupled with the passive targeting of macromolecules to 




As can be seen from the preceding chapters, the concept of macromolecular pro-drugs 
has been widely investigated, particularly in the treatment of cancer. The technology is 
also suitable for the preparation of macromolecular contrast enhancement agents. 
These are particularly interesting; binding of the agent to a macromolecule not only 
increases the relaxivity of the conjugate and, hence, the contrast enhancement but also 
allows accumulation in the tumour to be imaged, due to the EPR effect.
In this thesis, work is presented on the development of a new series of polymers 
suitable both for use in macromolecular pro-drugs and macromolecular contrast 
agents.
The main disadvantage with previously used synthetic polymers, such as HPMA, has 
been their lack of degradability in vivo. This limits their use in pro-drugs to conjugates 
that have a molecular weight lower than the renal filtration threshold, i.e. to 
conjugates that can be excreted. This may, however, reduce the effectiveness of the 
conjugates by limiting the extent of accumulation of the macromolecule in a tumour, a 
size dependent process.
Thus, an ideal polymer would combine biodegradability of the backbone, to allow 
excretion, with the advantageous properties of synthetic polymers, such as water 
solubility, reduced immunogenicity, and low toxicity. An approach to this is to 
prepare a co-polymer of a synthetic polymer with a biodegradable unit. From the 
work of Duncan, Kopecek and Trouet, it is apparent that some small peptide 
sequences can show selective biodegradability in vivo. That is, they are degradable in 
lysosomes but not in the blood stream. If a polymer can be prepared incorporating 
such a sequence, it can be used as a high molecular weight pro-drug without fear of 
unwanted accumulation. High tumour tropism will be achieved; however, after
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delivery of the drug, through the endocytic pathway, the degradable unit would be 
cleaved in the lysosome to yield smaller oligomers which can be excreted.
To this end, this thesis examines the preparation of a co-polymer of poly(ethylene 
glycol) and a degradable unit for use in macromolecular conjugates. Ulbrich et a l78 
have prepared a number of degradable co-polymers of PEG in which the degradability 
is imparted by just one amino acid, Phe, and Yokoyama 153’154, a degradable co­
polymer of PEG and poly(aspartic acid). However, these polymers do not display 
selective biodegradability; thus it was proposed to incorporate the well-known 
sequence GlyPheLeuGly. This has proved selectively degradable in two situations; as 
a crosslink in HPMA and to link a drug to HPMA, however as yet it had not been 
evaluated as a in chain sequence.
However, as both PEG and the peptide unit have no side-chain functionality, a further 
unit must be incorporated into the co-polymer to allow attachment of a drug 
molecule. This can be achieved in many fashions; however, the peptide unit can be 
easily functionalised by the inclusion of a further amino acid to the peptide sequence. 
Many amino acids are suitable. Glutamic acid and lysine have been evaluated allowing 
the development of a number of coupling reactions.
Polymerisation of PEG and the peptide unit can be achieved in many ways. PEG can 
be modified to an a,©-bis-nucleophile, such as the a,©-di-amine, or to an a,©-bis- 
electrophile, such as the a,©-diglycidyl ether. The peptide unit can then be suitably 
prepared to provide suitable reactive termini for polymerisation. In this work, the 
synthetic strategy employed for the polymerisation is the reaction between an a,©- 
diglycidyl ether derivative of PEG and a,©-bis(secondary amino) peptide unit. The 
secondary amine is essential to avoid cross-linking or branching of the polymer. A 
secondary amine can be easily incorporated at the N-terminus of the peptide unit by 
extending the peptide chain further by inclusion of the amino acid sarcosine (N- 
methylglycine). To provide a secondary amine of similar reactivity at the C-terminus is 
more complex. A retro-inverso unit must be incorporated to change the sense of the
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peptide chain. This reveals an amine at the C-terminus which can be coupled with 
sarcosine to give the a,o-bis(secondary amine).
For preliminary evaluations, a conjugate suitable for evaluation as a macromolecular 
contrast agent was proposed. Unlike a drug molecule, which often has a number of 
functional groups, thus requiring protecting group strategies, contrast enhancement 
agents can be prepared which are monoftmctional. To this end monofunctional 
derivatives of tetraphenylporphyrin were chosen for attachment to the e-amine of 
lysine or the y-carboxylic acid of glutamic acid in the peptide unit. This can be used as 
a chelator of manganese (III) and similar derivatives have been previously used as 
contrast enhancers. To ensure reliable loading of the porphyrin onto the polymer, it 
was proposed to prepare peptide-porphyrin conjugates which could then be 
polymerised with PEG. Metal incorporation, however, would be a final step, due to 
difficulty of NMR analysis of metal-bearing compounds.
Drugs are often attached to macromolecules via spacer units. On the whole these are 
degradable to allow release of the drug in vivo and hence activity. With 
macromolecular contrast enhancement agents, however, the chelator is more effective 
when coupled to the macromolecule. Thus, in this work, a non-degradable spacer was 
incorporated between the porphyrin and peptide in a number of monomers.
Thus, the preparation of a monofunctionalised porphyrin suitable for attachment to 
both glutamic acid and lysine is presented in this thesis. The preparation of a number 
of potentially degradable peptide units is discussed; attachment of the porphyrin to the 
peptide monomers is also reported. Preliminary experiments on the polymerisation 





In order to prepare a linear polymer bearing a pendant porphyrin moiety, it was 
essential to synthesise a monofunctionalised porphyrin derivative. Most natural 
porphyrins, for example protoporphyrin IX, contain many functional groups suitable 
for attachment to polymers. However, because they are multi-fimctionalised, cross 
linked polymers are liable to be formed. Thus, a monofunctionalized synthetic 
porphyrin was required. The most simple monofunctional porphyrins are those with a 
meso alkyl substituent. These, however, are difficult to synthesise in high yields 244 
Mesotetraphenyl porphyrin (TPP) and its monofunctionalised derivatives are more 
easily synthesised and, as this type of porphyrin are known to localise in tumour 
cells 193, our work has been focused on the development of TPP derivatives.
The porphyrin is to be coupled to amino acids in the peptide sequence. Thus, it must 
be suitably functionalised to allow coupling to either amino or carboxylic acid side 
chains of amino acids. Therefore, either an carboxylic acid or amino derivative of TPP 
is required. As the porphyrin is being used as a model of a drug, it should be attached 
to the peptide via a spacer, although this does not need to be degradable in this 
situation.
5.2 Synthesis of Tetraphenylporphyrin
The unsubstituted porphine ring, the basis of all porphyrins, is difficult to synthesise. 
In addition to the desired product, chlorin rings can be formed. Although these can be 
easily oxidised to the porphine, yields of the porphine are still low. The main approach 
to the synthesis of porphyrins is via a condensation reaction between pyrrole and an
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aldehyde. In the case o f  porphine, this aldehyde is formaldehyde; for TPP, 
benzaldehyde.
Rothemund 242 reported the first synthesis o f  porphine (85) In this method,
condensation w as achieved by heating the reactants in a methanol / pyridine mixture. 
This was performed in sealed tubes and thus w as an anaerobic reaction. (Schem e
Using these conditions for the preparation o f  TPP, resulted in the formation o f  a large 
amount o f  chlorin 243 M odified reaction conditions, heating at 220°C  in pyridine, 
allowed enhanced preparation o f  TPP. However, even using this method, the yield o f  
porphyrin was less than 5% 243 (Schem e 5 .2). Addition o f  zinc acetate to the reaction 
mixture, as a template, resulted in slightly enhanced yields, 10% as the zinc 
porphyrin 244.
In 1967, Adler e t a l  245 presented an improved synthesis o f  TPP. In this method, 
pyrrole and benzaldehyde were heated for 30 minutes in refluxing propanoic acid. On















cooling, TPP crystallised from the solution and could be separated by filtration. U sing  
this approach, consistent yields o f  20% could be achieved. Even higher yields, 35- 
40% , could be achieved using acetic acid as the solvent 246. H ow ever the product does 
not crystallise from this solvent and thus is considerably more difficult to purify. Som e 
o f  the corresponding chlorin is also formed which can be easily removed by 
chromatography or sublimation 245 Alternatively it can be converted to the porphyrin 
by oxidation o f  




Num erous derivatives o f  TPP have been prepared by both the Adler and Rothemund 
approaches, including the tetrakis p a ra  chloro, p a ra  m ethoxy, p a ra  methyl and ortho  
and p a ra  nitro derivatives 244,246,247\
5 .3 Synthesis o f  mono-functionalised derivatives o f  TPP
There are several approaches to  the preparation o f  mono-functionalised porphyrins. 
Buchler e t a l  248 prepared mono-substituted porphyrin derivatives using a Vilsmeier 
formylation at a pyrrole P position.. More recently, Dolphin e t a l 249 have developed a
the crude material with 2,3 dichloro-5,6-dicyanobenzoquinone










mono functionalised porphyrin with an iodinated meso-position. This was suitable for 
the attachment of alkynes, including 17 a-ethynyltestosterone, via a Heck coupling.
The majority of mono-substituted porphyrins prepared have been based around 
substituents on meso-phenyl groups. Functionalised TPP can be prepared using two 
main methods, both based on condensation reactions, by modification of the Adler- 
Rothemund procedure or by the methods of Lindsey et al.
Both methods are based on a mixed condensation procedure. Functionality is 
incorporated into the macrocycle in the form of a modified benzaldehyde. A mixture 
of the functionalised benzaldehyde and benzaldehyde is treated with pyrrole. Thus, the 
ratios of aldehydes will determine the amount of mono functionalised porphyrin 
prepared. Using a 1 : 3 functionalised to unfimctionalised ratio, five main products 
will be formed. The majority product (42.2%) will theoretically be the mono 
substituted porphyrin. However, large quantities of both underivatized (31.6%) and 
disubstituted compound (21.1%) will also be prepared along with tri and tetrakis 
substituted derivatives. In the majority of cases, it is possible to separate the desired 
product from the side products by column chromatography with some difficulty.
5.3.1 Mono amino derivatives
In order to obtain the mono-amino derivative, the mono-nitro compound is first 
prepared and then reduced. Hasegawa 250 prepared the mono-nitro derivative, using a 
modification of the Adler-Rothemund procedure. Using this approach only an 
















Lindsey e t a l  have developed gentler conditions, in which condensation takes place at 
room  temperature, for the preparation o f  monofunctionalised porphyrins. In one 
approach, the aldehydes and pyrrole in chloroform are treated with BF3(OEt2) in 
ethanol in the absence o f  air. This co-catalysis results in the formation o f  a 







This is then oxidised, by treatment with DD Q  and O2, to  the desired porphyrin. In a 
slightly modified approach, condensation is initiated by the addition o f  trifluroacetic 
acid, and oxidation is achieved by treatment with /7-chloranil 251,252,253. In an 
alternative approach Lindsey e t a l  have prepared monoamino porphyrin (93) from the 




Evstegneeva e t a l  255 256 developed a modification o f  the Lindsey methods in the 
formation o f  m ono nitro porphyrin In this approach, the reactants are heated at reflux 
in a mixture o f  xylene and chloroacetic acid for one hour. After cooling, partial 
oxidation is achieved by the addition o f  DDQ  The resulting crude material is then 
applied to an alumina column, and eluted with xylene for 10 days. Whilst the product 
is on the column, further oxidation takes place to give the porphyrin These workers 
found difficulty in separating the mono functionalised porphyrin from tetraphenyl 
porphyrin, achieving a crude yield o f  21 %. (Schem e 5.6)
H CHO
(83) (8 6 ) (89)
Scheme 5.6
A completely different method for the preparation o f  mononitro TPP was reported by 
Kruper e t a l  in 1989 257 This involves direct functionalisation o f  TPP by fuming nitric 






conditions or sulphuric acid catalysis conditions, resulted in the nitration o f  the 
macrocycle, and the formation o f  5,15-dihydroxyporphodimethanes, rather than 
selective nitration o f  the phenyl 258. In this method both m ono, di and tri substituted 
derivatives could be prepared, by the slow  addition o f  fuming nitric acid to a solution  
o f  tetraphenylporphyrin in chloroform. Using this approach, yields o f  55% o f  the 
mononitro com pound could be achieved following chromatography (Schem e 5.7).
Fuming HNQ, 
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Reduction o f  the mononitro compound, to  the monoamine, w as achieved in all cases 
by treatment with tin (II) chloride in hydrochloric acid 250. The resulting amine w as 







5.3.2 M ono carboxylic acid derivatives
Carboxylic acid derivatives o f  porphyrins have been prepared in low  yields by both 
Adler-Rothemund and Lindsey methods 247. Lawley and Threadgill prepared a mono 
carboxyethoxy derivative o f  tetraphenylporphyrin using Lindsey conditions 
(Schem e 5.9). On a small scale, a yield o f  2.2%  w as achieved. H owever, attempts to  
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In order to couple a carboxylic acid derivative o f  tetraphenylporphyrin to a peptide, it 
must first be activated. Lindsey e t a l  252 have prepared a series o f  aldehydes, in which  
the carboxylic acid function is both activated and protected, by derivatisation to the 
N-hydroxysuccinimide or pentafluorophenyl ester These aldehydes are compatible 
with the conditions for mixed aldehyde condensation allowing the formation, in one 
step, o f  a derivatised and activated porphyrin (Schem e 5.10).
CHO
N-hy dro>y succininide






H owever, in this project, it was decided to prepare (4-aminophenyl)triphenylporphyrin 
(monoaminoporphyrin) This could be further derivatised, by incorporation o f  a 
spacer, to  provide a carboxylic acid function or an extended amino derivative 
Therefore, it would be possible to achieve coupling both to lysine residues and 
glutamic acid residues in the peptide.
Tetraphenylporphyrin was prepared using the Adler method on a large scale 
Consistent yields (19% ) o f  crude TPP were achieved using this method The crude 
crystals formed on cooling were not purified further.
Mononitration w as achieved using the method o f  Kruper e t a l  257. Chromatography 
enabled the isolation o f  both (4-nitrophenyl)triphenylporphyrin (mononitroporphyrin) 
and a di nitro derivative. The latter was formed in very low  yields. The mononitro 
compound w as successfully reduced (91% ) on treatment with tin (II) chloride in 
concentrated hydrochloric acid to give the desired amino porphyrin. For both  
reactions, increases in scale resulted in decreased percentage yields due to difficulties 
in chromatographic isolation
5 .4 Spacer Incorporation
Many methods have been developed to extend the fiinctionalisation o f  porphyrins. 
Collman e t a l  260 developed tw o techniques for the attachment o f  aliphatic spacers to  
the o/'Z/jo-amino-tetraphenylporphyrin. They found that standard approaches, using 
peptide chemistry techniques, such as direct DCC and active ester couplings, did not 
result in conjugate formation. Acyl chloride derivatives o f  the spacers can however be 









In an alternative approach, the spacer can be incorporated through urea linkages 260. 
The porphyrin amine can be activated, by phosgene, to the isocyanate, thus allowing 
easy coupling with amine spacers (Schem e 5.12).
Phosgene / CH2G2
(101)
] ^ N ( C H 2>jNH2
CH2G 2 / Pyridine
(102)
Scheme 5.12
Hunter and Sarson have also used acid chloride coupling procedures to provide a 
spacer between a porphyrin and pyridine 261
Aminomethylene chains can also be attached to a monoaminoporphyrin using a mixed 
anhydride method. Ding et a l  262 prepared a mixed anhydride o f  Boc-am inobutanoic 
acid with ethyl chloroformate. Coupling to the porphyrin amine was achieved in 80%  
yield (Schem e 5.13). Deprotection afforded an extended amino porphyrin derivative.






An interesting modification o f  monoamino tetraphenylporphyrin was developed by 
H asegawa et a l  250 263 in  this approach, acrylic or methacrylic acid chlorides were 
coupled with the porphyrin to form vinyl derivatives (Schem e 5.14). These derivatives 
w ere then polymerised, via a radical co-polymerisation, with styrene to give a number 
o f  porphyrin-containing polymers. Although, these polymers were developed as 
artificial oxygen carriers, they could be evaluated as relaxation enhancers in MRI.
y~ NHCQCH- CH2
(105)
Schem e 5 .14
5 .5 Synthesis o f  Spacer Derivatives
It was intended to incorporate an aliphatic spacer, o f  between 2 and 5 methylene 
units, onto the porphyrin Initially, the aminoporphyrin w as treated with succinic 
anhydride, to  provide a carboxylic acid derivative. This, following activation by 
standard peptide method w as expected to be coupled to the e-amino group o f  lysine 
residues in the peptide
The aminoporphyrin w as heated with an equivalent o f  succinic anhydride in 
chloroform, 4 -o x o -4 -(4 -( 10,15,20-triphenyl-2 l//,23//-porphin-5-yl)phenylam ino)-
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Scheme 5.15
This w as treated with pentafluorophenol and DCC in an EtOAc /  DM F mixture to  
prepare the activated pentafluorophenyl ester o f  the porphyrin. A  product, believed to 
be the desired ester, formed slowly. After tw o days, the solvents w ere evaporated and 
the crude material was added to a peptide sequence with a deprotected e-amino 
group. N o  coupling was observed on both stirring at room temperature or on heating 
at 40°C  for tw o days. Addition o f  DM AP, follow ed by heating at 60°C resulted in the 
formation o f  tw o  new porphyrin containing compounds. Chromatography allowed  
isolation o f  these products, however, these could not be identified. This may be due to  
a lack o f  purity o f  the peptide rather than difficulties with the coupling procedure. 
H owever, the difficulties encountered in the formation o f  the active ester led to  the 
investigation o f  other activation procedures.
Activation o f  the carboxylic acid as the acyl chloride w as then attempted. 4 -O xo-4-(4 - 
(10,15,20-triphenyl-21//,23//-porphin-5-yl)phenylam ino)butanoic acid in THF w as
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treated with oxalyl chloride. After one hour, total conversion o f  starting material was 
observed by TLC. Following the removal o f  excess reagent, the acid chloride was 











A number o f  products were produced and the main product was isolated by column  
chromatography. N M R  analysis o f  this compound showed the spacer to have cyclised  
to form the succinimide, rather than coupling to butylamine. This also makes this 
approach unsuitable for the coupling o f  porphyrin derivatives to  peptide sequences.
Owing to the problems with cyclisation, longer spacers were investigated for which 
cyclisation onto the phenyl amino would be unfavourable. A  joint coupling and 
activation procedure w as first investigated. The aminoporphyrin w as treated with an 
excess o f  1,6-diisocyanatohexane. This was intended to provide a urea linkage onto  










The coupling reaction proceeded very slowly, only after 5 days was com plete 
conversion o f  the starting material observed. Distillation o f  the excess spacer revealed  
an intractable solid. This is presumably a bis-porphyrin formed by the reaction o f  both 
isocyanate groups with porphyrin amines
An acid chloride approach was then utilised Hexanedioic acid monomethyl ester in 
CH2CI2 w as treated with oxalyl chloride for 18 hours (Schem e 5 18). Formation o f  the 
acid chloride w as confirmed by the IR spectrum (absence o f  an OH stretch). The 
crude material w as then added to a solution o f  the aminoporphyrin in CH2C12. After 
24 hours, com plete conversion to a single product w as observed. Following column 
chromatography, this product was confirmed, by N M R  and M S, to  be the desired 
methyl ester porphyrin derivative. In order to achieve coupling to a peptide the methyl 
ester must first be removed and then the revealed carboxylic acid activated. Base 
hydrolysis proceeded slowly due to the lack o f  solubility o f  the starting material. 
Follow ing heating at reflux, the crude material was isolated by addition o f  acid. This 
product w as sparingly soluble in most solvents. M ass Spectral analysis showed this 
material to  contain both the desired carboxylic acid and the methyl ester





In a further approach, 6-aminohexanoic acid was coupled directly to  an activated 
porphyrin derivative (Schem e 5.19). The aminoporphyrin was converted to  the 
isocyanate, on treatment with phosgene, and then allowed to  react with methyl 6- 
aminohexanoate. After 18 hours, formation o f  tw o new products w as observed, which  
were separated by column chromatography N M R  analysis showed the less polar
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product to be the desired methyl ester and the more polar spot to  be the carboxylic 
acid analogue The presence o f  the carboxylic acid compound was probably due to an 
impurity in the starting ester, rather than loss o f  the ester during coupling. However, 
both o f  these products w ere sparingly soluble suggesting that hydrolysis, and 
subsequent activation w ould be difficult to achieve. H ence this approach seemed  
unsuitable for the coupling o f  porphyrin to peptide sequences.
20% Phosgene in toluene








A new synthetic approach w as developed in which the peptide lysine or glutamic acid 
residues were extended prior to coupling with a non-extended porphyrin. Extension o f  
both residues with 6-am inohexanoic acid derivatives w ould result in peptide 
derivatives containing both amino and carboxylic acid groups. Hence, coupling 
procedures for the porphyrin to both types o f  functionalisation are required.
5.6.1 Coupling to  amines
In order to  develop a method o f  coupling to the amino peptide derivative, a model 
compound, N -(6-am inohexanoyl)leucine methyl ester hydrochloride, w as prepared. 
Activation o f  the porphyrin as the isocyanate had proved largely successful in the
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coupling with methyl 6-aminohexanoate. Thus, the isocyanate derivative was prepared 
and allowed to react with the new model compound (Schem e 5.20). After 24 hours, 
column chromatography gave compound (124) in 37 % yield. However, in an attempt 
to scale up this reaction, it proved difficult to isolate the desired compound by both 
column and preparative thin layer chromatography In both these cases, a second  
product is formed during the activation procedure. This corresponded to N ,N ’- 
bis(tetraphenylporphyrinyl)urea, in which the porphyrin amine reacts with porphyrin 
isocyanate in preference to  phosgene. Thus, as no purification o f  the activated 
porphyrin is undertaken, the crude material is o f  unknown purity.
N = 0 0  + a l l , iio
(93) (123)
(37%)
NHOONH(Ot2)5(X )N H ^ C 0 2Me
Scheme 5.20
Therefore, it w as proposed to use an isocyanate synthon, the corresponding 4- 
nitrophenyl carbamate, in the coupling reaction. This is relatively stable and can be 
purified prior to addition to the peptide, enabling a more controlled coupling reaction  
Treatment o f  aminoporphyrin with bis-(4-nitrophenyl)carbonate proved unsuccessful, 
only slow  conversion was observed over many days. Alternatively, treatment with the 










Column chromatography allowed the isolation of the pure product in 86% yield. This 
compound was then allowed to react with numerous peptide sequences as described 
in chapter 7.
5.6.2 Coupling to carboxylic acid groups
With glutamic acid peptides, incorporation of the spacer leads to formation of a y- 
acylazide. This activation procedure will be described in chapter 7. Attempts to 
couple this to aminoporphyrin, a reaction which can be considered straightforward, 
resulted in unacceptably low yields. These results, coupled with the difficulties 
encountered with addition of spacers to aminoporphyrin, suggested that the amine is 
of low nucleophilicity. This has also been suggested by other workers. In the 
preparation of porphyrin dimers, Lindsey et al 252 found that the reaction of 
aminoporphyrin with a pentafluorophenyl porphyrin derivative gave very low yields. 
However, by using the more reactive aminomethylporphyrin, 81% yield of dimers was 
achieved. This was also the case with proline derivatives of aminoporphyrin, where 
the aromatic amine is altered to a rigid aliphatic type amine .
In order to increase the reactivity of the aminoporphyrin, glycine was coupled to the 
porphyrin. Gribkova et al 256 used both a mixed anhydride and direct DCC coupling 
approaches to attach both tyrosine and tryptophan to aminoporphyrin. Yields of 75- 
80% were achieved using the DCC coupling technique; however, the 
dicyclohexylurea was difficult to remove from the products 255.
Thus, glycine was coupled to the aminoporphyrin by an active ester reaction. N- 
Bocglycine pentafluorophenyl ester was prepared from the protected amino acid and 
pentafluorophenol by a DCC method. Initially, coupling of the amino acid to the 
porphyrin was attempted at room temperature. The reaction proceeded slowly and 
required further addition of the active ester to reach completion. Column 
chromatography proved unsuccessful in the separation of the desired porphyrin 





In order to prepare a linear degradable polymer based on PEG, a degradable peptide 
sequence is required, which can be incorporated into the polymer. The potential of the 
peptide sequence GlyPheLeuGly to be used as a lysosomally degradable sequence has 
been demonstrated in both pendant and cross-link situations. However, it has not been 
used to provide degradability of a linear polymer chain. Ulbrich 78 has prepared a PEG 
co-polymer where an amino acid, Phe, is incorporated in chain and imparts 
degradability. In this case, however, there is no fimctionalisation of the polymer to 
allow for attachment of drugs or imaging agents. Thus, in this project, a number of 
peptide monomers have been prepared based on the sequence GlyPheLeuGly but also 
incorporating at least one amino acid which can be used to couple a drug molecule to 
the polymer, for example glutamic acid and lysine.
The polymerisation reaction was designed to be between PEG activated as a,o-bis- 
epoxide and a a,co-bis-amine derivative of the peptide sequence. To afford an easy 
polymerisation, the same degree of reactivity is required at each terminus of the 
peptide monomer. Furthermore, to avoid cross-linking of the polymer, a secondary 
amine, which can only react once with the activated PEG, is required. The non- 
proteiogenic amino acid sarcosine (N-methylglycine) can be used to provide the 
secondary amine. This can be easily attached at the N-terminus of a peptide sequence 
by simple extension of the chain. To incorporate this amino acid at the C-terminus, 
however, requires the inclusion of a retro-inverso unit to change both the sense of the 
peptide chain and also the functionality. Of the many a,co-bis-amines which are 
suitable for use as a retro-inverso unit, the small ethane-1,2-diamine unit was 
investigated.
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Using this strategy a bis amine potentially degradable monomer suitable for inclusion  
in a polymer, can be prepared (Figure 6.1).
X = CO2H (Gutanic acid)
(O ^ N H z  (Lysine)
Figure 6.1
6.2 Peptide synthesis
In order to prepare a single dipeptide from tw o different amino acids, one must have a 
protected amino group and one, on the whole, should be activated at the carboxylic 
position. I f  no protection is in place, the single amino acid can couple to itself to  give 
an unwanted dipeptide or polymers can be formed containing one or both amino 
acids.
6.2.1 Amino Protection
To protect the amine o f  an amino acid either its nucleophilicity should be suppressed 
by the use o f  an electron withdrawing substituent, or it should be sterically protected  
by the attachment o f  bulky substituents 264.
In the early days o f  solution phase peptide synthesis, simple N-acetyl and N-benzoyl 
protection were investigated. Although these afforded efficient protection for peptide 
synthesis, harsh conditions are required for the removal o f  these groups. The strong 
acids and bases used also lead to the destruction o f  peptide bonds and the collapse o f  
the peptide 265.
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Alkyloxycarbonyl derivatives, known as urethanes, were then investigated. These 
provide effective protection without racemisation and can be removed in conditions 
that do not affect the peptide bonds. In this situation, acyl-oxygen fission, to yield the 
free amine of the peptide, is very difficult to achieve. However, alkyl oxygen fission 
can occur easily in urethanes through a variety of mechanisms. This results in the 
formation of carbamic acids. These are highly unstable and undergo decarboxylation 
to yield the unprotected peptide 264,265.
Numerous urethanes have been developed, each with specific deprotection properties 
to enable the preparation of peptide sequences. In order to prepare a sequence, it is 
often essential to protect not only the N® position of the amino acid but also reactive 
groups in the side chains. The main side chain functional groups requiring protection 
are the N8 of lysine, the CO2H7 of glutamic acid, the OH of tyrosine and the SH of 
cysteine. Selective protection of these groups is often required in order to allow 
deprotection at one position in the peptide whilst retaining protection at other 
positions. Therefore, in designing a strategy for the preparation of a peptide sequence 
there is often a need for orthogonal protecting groups. There are two types of 
orthogonal protecting groups. Firstly, with truly orthogonal protecting groups, both 
groups can be removed without removing the other. Alternatively, partially 
orthogonal groups can be used in some cases. In this case the first group can be 
removed whilst the second is retained, whereas removal of the second group also 
results in the removal of the first 264,265.
The main urethane protecting groups are truly orthogonal. The original 
benzyloxycarbonyl (Z) group, reported by Bergman and Zervas in 1932, is stable to 
mild acid and base but can be removed on treatment with hydrogen bromide in glacial 
acetic acid (HBr / Acetic acid) or by catalytic hydogenolysis. Boc, t-butoxy carbonyl, 
in contrast, is unaffected by catalytic treatment with hydrogen but is easily removed 
by acids such as trifluoroacetic acid (TFA) which leaves the Z group unharmed. The 
properties of these two protecting groups have led to their widespread use in peptide 
synthesis. More recently, a series of urethanes has been prepared which can be 
removed by treatment with base, through a proton extraction mechanism 264,265. The
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m ost com monly used example is Fmoc, 9-fluorenylmethyloxycarbonyl. This is stable 
in both weak and strong acids and therefore can be retained during acidic 
deprotections o f  Z and B oc groups. It is, however, susceptible to hydogenolysis so is 
not truly orthogonal to  the Z group. Fmoc, itself, can be removed by treatment with  
secondary amines such as piperidine, which leave both Z and B oc unharmed The 
introduction o f  this protecting group has lead to greater versatility in peptide synthesis 
strategies especially using solid phase methods 264 265.
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Protection o f  side-chain functional groups, apart from the amino groups o f  lysine and 
ornithine, is residue-specific. M ethods are available for the selective protection o f  all 
amino acids. These are unimportant, however, within the context o f  this work.
6 .2 .2  Carboxyl Activation and Coupling
To achieve coupling o f  amino acids to peptides or other amino acids, it is usually 
necessary to  activate the carboxylic acid moiety o f  the protected amino acid. 
Fischer 264 used acid chlorides to achieve amino acid coupling. This is an attractive 
technique as the reactions proceed very rapidly. H owever, because the conditions 
required to  form the acid chlorides are harsh and acid chlorides are prone to  
racemization, this method is now only rarely used. There has been an increase in 
interest in this method more recently, since it was discovered that the acid chlorides o f  





Curtius presented a coupling method based on acid azides. This is an attractive 
method as it appears to take place without racemization. Furthermore, esters o f  amino 
acids can be converted to hydrazides and hence azides without formal ester hydrolysis 
to the carboxylic acid. The major difficulty with this approach is the tendency o f  the 
azide to undergo intramolecular rearrangement to  the isocyanate. This rearrangement 
can lead to peptide derivatives where the amino acid residues are linked via  urea 
rather than peptide bonds. These peptide-like com pounds are difficult to  separate 
from the desired peptide. This azide coupling method will be described in more detail 
in Chapter 7 264’265.
M ore recently anhydrides o f  amino acids have been prepared and used in peptide 
synthesis. T w o types o f  anhydrides can be prepared. Firstly unsymmetrical or mixed 
anhydrides can be used. In this case the anhydride is formed between the amino acid 
and an organic acid Therefore treatment o f  a peptide with a mixed anhydride can 
result in acylation o f  the peptide by both the amino acid and organic acid. This is 
particularly the case where the organic acid is benzoic acid as both the electrophilic 
sites have the same reactivity. This can be overcom e by using half esters o f  carbonic 
acids to  form the anhydride The inclusion o f  an extra oxygen atom in this component 
reduces its reactivity and thus the major reaction is the acylation o f  the peptide by the 
amino acid. M ixed anhydrides, formed on treatment o f  the N -protected amino acid by 
ethyl chloroformate or isobutyl chloroformate, have been widely used in both peptide 
synthesis and in the attachment o f  drug molecule to peptides 264 265
R
^ n^ c—or
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(134)
Scheme 6.1 : Mixed Anhydride
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Symmetrical anhydrides are formed from tw o molecules o f  the amino acid. Thus, each 
component has the same reactivity and only one product can be formed. H owever, 
this approach is inherently wasteful, as one molecule o f  the protected amino acid is 
lost on each coupling 264,265.
An alternative activation procedure is the formation o f  active esters. The majority o f  
these active esters are phenyl esters. The effectiveness o f  these esters is dependent on  
the electron-withdrawing properties o f  the ring i.e. on the ring substituents. Initially, 
nitro substituted phenyl esters were investigated; this led to the development and 
extensive use o f  p-nitrophenyl esters o f  amino acids in peptide synthesis. 
Kupryszewski investigated pentachlorophenyl esters and found them to be highly 
reactive 265. H ow ever, because the chloro groups are bulky, steric hindrance can lead 
to decreased reactivity in peptide couplings where there is steric interference. 
Pentafluorophenyl esters, however, are as active as the chloro derivatives but do not 
have the deleterious steric properties. 2,4,5-Trichlorophenyl esters are also highly 
















Figure 6.3 : Active Esters
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In a slightly different approach, active esters based on hydroxamic acids have been 
developed. In particular, N-hydroxysuccinimide has been widely used. It is attractive 
as, as well as having high leaving group reactivity, it confers enhanced water solubility 
on the amino acid. The activity o f  all these esters can be enhanced by addition o f  
auxiliary nucleophiles to  the coupling reaction. These compounds, such as 1- 
hydroxybenzotriazole (H O BT) and 4-dimethylaminopiperidine (DM AP), catalyse the 
aminolysis o f  the esters and can form more reactive electrophiles in  situ.
The final approach to coupling does not rely on isolatable active forms o f  the amino 
acid. Direct condensation, leading to formation o f  the peptide bond can be achieved  
using condensing agents. The most widely used agent is dicyclohexylcarbodiimide 
(DC C), which w as developed in 1955 by Sheenan and Hass In this method, a 
conjugate o f  the amino acid to be coupled and DCC is formed which can then be 
broken either by coupling o f  the carbonyl to the amine, or by formation o f  a 
symmetrical anhydride (Schem e 6.2). Regardless o f  mechanism, the coupling 
procedure is highly effective
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(146)
Scheme 6.2
Tw o difficulties have been recognised in the use o f  this approach. Firstly, once  
coupling has taken place the condensing agent is transformed to dicyclohexylurea 
(D C U ) This is almost insoluble in most organic solvents, so can be filtered from the
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reaction mixture. H owever, a small portion can remain in solution and is thus difficult 
to remove. Secondly, intramolecular rearrangements can occur with the O-acyl 
conjugate. A  N-acyl urea is formed which cannot react further to allow coupling and 
is also difficult to  remove from the peptide as it is freely soluble (Schem e 6.3).
O O
H M
,— vR-C-O  ,— v t— > R—C O ,— v
0 _ h_ c^ n~ 0  *  O - n- c- n^ )
(143) (147)
Scheme 6.3
Other condensing agents have also been developed including water soluble 
carbodiimide and carbonyldiimidazole (CDI). Apart from acting as a condensing agent 
in coupling reactions, DCC has been used for the formation o f  active ester and 
symmetrical anhydride derivatives o f  amino acids
Q - I W V N - Q  C^CHjN-C-NKCH^NfCH^, HQ
Dicy ck)he>a k:aibodiimde Water soluble caibodimide'
DCC wsa




Figure 6.4 : Coupling Reagents
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6.3 Non-degradable monomers
6.3.1 Boc and Fmoc protecting group strategy
In the first place, small peptides were prepared to test the suitability of the strategy 
and to develop protection tactics for preparation of the degradable monomers. These 
are built up of only a functionalised amino acid, glutamic acid or lysine, rather than 
the degradable sequence.
Two protecting groups are required in the synthesis of these monomers. One is 
necessary for the long-term protection of sarcosine and one for the temporary 
protection of the functionalised amino acid. Obviously the protecting group for the 
functionalised amino acid must be removed selectively in the presence of the sarcosine 
protecting group. Thus, the orthogonal protecting groups Fmoc and Boc were initially 
proposed. Fmoc was chosen as the temporary protecting group and Boc as the more 
permanent.
Boc-sarcosine was easily prepared using a modification of the method of Anderson 
and MacGregor 266 (Scheme 6.4). Acylation was achieved in a basic dioxane / water 
mixture by application of di-/-butyl dicarbonate (Boc^O. Some workers have 
suggested 267 that Boc protecting groups can be lost during work up procedures with 
strong inorganic acids. Thus they suggest that the weaker citric acid should be used. 
However, result in this laboratory 268 have demonstrated that the protection can be 
retained during brief treatments of the Boc-amino acids in immiscible organic solvent 
with cold 10% aqueous sulphuric acid.
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Throughout this work, peptide couplings are achieved using active ester procedures. 
Active esters w ere prepared by treatment o f  the amino acid with the substituted 
phenol derivative and DCC in a suitable organic solvent. Thus BocSarO NP was 
prepared by treatment o f  compound (151) with /?-nitrophenol.
In order to prepare a mono sarcosyl derivative o f  ethane-1,2-diamine, the activated 
amino acid w as added to a 20 fold excess o f  ethane-1,2-diamine in CH2CI2. This 
approach enabled the isolation o f  the mono acyl compound (153) in 93% yield. N o  di 
acyl com pound w as isolated.
6.3.1.1 Protection o f  glutamic acid
Glutamic acid has tw o  carboxylic acid functions and, thus, on activation, would  
provide a mixture o f  activated products which could take part in peptide couplings 
To avoid this occurring, the y-carboxylic acid group must be protected. This is most
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easily achieved using esters and a number o f y-protected glutamic acid derivatives are 
available. Initially, the y-benzyl ester was chosen as this protecting group has 
deprotection strategies which are orthogonal to both Fm oc and Boc.
Fmoc was an attractive candidate for the N” amino protection as it is both fully 
orthogonal to  B o c and can usually be easily deprotected B rief treatment o f  the 
Fmoc-amino acid with piperidine results in the formation o f  both the desired 
deprotected com pound and a derivative o f  Fm oc, dibenzofulvene, which can be 
removed by filtration 269 Alternatively, ammonia, diethylamine and ethylamine can be 
used. Although these deprotections proceed more slowly, these methods have the 
added advantage that the base can be removed by evaporation 270.
In a first approach, attempts were made to incorporate the Fm oc protecting group 
using the method o f  Carpino and Han 269 (Schem e 6.5). A  solution o f  fluorenylmethyl 
chloroformate w as added slowly to a solution o f  the y-benzyl glutamic acid in base. 
Unfortunately, coupling w as not achieved with this method. NM R analysis o f  the 
organic washes showed the presence o f  9-fluorenylmethanol. This suggests that either 
the desired product is formed but the protecting group is immediately cleaved or the 
chloroformate has decom posed.
C02CH2QH5 Op2CH2QH5
Fmoc Q  s '
Dioxane / H20 /  NaOH _ f
C-OH V ,  ^ N ^ C - Q H
O A  H o
(154) (155)
Scheme 6.5
As the Fm oc-protected amino acid will be transformed to  its active ester prior to  
coupling to  the ethane-1,2-diamine derivative, protection and activation using the 
method o f  Schon and Kisfaludy 271 was investigated. This method enables formation 
o f  a protected, activated amino acid in a one-pot process. This approach has proved
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successful with a large number o f  amino acids including the y-tert butyl ester o f  
glutamic acid 271. H owever, this approach proved unsuccessful with the y-benzyl 
derivative (Schem e 6.6). A  similar approach using Fmoc-succinimide has also been  
used to prepare the protected derivative of y-tert butyl ester o f  glutamic acid 272 273.
C02CH2QH5 C02CH2QH5
s ' Fmoc-pentafluorophenol (156) s ' p p 
f  NaHCpj / H20  f  \ ___/
H2In T" C -O H  Fm° C v  C—O—$  V - F




6.3 .2 B oc and Z protecting group strategy
6.3 .2.1 Glutamic acid monomers
As the Fmoc protection w as difficult to achieve, a new  synthetic strategy w as 
developed. A  new  protecting group which is orthogonal to  B oc was required The 
obvious candidate is the Z group. This could be used to protect the glutamic acid, like 
Fmoc. H ow ever, the conditions required for removal o f  Z groups; HBr /  A cetic acid 
or catalytic hydogenolysis make these reactions relatively difficult to perform. In 
comparison the removal o f  B oc is a fast and simple process. Thus, a new strategy w as 
proposed in which Z was used as the protecting group for sarcosine and B o c for the 
incoming amino acid, and in the long term, for all amino acids in the GlyPheLeuGly 
sequence
Z Sar (158) w as easily prepared from sarcosine using benzyl chloroformate under 
Schotten Bauman conditions. This w as then activated as the more reactive 
pentafluorophenyl ester and successfully coupled to ethane-1,2-diamine to afford 
ZSar-ethane-1,2-diamine unit (160) in 93% yield (Schem e 6.7). B oc-protected  
glutamic acid y-benzyl ester is commercially available and w as successfully activated
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as the pentafluorophenyl ester and coupled to (160) yielding (162) (75% ) (Schem e 
6 .8).
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B oc protecting groups are easily and rapidly removed on treatment with acids. The 
most com m on method involves the treatment o f  the peptide with TFA. This acts both  
as the solvent and reagent yielding the unprotected peptide as the trifluroacetic acid 
salt. H ow ever, TFA has been shown to cleave Z groups on prolonged exposure 265 
Previous experience in this laboratory has demonstrated that treatment o f  the peptide 
in an organic solvent with gaseous HC1 yields the hydrochloride salt o f  the peptide. 
This is an attractive approach as the reaction is rapid and both the solvent and excess  
reagent can be easily removed by evaporation. Thus compound (163) in dioxane w as 
treated with HC1 to g ive the hydrochloride salt (164) in 85% yield.
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Coupling o f  the final amino acid, Z Sar, could prove difficult due to steric 
interference, especially with longer peptide sequences. Thus, an acid chloride coupling 
method w as investigated for this step. The acid chloride w as prepared by treatment o f  
the protected amino acid with oxalyl chloride and DMF. On formation, the solvents 
and excess reagent were evaporated and the acid chloride added to an excess o f  a 
model amine, cyclopropylamine. Unfortunately, a number o f  products were formed in 
this coupling reaction. Thus, an active ester approach w as utilised. ZSarOPFP 
coupled easily with compound (164) to  give the bis-amine monomer (166) in 73%  
yield.
In the above situation, removal o f  the benzyl protecting group, to  allow coupling o f  
the porphyrin, or o f  the Z group, to  allow polymerisation would result in the loss o f
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both protecting groups. Thus, three amines would be exposed which could result in 
branched polymers or the attachment of more than one porphyrin molecule. Although 
no differentiation is apparent using catalytic hydogenolysis deprotection, Ben Ishai 274 
has demonstrated that, in some circumstances, the Z group can be preferentially 
removed on treatment with HBr / Acetic acid. Ideally a truly orthogonal protecting 
group would be preferable.
A commonly used ester protecting group is the tert-butyl group. However, this is not 
suitable as it is difficult to achieve selective removal of this group in the presence of a 
Boc group 265. Interestingly, some workers have suggested that, with care, Boc can be 
removed in preference to the tert butyl ester by treatment with TFA in EtOAc.275
An attractive alternative is the methyl ester. This is unaffected by treatment with TFA, 
HC1, HBr / Acetic acid and catalytic hydrogenolysis and is therefore orthogonal to Z 
and Boc. However, if this amino acid derivative were to be incorporated into a 
peptide sequence, there would be a risk of pyroglutamate formation and subsequent 
loss of the methyl ester upon removal of the Boc protection 264,265. As coupling of the 
porphyrin was found to be easier through an extended peptide derivative, an amide- 
linked spacer terminating in the Me ester was used to protect the y-position. In this 
case pyroglutamate formation cannot occur.
Boc-glutamic acid a  benzyl ester was activated at the y-position as the 2,4,5- 
trichlorophenyl ester (TCP ester). These esters are less reactive than 
pentafluorophenol esters; however, in situations where steric hindrance is minimal, 
satisfactory rates of coupling can be achieved. It also offers the more mundane 
advantage that it is less expensive, an important consideration in large scale synthesis. 
TCP esters can be prepared using the standard method, DCC in organic solvent. 
Alternatively an activated TCP derivative can be prepared which reacts directly with 
the amino acid267
This was successfully coupled with methyl 6-aminohexanoate to give the extended 
derivative, (169) in 87% yield. The a-benzyl ester was then removed by catalytic
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hydrogenolysis in THF to give the free carboxylic acid. Treatment o f  this with  
TCPOH and DCC afforded the 2,4,5-trichlorophenyl ester (171). This ester was 
coupled efficiently to the ethane-1,2-diamine and deprotected on treatment with HC1. 
ZsarOPFP was successfully coupled to give (174) in 70% yield.
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6.3 .2 2 Lysine M onomer
Lysine offers further opportunities in the design o f  an orthogonal protecting group 
strategy. The e amino group has comparable reactivity to  the a  amino group so, if  
unprotected, could react with an activated amino acid to form a branched peptide 601. 
There are four major approaches to  differential protection o f  the amino groups o f  
lysine. Bergman and Zervas proposed a method based on the selective deprotection o f  
a di-Z-protected lysine using phosphorus trichloride and base 264. (Schem e 6.11).
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Alternatively the Z protecting group can be selectively introduced onto the ex­
position W unsh 265 developed a process in which the e-amine is temporarily protected 
by treatment with benzaldehyde, allowing the Z group to be selectively introduced to  
the e-amine. (Schem e 6 12)
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A method, developed by Schallenberg and Calvin 276, relies on the different solubility 
characteristics o f  the a  and e amino protected compounds. Treatment o f  an amino
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acid with ethylthioltrifluoroacetate in mildly basic conditions results in the formation 
o f  protected amino acid. This protecting group is stable in most conditions but can be 
cleaved by raising the pH to 10 either by treatment with aq. NaO H  or conc. ammonia. 
H owever, for lysine, it is possible to isolate the e-protected derivative alone in 52%  
yield. This is not thought to be due to a regio-specific mechanism as the a  position o f  
many amino acids can be selectively protected in this manner but is probably due to a 
lack o f  solubility o f  the e-protected compound, allowing its isolation by 
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Scheme 6.13
The most popular method o f  selective protection o f  lysine is based on the formation 
o f  copper (II) com plexes Addition o f  copper (II) carbonate to a solution o f  lysine 
results in a com plex o f  tw o lysine residues and one Cu2+ ion, in which the a-am ine  
provides a ligand for the ion and is thus unavailable for reaction. The com plex can 
then be treated with most protecting groups to afford the e-amino protected  
compound. The com plex can then be broken on treatment with H2S leaving a free a -  
amine which can be protected with an orthogonal protecting group if  desired. One o f  
the most com m on derivatives formed using this method is the a -Z -e-tosy l lysine. 
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Initially, attempts w ere made to prepare the s-trifluoroacetyl derivative o f  lysine using 
the method o f  Schallenberg and Calvin . This is an attractive protecting group as it 
is stable to  treatment with H Br/Acetic acid and to cone HC1. H owever it can be easily 
cleaved on treatment with inorganic base (N a2C 0 3, K2C 0 3) in methanol. The 
acetylating agent, ethylthioltrifluoroacetate, was easily prepared in 49%  yield. 
Treatment o f  lysine with this reagent, following the method o f  Bodanszky 267, resulted 
in a low  yield (7% ) o f  a solid upon recrystallisation. This was not soluble in any o f  the
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available NMR solvents and thus was not characterised. This low yield, lead to the 
development of a new approach.
Copper complex methods were then investigated. The most widely used group, tosyl, 
is unsuitable for a Z / Boc protection strategy. Although it can be removed selectively 
by treatment with KOH in MeOH on heating, most other deprotection methods also 
result in the cleavage of Z or BOC for example, treatment with HF, HBr / Acetic acid 
or sodium in liquid ammonia 277. After consideration, a less widely used protecting 
group was chosen for the protection of the e-amine. 2,2,2-Trichloroethoxycarbonyl 
(Troc) protection can be easily introduced, via the chloroformate, to an amine. It is 
resistant to treatment with HC1 and thus is orthogonal to Boc. Although it is resistant 
to treatment with HBr / Acetic acid, it is usually affected by catalytic hydrogenolysis. 
During hydrogenation, one or more chlorines can be replaced by hydrogen, thus 
rendering the protection permanent. It can be selectively cleaved by treatment with 
zinc or cadmium in a variety of solvents 264,265. (Chapter 7).
The copper complex of lysine was formed easily following the method of Yajima et 
al 278 The Troc group was successfully introduced using Schotten Baumann 
conditions. As discussed the complex can be easily broken with H2S. However, as this 
gas is toxic, the same reaction can be achieved using thioacetamide in base. An 
alternative approach is to break the complex using the chelator EDTA. Using this 
latter approach the complex was easily broken. Treatment with (Boc^O yielded 
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Scheme 6.15
This diprotected amino acid w as then successfully activated as the PFP ester. This 
was efficiently coupled to the ZSar-ethane-1,2-diamine unit yielding (192) (85% ). The 
compound w as then successfully deprotected, by treatment with HC1, without loss o f  
the Troc protection. The final coupling o f  ZSarOPFP gave compound (194) in 60%  
yield.
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Thus simple monomers containing glutamic acid and lysine were successfully 
prepared Thus proving both the suitability o f  the monomer preparation strategy and 
the potential for inclusion o f  a functionalised amino acid, with or without extension o f  
the side chain. From this base, peptide sequences were prepared in which both a 
functionalised amino acid and the degradable sequence were present.
6.4 Degradable Monomers
6.4.1 M onom ers with one functionalised amino acid
In the preparation o f  larger peptide sequences, tw o synthetic approaches can be used. 
A  convergent synthesis where units o f  a few  amino acids are condensed in a final step
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is particularly attractive. In this situation, the yield o f  the desired peptide is higher 
than if  each amino acid is added to the growing peptide in a stepwise manner. It is 
also easier to isolate a final product formed using a convergent method as it is 
significantly different to the starting components. With a stepwise synthesis, it can be 
difficult to separate the desired peptide from peptidyl impurities which have a missing 
amino acid at som e point in the sequence H owever, it is essential when developing a 
convergent approach to choose the position o f  final condensation carefully so as to  
minimise racemisation and enable straightforward synthesis 265
Initially, the peptide monomer incorporating lysine and the biodegradable unit 
GlyPheLeuGly w as synthesised. In this synthesis, a convergent approach w as first 
investigated. T w o target peptides were designed, one being the tripeptide SarLysGly 
(196), the other being PheLeuGly attached to  the ZSar-ethane- 1,2-diamine unit (195) 










For this synthesis, the active esters o f  all the commercial B oc protected amino acids 
were prepared using the standard DCC coupling approach. For all amino acids, except
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Phe, active esters o f  TCP were used. For Phe, it has been previously found that
com pounded in this situation where a coupling occurs between Phe and Leu, Phe w as 
activated as the more reactive PFP ester
Synthesis o f  the C terminus portion proceeded swiftly. Coupling o f  glycine to the 
ZSar-ethane-1,2-diamine unit w as rapid, resulting in the formation o f (198) in 79%  
yield. This w as easily deprotected, by treatment with HCi, and coupled to  
BocLeuOTCP. Subsequently, this peptide was deprotected and coupled to the 
activated Phe, yielding (204) (65% ).
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Preparation o f  the N-terminal portion was more complex. Firstly a carboxyl-protected  
derivative o f  glycine w as required. The simple methyl ester was chosen as it is 
commercially available This reacted successfully with the TCP ester o f  FT-Boc-N®- 
TrocLysine to g ive the dipeptide in 82% yield (Schem e 6.18). The B o c protection  
was removed. Coupling o f  this compound with ZSarOPFP, however, proved  
problematic. Num erous products were formed and isolated by column 
chromatography. They w ere however unidentifiable This is probably due to a loss o f  
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From this, it was decided to  abandon the convergent approach in favour o f  a stepwise 
approach. As a tripeptide C-terminal portion had already been prepared, this w as 
deprotected and allowed to couple sequentially with the Boc-protected active esters 
o f  Gly and Ff-protected-Lys. Final deprotection, follow ed by coupling o f  ZSarOPFP, 
gave the desired peptide monomer, (215) in 62% yield (Schem e 6.19).
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From this basis, tw o  further peptide monomers could be prepared. Firstly a monomer 
consisting o f  the degradable sequence GlyPheLeuGly and no functionalised amino 
acid and secondly, one containing the degradable sequence and the extended glutamic 
acid. Thus, it is apparent that a stepwise synthesis is advantageous for the synthesis o f  
monomers, as it is possible to prepare three separate monomers in at the most four 
simple steps from one precursor The GlyPheLeuGly monomer (216) w as easily 
prepared in 65%  yield by coupling o f  ZSarOPFP to (212).
With the glutamic acid derivative, coupling o f  the derivatised amino acid enabled 
isolation o f  the peptides as solids, on trituration with ether. However, higher yields o f  
the peptides w ere obtained using column chromatography. Thus, the desired 
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In an alternative approach, it was proposed to prepare monomers in which the 
derivatised amino acid and the degradable sequence were in a different order in the 
sequence That is, the derivatised amino acid is adjacent to  the ZSar-ethane-1,2- 
diamine unit. Initially, the glutamic acid monomer was investigated. A s discussed  
earlier, the glutamic acid derivative can be easily coupled to the ZSar-ethane-1,2- 
diamine unit. B ocG ly can then be coupled to the deprotected compound. This 
coupling progressed very slowly with the reactants com ing out o f  solution. H owever,
148
the desired compound w as isolated in 74% yield on trituration with ether (Schem e  
6.22). This was successfully deprotected by treatment with HC1 in a mixture o f  THF 
and MeOH. Attempts to couple leucine proved unsuccessful, in that the reaction 
mixture gelled, requiring an increased dilution o f  the reactants and addition o f  further 
molar equivalents o f  the active ester. Even so, after 10 days the reaction had not 
proceeded to com pletion and the desired product could not be isolated due to the lack 
o f  solubility o f  both this product and the starting peptide. Thus, it is apparent that 
inclusion o f  the glutamic acid derivative enables easy isolation o f  som e products due 
to  ease o f  precipitation, but can reduce the rate o f  coupling o f  further amino acids to  
the sequence. Later results, in which the coupling o f  a spacer to lysine monomers 
proved difficult due to low  solubility suggest that the lack o f  solubility, is due to  a 














Therefore, the peptide monomer with glutamic acid at the C-terminus was abandoned. 
However, the corresponding lysine monomer w as easily prepared. In this case, all 
amino acids w ere coupled through their PFP esters to  ensure efficient coupling. A lso, 
in the latter stages o f  synthesis, as all products w ere to  be isolated by column  
chromatography, an excess o f  the active amino acid w as used to enhance the yield o f  
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6 .4 .2  M onomer incorporating tw o functionalised amino acids
To achieve attachment o f  the porphyrin, only one functionalised amino acid is 
required in the sequence. H owever, if  a drug were attached to  the monomer, it would  
be advantageous to have more than one functionalised amino acid in the sequence to  
achieve the highest loading possible. Also, i f  there was more than one functionalised 
amino acid, it w ould be possible to attach a targeting moiety as well as a drug. To
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achieve a high loading, the same amino acid should be incorporated twice. To attach a 
targeting group, however, it is desirable to  prepare a monomer which contains 
different functionalised amino acids, preferably with orthoganality o f  protecting 
groups. Towards this latter aim, a monomer containing both glutamic acid and lysine 
has been prepared The glutamic acid derivative w as easily coupled to (232) to give  
(234) in 73% yield This compound w as then deprotected and coupled to ZSarOPFP 
to  give the bis functionalised monomer (236) (40% ) (Schem e 6.25).
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6.5 Characterisation of Peptide Derivatives
All peptides were characterised by proton NMR analysis. Appropriate intermediates 
were also characterised by 19F NMR. Due to restricted rotation around the C-N bond 
in both Z-and Boc-protected sarcosines, all peptides containing this residue exhibited 
two sets of signals for both the Sar CH3 and CH2 and also for the benzyl CH2 in the Z 
derivative. Heating the samples to 80°C confirms that these signals are due to 
rotamers as the signals coalesce to give a simpler spectrum. For all peptide sequences 
it was possible to characterise authoritatively the compounds. For the larger 
sequences, 2D COSY analysis was required to establish exact assignments of the 
spectra. An example of such a spectrum for compound 259 is shown on page 154.
In a normal spectrum the Leu-CH3 is found between 6 0.7-0.9 and the CH2 signals for 
Lys, Leu, Glu and the central portion of the spacer between 5 1.0-2.0. Glu y-H2 and 
the spacer CH2 adjacent to a carboxyl give triplets at approximately 8 1.8-2.2. The 
Phe P-H2 signals are seen as two separate double doublets at around 8 2.8 and 8 3.05. 
The ethane-1,2-diamine protons give a broad signal at 8 3.11. Lys e-CH2 and the 
spacer CH2 adjacent to nitrogen appear as overlying multiplets. Gly CH2, as a 
multiplet and Sar-CH2, as a singlet, are located between 8 3.5-4.0. All the a-H give 
signals between 8 4.0-5.0. The CH2 in both the Troc and Z protecting groups are seen 
as singlets between 8 4.8 and 5.2. Phe and Z aromatic protons give multiplets in the 
region 8 7.1-7.4. The signals due to NH protons are seen between 8 6.8 and 9.0.
The identification of all the peptide sequences was confirmed by FAB mass spectra. 
Certain key intermediates and target compounds were also subjected to accurate FAB 
mass spectral analysis.
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Figure 6 6 COSY 90 : Compound 259 (80°C)
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Using an orthogonal protecting group strategy based on Z and Boc protection and 
active ester coupling procedures, a number of peptide monomers have been prepared. 
Three non-degradable monomers, suitable for the attachment of a derivatised 
porphyrin and polymerisation, were initially synthesised. Subsequently, five monomers 
have been prepared incorporating the degradable unit GlyPheLeuGly. Four of these 






As described in Chapters 5 and 6, both the porphyrin and peptide components of the 
polymer have been prepared. For ease of synthesis and characterisation, it is desirable 
to attach the porphyrin to the peptide monomer prior to polymerisation. This would 
also enable efficient loading of porphyrin on the polymer. Conjugation after 
polymerisation is likely to proceed slowly, owing to steric interference, and would be 
unlikely to result in quantitative loading.
However, with the monomer containing both a glutamic acid and a lysine residue, 
only one of the amino acids will be used for the coupling of the porphyrin derivative. 
The other amino acid will remain protected throughout the porphyrin coupling and 
polymerisation. After polymerisation, the protecting group could be removed and 
used to attach targeting groups, such as MSH. In the attachment of such groups, the 
loading ratio is of lesser importance as only one interaction between the polymer and 
cellular receptor is required to enable targeting. Thus, the porphyrin derivatives (125) 
and (128) (Figure 7.1) have been coupled to lysine and glutamic acid residues to give 
nine peptide-porphyrin conjugates suitable for polymerisation, following deprotection, 
with PEG.
7.2 Lysine-Porphyrin Monomers
In order to prepare a conjugate of a lysine monomer and the electrophilic porphyrin 
derivative (125), it is first essential to remove the Troc protecting group to reveal the 
primary amine. This is suitable for direct coupling with the porphyrin. However, in a 
number of cases, a six-carbon chain spacer has been coupled to the peptide prior to
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( 128)(125)
Figure 7.1
treatment with the activated porphyrin. This enables the investigation o f  tw o  
previously reported properties o f  polymers. Firstly, coupling o f  a porphyrin to a 
poly(amino acid) has been demonstrated to be increased i f  a spacer unit is 
incorporated into the polymer 215 216’217 i f  this is the case, more efficient loading o f  the 
porphyrin could be expected to lead to an increased incorporation o f  manganese per 
macromolecule and thus to an increased relaxivity per m ole o f  polymer. Secondly, it 
has been suggested that the relaxivity o f  a macromolecule is dependent on its 
rigidity 160. Incorporation o f  a spacer unit would impart greater flexibility to  the 
system. Thus it could be proposed that inclusion o f  the spacer would reduce the 
relaxivity o f  the macromolecule.
7.2 .1 Removal o f  Troc
Removal o f  Troc is a relatively simple procedure. M ost methods invoke a reductive 
mechanism in which zinc is used to  abstract a chlorine atom from the protecting group  
forcing alkyl-oxygen fission. The most well known method involves treatment o f  the 
peptide with zinc in acetic acid, although numerous other solvents have been used  
265,279 m a jn  proj3|em ^ h  all these approaches is that som e zinc salts are soluble 
in the solvent and thus are difficult to  remove from the peptide This could prove
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critical where a porphyrin is attached to a deprotected peptide as, if  the peptide is not 
pure, zinc could be incorporated into the porphyrin.
An alternative method, which reduces the amount o f  zinc which is solubilised, was 
proposed by Just and Grozinger 279. In this approach, the protected peptide is treated 
with zinc and acid (KH2PO4) in THF With this procedure, high yields o f  around 80%  
are achieved (Schem e 7.1).




Yajima e t a l  described a process whereby the peptide is treated with zinc in a 
refluxing methanolic solution. This is an attractive method as it is simple and provides 
the deprotected peptide in high yield (Schem e 7.2).
NHCOzO^ CCb
Zn / 70% MeOH in HzO r  O
C—OH H2N ^ ( T NN ^ CvN ^ C - O H6 (63%) b H b
(239) (240)
Scheme 7.2
In a comprehensive study on potential solvents for zinc-based reduction o f  the Troc 
group, H ancock et al. also demonstrated the ability o f  cadmium to afford peptide 
deprotections. Deprotection o f (241) w as achieved in eight hours by treatment with 









7 .2 .2  Non-Degradable M onomers
Initial experiments were performed on the non-degradable monomer (194), as a model 
for the more com plex degradable monomers
this monomer. Deprotection w as highly successful, in that the free amine w as isolated 
in 79% yield after 7 hours treatment with zinc in 70% methanol in water. In a slight 
modification o f  this method, the product (243) was isolated by evaporation o f  the 
solvent mixture following filtration.
W ith this monomer, a spacer was then incorporated. The spacer chosen was based 
upon 6-am inohexanoic acid. This was easily protected with B oc and then activated as 
the pentafluorophenyl ester (Schem e 7 4).
The mild conditions developed by Yajima 278 were employed in the deprotection o f
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Coupling o f  the spacer to the peptide initially proved problematic. Gelling o f  the 
reaction mixture w as observed, similar to  the gelling seen previously with the glutamic 
acid monomers (Chapter 6). H owever, this problem w as overcom e by using a mixture 
o f  solvents, CH2CI2 and DM F, and an excess o f  the activated spacer Thus (245) was 
isolated, follow ing chromatography, in 85% yield.
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HQ / CH2a 2 / MeOH (96%)




This compound w as easily deprotected by treatment with HC1 to  provide an amine for 
coupling with the activated porphyrin (125). Again to ensure solution, this reaction 
was performed in a mixed solvent system, CH2CI2 /  MeOH. Coupling with the 










Thus the synthetic strategies for the deprotection, incorporation o f  spacer and 
coupling o f  porphyrin have been successfully developed. This approach was then used  
to prepare the porphyrin conjugates o f  both peptide monomers consisting o f  lysine 
together with the degradable unit (215) and (233) (Figure 7.2). With both these 
monomers, tw o conjugates were prepared, one in which the porphyrin is directly 




With monomer (215), removal o f  the Troc protecting group with zinc in methanol 
was successfully achieved (94% ). H owever, prolonged heating w as required, 
com plete conversion only being accomplished after 24 hours. Coupling o f  the spacer 
to this compound again proved problematic. Despite use o f  a great excess o f  spacer 
and a mixed solvent system, coupling proceeded slowly and incompletely. Thus, the
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extended peptide (249) w as prepared in 55% yield. This product was, as expected, o f  
low  solubility but w as easily deprotected to provide a primary amine for coupling to  
the porphyrin.
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Porphyrin conjugates were then prepared. With the non extended monomer (248), the 
coupling w as carried out in a DM F and CHCI3 solution to obviate potential problems 
o f  gelling o f  the reaction mixture as seen with the coupling o f  spacers. 
Chromatography o f  the reaction mixture gave the peptide-porphyrin conjugate (251) 


















(i) HQ / CH2C12 / M eO H \(64% )
(ii) p-C^NQ^C^CHNTPP
As it w as o f  known low  solubility, a mixed solvent system w as again employed with  
the extended monomer. This coupling w as less successful than with the corresponding 
non-extended monomer. Com plete conversion o f  the activated porphyrin was 
achieved within 24  hours, but more than one product w as formed. Thus, (252) was 
isolated in 64% yield.
Similar problems were encountered with the synthesis o f  the porphyrin conjugates o f  
monomer (233). With this monomer however, cleaner coupling o f  the porphyrin to  
the extended monomer w as achieved Thus (257) w as prepared in 81% yield.
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In a final study, the monomer containing both functionalised amino acids (Glu and 
Lys) w as coupled to a porphyrin through the lysine residue. Obviously, in this case, 
deprotection o f  the lysine residue must be achieved without a loss o f  integrity o f  the 
glutamic acid protection. Deprotection o f  the monomer w as achieved using zinc in 
70% methanol in water without loss o f  the methyl ester. Coupling o f  the spacer, as its 
active ester, w as highly efficient giving (259) in 89% yield.
N—GyLeuPheGy —
(236)
Zn / 70% MeOH in H20  
Reflux
(89%)
N— Gy LeuPheGy —
•CH3
NH







As this product w as expected to be only slightly soluble in CH2CI2, this coupling was 
again performed in a mixed solvent system. The base used in the reaction was also
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altered, to the more volatile diethylmethylamine, to enable efficient isolation of the 
product by chromatography. This may, however, have also been responsible for the 
increased efficiency of the coupling reaction. The Boc protecting group was easily 
removed. Coupling of the porphyrin (125) gave a number of products from which 
(261) was isolated in 85% yield.
Thus, the attachment of a monofunctionalised porphyrin to a peptide monomer 
containing lysine has been achieved in high yield in a variety of situations. Inclusion of 
the spacer has, if any, a negative effect on the coupling of the porphyrin, in contrast to 
previously reported results. It is yet to be seen if inclusion of the spacer has any effect 
on proton relaxation enhancement.
7.3 Glutamic Acid-Porphyrin Monomers
7.3.1 Non-Degradable Monomers
As has been described in chapter 6, three monomers containing an extended glutamic 
acid residue have been prepared. The carboxylic acid function in these monomers is 
protected as the methyl ester. Therefore, this protecting group must first be removed 
and then the peptide monomer activated to enable coupling of the monofunctionalised 
porphyrin (128).
In a first approach, saponification was investigated as a method of ester removal. 
Following removal of the ester, it was intended to form a pentafluorophenyl active 
ester of the peptide monomer which could be coupled to the porphyrin using the 
previously developed methods.
Initial studies were carried out on protected peptide intermediates. Treatment of (221) 
with two molar equivalents of NaOH in MeOH gave, on acidification, a number of 
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In a second approach, less base was initially used in an attempt to avoid peptide 
cleavage. H owever, this reaction proceeded slowly, requiring further addition o f  base 
to achieve conversion o f  starting material. Again a number o f  products w ere formed. 
Thus it seems unlikely that selective cleavage o f  the methyl esters by base hydrolysis 
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In an alternative approach, direct activation o f  the peptide w as investigated. 
Hydrazides can be prepared from the esters o f  amino acids. These can then be 
activated to azides which can couple efficiently with amines. Thus the peptide could  
be converted to its hydrazide and coupled to the porphyrin via an azide.
The activation o f  the non degradable monomer (174) w as first evaluated. Hydrazides 
are easily formed on treatment o f  an ester with an excess o f  hydrazine hydrate in 
methanol or ethanol 281’282*283 Although, with a number o f  peptides, hydrazides can be 
formed at room  temperature, for this monomer, the hydrazide w as more efficiently 
prepared on heating to  40°C. Thus quantitative conversion w as achieved in seven  
hours.
The formation o f  an azide from a hydrazide is more complex. Side reactions can occur 
leading to loss o f  activity or the formation o f  alternative products. In the majority o f
amine. A  method which has been widely used in peptide synthesis involves the
H ydrate hydrate (Quantitative) 
M eOH/40 C
I




cases, the azide formed in a reaction is not isolated and is used directly to  couple to an
treatment o f  a hydrazide with an acidic solution o f  sodium nitrite (nitrous acid) 267 
(Schem e 7.18 )
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In a modification o f  this approach, Honzl and Rudinger 284 prepared azides using 
either butyl nitrite or nitrosyl chloride. Both o f  these methods are highly successful, 
however, at present, the butyl nitrite method has been most widely adopted 281 .
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Scheme 7.19
Recently, tw o  different methods have been presented in which azide formation is 
achieved through the action o f  nitrosonium ions on a hydrazide Dinitrogen tetroxide 
is in equilibrium with nitrosonium ions in solution, the treatment o f  a hydrazide with  
dinitrogen tetroxide in acetonitrile results in the formation o f  an azide
Z A 7 1




In a mechanistically related approach, Clayfen (clay supported ferric nitrate) has been 
used as a source of nitrosonium ions in the preparation of azides 286.
Side reactions are, however, a problem with azide formation. Inactive amides can be 
formed during azide preparation. This is probably due to rearrangement of an 
intermediate 283 rather than hydrolysis of the azide. Alternatively, azides, once formed, 
can undergo a Curtius rearrangement to the isocyanate. Both of these reactions lead 
to a reduced yield of the desired product in coupling reactions. However, reducing the 
temperature during azide formation can substantially reduce formation of these 
unwanted derivatives.
Although formation of the isocyanate is a problem in peptide synthesis, as peptide-like 
molecules linked by urea bonds are formed, it can be beneficial in some situations. 
Thus, some workers have prepared an azide and converted it to the more reactive 
isocyanate to afford the attachment of an antibody to a peptide sequence 282 In this 
situation, the nature of the bond is not of importance. As has already been discussed, 
the porphyrin is linked to the lysine based monomers through a urea. Thus, it would 
be acceptable to have the glutamic acid linked to the porphyrin through a urea. When 
considering such an approach, it is essential to ensure complete conversion of the 
azide to the isocyanate, if this is not achieved a mixture of two products, with very 
similar physical properties, is likely to be formed during coupling making separation 
difficult.
Therefore in an initial approach to coupling the porphyrin to the small monomer 
(174), the hydrazide (264) was converted to an azide (267) and then heated to force 
the Curtius rearrangement to the isocyanate. The hydrazide was converted to the 
azide using a nitrous acid method. The product was not isolated and was heated at 
reflux, in EtOAc, for 30 minutes to form the isocyanate. The reaction mixture was 
then treated with the porphyrin derivative (93). A number of products were formed, 
none of which was the desired conjugate
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In a second attempt, the azide was prepared using a modification of the alkyl nitrite 
method of Tomatis et a l 281. The intermediate was heated in CHCI3 and then treated 
with the porphyrin. Again a number of products were prepared. From these results it 
appears that other rearrangements take place on heating the azide, possibly to the 
amide, resulting in inactivation.
Thus the azide approach was re-evaluated. If the temperature is kept low, for both the 
activation and coupling reactions, isocyanate and amide formation should be minimal. 
Therefore, it should be possible to prepare a conjugate linked through a peptide bond 
at low temperatures. This was investigated using monomer (174). The azide was 
formed by treatment of the hydrazide (264) with fe/7-butyl nitrite. This was then 
allowed to react with aminoporphyrin (93). The porphyrin was added to the reaction 
mixture at -50°C and the vessel allowed to warm slowly to room temperature. After 
24 hours coupling had been achieved giving (270) in 37% yield
This confirmed the suitability of the azide coupling reaction, however, the yield was 
disappointingly low. This was thought to be due to a lack of nucleophilicity of the 
aminoporphyrin rather than incomplete formation of the azide. This theory was 
confirmed by the reaction of the azide (267) with a more nucleophilic derivative of the 
porphyrin (128). Coupling, using the same conditions, gave (271) in 76% yield.
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Scheme 7.24
7.3 .2 Degradable Monomers
This success led to the extension o f  the azide coupling strategy, combined with  
activation o f  the porphyrin, to  the degradable m onomers containing glutamic acid 
(220) and (233).
With the monomer consisting o f  only glutamic acid and the degradable sequence 
(220), formation o f  the hydrazide proved difficult. It w as necessary to heat the 
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This w as then converted to the azide, again this required longer treatment with the 
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(11) Q* 'tH3NCH2COHNTPP
Solubility problems w ere encountered with the large monomer containing both 
functionalised amino acids. Hydrazide formation was achieved on a suspension o f  the 
peptide in a large excess o f  hydrazine hydrate and did not affect the Troc protection  
o f  the lysine residue. Formation o f  the azide w as slow , increased dilution o f  the 
reaction was required to enable solution, however, the azide was successfully formed 
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Thus, it is possible to  couple a monofunctionalised TPP derivative to the prepared 
peptide monomers. The isocyanate synthon, p-nitrophenyl carbamate, is an effective 
electrophile for coupling to  amine containing peptides or more universally to  amine- 
containing drugs. L ikewise, extension o f  the porphyrin, to  give an aliphatic amine 
derivative, provides an effective nucleophile. Although in this work coupling to this 









.N-QyLeuPheGy —<■hr y H
H 1
H
'n' c^ n' zii i 
O Me (275)
NHC02CH2CC13
c o n h n h 2
H
(i) 4N HQ in dio>anc 
DMF / THF/ /-Butyl nitrite 
-2 0  C
(ii) a  4H3NCH2COHNTPP
(83%)








As discussed in earlier chapters, a number of monomers have been prepared, both 
degradable and non degradable, and either containing or not containing porphyrin. To 
prepare polymers from these monomers it is essential to remove the Z protecting 
group. The deprotected monomer can then be allowed to react with activated PEG to 
form a polymer. Following polymerisation, incorporation of manganese, in order to 
measure the relaxivity of the polymer-porphyrin conjugates, must be achieved.
In this chapter, a number of model reactions are reported. Successful deprotection of 
both types of monomers has been achieved. PEG activation, as the diglycidyl ether, 
has also been accomplished. Model polymerisation results have demonstrated the 
feasibility of the intended polymerisation reaction between a bis (secondary amine) 
and a bis diglycidyl ether derivative of PEG.
8.2 Polymerisation Investigations
8.2.1 Reaction between sarcosine and an epoxide
In the first instance, it was essential to confirm that the secondary amine of sarcosine 
would react with an epoxide. ZSarOPFP was allowed to react with a simple amine, 
isopropylamine (Scheme 8.1). This compound was then deprotected and treated with 
the model epoxide, epoxy-3-phenoxypropane.
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Deprotection o f  Z protected peptides can be achieved by numerous methods. The 
most well known method is catalytic hydrogenolysis with palladium on charcoal. 
Many solvents can be used to perform the reaction. Methanol and ethanol are the 
most easy to use, however, solvents such as acetic acid, acetic acid and water 
mixtures and DM F can be used where the peptide is o f  low  solubility 606.
Another popular approach is treatment o f  the peptide with hydrogen bromide in acetic 
acid (HBr /  A cetic acid) 274 287 This was developed by Ben Ishai following from 
reports that hydrogen iodide was successful in the removal o f  Z groups. It is 
particularly attractive, as it can be used to remove Z groups selectively in the presence 
o f  benzyl esters and can afford the deprotection o f  sulphur-containing peptides which  
are known to  poison hydrogenation catalysts. Unfortunately, the hydrobromide salts 
prepared by this route are highly hygroscopic Alternatively, L ew is acids, such as 
trimethylsilyl iodide and boron tribromide, can be used to  afford the cleavage o f  Z 
groups 265.
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Sodium in liquid ammonia ’ can also be used for the removal o f  Z groups. 
H owever, this harsh method is usually confined to  situations where both a Z and 
Tosyl group are to  be removed from a peptide.
In this m odel reaction, deprotection was achieved using the HBr / Acetic acid method  
to  give the hydrobromide salt in 85% yield. Treatment o f  this amine with epoxy-3- 
phenoxypropane in ethanol and base gave (280) in 86% yield. This confirmed the 
feasibility o f  the reaction on which polymerisation w as to  be based (Schem e 8 .1) .
8 .2.2 M odel Polymerisation
8.2.2.1 M odel B is-A m ine M onomers
In order to extend these studies further, a model bis-amine w as prepared to resemble 
the peptide monomers. Initially the model compound chosen was 4 ,9 -d io x a -l,2 -  
dodecane-1,12-diamine. This was successfully treated with ZSarOPFP to give the a ,  
















Deprotection o f  this compound proved troublesome. Treatment with HBr /  Acetic 
acid resulted in the formation o f  tw o products, one o f  which was the desired  
deprotected compound and one that was unidentifiable As prolonged treatment had 
been required to  afford transformation o f  the starting material, cleavage o f  the ether 
bonds may have occurred. In a second approach, the model compound w as subjected 
to catalytic hydrogenolysis. Treatment in THF with hydrogen and palladium gave a 
number o f  products that were not identifiable. To investigate the reaction further, the 
products formed on hydrogenolysis were reprotected with Z. In this reprotection, a 
number o f  products were again formed although, none o f  the original starting material 
w as formed. This suggested that catalytic hydrogenolysis also resulted in the cleavage 
o f  the ether bonds.
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Thus a second model compound w as chosen, nonane- 1,9-diamine. This was easily 
transformed to a diprotected a,© -secondary amine on treatment with ZSarOPFP 
(91% ). This w as then treated, in methanol, with hydrogen and catalyst to  g ive the 

















8 .2 .2 2 Activation o f  PEG
A a,co-bis-electrophilic PEG derivative was then required to  facilitate a model 
polymerisation study. The formation o f  diglycidyl ethers from diols and 
epichlorohydrin is well known but sometimes difficult to  achieve 290. By-products can 
be formed, either the monoglycidyl ethers or oligomers. Simple methods 289 using 
epichlorohydrin and base require prolonged treatment at elevated temperatures e.g. 11 
hours at 60°C. H ow ever, Gu e t a l  290 developed a method in which phase transfer 
catalysts, such as crown ethers and quaternary ammonium salts, could be used to  
enable fast and efficient transformation o f  diols to  diglycidyl ethers using 
epichlorhydrin and sodium hydroxide. Quaternary ammonium salts, such as 
tetrabutylammonium hydrogen sulphate, were most efficient.
Following a modification o f  this method, the a,co-bis-(glycidyl ether) o f  pentaethylene 
glycol w as prepared in 90% yield (Schem e 8.5). H owever, using the published work­
up procedures o f  this method, the phase transfer catalyst is likely to  remain, in part, in 
the product. This was unacceptable, as it could interfere in the polymerisation reaction
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and would be difficult to  remove from any resulting polymer. Thus an alternative 
method was required. Gu et a!., had demonstrated that, better results were obtained 
with higher chain-length glycols, in comparison to  short chains, even in the absence o f  
phase transfer catalyst. These results were further improved by addition o f  the 
catalyst. This w as proposed to be due to increased solubilisation o f  the catalyst in 
epichlorohydrin as the molecular weight o f  the diol increases. H owever, other 
workers 291’292j have proposed that PEG can itself act as a phase transfer catalyst This 
is not surprising as crown ethers, which also contain repeating OCH2CH2 units, are 
effective catalysts. Thus, these workers were able to prepare a number o f a,G>- 
diglycidyl ethers using PEG 400 as a catalyst.
Therefore, it is possible that the effects seen by Gu et al. 290, with the long chain 
glycols, are due to  self-catalysis. To investigate this possibility, the diglycidyl ether o f  
PEG 400 w as prepared using tw o methods (Schem e 8.6). In the first case, the 
derivative w as prepared using the catalyst tetrabutylammonium hydroxide and, in the 
second case, using the same conditions but without the catalyst. Using the catalyst, 
the diglycidyl ether w as successfully prepared. The derivative w as also prepared 
without inclusion o f  the catalyst, although recovery from the reaction mixture was 
reduced, giving a cleaner product. This confirmed the ability o f  PEG 400 to act as a 
catalyst and thus a simpler and cleaner method for the preparation of a,co-diglycidyl 
ethers o f  PEG is available.
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A  model polymerisation reaction was then performed, between the activated PEG  
400, prepared without catalyst, and the model bis-amine (287) (Schem e 8.7). The tw o  
com ponents w ere heated at reflux for 15 hours. N M R  analysis o f  the reaction  
demonstrated the reaction to have reached completion. This w as most elegantly seen  
in the transformation o f  the singlet signal o f  sarcosine CH2 in the monomer to a pair 
o f  doublets, ow ing to  the asymmetric environment, in the ‘polym er’.




















To ascertain the extent of polymerisation and the role of ethanol-based chain 
termination, a sample was subjected to size-analysis using a size-exclusion gel 
permeation column. This analysis was performed by Dr Gareth Price, School of 
Chemistry, University of Bath. The results provided were compared with those for 
both the monomers. These results apparently conflict with the NMR interpretation of 
efficient polymerisation. Only small oligomers appeared to have been prepared. This is 
surprising, since if only small oligomers had been formed, a large number of ‘end 
groups’ (oxiranes and chiral C H 2N H C H 3  units) would remain which would be seen on 
the NMR spectrum.
However, electrospray mass spectral analysis reconciled the apparent dichotomy. A 
series of mass ions were seen which had an identical distribution to those seen with 
PEG 400. PEG 400 is composed of a number of PEG polymers with varying chain 
length; thus, with mass spectral analysis, a number of mass ions are seen which are 
related to the number of CH2CH2O units in each fraction. However, with the sample 
from the ‘polymerisation’, these signals were of mass numbers corresponding to a 
macrocycle formed by the reaction of both epoxides of one PEG chain with both 
amines of one model monomer. This was unexpected as macrocycles are usually very 
difficult to synthesise, requiring high dilution conditions. However, in this reaction, 
the reagents were present in -10% w/v concentration. The formation of the 
macrocycle is probably due to a property of the model bis-secondary amine, perhaps 
its lack of rigidity, or due to the relative length of the two components in solution, 
rather than an intrinsic problem with the polymerisation reaction. This could be 
further investigated by co-polymerising this bis-amine with PEG a,©-diglycidyl ethers 
of different molecular weights.
8.3 Polymerisation of Peptide Monomers
For the polymerisation of the peptide monomers, PEG of mean molecular weight 
1500 was chosen as the co-monomer. This was selected as it is of a similar molecular 
weight to the peptide monomers. Thus, in the polymerisation, an approximately 1:1
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molecular weight polymer will be formed. PEG 1500 w as easily activated as the a,co- 
diglycidyl ether by the method previously described.
In order to  investigate the polymerisation fully, tw o peptide monomers w ere chosen  
to  be polymerised. Firstly, the degradable but non-functionalised monomer (216) and 
secondly, the non-degradable lysine-porphyrin monomer (252). In this way, the effects 
o f  all potentially problematic amino acid residues could be investigated.
M onom er (216) w as deprotected using catalytic hydrogenolysis. As this compound 
w as only sparing soluble in methanol, the reaction w as heated to 60°C , prior to  
addition o f  the catalyst, to  ensure dissolution. Complete loss o f  the protecting groups 
w as observed after 30 hours. The deprotected compound w as then allowed to react 
with the a,co-diglycidyl ether derivative o f  PEG 1500 (294) in ethanol. After 48  
hours, the reaction w as halted by evaporation o f  the solvent (Schem e 8 .8).
( 2 1 6 )
H 2 /  P a l l a d i u m  o n  c h a r c o a l ( 9 8 % )
P E G  1 5 0 0  b i s  ( o x i r a n y l m e t h y l  e t h e r )  
B t h a n o l  /  R e f l u x
4 8 h  ,
(OCH2CH2)hOCH2.
CHjOfCHjCHzO)*,
( 2 9 6 ) m
Scheme 8 .8
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This product was subjected to electrospray mass spectral analysis. However, no 
signals were seen which related to the mass numbers of either the monomers or 
polymers. Equally, NMR analysis did not enable interpretation of polymerisation. Size 
exclusion analysis did however provide promising data. In comparison with a sample 
of the PEG 1500 a,©-diglycidyl ether, a higher molecular weight population was seen 
with the purported polymer. This suggests that some polymerisation has occurred. 
Unfortunately, it appears that some of the epoxide remained unreacted. The degree of 
polymerisation is difficult to ascertain, although it is likely that only small molecular 
weight polymers have been formed.
With the porphyrin monomer, deprotection was more difficult. The compound was of 
low solubility in many simple solvents suitable for hydrogenolysis, however, it was 
soluble in acetic acid. Treatment with hydrogen, in the presence of palladised 
charcoal, resulted in the slow conversion of starting material over 10 days. A number 
of unidentifiable products were prepared. Deprotection with HBr / Acetic acid was 
then investigated. This was highly successful, complete conversion being observed 
after 45 minutes; the product precipitated on addition of ether (Scheme 8.9). NMR 
analysis showed the porphyrin to be protonated at the pyrrolic nitrogens suggesting 
that the product was present as the tetrahydrobromide salt.
The deprotected compound was then allowed to react with PEG 1500 diglycidyl ether 
in boiling ethanol. As the monomer was present as its hydrobromide, five equivalents 
of inorganic base (K2CO3) were also added to the polymerisation. After 48 hours, the 
solution was filtered to remove the base and the solvent was evaporated to halt the 
reaction.
As with the degradable monomer, electrospray mass spectral analysis and NMR 
analysis were unsuccessful in determining the extent of polymerisation. Analysis using 
size exclusion chromatography was also unable to provide confirmation of 
polymerisation. For the purported polymer, the majority of the population was of 
similar size to the monomeric PEG 1500 a,©-diglycidyl ether. Although this may
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mean that polymerisation was unsuccesful, it is more likely due to  an artifact o f  the 
porphyrin in the GPC system. The solubility o f  the polymer in the eluting solvent, 
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8.4 Incorporation of Manganese
In a final step, the incorporation of manganese into the porphyrin was investigated. 
Although, for the polymers, metallation will be the last step following polymerisation, 
the method was developed using deprotected monomers.
The metallation of porphyrins can be achieved in many ways, dependant on the ion to 
be chelated. Lawley and Threadgill 293 investigated the preparation of a manganese 
derivative of TPP. In a modification of the method of Kennedy and Murray, TPP was 
heated at reflux with manganese (II) acetate in DMF. The resulting chelate was 
treated with brine to replace the labile acetate ligand with the more stable chloride 
ligand. However, they were unable to isolate the product without concomitant 
precipitation of sodium chloride.
In a different approach following the method of Adler et al. 294, the nondegradable 
lysine-porphyrin monomer was treated with manganese (H) chloride in DMF (Scheme 
8.10). At reflux both the monomer and the metal are sufficiently soluble to allow 
chelation to take place. The reaction was followed by the UV spectrum of the 
reaction mixture. The starting material had a UV spectrum similar to that of TPP, i.e. 
an etio type spectrum. Thus, a strong Soret band can be seen and in the visible region 
four smaller bands decreasing in intensity with increasing wavelength. As metallation 
occurred a shift in the Soret band was observed along with the disappearance of signal 
I and a change in the structure of peaks n , III and IV. Metallation was extremely 
slow, therefore numerous equivalents of manganese (II) chloride were added. After 
30 hours the reaction was considered to have reached completion. As this compound 
cannot be analysed by NMR, owing to the presence of the paramagnetism, mass 
spectral analysis was undertaken. Unfortunately none of the mass ions obtained were 
identifiable either as expected product or fragments. Therefore, although metallation 
has occurred, as shown by UV, no information has been obtained on the integrity of 
the peptide. As this method involved prolonged heating in DMF, it is possible that the 
peptide has been damaged.
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In a second approach, the same method was used, except that a large excess of 
manganese (II) chloride was added initially and the temperature was carefully 
maintained to ensure reflux (Scheme 8.11). In this case, the non-degradable glutamic 
acid-porphyrin monomer was investigated. After 2 hours, similar changes in the UV 
spectrum were observed and the reaction was halted. Again no information could be 
obtained by mass spectral analysis.
Thus it is essential for further work to be performed on this metallation reaction, 
firstly, to ensure the peptide remains intact and, secondly, to confirm that no free 
manganese (II), which could alter the apparent relaxivity of the polymer preparation, 
is present.
From these model reactions, it is apparent that both polymerisation and metallation of 
the monomers will be easily achieved.
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Synthetic strategies have been successfully developed for the preparation of a co­
polymer of poly(ethylene glycol) and a biodegradable peptide unit and a conjugate of 
this polymer with the potential contrast enhancement agent chlorotetraphenyl- 
porphyrinatomanganese (HI)
Investigations towards the synthesis of a monofimctionalised derivative of tetraphenyl 
porphyrin demonstrated that the monoamine derivative can be easily prepared by the 
method of Kruper et al 257. Initial attempts to extend or modify the functionalisation, 
by incorporation of an aliphatic spacer, resulted in compounds of limited solubility 
which were subsequently difficult to couple to the peptide monomers. However, 
activated monofimctionalised porphyrins were prepared, which could be coupled to 
the peptide monomers extended by a six-carbon chain spacer. Thus, for attachment of 
the porphyrin to a lysine residue, the electrophilic /?-nitrophenyl carbamate was 
successfully prepared. To enhance the nucleophilicity of the amine derivative prior to 
coupling with an activate glutamic acid derivative, a glycine derivative has been 
prepared which provides a more nucleophilic aliphatic amine.
A number of peptide units have been prepared using suitable orthogonal protecting 
groups and an active ester coupling strategy. Ethane-1,2-diamine has been used as a 
retro-inverso sequence. This allows the coupling of sarcosine at both termini of the 
peptide to provide the a,©-bis(secondary amine) monomer required for 
polymerisation with the a,o-bis(glycidyl ether) derivatives of PEG. Initially, three 
non-degradable monomers were prepared in which only one amino acid, glutamic acid 
or lysine, was present, these monomers have suitable functionality for the attachment 
of porphyrin. A further monomer has been prepared in which the degradable sequence 
is present but no functionalised amino acid. These monomers are useful as models for
200
coupling and polymerisation reactions and for comparative purposes in degradability 
studies.
Four peptide monomers have been prepared in which the degradable unit and a 
functionalised amino acid are present. In two sequences, however, lysine is present; in 
one it is situated at the N-terminus of the GlyPheLeuGly sequence and in the other at 
the C-terminus. The lysine moiety in these monomers has been deprotected and 
extended via a spacer unit. In a third monomer glutamic acid has been incorporated at 
the N-terminus. The glutamic acid is derivatised with the spacer, prior to 
incorporation into the peptide sequence. In an alternative approach, a degradable 
monomer has been prepared in which both derivatised glutamic acid and lysine are 
incorporated. This offers great potential, both for increasing the loading of the 
porphyrin onto the peptide and for the incorporation of a targeting moiety to the 
polymer, this monomer has also been successfully deprotected at the lysine s-amine to 
prepare a monomer bearing two six-carbon spacer units.
Nine porphyrin-peptide conjugates have been prepared. With monomers containing 
lysine residues, treatment of either the deprotected lysine or the spacer-extended 
lysine with the electrophilic porphyrin derivative yielded conjugates linked via a urea 
bond. With glutamic acid containing monomers, the peptide was easily activated as 
the azide to couple efficiently to the enhanced nucleophilic porphyrin derivative. With 
the monomer incorporating both glu and lys residues, conjugates have been prepared 
in which the porphyrin is attached either to the lysine or glutamic acid.
Model polymerisation reactions have demonstrated the suitability of the proposed 
polymerisation reaction between a diglycidyl ether and a secondary amine. PEG of 
various chain lengths has been activated as the a,o-bis(glycidyl ether). During model 
studies polymerisation of the activated PEG 400 with sarcosine N-(9-(sarcosyl- 
amino)nonyl)amide resulted in the formation of a macrocycle. However, in 
preliminary polymerisation studies with the GlyPheLeuGly monomer and PEG 1500, 
linear polymer is believed to have been formed. Initial experiments on the
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incorporation of manganese into simple porphyin-peptide monomers have 
demonstrated chelation of the metal. Further evaluation of both polymerisation and 




IR spectra were recorded as liquid films using a Perkin Elmer 782 instrument. UV spectra 
were obtained of solutions in methanol with a Perkin Elmer Lambda 3 spectrometer. ]H 
and 19F NMR data were recorded on a Jeol GX270 spectrometer (270.05 MHz for ’H) 
and a Jeol EX400 (399.65 MHz for *H and 376 MHz for 19F). Tetramethylsilane was 
used as an internal standard for samples dissolved in CDC13 and (CD3)2SO. 19F chemical 
shifts are referenced to external fluorotrichloromethane. Multiplicities are indicated as 
follows s (singlet), d (doublet), dd (double doublet), t (triplet), q (quartet) and m 
(multiplet). Where two sets of data are listed, the compound exists as discrete rotamers at 
ambient temperature. COSY spectra were used to assign signals in the *H spectra where 
stated. Mass spectra were obtained by electron impact (El), chemical ionisation (Cl), fast 
atom bombardment (FAB) or electrospray using a VG7070 spectrometer and are 
reported in the form m/z for selected ions.
Thin layer chromatography was carried out using Merck Kieselgel 60F plates,
visualisation was achieved by UV light and ninhydrin. Solvents systems were :
A : CH2C12 : Hexane (1 : 1)
B : CH2CI2
C : CHCI3 : MeOH (9 : 1)
D : CH2CI2 : Et20  (20 : 1)
E : Et20  : MeOH (1 : 1)
F : CHCI3 : MeOH (19 : 1)
G : C H C I 3
Flash chromatography was performed using Merck Silica Gel 60 (0.040-0.063 mm) flash 
silica. Melting points are uncorrected. All chiral amino acids are (L), unless otherwise 
stated.
Unless otherwise stated all solutions were dried with MgS04 and all solvents evaporated 
under reduced pressure. The following abbreviations have been used throughout the text: 
CH2CI2 (dichloromethane), CHC13 (chloroform), Et20  (diethyl ether). EtOAc (ethyl
acetate), DCC (N,N’-dicyclohexylcarbodiimide), DMF (dimethylformamide), brine 
(saturated aqueous sodium chloride), DMAP (4-dimethylaminopyridine), MeOH 
(methanol), THF (tetrahydrofuran).
5-(4-NitrophenyI)-10,15,20-triphenyl-21H,23//-porphine (90)
Fuming nitric acid (d. 1.5 g ml1) (2.26 ml) was added stepwise during 2 h to a solution of
5,10,15,20-tetraphenyl-2l//,23//-porphine (2.00 g, 3.26 mmol) in ethanol-free CHC13 
(300 ml). After a further 1 h, the solution was washed five times with water (300 ml). 
The solution was dried with a mixture of Na^C^ and MgS04 and the solvent was 
evaporated. Chromatography (CH2CI2 / hexane 3:2) gave 5-(4-nitrophenyl)-l 0,15,20- 
triphenyl-2l//,23//-porphine (1.17 g, 55%) as a purple solid. Mp >300°C
'HNMRCCDClj)
6 -2.75 (2 H, s, 21,23-H2), 7.75 (9 H, m, 3 x Ph 3,4,5-H}), 8.20 (6 H, m, 3 x Ph 2,6-H2), 
8.36 (2 H, d, J  = 8.3 Hz, disubstituted aromatic-H2), 8.60 (2 H, d, J  = 8.7 Hz, 
disubstituted aromatic-H2), 8.71 (2 H, dyJ=  4.8 Hz, 2t3,7,8,12,13,17,18-H1\  8.87 (6 H, 
m, 2,3,7,8,12,13,17,18-Ht).
T.L.C. (A) Rf = 0.38
4-(10,15,20-Triphenyl-21//,23//-porphin-5-yI)benzeneamine (93)
Tin (II) chloride (0.595 g, 2.64 mmol) was added to 5-(4-nitrophenyl)-10,15,20-tri- 
phenyl-2l//,23//-porphine (580 mg, 0.88 mmol) in aq. HC1 (9M, 20 ml). The solution 
was heated at 65°C for 2 h and then allowed to cool. The solution was added to water 
(70 ml) and taken to pH 8 by the addition of concentrated aq. ammonia. The suspension 
was extracted nine times with CHC13. The organic layer was dried and the solvent was 
evaporated. Chromatography (CH2C12 / hexane 5:1) gave 4-(10,15,20-triphenyl- 
21//,23//-porphin-5-yl)benzeneamine (462 mg, 84%) as a purple solid. Mp > 300°C
'HNMR(CDC13)
8 -2.76 (2 H, s, 21,23-Hi), 3.98 (2 H, br, NH2), 7.05 (2 H, d , J =  8.6 Hz, disubstituted 
aromatic-H2), 7.77 (9 H, m, 3 x Ph 3,4,5-H3), 8.02 (2 H, d, J  = 8.2 Hz, disubstituted
aromatic-H2), 8.26 (6 H, m, 3 x Ph 2,6-H2), 8.87 (6 H, m, 2,3,7,8,12,13,17,18-^*), 8 98 
(2 H, d, J = 4.9 Hz, 2,3,7,8,12,13,17,18-H2)
T.L.C. (B) Rf= 0.53
4-Oxo-4-(4-(10,15,20-triphenyl-21//,23//-porphin-5-yl)phenylamino)butanoic acid 
(105)
Succinic anhydride (79 mg, 0.79 mmol) was added to 4-( 10,15,20-triphenyl-2\H,23H- 
porphin-5-yl)benzeneamine (500 mg, 0.79 mmol) in ethanol-free C H C I 3  (20 ml). The 
mixture was boiled under reflux for 4 h. The mixture was cooled to ambient temperature 
and the precipitated solid was collected by filtration to give 4-oxo-4-(4-(l 0,15,20- 
triphenyl-21//,23//-porphin-5-yl)phenylamino)butanoic acid (502 mg, 87%) as a purple 
solid. Mp > 300°C
‘HNMR(CDClj)
8 - 2.9 (2 H, s, 2/,2J-H2), 2.67 (2 H, d, J=  5.5 Hz, NHCOCTfcCHjCOjH), 2.74 (2 H, d, 
J  = 5.5 Hz, NHCOCHjCHjCOjH), 7.82 (9 H, m, 3 x Ph 3,4,5-Hj), 8.06 (2 H, d, 
J=  8.8 Hz, disubstituted aromatic-H2), 8.15 (2 H, d, J  = 8.8 Hz, disubstituted aromatic- 
H2), 8.23 (6 H, m, 3 x Ph 2,6-H2), 8.82 (6 H, m, 2,3,7,8,12,13,17,18-11*), 8.91 (2 H, d, 
J=  4.7 Hz, 2,3,7,8,12,13,17,7<5-H2), 10.46 (1 H, s, NH), 12.06 (1 H, br, OH)
T.L.C. (C) Rf = 0.67 
MS (FAB+) 730 (M + H).
Microanalysis C4.H33N3 Found C 77.1% H 4.69% N 9.3% Calc'd. C 78.99% 
H 4.83% N 9.59%.
N-Butyl-N’-(4-(10,15,20-triphenyl-21//,23//-porphin-5-yI)phenyI)butanediamide
(110)
4-Oxo-4-(4-( 10,15,20-triphenyl-2 l//,23//-porphin-5-yl)phenylamino)butanoic acid
(493 mg, 0.68 mmol) was treated with oxalyl chloride (345 mg, 2.72 mmol) in THF 
(20 ml) and DMF (1.00 ml) for 1 h. The solvent and excess reagent were evaporated and 
the residue in THF (20 ml) was treated with butylamine (303 mg, 4.15 mmol). The
solution was stirred for 24 hours and then the solvent and excess reagent was evaporated. 
Chromatography (Et20 : EtOAc 1:1) gave a material characterised as 5-(4- 
succinimido)phenyl-10,15,20-triphenyl-21//,23//-porphine as a purple glass (150 mg, 
21%).
‘HNMR(CDClj)
8 -2.78 (2 H, s, 21,23-Hi), 3.03 (4 H, s, NCOCH2CH2CO2), 7.70 (2 H, d, J =  8.5 Hz, 
disubstituted aromatic-H2), 7.78 (9 H, m, 3 x Ph 3,4,5-H3), 8.21 (6 H, m, 3 x Ph 2,6-H2), 
8.32 (2 H, d, J=  8.0 Hz, disubstituted aromatic-H2), 8.85 (8 H, m, 2,3,7,8,12,13,17,18- 
Hg)
T.L.C. (C) Rf = 0.81
Methyl 6-oxo-6-(4-(10,15,20-triphenyI-21//,23//-porphin-5-yI)phenylamino)-
hexanoate (114)
Hexanedioic acid monomethyl ester (1.00 g, 6.24 mmol) in CH2C12 / DMF was treated 
with oxalyl chloride (1.58 g, 12.49 mmol) and the solution was stirred for 18 h. The 
solvent and excess reagent were evaporated. A portion of the acid chloride (1 mmol) was 
added to 4-( 10,15,20-triphenyl-2 l//,23//-porphin-5-yl)benzeneamine (629 mg,
1.00 mmol) and N,N-diisopropylethylamine (258 mg, 1.00 mmol) in CH2C12(20 ml). The 
solution was stirred for 24 h and was then washed with water, cold 10% aq. H2S04 and 
10% aq. Na2C03. The solution was dried and the solvent was evaporated to give methyl 
6-oxo-6-(4-( 10,15,20-triphenyl-2 l//,23//-porphin-5-yl)phenylamino)hexanoate (620 mg, 
80%) as a purple glass.
‘H NMR (CDC13)
8 -2.79 (2 H, s, 21,23-H2), 1.86 (4 H, m, CHjCHjC&CHj), 2.44 (2 H, t, J  = 6.8 Hz 
COCHjCHjCHjCHjCO), 2.53 (2 H, t,J =  6.8 Hz, COCHjCHjCHjCHjCO), 3.82 (3 H, 
s, OCHj) 7.75 (9 H, m, 3 x Ph 3,4,5-Hj), 7.91 (2 H, d, J  = 8.3 Hz, disubstituted 
aromatic-H2), 8.14 (2 H, d, J=  8.3 Hz, disubstituted aromatic-H2), 8.22 (6 H, m, 3 x Ph 
2,6-H2), 8.84 (6 H, m, 2,3,7,8,12,13,17,18^), 8.87 (2 H, d, J  = 4.9 Hz,
2,3,7,8,12,13,17,18-H2)
iv
T.L.C. (C) Rf = 0.83 
MS (FAB+) 772 (M + H)
6-Oxo-6-(4-(10,15,20-triphenyl-21//,23//-porphin-5-yI)phenylamino)hexanoic acid
(115)
Methyl 6-oxo-6-(4-( 10,15,20-triphenyl-2 177,23//-porphin-5-yl)phenylamino)hexanoate
(530 mg, 0.69 mmol) was stirred at reflux with NaOH (500 mg, 12.5 mmol) in MeOH 
(40 ml) and water (2 ml) for 5 d. Hydrochloric acid (9 M, 1.25 ml) was added and the 
suspension was filtered to remove precipitated NaCl. The solvent was evaporated from 
the filtrate to give a purple glass which was shown by MS to comprise a mixture of the 
educt and the product.
MS (FAB+) 772 (M+H for ester), 758 (M+H for acid).
Methyl 6-aminohexanoate hydrochloride (117)
Thionyl chloride (10 ml) was added slowly to a suspension of 6-aminohexanoic acid (6 g,
45.8 mmol) in MeOH (50 ml) and the resulting solution was stirred for 2 d. The solvent 
and excess reagent were evaporated to give methyl 6-aminohexanoate hydrochloride 
(8.32 g, quantitative) as a white crystalline solid. Mp 81-83°C
‘H NMR (CDClj)
8 1.45 (2 H, m, NCHjCHjClfcCHjCH^, 1.64 (2 H, m, NCHjC&CHiOtCH^, 1.73 (2 
H, br, NCHjCHjCHjCHzCHj), 2.34 (2 H, t, J  = 7.2 Hz, NCHjCHjCHjCHjCHj), 3.03 





Phosgene in toluene (20%, 2.22 ml, 4.2 mmol) was added to 4-(10,15,20-triphenyl- 
2 l//,23//-porphin-5-yl)benzeneamine (1.32 g, 2.1 mmol), triethylamine (850 mg,
8.4 mmol) in CH2CI2 . The solution was stirred for 6 h. The solvent and excess reagent 
were evaporated. The residue was dissolved in CH2CI2 . Methyl 6-aminohexanoate hydro­
chloride (381 mg, 2.10 mmol) and triethylamine (213 mg, 2.10 mmol) were added. The 
solution was stirred for 24 h and the solvent was evaporated. Chromatography (CH2CI2 
then CH2CI2 / MeOH 40:1) gave methyl 6-(N'-(4-( 10,15,20-triphenyl-2 l//,23//-porphin-
5-yl)phenyl)ureido)hexanoate (1.04 g, 62%) and 6-(N'-(4-( 10,15,20-triphenyl-21//,23//- 
porphin-5-yl)phenyl)ureido)hexanoic acid (286 mg, 17%) as purple glasses.
'H  NMR ((CD3)jSO)
8 -2.90 (2 H, s, 21,23-H2), 1.38 (2 H, m, NCH2CH2CH2 CH2CH2), 1.57 (4 H, m, 
NCHjCHjC^CHjCHj), 2.27 (2 H, t, J=  7.3 Hz, NCH2CH2CH2CH2CH2 ), 3.19 (2 H, m, 
NCH2CH2CH2CH2CH2), 3.35 (3 H, s, OCH3), 6.37 (1 H, m, NHCH2), 7.83 (11 H, m, 3 
x Ph 3,4,5-Hj + disubstituted aromatic-H2), 8.07 (2 H, d, J  = 8.4 Hz, disubstituted 
aromatic-H2), 8.22 (6 H, m, 3 x Ph 2,6-H2), 8.82 (6 H, br, 2,3,7,8,12,13,17,18-Hj) 8.92 
(2 H, t ,7  = 4 .7H z,2,3,7,8,12,13,17,78-H2), 12.06(1 H, s,NHCO)
T.L.C. (C )R f= 0  65
‘HNMR(CDClj)
8 -2.90 (2 H, s, 21,23-Hi), 1.26 (2 H, m, NCHjCHjCHjCHjCHj), 1.55 (2 H, m, 
NCH2CH2CH2CH2CH2), 2.23 (2 H, t, J=  7.9 Hz, NCHjCHjCHjCHjCHj), 3.19 (2 H, q, 
J=  7.9 Hz, NCHjCHjCHjCHjCHj), 6.45 (1 H, m, NHCH2), 7.32 (2 H, d, J  = 7.9 Hz, 
disubstituted aromatic-H2), 7.59 (9 H, m, 3 x Ph 3,4,5-H3), 7.88 (2 H, d, J  = 8.0 Hz, 
disubstituted aromatic-H2), 8.12 (6 H, m, 3 x Ph 2,6-H2), 8.82 (8 H, m,
2,3,7,8,12,13,17,18-Hs)
T.L.C. (C) Rf = 0.27
vi
N-(6-(l,l-Dimethylethoxycarbonylamino)hexanoyl)leucine methyl ester 
hydrochloride (122)
2,4,5-Trichlorophenyl 6-(l,l-dimethylethoxycarbonylamino)hexanoate (3.50 g, 
8.52 mmol) was added to leucine methyl ester hydrochloride (1.55 g, 8.52 mmol), N,N- 
diisopropylethylamine (2.20 g, 17.04 mmol) and DMAP (10 mg) in CH2C12 (30 ml). The 
solution was stirred for 4 d and 2,4,5-trichlorophenyl 6-(l,l-dimethylethoxycarbonyl- 
amino)hexanoate (1.75 g, 4.26 mmol) was added. The solution was stirred for 3 d and 
was then washed with cold 10% aq. H2S04 and with 10% aq. Na2C03. The solution was 
dried and the solvent was evaporated. Chromatography (EtOAc / hexane 1:1) yielded 
N-(6-(l,l dimethylethoxycarbonylamino)hexanoyl)leucine methyl ester (2.07 g, 68%) as 
a pale yellow oil.
*H NMR ( C D C I 3 )
6 0.87 (3 H, d, J  = 6.1 Hz, Leu-H3), 0.91 (3 H, d, J  = 6.1 Hz, Leu-H3), 1.35 (2 H, m, 
NCH2CH2CH2CH2CH2), 1.42 (12 H, m, Bu-t, + Leu 0-H2 + NCH2CH2CH2CH2CH2), 
1.65 (4 H, m, Leu y-H + Leu p-H2, + NCH2CH2CH2CH2CH2), 2.22 (2 H, t, J = 7.4 Hz, 
NCH^H^HjCHzCIL), 3.13 (2 H, m, NCH2CH2CH2CH2CH2), 3.73 (3 H, s, OCH3),
4.64 (2 H, m, Leu a-H + NH), 5.88 (1 H, d,J=  7.9 Hz, Leu-NH)
T.L.C. (C) Rf = 0.34
N-(6-Aminohexanoyl)leucine methyl ester hydrochloride (123)
Hydrogen chloride was passed through N-(6-( 1,1 -dimethylethoxycarbonylamino)- 
hexanoyl)leucine methyl ester (1.91 g, 5.33 mmol) in CH2C12 for 20 min. The solvent and 
excess reagent were evaporated to give N-(6-aminohexanoyl)leucine methyl ester 
hydrochloride (1.57 g, quantitative) as a yellow oil.
'H NMR ((CD3)2SO)
5 0.82 (2 H, d, J  = 6.4 Hz, Leu-Hj), 0.87 (2 H, d, J =  6.4 Hz, Leu-H3), 1.29 (2 H, m, 
NCHjCHjCHjCHjCHj), 1.55 (7 H, m, Leu 3-H2 + Leu y-H + NCH2CH2CH2CH2CH2),
2.11 (2 H, t , J=  7.3 Hz, NCH2CH2CH2CH2CH2), 2.69 (2 H, m, NCHjCHjCHjCHjCHj), 
4.25 (1 H, m, Leu a-H), 8.07 (3 H, br, NHJ+), 8.25 (1 H, d, J =  7.5 Hz, NHCH2)
T.L.C. (C)Rf=0.12
N-(6-(N’-(4-(10,15,20-Triphenyl-21//,23ff-porphin-5-yl)phenyl)ureido)heiaaoyl>- 
leucine methyl ester (124)
Phosgene in toluene (20%, 0.72 ml, 1.36 mmol) was added to triethylamine (275 mg,
2.7 mmol) in CH2C12 (20 ml). 4-( 10,15,20-Triphenyl-2l//,23//-porphin-5-yl)benzene- 
amine (426 mg, 0.68 mmol) was added during 10 min and the solution was stirred for 
3 h. Phosgene in toluene (20%, 0.36 ml, 0.68 mmol) was added and stirring was 
continued for 1 h. Phosgene in toluene (20%, 1.08 ml, 2.04 mmol) was added and stirring 
continued for 1.5 h. The solvent and excess reagent were evaporated. The residue was 
dissolved in CH2C12 (20 ml). N-(6-Aminohexanoyl)leucine methyl ester hydrochloride 
(100 mg, 0.34 mmol) and triethylamine (69 mg, 0.68 mmol) were added. The solution 
was stirred for 24 h. Chromatography (CH2C12 / MeOH 15:1) gave N-(N-(N-(N-4- 
(10,15,20-triphenyl-2 l//,237/-porphin-5-yl)phenylamino)ureido)-6-hexanoyl)leucine 
methyl ester (115 mg, 37%) as a purple glass.
*H NMR ( C D C I 3 )
5 -2.78 (2 H, br, 21,23-H2), 0.93 (3 H, d, J=  6.2 Hz, Leu-H3), 0.94 (3 H, d, J = 5.9 Hz, 
Leu-Hs), 1.4-1.8 (6 H, m, NCHjCILCHjCHzCHj), 2.31 (2 H, t, J  = 7.3 Hz, 
NCH2CH2CH2CH2CH2), 3.31 (2 H, m, NCH2CH2CH2CH2CH2), 3.75 (3 H, s, OCH3),
4.65 (1 H, m, Leu a-H), 6.03 (1 H, d, J=  7.3 Hz, Leu NH), 6.96 (1 H, br, NH), 7.55 
(2 H, d, J=  8.1 Hz, disubstituted aromatic-H2), 7.7 (9 H, m, 3 x Ph 3,4,5-H3), 8.03 (2 H, 
d, J -  8.4 Hz, disubstituted aromatic-H2), 8.2 (6 H, m, 3 x Ph 2,6-H2), 8.77 (2 H, d, J  -
4.8 Hz, 2,18-H2), 8.85 (4 H, m, 7,8,12,13-^1 8.90 (2 H, d, J=  4.8 Hz, 3,17-H2)
T.L.C. (C) Rf = 0.50
Acc. Mass 914.4409 (M + H) ( C ^ N ^  requires 914.4394)
5-(4-(4-Nitrophenoxycarbonylamino)phenyl)-10,15,20-triphenyl-21/7,23i/-porphine
(125)
4-Nitrophenyl chloroformate (1.36 g, 6.74 mmol) was added to 4-(10,15,20-triphenyl- 
2l//,23//-porphin-5-yl)benzeneamine (4.15 g, 6.74 mmol) and N,N-diisopropylethyl- 
amine (867 mg, 6.74 mmol) in CHC13 (50 ml). The solution was stirred for 24 h. The 
solvent was evaporated. Chromatography (EtOAc / hexane 1:3) yielded 5-(4-(4-nitro- 
phenoxycarbonylamino)phenyl)-10,15,20-triphenyl-2l//,23//-porphine (4.51 g, 86%) as a 
purple glass.
'H NMR (CDC13)
8 -2.73 (2 H, br, 21,23-H,), 7.36 (2 H, d, J =  9.2 Hz, Ar-2,6), 7.76 (11 H, m, 3 x Ph
3,4,5-H3 + disubstituted aromatic-H2), 8.22 (10 H, m, 3 x Ph 2,6-H2 + disubstituted 
aromatic-H2 + Ar-3,5), 8.84 (8 H, m, 2,3,7,8,12,13,17,18-H8)
T.L.C. (C) Rf = 0.95
N-(l,l-DimethylethoxycarbonyI)glycine pentafluorophenyl ester (126)
N-(l,l-Dimethylethoxycarbonyl)glycine (59.14 g, 340 mmol) in EtOAc (300 ml) was 
cooled to 0°C. DCC (70.1 g, 340 mmol) and pentafluorophenol (62.6 g, 340 mmol) were 
added and the suspension was stirred for 48 h at 0°C. The suspension was filtered and the 
solvent was evaporated. The residue was dissolved in EtOAc and was filtered to give N- 
(l,l-dimethylethoxycarbonyl)glycine pentafluorophenyl ester (115.3 g, 99%) as a white 
wax.
'HNMR(CDC1j)
8 1.46 (9 H, s, Bu-t), 4.28 (2 H, d, J  = 6.1 Hz, Gly-H2), 5.12 (1 H, br, NH) 
I9FNMR(CDC13)
8 -152.7 (2 F, d, J=  19 Hz, 2,6-Ar), -157.75 (1 F, t, J =  23 Hz, 4-Ar), -162.4 (2 F, t, 
J=  23 Hz, 3,5-Ar)
X
8 -153.2 (2 F, d, J=  19 Hz, 2,6-Ar), -157.65 (1 F, t, J  = 23 Hz, 4-Ar), -162.3 (2 F, t, 
7=  23 Hz, 3,5-Ar)
T.L.C. (C) Rf = 0.95
5-(4-(N-(l,l-DimethylethoxycarbonyI)glycylamino)phenyI)-10,15,20-triphenyI-21//- 
237/-porphine (127)
N-(l,l-Dimethylethoxycarbonyl)glycine 95.58 g, 16.3 mmol) was added to 4-(10,15,20- 
triphenyl-21 //,23//-porphin-5-yl)benzeneamine (5.00 g, 8.2 mmol) in C H C I 3  (40 ml). The 
solution was heated at 40°C for 46 h. The solvent was evaporated. Chromatography 
( C H C I 3  / EtOAc 10:1) gave 5-(4-(N-(l,l-dimethylethoxycarbonyl)glycylamino)phenyl)-
10,15,20-triphenyl-2l//-23//-porphine (6.00 g, 95%) as a deep purple glass.
‘HNMR(CDC13)
8 1.56 (9 H, s, Bu-t), 4.08 (1 H, s, Gly-H2). 4.11 (1 H, s, Gly-H2), 5.48 (1 H, br, 
Gly-NH), 7.73 (9 H, m, 3 x Ph 3,4,5-H3), 7.92 (2 H, d, J  = 8.4 Hz, disubstituted 
aromatic-H2), 8 .18 (8H ,m ,3  xPh  2,6-H2 + disubstituted aromatic-H2), 8.83 (6 H, s,
2,3,7,8,12,13,17,18-Ht), 8.85 (2 H, t, 7=4.8 Hz, 2,3,7,8,12,13,17,18-U2)
T.L.C. (C) Rf = 0.88
5-(4-GlycyIaminophenyl)-1045,20-triphenyl-21i/-23//-porphine trihydrochloride 
(128)
Hydrogen chloride was passed through 5-(4-(N-(l,l-dimethylethoxycarbonyl)glycyl- 
amino)phenyl)-10,15,20-triphenyl-21//-23//-porphine (2.24 g, 2.9 mmol) in CH2C12 
(30 ml) for 1 h. The solvent and excess reagent were evaporated to reveal 5-(4-glycyl- 
aminophenyl)-10,15,20-triphenyl-2 l//-23//-porphine trihydrochloride (2.27 g,
quantitative) as an emerald green glass.
xi
’HNMR((CD3)2SO)
8 0 . 3 4  ( 2  H, br, 21,22,23,24-V^), 0 . 4 5  ( 2  H ,  br, 21,22,2,24-K , ) ,  4 . 0 7  ( 2  H ,  m ,  Gly-H2), 
7 . 8 6 - 8 . 8 4  ( 3 1  H ,  m ,  3  x Ph 2 , 3 , 4 , 5 , 6 - H 5 + disubstituted aromatic-H4 + 
2,3,7,8,12,13,17,7 8 - H g  +  N H  +  N H j * )
T.L.C. (C) Rf = 0.28
N - (  1, l-DimethyIethoxycarbonyl)sarcosine (151)
Di-f-butyl dicarbonate (52.1 g, 239 mmol) in dioxane (200 ml) was added to sarcosine 
(20.0 g, 225 mmol) in water (100 ml) containing sodium hydroxide (12.7 g, 318.4 mmol) 
and stirred for 12 h. Water (200 ml) was then added and stirring continued for 6 h. The 
reaction was washed with Et20  (300 ml). EtOAc (300 ml) was added to the aqueous 
layer and the aqueous layer acidified by the addition of 10% aq. H2S04. A white 
precipitate formed in the aqueous layer which slowly dissolved in the organic layer. When 
no more precipitate formed, the EtOAc layer was dried and the solvent was evaporated 
to give N-(l,l-dimethylethoxycarbonyl)sarcosine (35.53g, 84%) as a white crystalline 
solid. Mp 87-89°C (Lit.296 mp. 89-90°C)
'HNMRtCDCIs)
8 1.34 (9 H, s, Bu-t), 2.78 (2 H, s, Sar-H3), 3.83 (2 H, s, Sar-H2)
8 1.39 (9 H, s, Bu-t), 2.82 (2 H, s, Sar-H3), 3.84 (2 H, s, Sar-H2)
T.L.C. (C)Rf=0.37
N-(l,l-DimethylethoxycarbonyI)sarcosine 4-nitrophenyl ester (152)
4-Nitrophenol (1.47 g, 10.58 mmol) was added to a stirred solution of N-(l,l-dimethyl-
ethoxycarbonyl)sarcosine (2 g, 10.6 mmol) in dry dioxane (30 ml). After 15 min, DCC
(2.18 g, 10.6 mmol) in dry dioxane (10 ml) was added to the stirred solution. Stirring was 
continued for 2 h at ambient temperature and the mixture allowed to stand at 4°C for
16 h. The suspension was allowed to warm to ambient temperature and was then filtered. 
The solvent was evaporated from the filtrate to give N-(l,l-dimethylethoxycarbonyl)- 
sarcosine 4-nitrophenyl ester (2.82 g, 64.5%) as an pale orange oil.
‘h NMR(CDC13)
8 1.47 (9 H, s, Bu-t), 3.04 (3 H, s, Sar-Hj), 4.19 (2 H, s, Sar-H2), 7.31 (1 H, d, 
J=  8.8 Hz, Ar-2,6), 7.33 (1 H, d, J=  8.8 Hz, Ar-2,6), 8.27 (1 H, d, J =  9.4 Hz, Ar-3,5),
8.30 (1 H, d, J  = 9.4 Hz, Ar-3,5)
8 1.49 (9 H, s, Bu-t), 3.02 (3 H, s, Sar-Hj), 4.26 (2 H, s, Sar-H2), 7.31 (1 H, d, 
J=  8.8 Hz, Ar-2,6), 7.33 (1 H, d, J = 8.8 Hz, Ar-2,6), 8.27 (1 H, d , J=  9.4 Hz, Ar-3,5),
8.30 (1 H, d, J  = 9.4 Hz, Ar-3,5)
T.L.C. (C) Rf = 0.95 
MS (Cl) 311 (M + H).
N-(l,l-Dimethylethoxycarbonyl)sarcosine N-(2-aminoethyl)amide (153)
Ethane-1,2-diamine (12.0 g, 200 mmol) in CHJC^ (250 ml) was added dropwise over 
30min to a stirred solution of N-(l,l-dimethylethoxycarbonyl)sarcosine 4-nitrophenyl 
ester (2.96 g, 10 mmol) in (50 ml). After 2 h, the reaction mixture was washed
once with water (50 ml) and twice with 10% aq. Na^C^ (50 ml). The CH2C12 layer was 
dried with Na^C^ and the solvent was evaporated to give N-(l,l-dimethylethoxy- 
carbonyl)sarcosine N-(2-aminoethyl)amide (2.27 g, 93%) as a pale orange oil.
*H NMR (CDC13)
8 1.47 (9H, s, Bu-t), 1.92 (2 H, br, NH2), 2.84 (2 H, t, J=  5.8 Hz, CHjNHj), 2.95 (3 H, 
s, Sar-H3), 3.33 (2H, q , J =  5.8 Hz, CHjNH), 3.87 (2 H , s, Ar-CH2), 6.68 (1 H, br, NH)
T.L.C. (D)Rf= 0.28 
MS (Cl) 232 (M + H)
xiii
Fluoren-9-ylmethyl pentafluorophenyl carbonate (156)
Fluoren-9-ylmethyl chloroformate (2.00 g, 7.7 mmol) and pentafluorophenol (1.42 g,
7.7 mmol) were dissolved in Et20  (50 ml) and cooled to 0°C. Triethylamine (1.1 ml) was 
added dropwise to the stirred solution and stirring continued for 2 h. The solution was 
then washed three times with water (50 ml) and dried. The solution was then treated with 
charcoal. The solvent was evaporated to give fluoren-9-ylmethyl pentafluorophenyl 
carbonate (2.71 g, 87%) as a white solid. Mp 72 - 74°C (Lit. 270 mp. 84 - 8 6 °C).
T.L.C. (C) Rf = 0.95
N-(Phenylmethoxycarbonyl)sarcosine (158)
Phenylmethyl chloroformate (27.0 g, 158 mmol) was added slowly to sarcosine (11.74 g, 
132 mmol) in water (20 ml) containing NaOH (10.52 g, 264 mmol) and the mixture was 
stirred vigorously. After 5 h, the solution was washed with Et20  (20 ml) then acidified by 
addition of 10% aq. HSC^and extracted into EtOAc. The EtOAc layer was then washed 
with brine and dried. The solvent was evaporated to give N-(phenylmethoxycarbonyl)- 
sarcosine (27.98 g, 95%) as a colourless oil.
'HNMR(CDC13)
8  2.99 (3 H, s, CHj), 4.03 (2 H, s, Sar-H2), 5.13 ( 2  H, s, Ar-CHj), 7.35 (5 H, m, Ar),
8.70 ( 1  H, br, OH)
8  2.99 (3 H, s, CHj), 4.08 (2 H, s, Sar-H2), 5.16 (2 H, s, Ar-CH2), 7.35 (5 H, m, Ar),
8.70 ( 1  H, br, OH)
T.L.C. (C) Rf = 0.29
xiv
N-(PhenyImethoxycarbonyl)sarcosine 4-nitrophenyl ester (159)
4-Nitrophenol (1.53 g, 11 mmol) was added to a stirred solution of N-(phenylmethoxy- 
carbonyl)sarcosine (2.47 g, 11 mmol) in dry dioxane (20 ml). After 15 min, DCC (2.27 g, 
11 mmol) was added and the solution stirred for 2 h. The suspension was allowed to 
stand at 4°C for 16 h, then warmed to room temperature before being filtered. The 
solvent was evaporated from the filtrate to give N-(phenylmethoxycarbonyl)sarcosine 4- 
nitrophenyl ester (3.81 g, quantitative) as a yellow oil.
'H NMR (CDClj)
8  3.11 (3 H, s, Sar-Hj), 4.33 (2 H, s, Sar-H2), 5.19 (2 H, s, Ar-CH2), 7.35 ( 7  H, m, Ar + 
Ar’-2,6), 8.26 (2 H, m, Ar’-3,5)
8  3.12 (3 H, s, Sar-Hj), 4.27 (2 H, s, Sar-H2), 5.18 (2 H, s, Ar-CH2), 7.35 (7 H, m, Ar + 
Ar’-2,6), 8.26 (2 H, m, Ar’-3,5)
T.L.C. (C) Rf = 0.90
N-(Phenylmethoxycarbonyl)sarcosine N-(2-aminoethyI)amide (160)
Ethane-1,2-diamine (18.36 g, 306 mmol) in (300 ml) was added dropwise during
30 min to a stirred solution of N-(phenylmethoxycarbonyl)sarcosine 2,4,5-trichlorophenyl 
ester (6.16 g, 15.3 mmol) in CHjC^ (50 ml). The solution was stirred overnight and then 
washed once with water (50 ml) and twice with 10% aq. NajCC^ (20 ml). The solution 
was dried and the solvent was evaporated to give N-(phenylmethoxycarbonyl)sarcosine 
N-(2-aminoethyl)amide (4.01 g, 99%) as a yellow oil.
This compound was also prepared using N-(phenylmethoxycarbonyl)sarcosine 4-nitro­
phenyl ester and using N-(phenylmethoxycarbonyl)sarcosine pentafluorophenyl ester.
'HNMR(CDC13)
8  1.81 (2 H, br, NH2) 2.75 (2 H, m, CHj-NHj), 3.01 (3 H, s, CHj), 3.26 (2 H, m, CHj- 
NH), 3.91 (2 H, s, Sar-Hj), 5.14 (2 H, s, Ar-CH2), 6.42 (1 H, br, NH), 7.34 (5 H, m, Ar)
XV
T.L.C. (E) Rf = 0.21 
MS (Cl) 266 (M+H).
N-(l,l-Dimethylethoxycarbonyl)glutamic acid a-pentafluorophenyl ester y-phenyl- 
methyl ester (162)
N-( 1,1 -Dimethylethoxycarbonyl)glutamic acid y-phenylmethyl ester (1.00 g, 2.9 mmol) 
in dry dioxane (10 ml) was cooled to 0 °C. DCC (0.50g, 2.9 mmol) and pentafluorophenol 
(0.53 g, 2.9 mmol) were added to the stirred solution. The resulting suspension was 
stirred for 1 h at 0°C and 1 h at ambient temperature. The suspension was then filtered 
and the solvent was evaporated from the filtrate to give N-(l,l-dimethylethoxycarbonyl)- 
glutamic acid a-pentafluorophenyl ester y-phenylmethyl ester (1.4 g, 96%) as a white 
solid. Mp 78 - 80°C.
'HNMR(CDClj)
6  1.45 (9 H, s, Bu-t), 1.21-1.47 (4 H, m, Glu P,y-H2), 4,70 (1 H, m, Glu a-H), 5.15 ( 2  H, 
s, Ar-CH2), 5.18 (1 H, m, NH), 7.36 (5 H, s, Ar)
19F NMR (CDCt3)
8  -153.1 (2 F, d, J =  20 Hz, 2,6-Ar), -159.2 (1 F, t, J  = 20 Hz, 4-Ar), -162.9 (2 F, t, 
J=  20 Hz, 3,5-Ar)
T.L.C. (F)Rf=0.88
N-(Ll-DiinethyIethoxycarbonyl)glutamic acid a-(N-(2-(N-(phenylmethoxy- 
carbonyl)sarcosyl)amino)ethyl)amide y-phenylmethyl ester (163)
N-(l,l-Dimethylethoxycarbonyl)glutamic acid a-pentafluorophenyl ester y-phenylmethyl 
ester (0.30 g, 1.1 mmol) was stirred with N-(phenylmethoxycarbonyl)sarcosine N-(2- 
aminoethyl)amide (0.569 g, 1 .1  mmol) and N,N-diisopropylethylamine (0.16 g, 
1.24 mmol) in C ^C lj (30 ml) for 20 h. The reaction mixture was washed once with cold
xvi
10% aq. t^SO ^lO  ml) and once with saturated aq. NaHCO3(10 ml). The solution was 
dried and the solvent was evaporated. Chromatography (CHCI3 / MeOH 10:1) gave N- 
(1,1 -dimethylethoxycarbonyl)glutamic acid a-(N-(2-(N-(phenylmethoxycarbonyl)-
sarcosyl)amino)ethyl)amide y-phenylmethyl ester (440 mg, 75%) as buff crystals. Mp 
134-136°C.
‘H NMR (CDCIa)
8  1.42 (9 H, s, Bu-t), 1.91 (2 H, m, Glu P-H2), 2 .11 (2 H, m, Glu y-H2), 3.00 (3 H, s, 
Sar-Hj), 3.35 (4 H, br, NCH2CH2N), 3.89 (3 H, s, Sar-H2), 4.10 (1 H, m, Glu a-H), 5.11 
(2 H, s, Ar-CH2), 5.16 (2 H, s, Ar-CH2), 5.47 (1 H, m, NH), 6.76 (2 H, br, 2 x NH),
7.34 (10 H, m, Ar)
8  1.42 (9 H, s, Bu-t), 1.91 (2 H, m, Glu P-H2), 2.11 (2 H, m, Glu y-H2), 3.00 (3 H, s, 
Sar-H3), 3.35 (4 H, br, NCH2CH2N), 3.90 (3 H, s, Sar-H2), 4.10 (1 H, m, Glu a-H), 5.11 
(2 H, s, Ar-CH2), 5.16 (2 H, s, Ar-CH2), 5.47 (1 H, m, NH), 6.76 (2 H, br, 2 x NH),
7.34 (10H,m , Ar)
T.L.C. (C )Rf= 0.63
Glutamic acid a-(N-(2-(N-(phenylmethoxycarbonyl)sarcosyl)amino)ethyl)amide y- 
phenylmethyl ester hydrochloride (164)
Hydrogen chloride was bubbled through a solution of N-( 1,1 -dimethylethoxycarbonyl)- 
glutamic acid a-(N-(2-(N-(phenylmethoxycarbonyl)sarcosyl)amino)ethyl)amide in CH2C12 
for 30 min. The solvent and excess hydrogen chloride were evaporated to give glutamic 
acid a-(N-(2-(N-(phenylmethoxycarbonyl)sarcosyl)amino)ethyl)amide y-phenylmethyl 
ester hydrochloride (330m g, 85%) as an off-white glass.
'HNMR((CD3)2 SO)
8  2.34 (2 H, m, Glu P-H2), 2.58 (2 H, m, Glu y-H2), 2.96 (3 H, s, Sar-H3), 3.06-3.57 
(4H, br, NCH2CH2N), 3.92 (2 H, br, Sar-H2), 4.24 (1 H, m, Glu a-H), 5.01 (2 H, s, 
Ar-CH20 2CN), 5.24 (2 H, s, Ar-CHjOjCCH), 7.29 (10 H, m, Ar), 7.69 (1 H, br, NH),
8.38 (3 H, br, NH3+), 8.44 (1 H, m, NH)
6  2.34 (2 H, m, Glu p-H2), 2.58 (2 H, m, Glu y-H2), 2.96 (3 H, s, Sar-H3), 3.06-3.57 
(4H, br, NCH2CH2N), 3.92 (2 H, br, Sar-Hj), 4.24 (1 H, m, Glu a-H), 5.04 (2 H, s, 
Ar-CH20 2CN), 5.24 ( 2  H, s, Ar-CHj02CCH), 7.29 (10 H, m, Ar), 7.69 ( 1  H, br, NH),
8.38 (3 H, br, NHj+), 8.44 (1 H, m, NH)
T.L.C. (C)Rf= 0.92
N-(PhenyImethoxycarbonyI)sarcosine pentafluorophenyl ester (165)
Pentafluorophenol (2.46 g, 13.45 mmol) in EtOAc ( 1 0  ml) was cooled to 0°C. DCC 
(2.32 g, 13.45 mmol) and N-(phenylmethoxycarbonyl)sarcosine (3.0 g, 13.45 mmol) in 
EtOAc ( 1 0  ml) were cooled to 0°C and added to the stirred solution of 
pentafluorophenol. The suspension was stirred at 0°C for 2 h then filtered. The solvent 
was evaporated from the filtrate and the residue redissolved in EtOAc. This was filtered 
and the solvent was removed from the filtrate to give N- 
(phenylmethoxycarbonyl)sarcosine pentafluorophenyl ester (4.66 g, 89%) as a pale pink 
oil.
IR (film) v 1810 (ester C=0), 1715 (carbamate C=0).
‘H NMR (CDClj)
8  3.08 (3 H, s, Sar-Hj), 4.43 (2 H, s, Sar-H2), 5.19 (2 H, s, Ar-CH2), 7.34 (5 H, s, Ar)
8  3.09 (3 H, s, Sar-Hj), 4.36 (2 H, s, Sar-H2), 5.16 (2 H, s, Ar-CH2), 7.36 (5 H, s, Ar) 
19FNMR(CDC1j)
8  -152.6 (2 F, d, J  = 23 Hz, 2,6-Ar), -157.6 ( 1  F, t, J  = 21 Hz, 4-Ar), -162.3 (2 F, dd, 
J =  21,23 Hz, 3,5-Ar)
8  -153.1 (2 F, d, J =  23 Hz, 2,6-Ar), -157.8 (1 F, t, J =  21 Hz, 4-Ar), -162.4 (2 F, dd, 
J=  21,23 Hz, 3,5-Ar)
T.L.C. (G)Rf= 0.56
xviii
N-(N-(Phenylmethoxycarbonyl)sarcosyl)gIutamic acid a-(N-(2-(N-(phenylmethoxy- 
carbonyI)sarcosyl)amino)ethyI)amide y-phenylmethyl ester (166)
Glutamic acid a-(N-(2-(N-(phenylmethoxycarbonyl)sarcosyl)amino)ethyl)amide y- 
phenylmethyl ester hydrochloride (320 mg, 0.62 mmol) was stirred with N-(phenyl- 
methoxycarbonyl)sarcosine pentafluorophenol ester (239 mg, 0.62 mmol) and N,N- 
diisopropylethylamine (130 mg, 1.24 mmol) in CH2C12 for 20 h. The reaction mixture was 
washed once with water ( 1 0  ml), twice with 1 0 % aq. t^SO^lO  ml), once with saturated 
aq. NaHC03 (10 ml) and once with brine. The solution was dried and the solvent was 
evaporated. Chromatography (CHCI3 / MeOH 10:1) gave N-(N-(phenylmethoxy- 
carbonyl)sarcosyl)glutamic acid a-(N-(2-(N-(phenylmethoxycarbonyl)sarcosyl)amino)- 
ethyl)amide y-phenylmethyl ester (260 mg, 73%) as a viscous straw-coloured oil.
‘h n m r (cd c i3)
8  1.95 (1 H, m, Glu P-H2), 2.14 ( 1  H, m, Glu P-H2), 2.46 (2 H, Glu y-H2), 3.02 (3 H, s, 
Sar-Hj), 3.31 (4 H, br, NCH2CH2N), 3.79 (2 H, s, Sar-H2), 3.89 (2 H, br, Sar-H2), 4.36 
(1 H, m, Glu a-H), 5.13 ( 6  H, m, 2  x Ar-CH2 + Ar’-CH2), 6.61 (1 H, br, NH), 6.82 (1 H, 
br, NH), 7.00(1 H, br, NH), 7.34 (15 H, br, Ar + Ar’)
T.L.C. (C)Rf=0.42
N-(l,l-DimethyIethoxycarbonyl)glutamic acid a-phenylmethyl ester y-(2,4,5-tri- 
chlorophenyl) ester (168)
N-(l,l-Dimethylethoxycarbonyl)glutamic acid a-phenylmethyl ester (24.86 g,
73.7 mmol) was stirred with DCC (15.2 g, 73.7 mmol) and 2,4,5-trichlorophenol (14.4 g,
73.7 mmol) in EtOAc (300 ml) at 0°C for 18 h. The suspension was filtered and the 
solvent was evaporated from the filtrate. The residue was redissolved in EtOAc, filtered 
and the solvent was evaporated to give N-(l,l-dimethylethoxycarbonyl)glutamic acid a-
xk
phenylmethyl ester y-(2,4,5-trichlorophenyl) ester (37.6 g, 98%) as an off-white solid. 
Mp. 78-80°C
*H NMR ( C D C I 3 )
8  1.45 (9 H, s, Bu-t), 2.34 (2 H, Glu |)-H2), 2.69 ( 2  H, m, Glu y-H2), 4.46 (1 H, m, Glu 





N-(l,l-Dimethylethoxycarbonyl)glutamic acid a-phenylmethyl ester y-(2,4,5-trichloro- 
phenyl) ester (8.22 g, 14.8 mmol) was added to a solution of methyl 6 -aminohexanoate 
hydrochloride (2.79 g, 14.8 mmol), N,N-diisopropylethylamine (4.18 g, 29,6 mmol) and 
DMAP (10 mg) in CH2CI2 (50 ml). The mixture was stirred for 4 d and the solvent was 
evaporated. The residue was dissolved in EtOAc and washed with cold 10% aq. HjSO*, 
and with 10% aq. Na2C03. The solution was dried and the solvent was evaporated. 
Chromatography (CHC13 / MeOH 40 : 1 ) gave Na-(l,l-dimethylethoxycarbonyl)-N6-(6 - 
methoxy-6 -oxohexyl)glutamine phenylmethyl ester (5.93 g, 87 %) as a white solid. Mp 
60-63°C
'HNMR(CDC13)
8  1.28-1.51 (13 H, m, Bu-t + NCHjCHjCHjCHjCHj), 1.63 (2 H, m, 
NCHjCHjCHjCHjCHj), 1.90 (2 H, m, Glu p-H2), 2.22 (2 H, m, Glu y-H2), 2.31 (2 H, t, 
J =  7 . 3  Hz, NCHjCHjCHjCHjCHj), 3.23 (2 H, q, J =  6 . 6  Hz, NCHjCHjCHjCHjCHj), 
3.66 (3 H, s, CH3), 4.30 (1 H, m, Glu a-H), 5.14 (1 H, s, Ar-CH2), 5.18 ( 1  H, s, Ar- 
CH2), 5.39 (1 H, d, J=  9 Hz, a-NH), 6.23 (1 H, br, NHCHj), 7.35 (5 H, s, Ar)
MS (FAB+) 465 (M + H)
T.L.C. (C)Rf= 0.33
XX
Na-(l,l-Diniethylethoxycarbonyl)-N5-(6 -niethoxy-6 -oxohexyI)gIutainine (170)
10% Palladium on charcoal (2.2 g) was added to a solution of Na-(l,l-dimethylethoxy- 
carbonyl)-N5-(6 -methoxy-6 -oxohexyl)glutamine phenylmethyl ester (11.97 g, 25.8 mmol) 
in THF (150 ml). The mixture was treated with hydrogen for 24 h then filtered through 
Celite®- The solvent was evaporated from the filtrate to give Na-(l,l-dimethylethoxy- 
carbonyl)-N5-(6 -methoxy-6 -oxohexyl)glutamine (8.81 g, 91%) as a pale green oil.
*H NMR (CDCI3)
6  1.24-1.63 (15 H, m, Bu-t + NCHjCIfcCHzCHjCHj), 1.84 (2 H, m, Glu 0-H2), 1.91-
2.15 (2 H, m, Glu y-H2), 2.32 (2 H, t, J - 7.3 Hz, NCH2CH2CH2CH2CH2), 3.28 (2 H, m, 
NCH2CH2CH2CH2CH2), 3.67 (3 H, s, OCH3), 4.22 (1 H, m, Glu a-H), 5.61 (1 H, br, 
NHCH2)
T.L.C. (C) Rf = 0.08
Na-(l,l-DimethyIethoxycarbonyI)-N5-(6 -inethoxy-6 -oxohexyl)glutainine 2,4,5-tri­
chlorophenyl ester (171)
N“-( 1,1 -Dimethylethoxycarbonyl)-Ns-(6 -methoxy-6 -oxohexyl)glutamine (27.0 g,
72 mmol) was added to a stirred solution of DCC (14.86 g, 72 mmol) and 2,4,5-tri- 
chlorophenol (14.24 g, 72 mmol) in EtOAc (500 ml). The resulting suspension was 
stirred for 18 h and was then filtered. The filtrate was evaporated and the residue 
redissolved in EtOAc and filtered. The solvent was evaporated to give an oil which, on 
trituration with Et20 , yielded Na-(l,l-dimethylethoxycarbonyl)-N6-(6 -methoxy-6 -oxo- 
hexyl)glutamine 2,4,5 trichlorophenyl ester (28.04 g, 70%) as a white solid. Mp 92-94°C.
lH NMR (CDCI3)
8  1.36-1.50 (13 H, m, Bu-t + NCHjCHjCHjCHjCHj), 1.75 (NCHjCHjCHjCHjCHj),
1.91 ( 2  H, m, Glu P-H2), 2.14 ( 2  H, m, Glu y-H2), 2 . 6  ( 2  H, m, NCHjCHjCHjCHjCHj),
3.49 (2 H, m, NCHjCHjCHjC ^C H j), 3.91 (3 H, s, OCH3), 4.42 (1 H, m, Glu a-H),
xxi
5.59 (1 H, m, NHCH2), 6.48 (1 H, m, Glu-NH), 7.36 (1 H, s, Ar-6 H), 7.64 (1 H, s, 
Ar-3H)
T.L.C. (C)Rf= 0.80
Na-(l,l-Diinethylethoxycarbonyl)-N5-(6 -methoxy-6 -oxohexyI)glutamine N-(2-(N- 
(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (172)
N“-( 1,1 -Dimethylethoxycarbonyl)-Ns-(6 -methoxy-6 -oxohexyl)glutamine 2,4,5-trichloro­
phenyl ester (11.09 g, 20 mmol) was added to a stirred solution of N-(phenylmethoxy- 
carbonyl)sarcosine N-(2-aminoethyl)amide (5.30 g, 2 0  mmol) in CH2C12 (50 ml) 
containing N,N-diisopropylethylamine (5.69 g, 44 mmol) and DMAP (10 mg). The 
solution was stirred for 4 d, then washed twice with cold 10% aq. USO* and twice with 
10% aq. Na2CC>3 . The solution was dried and the solvent was evaporated to give an oil. 
Trituration with Et20  yielded Na-(l,l-dimethylethoxycarbonyl)-N5-(6 -methoxy-6 -oxo- 
hexyl)glutamine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (8.97 g, 
72%) as a buff solid. Mp 88-90°C
‘HNMR((CD3)2 SO)
5 1.43 (2 H, m, NCHjCHjCHjCHjCHj), 1.47 ( 1 1  H, m, Bu-t + NCHjCHjCHjCHjCHj). 
1.51 (2 H, m, NCHjCHjCHjCHjCHj), 1.60 (2 H, m, Glu |3-H2), 2.00 (2H, br, Glu 
r-H2), 2.29 (2 H, m, NCHjCHjCHjCHjCHj), 3.01 (3 H, s, Sar-Hj), 3.18 (2H, m, 
NCHjCH2CH2CH2CHj), 3.36 (4 H, br, NCH2CH2N), 3.63 (3 H, OCH3), 3.89 (2 H, s, 
Sar-H2), 4.12 (1 H, m, Glu a-H), 5.13 (2 H, s, Ar-CH2), 5.85 (1 H, m, NH), 6.46 ( 1  H, 
m, NH), 7.11 (1 H, br, NH), 7.34 ( 6  H, m, Ar + NH)
T.L.C. (C)Rf= 0.43
xxii
N5-(6 -Methoxy-6 -oxohexyl)glutamine N-(2-(N-(phenyImethoxycarbonyl)sarcosyI- 
amino)ethyI)amide hydrochloride (173)
Hydrogen chloride was bubbled through a solution of N“-( 1 ,1  -dimethylethoxycarbonyl)- 
N6-(6 -methoxy-6 -oxohexyl)glutamine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)- 
ethyl)amide (8.97 g, 14.4 mmol) in CH2C12 (300 ml) for 30 min. MeOH (1 ml) was added 
and the solvents were evaporated to give N5-(6 -methoxy-6 -oxohexyl)glutamine N-(2-(N- 
(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide hydrochloride (7.96 g, 99%) as a 
buff foam.
‘HNMR((CDj)2SO)
S 1.43 (2 H, m, NCHjCHjCHjCHjCHj), 1.47 (2 H, m, NCHjCHjCHjCHjCHj), 1.51 
(4H, m, Glu P-Hj + NCHjCHjCHjCHjCHj), 1.92 ( 2  H, br, Glu y-H2), 2 . 2 1  ( 2  H, m, 
NCH2CH2CH2CH2CH2), 2.85 (3 H, s, Sar-Hj), 3.02 (2 H, m, NCHjCHjCHjCHjOfc),
3.16 (4 H, br, NCH2CH2N), 3.50 (3 H, OCH3), 3.86 (2 H, s, Sar-H2), 4.12 (1 H, m, Glu 
a-H), 5.04 (2 H, s, Ar-CH2), 7.32 (5 H, m, Ar), 8.03 (1 H, br, NH), 8.19 (1 H, m, NH),
8.32 (3 H, m, NH3+), 8.70 ( 1  H, br, NH)
5 1.43 (2 H, m, NCHjCHjCHjCHjCHj), 1.47 (2 H, m, NCHjCHjCHjCHjCHj), 1.51 
(4 H, m, Glu P-H2 + NCHjCHjCHjCHjCHj), 1.92 (2 H, br, Glu y-H2), 2.21 ( 2  H, m, 
NCHjCHjCHjCHjCHj), 2.89 (3 H, s, Sar-H3), 3.02 (2 H, m, NCIfcCHjCHjCHjCHj),
3.16 (4 H, br, NCH2CH2N), 3.50 (3 H, OCH3), 3.87 (2 H, s, Sar-H2), 4.12 (1 H, m, Glu 
a-H), 5.07 (2 H, s, Ar-CH2), 7.32 (5 H, m, Ar), 8.03 (1 H, br, NH), 8.19 (1 H, m, NH),
8.32 (3 H, m, NH3+), 8.70 (1 H, br, NH)
T.L.C. (C) Rf = 0.05
N5-(6 -Methoxy-6 -oxohexyI)-N0t"(N-(phenyImethoxycarbonyl)sarcosyl)gIutamine N- 
(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (174)
N-(Phenylmethoxycarbonyl)sarcosine 2,4,5-trichlorophenyl ester (5.33 g, 13.23 mmol) 
was added to Ns-(6 -methoxy-6 -oxohexyl)glutamine N-(2-(N-(phenylmethoxycarbonyl)- 
sarcosylamino)ethyl)amide hydrochloride (2.46 g, 4.41 mmol), N,N-diisopropylethyl-
amine (2.28 g, 17.64 mmol) and DMAP (20 mg) in CH2CI2 (50 ml). The solution was 
stirred for 48 h. The solution was washed with cold 10% aq. H2 S04, with 10% aq. 
Na2C0 3 and with brine. The solution was dried and the solvent evaporated. 
Chromatography (CH2C12 / MeOH 40:1 then CH2C12 / MeOH 30:1) gave N5-(6 - 
methoxy-6 -oxohexyl)-Na-(N-(phenylmethoxycarbonyl)sarcosyl)glutamine N-(2-(N- 
(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (2.23 g, 70%) as a pale yellow glass.
‘h n m r ( ( c d 3)2so )
8  1.24 (2 H, m, NCH2CH2CHiCH2CH2), 1.36 (2 H, m, NCHjCHjCHjCHjCHj), 1.49 
(2H, m, NCHjCHjCHjCHjCHj), 1.72 (1 H, m, Glu 0-H2), 1.88 (1 H, m, Glu p-H2),
2.26 (2 H, m, Gluy-H2), 2.27 (2 H, t, J =  7.3 Hz, NCH2CH2CH2CH2CH2), 2.85 (3 H, s, 
Sar-Hj), 2.89 (3 H, s, Sar-H,), 2.99 (2 H, q, J  = 6.3 Hz, NCHjCH2CH2CH2CH2), 3.12 
(4 H, br, NCH2CH2N), 3.57 (3 H, s, OCH3), 3.83 (2 H, s, Sar-H2), 3.91 (2 H, s, Sar-H2),
4.19 (1 H, m, Glu a-H), 5.03 (2 H, s, Ar-CH2), 5.07 (2 H, s, Ar-CH2), 7.36 (10 H, m, 
Ar), 7.77 (1 H, m, NHCH2CH2CH2), 7.90 (2 H, br, NHCH2CH2NH), 8.18 (1 H, d, 
J=  6 . 8  Hz, Glu-NH)
8  1.24 (2 H, m, NC^C^CHjCHjCHj), 1.36 (2 H, m, NCHjCHjCHjCHjCHj), 1.49 
(2 H, m, NCHjCHjCHjCHjCHj), 1.72 (1 H, m, Glu P-H2), 1.88 ( 1  H, m, Glu P-H2),
2.26 (2 H, m, Glu y-H2), 2.27 (2 H, t, J  = 7.3 Hz, NCH2CH2CH2CH2CHj), 2 . 8 6  (3 H, s, 
Sar-Hj), 2.99 (2 H, q, J =  6.3 Hz, NCHjCHjCHjCHjCHj), 3.00 (3 H, s, Sar-Hj), 3.12 
(4 H, br, NCH2CH2N), 3.57 (3 H, s, OCH3), 3.83 (2 H, s, Sar-H2), 3.93 (2 H, s, Sar-H2),
4.19 (1 H, m, Glu a-H), 5.03 (2 H, s, Ar-CH2), 5.07 (2 H, s, Ar-CH2), 7.36 (10 H, m, 
Ar), 7.77 (1 H, m, NHCH2CH2CH2), 7.90 (2 H, br, NHCH2CH2NH), 8.18 (1 H, d, 
7=  6 . 8  Hz, Glu-NH)
T.L.C. (C)Rf= 0.47 
MS (FAB+) 727 (M + H).
Ne-Trifluoroacetyllysme (181)
Trifluoroacetic anhydride (65.5 g, 313 mmol) was added dropwise during one hour to 
ethanethiol (12.42 g, 200 mmol) cooled in an ice-water bath. The stirred solution was 
allowed to stand under a reflux condenser fitted with a CaC^ drying tube for 1 h then
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heated at reflux for 16 h. The solution was allowed to cool to room temperature and then 
dissolved in CHjCl^ This was washed twice with 5% aqueous KOH (200 ml) then once 
with water and once with brine. The solution was dried and then distilled to give ethyl 
trifluorothioacetate (9.32 g, 49%) as a colourless liquid. The isolated compound ( 8  g, 
50.6 mmol) was added to lysine monohydrochloride (5.86 g, 32 mmol) in 1M aqueous 
NaOH (32 ml). The mixture was stirred vigorously for 6  h and then cooled in an ice- 
water bath. A precipitate formed and was collected by filtration. The crude solid was 
recrystallised from water and ethanol to give crude Ne-trifluoroacetyilysine (550 mg, 
7.1%). The product was not soluble in any available NMR solvents.
Na-(l,l-Din»cthyIethoxycarbonyI)-Ne-(2,2,2-trichIoroethoxycarbonyl)lysine (190)
Lysine monohydrochloride (62.Og, 339 mmol) was boiled under reflux with CuC03 
(121.7 g, 509 mmol) in water (1200 ml) for 4 h. The solution was filtered whilst hot and 
the filtrate was allowed to cool to 20°C. Trichloroethyl chloroformate (143.2 g, 
679 mmol) and aqueous NajCOj (108 g, 1.02 mol) were added alternately in portions to 
the filtrate during 2 h. The solution was stirred vigorously at 0°C for 20 h. The 
precipitate was collected and was boiled under reflux with ethylenediaminetetraacetic acid 
disodium salt (126.3 g, 679 mmol) in water (2000 ml) for 2 h. The solution was cooled to 
0°C during 48 h and the crude N8-(2,2,2-trichloroethoxycarbonyl)lysine was collected by 
filtration. Di-f-butyl dicarbonate (92.6 g, 424 mmol) in dioxane (200 ml) was added to 
this material in water (500 ml) and triethylamine (20.2 g, 200 mmol) and the mixture was 
stirred vigorously for 4 d. The mixture was washed with Et20  (500 ml). EtOAc (500 ml) 
was added to the mixture which was then acidified by addition of cold 1 0 % aq.
The organic layer was dried and the solvent was evaporated to give Na-(1,1-dimethy 1- 




8  1.45 (9 H , s, Bu-t), 1.58-1.88 ( 6  H, m, Lys P,y,8 -H2), 3.23 (2 H, q, J  = 6.7 Hz, Lys 
e-H2), 4.30 (1 H, m, Lys a-H), 4.73 (2 H, s, CH2CC13), 5.28 ( 1  H, m, NH), 6.38 (1H, m, 
NH)
T.L.C. (C) R f= 0.43
Na-(l,l-Dimethylethoxycarbonyl)-Ne-(2,2,2-trichloroethoxycarbonyl)Iysine penta­
fluorophenyl ester (191)
Na-( 1,1 -Dimethylethoxycarbonyl)-Ne-(2,2,2-trichloroethoxycarbonyl)lysine (2.00 g,
4.7 mmol) was stirred with DCC (0.82 g, 4.7 mmol) and pentafluorophenol (0.87 g,
4.7 mmol) in EtOAc (60 ml) at 0°C for 6  h. The suspension was filtered and the solvent 
was evaporated from the filtrate to give N“-(l,l-dimethylethoxycarbonyl)-Ne-(2,2,2- 
trichloroethoxycarbonyl)lysine pentafluorophenyl ester (2.50 g, 91%) as a yellow oil.
IR (film) v 3360 (N-H), 1800 (ester C=0), 1725 (carbamate C=0).
‘H  N M R  ( C D C I j )
8  1.47 (9 H, s, Bu-t), 1.51-1.95 ( 6  H, m, Lys p,y,8 -H2), 3.28 ( 2  H, q, J  = 7.3 Hz, Lys 
e-H2), 4.61 (1 H, m, Lys a-H), 4.74 (2 H, s, CH2CC13), 5.22 ( 2  H, m, 2  x NH)
I9FNMR(CDC13)
8  -152.7 (2 F, d, J  = 20 Hz, 2,6-Ar), -158.6 (1 F, t, J  = 20 Hz, 4-Ar), -162.7 (2 F, t, 
J=  2 0  Hz, 3,5-Ar)




Na-( 1,1 -Dimethylethoxycarbonyl)-NE-(2,2,2-trichloroethoxycarbonyl)lysine pentafluoro­
phenyl ester (2.0 g, 3.5 mmol) was stirred with N-(phenylmethoxycarbonyl)sarcosine N- 
(2-aminoethyl)amide (918 mg, 3.5 mmol) and N,N-diisopropylethylamine (490 mg,
3.8 mmol) in CH2C12 for 5 h. The solution was washed with cold 10% aq. H2S04 (10 ml) 
and with saturated aq. NaHC03 ( 1 0  ml). The solution was dried and the solvent was 
evaporated. Chromatography (CHCI3 / MeOH 1 0 :1 ) gave Na-(l,l-dimethylethoxy- 
carbonyl)-Ne-(2,2,2-trichloroethoxycarbonyl)lysine N-(2-(N-(phenylmethoxycarbonyl)- 
sarcosylamino)ethyl)amide (1.97 g, 85%) as a buff foam.
‘H NMR ((CD3)jSO)
8  1.11-1.71 (15 H, m, Bu-t + Lys P,y,8 -H2), 2.84 (3 H, s, Sar-H3), 3.01 (2 H, q, 
J=  6.7 Hz, Lys e-H2), 3.14 (4H .n i, NCH2CH2N), 3.82 (3 H, br, Sar-H2 + Lys a-H),
4.76 (2 H, s, CH2CC13), 5.05 (3 H, s, Ar-H2), 6.74 ( 1  H, d, J =  8.5 Hz, Lys NH), 7.36 (5 
H, m, Ar), 7.64 (1 H, t, J =  5.1 Hz, NH), 7.87 (1 H, br, NH), 7.94 (1 H, m, NH).
8  1.11-1.71 (15 H, m, Bu-t + Lys P,y,8 -H2), 2.89 (3 H, s, Sar-H3), 3.01 (2 H, q, 
J=  6.7 Hz, Lys e-H2), 3.14 (4 H, m, NCH2CH2N), 3.82 (3 H, br, Sar-H2 + Lys a-H),
4.76 (2H, s, CH2CC13), 5.08 (3 H, s, Ar-H2), 6.74 ( 1  H, d , J=  8.5 Hz, Lys NH), 7.36 (5 
H, m, Ar), 7.64 (1 H, t, 7 =  5.1 Hz, NH), 7.87 (1 H, br, NH), 7.94 (1 H, m, NH).
T.L.C. (C)Rf=0.31 
MS (FAB+) 670 (M + H).
Ne-(2,2,2-Trichloroethoxycarbonyl)lysine N-(2-(N-(phenylmethoxycarbonyl)-
sarcosylamino)ethyl)amide hydrochloride (193)
Hydrogen chloride was bubbled through a solution of Na-( 1,1 -dimethylethoxycarbonyl)- 
Ne-(2,2,2-trichloroethoxycarbonyl)lysine N-(2-(N-(phenylmethoxycarbonyl)sarcosyl- 
amino)ethyl)amide (1.64 g, 2.45 mmol) in CHJC^ (20 ml) for 30 min. The solvent and
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excess reagent were evaporated to give Ne-(2,2,2-trichloroethoxycarbonyl)lysine N-(2- 
(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide hydrochloride (1.47 g, 99%) as a 
colourless glass.
‘H NMR ((CD3)2SO)
8  1.26 (2 H, m, Lys p,y,8 -H2), 1.41 (2 H, m, Lys P,y,8 -H2), 1.67 (2 H, m, Lys P,y,8 -H 2),
2.84 (3 H, s, Sar-Hj), 3.00 (2 H, m, Lys s-H2), 3.14 (4 H, br, NCH2CH2N), 3 . 6 6  ( 1  H, 
Lys a-H), 3.84 (2 H, s, Sar-H2), 4.76 (2 H, s, CH2CC13), 5.03 (2 H, s, Ar-CH2), 7.35 (5 
H, m, Ar), 7.69 (1 H, m, NH), 8.31 (4 H, br, NH3+ + NH), 8.71 (1 H, m, NH)
8  1.26 (2 H, m, Lys P,y,8 -H2), 1.41 (2 H, m, Lys P,y,8 -H2), 1.67 (2 H, m, Lys p,y,8 -H2),
2.87 (3 H, s, Sar-H3), 3.00 (2 H, m, Lys 8 -H2), 3.14 (4 H, br, NCH2CH2N), 3.66 (1 H, 
Lys a-H), 3.85 (2 H, s, Sar-H2), 4.76 (2 H, s, CH2CC13), 5.06 (2 H, s, Ar-CH2), 7.35 (5 
H, m, Ar), 7.69 ( 1  H, m, NH), 8.31 (4 H, br, NH3* +NH), 8.71 ( 1  H, m, NH)
T.L.C. (C) Rf = 0.08 




amino)ethyl)amide hydrochloride (1.41 g, 2.3 mmol) was stirred with N-(phenylmethoxy- 
carbonyl)sarcosine pentafluorophenyl ester (908 mg, 2.3 mmol) and triethylamine 
(470 mg, 4.68 mmol) in CI^Clj (30 ml) for 5 h. The solution was washed with water 
( 1 0  ml), with cold 10% aq. ( 1 0  ml) and with saturated aq. NaHC03 ( 1 0  ml). The 
solution was dried and the solvent was evaporated. The residue was redissolved in 
CHjClj and washed twice with cold 1 0 % aq. HjSC^ and four times with 1 0 % aq. NajCC^. 
The solution was dried and the solvent was evaporated. Chromatography (CHC13 / 
MeOH 1 0 :1 ) gave Na-(N-(phenylmethoxycarbonyl)sarcosyl)-Ne-(2,2,2-trichloroethoxy- 
carbonyl)lysine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (1.08 g, 
60%) as a brown solid. Mp 76 - 78°C.
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lH NMR ((CD3)2SO) 20°C
8  1.24 (2 H, m, Lys P,y-H2), 1.38 (2 H, m, Lys 8 -H2), 1.62 (2 H, m, Lys P,y-H2), 2.84 (3 
H, s, Sar-H3), 2.98 (2 H, m, Lys e-H2), 3.10 (4 H, br, NCH2CH2N), 3.82 (2 H, s, 
Sar-H2), 3.93 (2 H, s, Sar-H2), 4.19 (1 H, m, Lys a-H), 4.79 (2 H, s, CH2CC13), 5.03 
(2 H, s, Ar-CH2), 5.08 (2 H, s, Ar-CH2), 7.34 (10 H, m, Ar), 7.68 (1 H, m, NH), 8.02 
(3 H, m, 3 x NH).
6  1.24 (2 H, m, Lys P,y-H2), 1.38 (2 H, m, Lys 8 -H2), 1.62 (2 H, m, Lys P,y-H2), 2.86 
(3 H, s, Sar-H3), 2.98 (2 H, m, Lys e-H2), 3.10 (4 H, br, NCH2CH2N), 3.82 (2 H, s, 
Sar-H2), 3.91 (2 H, s, Sar-H2), 4.19 (1 H, m, Lys a-H), 4.79 (2 H, s, CH2CC13), 5.04 
(2 H, s, Ar-CH2), 5.08 (2 H, s, Ar-CH2), 7.34 (10 H, m, Ar), 7.68 (1 H, m, NH), 8.02 
(3 H, m, 3 x NH).
*H NMR ((CD3)2SO) 80°C
8  1.25 (2 H, m, Lys p,y,8 -H2), 1.46 (2 H, m, Lys p,y,8 -H2), 1.65 (2 H, m, Lys P,y,8 -H2),
2.88 (3 H, s, Sar-H3), 3.02 (2 H, m, Lys e-H 2), 3.14 (4 H, br, NCH2CH2N), 3.82 (2 H, s, 
Sar-H2), 3.91 (2 H, s, Sar-H2), 4.22 (1 H, m, Lys a-H), 4.74 (2 H, s, CH2CC13), 5.06 
(4 H, s, Ar-CH2), 7.33 (11 H, m, Ar + NH), 7.66 (2 H, m, 2 x NH), 7.73 (1 H, m, NH).
T.L.C. (C) Rf = 0.43 
MS (FAB+) 775 (M+ H).
N-(l,l-Dimethylethoxycarbonyl)glycine 2,4,5-trichlorophenyl ester (197)
N-(l,l-Dimethylethoxycarbonyl)glycine (16.6 g, 95 mmol) was stirred with DCC 
(19.57 g, 95 mmol) and 2,4,5-trichlorophenol (18.76 g, 95 mmol) in EtOAc (150 ml) at 
0°C for 16 h. The suspension was filtered and the solvent was evaporated from the 
filtrate. The residue was redissolved in EtOAc and filtered. The solvent was evaporated 
from the filtrate to give N-(l,l-dimethylethoxycarbonyl)glycine 2,4,5-trichlorophenyl 
ester (32.2 g, 95%) as a white solid. Mp 95 - 97°C (Lit. mp. 106 - 107°C).
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‘HNMR(CDC13)
8  1.47 (9H, s, Bu-t), 4.22 (2 H, d ,J =  5.9 Hz, Gly-H2), 5.08 (1 H, br, NH), 7.32 (1 H, s, 
Ar-6 H), 7.56 (1 H, s, Ar-3H)
T.L.C. (C )Rf= 0.81
N-(l,l-DimethyIethoxycarbonyI)glycine N-(2-(N-(phenylmethoxycarbonyl)sarcosyI- 
amino)ethyl)amide (198)
N-(l,l-Dimethylethoxycarbonyl)glycine 2,4,5-trichlorophenyl ester (4.96 g, 14 mmol) 
was stirred with N-(phenylmethoxycarbonyl)sarcosine N-(2-aminoethyl)amide (3.71 g, 
14 mmol) and N,N-diisopropylethylamine (1.99 g, 15.4 mmol) in (100 ml) for
20 h. The solution was washed twice with cold 10% aq. and four times with
saturated aq. NaHC03. The solution was dried and the solvent was evaporated. 
Chromatography (EtOAc / MeOH 10:1, then EtOAc / MeOH 5:1, then EtOAc / MeOH 
3 :1 )  gave N-(l,l-dimethylethoxycarbonyl)glycine N-(2-(N-(phenylmethoxycarbonyl)- 
sarcosylamino)ethyl)amide (4.53 g, 79%) as a colourless foam.
‘HNMR^CDClj)
8  1.42 (9 H, s, Bu-t), 3.00 (3 H, s, Sar-H3), 3.38 (4 H, br, NCH2CH2N), 3.74 (2 H, m, 
Gly-H2), 3.91 (2 H, s, Sar-H2), 5.23 (2 H, s, Ar-CH2), 5.49 (1 H, br, Gly-NH), 6.73 (2 H, 
br, HNCH2CH2NH), 7.38 (5 H, m, Ar)
T.L.C. (C)Rf=0.41 




Hydrogen chloride was bubbled through a solution of N-(l,l-dimethylethoxycarbonyl)- 
glycineN-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (2.04 g, 4.95 mmol) 
in CHjC^ (50 ml) for 1 h. The solvent and excess reagent were evaporated to give 
glycine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide hydrochloride 
(1.71 g, 97%) as a buff foam.
1HNMR((CD3)2SO)
5 2.86 (3 H, s, CH3), 3.15 (4 H, br, NCH2CH2N), 3.49 (2 H, m, Gly-H2), 3.86 (2 H, s, 
Sar-H2), 5.07 (2 H, s, Ar-CH2), 7.35 (5 H, m, Ar), 8 . 2 0  (3 H, m, NH3+) 8.63-9.12 (2 H, 
m, 2 x NH)
8  2.89 (3 H, s, CH3), 3.15 (4 H, m, NCH2CH2N), 3.51 (2 H, m, Gly-H2), 3.85 ( 2  H, s, 
Sar-H2), 5.04 (2 H, s, Ar-CH2), 7.35 (5 H, m, Ar), 8.20 (3 H, m, NH3+) 8.63-9.12 (2 H, 
m, 2  x NH)
T.L.C. (C) Rf = 0.10 
MS (FAB+) 323 (M + H).
N-(l,l-DimethyIethoxycarbonyl)leucine 2,4,5-trichlorophenyl ester (200)
N-(l,l-Dimethylethoxycarbonyl)leucine (3.52 g, 15.2 mmol) was stirred with DCC 
(3.14 g, 15.2 mmol) and 2,4,5-trichlorophenol (3.01 g, 15.2 mmol) in EtOAc (50 ml) at 
-10°C for 4 h. The suspension was filtered and the solvent was evaporated from the 
filtrate. The residue was redissolved in EtOAc and filtered. The solvent was evaporated 
from the filtrate to give N-(l,l-dimethylethoxycarbonyl)leucine 2,4,5-trichlorophenyl 
ester (6.2 g, 99%) as a buff wax.
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'H NMR (CDCI3)
8  1.02 ( 6  H, d, J =  6.4 Hz, 2 x Leu-CHj), 1.47 (9 H, s, Bu-t), 1.65 (1 H, m, Leu P-H2),
1.84 (2 H, m, Leu y-H + Leu-p-H2), 4.56 (1 H, dt, J  = 4, 8  Hz, Leu a-H), 4.92 (1 H, d, 
J =  8  Hz, NH), 7.32 (1 H, s, Ar-6 H), 7.55 (1 H, s, Ar-3H)
T.L.C. (C) Rf = 0.91
N-(N-(l,l-Dimethylethoxycarbonyl)leucyl)glycine N-(2-(N-(phenylmethoxy-
carbonyl)sarcosylamino)ethyl)amide (201)
Glycine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide hydrochloride 
(3.21 g, 7.9 mmol) was stirred with N-(l,l-dimethylethoxycarbonyl)leucine 2,4,5-tri- 
chlorophenyl ester (3.19 g, 7.8 mmol) and N,N-diisopropylethylamine (3.21 g, 25 mmol) 
in DMF (30 ml) for 3 d. The solvent was evaporated and the residue was dissolved in 
EtOAc. The solution was washed twice with cold 10% aq. and twice with 10%
aq. NajCC^. The solvent was evaporated and the residue was dissolved in MeOH. NaOH 
(1 M, 8  ml, 8  mmol) was added and the solution stirred for 5 min. The MeOH was 
evaporated and the aqueous layer was extracted with EtOAc. The EtOAc layer was dried 
and the solvent was evaporated to give N-(N-(l,l-dimethylethoxycarbonyl)leucyl)glycine 
N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (3.26 g, 78%) as a pale 
brown oil.
*H NMR (CDClj)
8  0.86 ( 6  H, d, J =  5.8 Hz, 2 x CH3), 1.36 ( 1 0  H, s, Bu-t + Leu P-H2), 1.61 (2 H, br, Leu 
P-H2 + Leu y-H), 3.03 (3 H, s, Sar-H3), 3.26 (4 H, br, NCH2CH2N), 3.74 (2 H, m, 
Gly-H2), 4.02 (3 H, m, Sar-H2 + Leu a-H), 5.07 (2 H, s, Ar-CHj), 5.16 ( 1  H, m, NH),
6.89 (1 H, m, NH), 7.16 ( 1  H, m, NH), 7.40 ( 6  H, m, Ar + NH)
T.L.C. (C) Rf = 0.48 




Hydrogen chloride was bubbled through a solution of N-( 1,1-dimethylethoxycarbonyl)- 
leucyl)glycine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl amide (3.00 g, 
5.61 mmol) in CH2C12 (50 ml) for 1 h. The solvent and excess hydrogen chloride were 
evaporated to give N-leucylglycine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)- 
ethyl)amide hydrochloride (2 . 6  g, quantitative) as a colourless foam.
l H  N M R  ( ( C D j ^ S O )  2 0 ° C
8  0.87 ( 3  H, d, J  = 6  4  Hz, Leu-CHj), 0.90 (3 H, d, J =  6.4 Hz, Leu-CHj), 1.52-1.60 
(2 H, m, Leu p-H2), 1.62-1.70 (1 H, m, Leu y-H), 2.85 (3 H, s, Sar-CHj), 3.13 (4 H, br, 
NCHjCHjN), 3.67 (1 H, dd, J = 16, 5 Hz, Gly-Hj), 3.76-3.86 (4 H, s, Sar-H2 + Gly-H2 + 
Leu a-H), 5.04 (2 H, s, Ar-CH2), 7.33 (5 H, m, Ar), 8.12- 8.19 (2 H, br, 2  x NH), 8.42 
(3 H, br, NH34), 8.98 (1 H, t, 5.9 Hz, NH)
8  0.87 (3 H, d, J =  6.4 Hz, Leu-CHj), 0.90 (3 H, d, J  = 6.4 Hz, Leu-CHj), 1.52-1.60 
(2 H, m, Leu P-H2), 1.62-1.70 (1 H, m, Leu y-H), 2 . 8 8  (3 H, s, Sar-CHj), 3.13 (4 H, m, 
NCH2CH2N), 3.67 (1 H, dd, J =  16, 5 Hz, Gly-H2), 3.85 (4 H, s, Sar-H2 + Gly-H2 + Leu 
a-H), 5.07 (2 H, s, Ar-CH2), 7.33 (5 H, m, Ar), 8.12-8.19 (1 H, br, 2 x NH), 8.42 (3 H, 
br, NHj*), 8.98 ( 1  H, t, J = 5.9 Hz, NH).
‘H  N M R  ( ( C D j ^ S O )  8 0 ° C
8  0.87 (3 H, d, J =  6.4 Hz, Leu-H3), 0.92 (3 H, d, J =  6.4 Hz, Leu-Hj), 1.52-1.72 (3 H, 
m, Leu y-H + Leu p-H2), 2.91 (3 H, s, Sar-H3), 3.13 (4 H, br, NCH2CH2N), 3.62 (2 H, 
m, Gly-H2), 3.89 (3 H, m, Sar-H2 + Leu a-H), 5.08 (2 H, s, Ar-CH2), 7.39 (5 H, Ar),
7.91 (1 H, br, NH), 7.96 (1 H, br, NH), 8.38 (3 H, br, NH3+), 8.67 (1 H, m, NH)
T.L.C. (C) Rf = 0.09 
MS (FAB+) 436 (M + H).
Acc. Mass 436.2551 (M + H) (C ^ H ^ O , requires 436.2560)
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N-(l,l-Dimethylethoxycarbonyl)phenylalanine pentafluorophenyl ester (203)
N-(l,l-Dimethylethoxycarbonyl)phenylalanine (6.36 g, 24 mmol) was stirred with DCC 
(4.94 g, 24 mmol) and pentafluorophenol (4.42 g, 24 mmol) in EtOAc at 0°C for 3 h. 
The suspension was filtered and the solvent was evaporated from the filtrate. The residue 
was redissolved in EtOAc and filtered to give N-(l,l-dimethylethoxycarbonyl)phenyl- 
alanine pentafluorophenyl ester (10.32 g, 99%) as a white solid. Mp 99 - 101°C (Lit. 297 
mp. 111-112°C)
‘HNMR(CDClj)
8  1.43 (9 H, s, Bu-t), 3.20 (1 H, dd, J=  14.0,6.1 Hz, Phe p-H2), 3.31 (1 H, dd, 7 =  14.0, 
5.3 Hz, Phe p-H2), 4.75 (1 H, m, Phe a-H), 4.93 (1H, br, NH), 7.32 (5 H, m, Ar)
19FNMR(CDC13)
8  -152.6 (2 F, d, J  = 20 Hz, 2,6-Ar), -158.5 ( 1  F, t, J  = 20 Hz, 4-Ar), -162.9 (2 F, t, 
J =  20 Hz, 3,5-Ar)
8  -153.3 (2 F, d, 7  = 2 0  Hz, 2,6-Ar), -157.5 ( 1  F, t, J =  20 Hz, 4-Ar), -162.4 (2 F, t, 
J =  20 Hz, 3,5-Ar)




chloride (1.09 g, 2.4 mmol) was added to a stirred solution of N-( 1,1 -dimethylethoxy- 
carbonyl)phenylalanine pentafluorophenyl ester (948 mg, 2.4 mmol) and N,N-diiso- 
propylethylamine (678 mg, 5.3 mmol) in CHjClj (30 ml) and the mixture was stirred for 
16 h. The solution was washed with cold 1 0 % aq. HjSC^ ( 1 0  ml), with 1 0 % aq. Na^C^ 
( 1 0  ml) and with brine ( 1 0  ml). The solution was dried and the solvent was evaporated. 
Chromatography (CHC13 then CHC13 / MeOH 2 0  . 1 ) gave N-(N-(N-(l,l-dimethyl-
xxxiv
ethoxycarbonyl)phenylalanyl)leucyl)glycine N-(2-(N-(phenylmethoxycarbonyl)sarcosyl- 
amino)ethyl)amide (1.05 g, 65%) as a buff foam.
*H NMR (CDCI3)
8  0.89 (3 H, d, J =  6.1 Hz, Leu-CH3), 0.91 (3 H, d, J =  6 . 1  Hz, Leu-CH3), 1.40 (9 H, s, 
Bu-t), 1,49 (2 H, m, Leu p-H2), 1.71 (1 H, m, Leu y-H), 2.93 (1 H, m, Phe p-H2), 3.03 
(3 H, m, Sar-CH3), 3.32 (5 H, m, NCH2CH2N+ Phe P-H2), 3.79 (2H, m, Gly-H2), 3.94 
(2 H, s, Sar-H2), 4.29 (2 H, m, Phe a-H + Leu a-H), 5.14 (2 H, s, Ar-CH2), 5.44 (1 H, 
m, NH), 6 . 8 6  (1 H, m, NH), 6.96 (1 H, m, NH), 7.07 (1 H, m, NH), 7.27 (11 H, m, Ar + 
NH)
T.L.C. (C) Rf = 0.38 
MS (FAB +) 683 (M+H).
Na-(l,l-Dimethylethoxycarbonyl)-NE-(2,2,2-trichloroethoxycarbonyl)lysine 2,4,5-tri- 
chlorophenyl ester (205)
Na-( 1,1 -Dimethylethoxycarbonyl)-Ne-(2,2,2-trichloroethoxycarbonyl)lysine (6.32 g,
15 mmol) was stirred with DCC (3.10 g,15 mmol) and 2,4,5-trichlorophenol (2.96 g, 
15 mmol) in EtOAc (100 ml) at 0°C for 2 0  h. The suspension was filtered and the solvent 
was evaporated from the filtrate. The residue was redissolved in EtOAc and filtered. The 
solvent was evaporated from the filtrate to give Na-(l,l-dimethylethoxycarbonyl)-NE- 




8  1.47 (9 H, s, Bu-t), 1.52- 1.96 ( 6  H, m, Lys P,y,8 -H2), 3.27 (2 H, q, J  = 6.4 Hz, Lys 
8 -H3), 4.54 ( 1  H, m, Lys a-H), 4.73 (2 H, s, CHjCClj), 5  .18 ( 2  H, m, 2  x NH), 7.32 
(1 H, s, Ar-6 H), 7.56 (1 H, s, Ar-3H)
T.L.C. (C) Rf = 0.89
N-(Na-(l,l-Dimethylethoxycarbonyl)-NE-(2,2,2-trichloroethoiycarbonyl)lysyl)- 
glycine methyl ester (206)
Na-( 1,1 -Dimethylethoxycarbonyl)-NE-(2,2,2-trichloroethoxycarbonyl)lysine 2,4,5-tri-
chlorophenyl ester (7.8 g, 14.5 mmol) was stirred with glycine methyl ester hydrochloride 
(1.82 g, 14.5 mmol) and N,N-diisopropylethylamine (4.7 g, 36 mmol) in CHjCl^O ml) 
for 20 h. The solution was washed with cold 10% aq. HjSC^ (50 m l), with 10% aq. 
Na^C^, with water and with brine. The solution was dried and the solvent was 
evaporated. The residue was dissolved in CHjClj and washed twice with cold 10% aq. 
HjSO,* and twice with 10% aq. Naj C03. The solution was dried and the solvent was 
evaporated. Chromatography (CHCb then CHC13 / MeOH 20:1 then CHC13 / MeOH 
15 : 1) gave N-(Na-( 1,1 -dimethylethoxycarbonyl)-NE-(2,2,2-trichloroethoxycarbonyl)- 
lysyl)glycine methyl ester (5.7 g, 82%) as a yellow oil.
*H NMR (CDCI3)
8  1.18-1.77 (13 H, m, Bu-t + Lys P,y-H2), 1.95 (2 H, m, Lys 8 -H2), 3.30 (2 H, q, J  = 6.4 
Hz, Lys e-H2), 3.82 (3 H, s, OCH3), 4.10 (2 H, t, J  = 6.2 Hz, Gly-H2), 4.20 (1 H, m, Lys 
a-H), 4.78 (2 H, s, CH2CC13), 5.25 (1 H, d, J  = 7.9 Hz, Lys-NH), 5.37 (1 H, t, 
7 =  4.5 Hz, NH), 6.83 (1 H, m, NH)
T.L.C. (C)Rf= 0.70
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N-(Ne-(2,2,2-Trichloroethoxycarbonyl)IysyI)gIycine methyl ester hydrochloride 
(207)
Hydrogen chloride was bubbled through a solution of N-(Na-(l,l-dimethylethoxy- 
carbonyl)-Ne-(2,2,2-trichloroethoxycarbonyl)lysyl)glycine methyl ester (5.65 g,
11.8 mmol) in (50 ml) for 30 min. The solvent and excess hydrogen chloride were
evaporated to give N-(NE-(2,2,2-trichloroethoxycarbonyl)lysyl)glycine methyl ester 
hydrochloride (4.66 g, 95%) as a pale yellow oil.
'H NMR ((CD3)2 SO)
8  1.25 (4 H, m, Lys P + y-H2), 1.74 ( 2  H, m, Lys 8 -H2), 3.01 (2 H, q, J =  6.4 Hz, Lys 
8 -Hj), 3.65 (3 H, s, OCHj), 3.82 (1 H, m, Lys a-H), 3.91 (1 H, dd, J =  17.6, 5.9 Hz, 
Gly-H2), 3.98 (1 H, dd, J =  17.6, 5.9 Hz, Gly-H2), 4.79 (2 H, s, CH2CC13), 7.68 (1 H, t, 
J=  5.4 Hz, NH), 8.31 (3 H, br, NH3+), 9.03 (1 H, t, J =  5.8 Hz, NH)
T.L.C. (C)Rf=0.05
N-(Phenylmethoxycarbonyl)sarcosine 2,4,5-trichlorophenyl ester (208)
N-(Phenylmethoxycarbonyl)sarcosine (8.92 g, 40 mmol) was stirred with DCC (8.24 g, 
40 mmol) and 2,4,5-trichlorophenol (7.9 g, 40 mmol) in EtOAc ( 1 0 0  ml) at 0°C for 4h. 
The suspension was filtered and the solvent was evaporated from the filtrate. The residue 
was redissolved in EtOAc and filtered. The solvent was evaporated from the filtrate to 
give N-(phenylmethoxycarbonyl)sarcosine 2,4,5-trichlorophenyl ester (13.73g, 85%) as a 
pale buff wax.
NMR (CDC13)
8  3.12 (3 H, s, CH3), 4.37 (2 H, s, Sar-H2), 5.19 (2 H, s, Ar-CH2), 7.03 (1 H, s, Ar’-6 H),
7.38 (5 H, m, Ar), 7.55 (1 H, s, Ar’-3H)
xxxvii
5 3.14 (3 H, s, CH3), 4.28 (2 H, s, Sar-H2), 5.18 (2 H, s, Ar-CH2), 7.12 (1 H, s, Ar’-6 H),
7.38 (5 H, m, Ar), 7.56 (1 H, s, Ar’-3H)
T.L.C. (C) R f= 0.88
N-(N-Phenylalanylleucy!)glycine N-(2-(N-(phenylmethoxycarbonyl)sarcosyIamino)- 
ethyl)amide hydrochloride (2 1 0 )
Hydrogen chloride was bubbled through a solution of N-(N-(N-(l,l-dimethylethoxy- 
carbonyl)phenylalanyl)leucyl)glycine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)- 
ethyl)amide (950 mg, 1.4 mmol) in CH2C12 (50 ml) for 30 min. The solvent and excess 
hydrogen chloride were evaporated to give N-(N-phenylalanylleucyl)glycine N-(2-(N- 
(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide hydrochloride (820 mg, 95%) as a 
colourless foam.
‘H NMR ((CD3)2 SO)
8  0.85 (3 H, d, 7 =  6 . 6  Hz, Leu-CHj), 0.88 (3 H, d, J =  6 . 6  Hz, Leu-CHj), 1.51 (2 H, m, 
Leu P-H2), 1.61 (I H, m, Leu y-H), 2.87 (3 H, s, Sar-CHj), 2.85 (2 H, m, Phe P-H2),
3.11 (4 H, m, NCHjCHjN), 3.74-3.89 (4 H, br, Gly-H2 + Sar-H2), 4.07 (1 H, m, Leu 
a-H), 4.34 (1 H, m, Phe a-H), 5.03 (2 H, s, Ar-CH2), 7.27 (10 H, m, Ar), 7.96 (2 H, m, 
2 x NH), 8.24 (3 H, m, NH3+), 8.82 (2 H, m, 2  x NH)
8  0.85 (3 H, d, J =  6 . 6  Hz, Leu-CH3), 0.88 (3 H, d, J =  6 . 6  Hz, Leu-CH3), 1.51 (2 H, m, 
Leu P-H2), 1.61 (1 H, m, Leu y-H), 2.85 (3 H, s, Sar-CH3), 2.88 (2 H, m, Phe P-H2),
3.11 (4 H, m, NCH2CH2N), 3.74 (2 H, m, Gly-H2), 3.89 (2 H, m, Sar-H2), 4.07 (1 H, m, 
Leu a-H), 4.34 (1 H, m, Phe a-H), 5.07 (2 H, s, Ar-CH2), 7.27 (10 H, m, Ar), 7.94 (1 H, 
m, NH), 8.03 (1 H, m, NH), 8.24 (3 H, m, NH3+), 8.82 ( 2  H, m, 2  x NH)
T.L.C. (C) Rf = 0.07 
MS (FAB -) 617 (M + Cl)





amide (1.58 g, 2.55 mmol) was added to a stirred solution of N-( 1,1-dimethylethoxy- 
carbonyl)glycine (904 mg, 2.55 mmol) and N,N-diisopropylethylamine (990 mg,
7.7 mmol) in CHjC^ (20 ml) and the mixture was stirred for 4 d. The solution was 
washed with cold 1 0 % aq. HjSO^ with 10% aq. NajCC^ and with brine. The solution 
was dried and the solvent was evaporated. Chromatography ( C H C I 3  / MeOH 1 0 : 1 ) gave 
N-(N-(N-(N-( 1,1 -dimethylethoxycarbonyl)glycyl)phenylalanyl)leucyl)glycine N-(2-(N-
(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (1.14g,61% )asa colourless foam.
1HNMR((CD3)2 SO)
6  0.83 (3 H, d, J  = 6.2 Hz Leu-H3), 0.88 ( 3 H , d , J  = 6.2 Hz Leu-H3), 1.36 (9 H, s, 
Bu-t), 1.49 (2 H, m, Leu P-H2), 1.59 (1 H, m, Leu y-H), 2.80 (1 H, dd, J =  13.5, 9 Hz, 
Phe P-H2), 2.87 (3 H, s, Sar-H3), 3.02 (1 H, dd, J=  13.5, 6  Hz, Phe P-H2), 3.12 (4 H, br, 
HCH2CH2N), 3.38-3.62 (2 H, m, Gly-H2), 3.66 (2 H, m, Gly-H2), 3.83 (2 H, br, Sar-H2),
4.27 (1 H, m, Leu a-H), 4.55 (1 H, m, Phe a-H), 5.04 (2 H, s, Ar-CH2), 6.94 (1 H, t, J=
4.5 Hz, NH), 7.37 (10 H, m, Ar), 7.80-8.12 (4 H, m, 4 x NH), 8.21 (1 H, d, 7.5 Hz)
6  0.83 (3 H, d, J  = 6.2 Hz Leu-H3), 0.88 (3 H, d, J  = 6.2 Hz Leu-H3), 1.36 (9 H, s, 
Bu-t), 1.49 (2 H, m, Leu P-H2), 1.59 (1 H, m, Leu y-H), 2.80 (1 H, dd, J =  13.5, 9 Hz, 
P-H2), 2.89 (3 H, s, Sar-H3), 3.02 (1 H, dd, J  = 13.5, 6  Hz, Phe P-H2), 3.12 (4 H, br, 
HCH2CH2N), 3.38-3.62 (2 H, m, Gly-H2), 3.66 (2 H, m, Gly-H2), 3.83 (2 H, br, Sar-H2),
4.27 (1 H, m, Leu a-H), 4.55 (1 H, m, Phe a-H), 5.08 (2 H, s, Ar-CH2), 6.94 (1 H, t, J=
4.5 Hz, NH), 7.37 (10 H, m, Ar), 7.80-8.12 (4 H, m, 4 x NH), 8.21 (1 H, d, J=  7.5 Hz)
T.L.C. (C) Rf = 0.39 




Hydrogen chloride was bubbled through a solution of N-(N-(N-(N-( 1,1 -dimethylethoxy- 
carbonyl)glycyl)phenylalanyl)leucyl)glycine N-(2-(N-(phenylmethoxycarbonyl)sarcosyl- 
amino)ethyl)amide (1.29 g, 2.0 mmol) in CHjClj (20 ml) for 30 min. MeOH (1 ml) was 
added and the solvents and excess hydrogen chloride were evaporated to give N-(N-(N- 
glycylphenylalanyl)leucyl)glycine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)- 
amide hydrochloride (1.17 g, 73%) as a buff foam.
‘H NMR ((CD3)2SO) (COSY 90)
8  0.83 (3 H, d, .7 = 6.1 Hz, Leu-CH3), 0.89 (3 H, d ,J  = 6.1 Hz, Leu-CH3), 1.52 (3 H, m, 
Leu y-H + Leu P-H2), 2.78 (1 H, dd, 14, 10 Hz, Phe p-H), 2.86 (3 H, m, Sar-CHj), 
3 .11 (5 H, m, NCH2CH2N + Phe p-H), 3.61 (2 H, m, 2 x Gly-H2), 3.85 (2 H, s, Sar-H2),
4.32 (1 H, m, Leu a-H), 4.65 (1 H, m, Phe a-H), 5.07 (2 H, s, Ar-CH2), 7.29 (11 H, m, 
Ar + Gly-NH), 7.95 (1 H, m, NHCH2CH2NH), 8.09 (4 H, br, NH3+ + NHCH2CH2NH),
8.49 (1 H, m, Leu-NH), 8.73 (1 H, m, Phe-NH)
8  0.83(3 H , d , J =  6.1 Hz, Leu-CH3), 0.89 (3 H ,d ,y =  6.1 Hz, Leu-CH3), 1.52 (3 H,m, 
Leu y-H + Leu p-H2), 2.78 (1 H, dd, J  = 14, 10 Hz, Phe P-H), 2.86 (3 H, m, Sar-CH3),
3.11 (5 H, m, NCH2CH2N + Phe P-H), 3.61 (2 H, m, 2 x Gly-H2), 3.84 (2 H, s, Sar-H2),
4.32 (1 H, m, Leu a-H), 4.65 (1 H, m, Phe a-H), 5.04 (2 H, s, Ar-CH2), 7.29 (11 H, m, 
Ar + Gly-NH), 7.95 (1 H, m, NHCH2CH2NH), 8.09 (4 H, br, NH3+ + NHCH2CH2NH),
8.49 (1 H, m, Leu-NH), 8.73 (1 H, m, Phe-NH)
T.L.C. (C) Rf = 0.10 
MS (FAB+) 640 (M + H)






amino)ethyl)amide hydrochloride (1.11 g, 1.64 mmol) was added to N,N-diisopropyl- 
ethylamine (683 mg, 5.3 mmol) in CHjCl^lO ml). Na-(l,l-Dimethylethoxycarbonyl)-Ne- 
(2,2,2-trichloroethoxycarbonyl)lysine 2,4,5-trichlorophenyl ester (950 mg, 1.77 mmol) 
and DMAP (10 mg) were added to this mixture and stirring continued for 3 d. The 
solution was washed with cold 10% aq. and with 10% aq. Na^C^ The solution
was dried and the solvent was evaporated. Chromatography (CHCI3 / MeOH 40:1 then 
CHCI3 / MeOH 20:1 then CHC13 / MeOH 10:1) gave N-(N-(N-(N-(N“-( 1,1 -dimethyl- 
ethoxycarbonyl)-NE-(2,2,2-trichloroethoxycarbonyl)lysyl)glycyl)phenylalanyl)leucyl)- 
glycine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (1.44 g, 78%) as a 
buff foam.
lHNMR((CD3)2SO)
8 0.83 (3 H, d, J =  6.2 Hz, Leu-H3), 0.88 (3 H, d, J =  6.2 Hz, Leu-H3), 1.25-1.65 (18 H, 
s + m, Bu-t + Lys P,y,8-H2 + Leu y-H + Leu P-H2), 2.75 (1 H, m, Phe P-H2), 2.84 (3 H, 
s, Sar-H3), 2.99 (3 H, m, Phe P-H2 + Lys e-H2), 3.11 (4 H, br, NCH2CH2N), 3.35 (2 H, s, 
Gly-H2), 3.65 (2 H, m, Gly-H2), 3.83 (2 H, br, Sar-H2), 3.84 (1 H, m, a-H), 4.25 (1 H, q, 
J=  6 Hz, a-H), 4.55 (1 H, m, a-H), 4.78 (2 H, s, CH2CC13), 5.03 (2 H, s, Ar-CH2), 6.87 
(1 H, d, J =  7 Hz, NH), 7.15-7.40 (10 H, m, Ar + Phe-Ar), 7.67 (1 H, t, J = 6 Hz, NH),
7.81 (1 H, br, NH), 7.93-8.06 (3 H, m, 3 x NH), 8.20 (1 H, d, J =  6 Hz, NH)
8 0.83 (3 H, d, J =  6.2 Hz, Leu-H3), 0.88 (3 H, d, J =  6.2 Hz, Leu-H3), 1.25-1.65 (18 H, 
s + m, Bu-t + Lys p,"/,8-H2 + Leu y-H + Leu P-H2), 2.75 (1 H, m, Phe P-H2), 2.89 (3 H, 
s, Sar-H3), 2.99 (3 H, m, Phe P-H2 + Lys e-H2), 3.11 (4 H, br, NCH2CH2N), 3.35 (2 H, s, 
Gly-H2), 3.65 (2 H, m, Gly-H2), 3.83 (2 H, br, Sar-H2), 3.84 (1 H, m, a-H), 4.25 (1 H, q, 
J =  6 Hz, a-H), 4.55 (1 H, m, a-H), 4.78 (2 H, s, CH2CC13), 5.07 (2 H, s, Ar-CH2), 6.87 
(1 H, d, J  = 7 Hz, NH), 7.15-7.40 (10 H, m, Ar + Phe-Ar), 7.67 (1 H, t, J = 6 Hz, NH),
7.81 (1 H, br, NH), 7.93-8.06 (3 H, m, 3 x NH), 8.20 (1 H, d, J=  6 Hz, NH)
x li
T.L.C. (C) Rf = 0.48
MS (FAB+) 1045 (M + H).
N-(N-(N-(N-(NE-(2,2,2-Trichloroethoxycarbonyl)lysyl)glycyl)phenyIalanyI)Ieucyl)- 
glycine N-(2-(N-(phenyImethoxycarbonyI)sarcosylainino)ethyl)amide hydrochloride 
(214)
Hydrogen chloride was bubbled through a solution of N-(N-(N-(N-(Na-(l,l-  
dimethylethoxycarbonyl)-NE-(2,2,2-trichloroethoxycarbonyl)lysyl)glycyl)phenylalanyl)- 
leucyl)glycine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (1.33 g,
1.27 mmol) in CH2C12 (10 ml) for 30 min. MeOH (1 ml) was added and the solvents and 
excess hydrogen chloride were evaporated to give N-(N-(N-(N-(Ne-(2,2,2-trichloro- 
ethoxycarbonyl)lysyl)glycyl)phenylalanyl)leucyl)glycine N-(2-(N-(phenylmethoxy-
carbonyl)sarcosylamino)ethyl)amide hydrochloride (1.14 g, 92%) as a buff foam.
‘H NMR ((CD3)2SO)
8  0.84 (3 H, d, J  = 6.2 Hz, Leu-CH3), 0.87 (3 H, d, J  = 6.2 Hz, Leu-CHj), 1.28-1.67 
(9H, m, Leu y-H + Leu P-H2 + Lys p,y,8 -H2), 2.80 ( 1  H, m, Phe P-H2), 2.86 (3 H, s, 
Sar-Hj), 3.04 (3 H, m, Lys e-H2 + Phe P-H2), 3.12 (4 H, br, NCH2CH2N), 3.59-3.91 
(7 H, m, Sar-H2 + 2  x Gly-H2 + Lys a-H), 4.26 (1 H, m, Leu a-H), 4.56 ( 1  H, m, Phe 
a-H), 4.78 (2 H, s, CH2CC13), 5.04 (2 H, s, Ar-CH2), 7.26 ( 1 1  H, m, Ar + NH), 7.69 
(1 H, t, J = 5.3 Hz, NH), 7.93 (1 H, br, NH), 8 .1 1 ( 2  H, m, 2  x NH), 8.31 (4 H, br, NH3+ 
+ NH), 8.70 ( l H , t , 7 =  5.3 Hz, NH).
5 0.84 (3 H, d, J =  6.2 Hz, Leu-CH3), 0.87 (3 H, d, J =  6.2 Hz, Leu-CH3), 1.28-1.67 
(9 H, m, Leu y-H + Leu p-H2 + Lys p,y,6 -H2), 2.80 (1 H, m, Phe P-H2), 2.89 (3 H, s, 
Sar-H3), 3.04 (3 H, m, Lys s-H2 + Phe P-H2), 3.12 (4 H, br, NCH2CH2N), 3.59-3.91 
(7 H, m, Sar-H2 + 2  x Gly-H2 + Lys a-H), 4.26 (1 H, m, Leu a-H), 4.56 (1 H, m, Phe 
a-H), 4.78 (2 H, s, CH2CC13), 5.08 (2 H, s, Ar-CH2), 7.26 (11 H, m, Ar + NH), 7.69 
(1 H, t, J = 5.3 Hz, NH), 7.93 (1 H, br, NH), 8 .11 (2 H, m, 2 x NH), 8.31 (4 H, br, NH3+ 
+ NH), 8.70 (1 H, t , J - 5.3 Hz, NH).
T.L.C. (C) R f= 0.12
xlii
MS (FAB+) 944 (M + H)





N-(2-(N-(phenylmethoxycarbonyI)sarcosylamino)ethyl)amide hydrochloride (980 mg, 
1.0 mmol) was added to N,N-diisopropylethylamine (402 mg, 3.0 mmol) in C H ^  
(30 ml). N-(Phenylmethoxycarbonyl)sarcosine 2,4,5-trichlorophenyl ester (418 mg, 
1 mmol) and DMAP (10 mg) were added to the mixture and the resulting solution was 
stirred for 20 h. The solution was washed with cold 10% aq. HjSC^ and with 1 0 % aq. 
NajCC^. The solution was dried and the solvent was evaporated. Chromatography 
(CHC13 / MeOH 20 : 1 then CHCI3 / MeOH 10 : 1) gave N-(N-(N-(N-(N“-(N-(phenyl- 
methoxycarbonyl)sarcosyl)-N6-(2,2,2-trichloroethoxycarbonyl)lysyl)glycyl)phenylalanyl)- 
leucyl)glycine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (719 mg, 
62%) as a friable foam.
1HNMR((CD3)2 SO)20oC
5 0.83 (3 H, d , J =  6.2 Hz, Leu-H3), 0.88 (3 H, d, , 7  = 6 . 2  Hz, Leu-H3), 1.23-1.59 (9 H, 
m, Leu y-H + Leu (3-H2 + Lys P,y,8 -H2), 2.76 ( 1  H, m, Phe P-H2), 2.84 (3 H, s, Sar-H3), 
2.86 (3 H, s, Sar-H3), 2.99 (3 H, m, Phe P-H2 + Lys b-H2), 3.12 (4 H, br, NCH2CH2N),
3.64 ( 4  H, m, 2  x Gly-H2), 3.83 (2 H, s, Sar-H2), 3.90 (2 H, br, Sar-H2), 4.25 (2 H, m, 
Lys a-H + Leu a-H), 4.54 (1 H, m, Phe a-H), 4.78 (2 H, s, CH2CC13), 5.03 (2 H, s, 
Ar-CH2), 5.07 (2 H, br, Ar-CH2), 7.36 (15 H, m, Ar), 7.68 (1 H, m, NH), 7.82 (1 H, m, 
NH), 8.02 ( 2  H, m, 2 x NH), 8.18 (4 H, br, 4 x NH)
8  0.83 (3 H, d, J =  6.2 Hz, Leu-H3), 0 . 8 8  (3 H ,d ,7 =  6.2 Hz, Leu-H3), 1.23-1.59 (9 H, 
m, Leu y-H + Leu P-H2 + Lys P,y,8 -H2), 2.76 ( 1  H, m, Phe P-H2), 2.84 (3 H, s, Sar-H3),
2.89 (3 H, s, Sar-H3), 2.99 (3 H, m, Phe P-H2 + Lys e-H2), 3.12 (4 H, br, NCH2CH2N),
xliii
3.64 (4 H, m, 2 x Gly-H2), 3.81 (2 H, s, Sar-H2), 3.90 (2 H, br, Sar-H2), 4.25 (2 H, m, 
Lys a-H + Leu a-H), 4.54 (1 H, m, Phe a-H), 4.78 (2 H, s, CH2CC13), 5.03 (2 H, s, 
Ar-CH2), 5.07 (2 H, br, Ar-CH2), 7.36 (15 H, m, Ar), 7.68 (1 H, m, NH), 7.82 (1 H, m, 
NH), 8.02 (2 H, m, 2 x NH), 8.18 (4 H, br, 4 x NH)
' H  N M R  ( ( C D j ^ S O )  8 0 ° C
8 0.85 (3 H, d, J =  6.4 Hz, Leu-Hj), 0.89 (3 H, d, 7 =  6.4 Hz, Leu-Hj), 1.29-1.69(9 H, 
m, Leu y-H + Leu p-H2 + Lys P,y,8 -H2), 2.85 (1 H, m, Phe P-H2), 2.88 (3 H, s, Sar-H3),
2.89 (3 H, s, Sar-H3), 3.01 (2 H, m, Lys e-H2), 3.07 (1 H, m, Phe P-H2), 3.16 (4 H, br, 
NCH2CH2N), 3.75 (2 H, m, Gly-H2), 3.84 (2 H, s, Sar-H2), 3.93 (2 H, s, Sar-H2), 4.26 
(2 H, m, Leu a-H, Lys a-H), 4.53 (1 H, m, Phe a-H), 5.05 (2 H, s, Ar-CH2), 5.07 (2 H, 
s, Ar-CH2), 7.34 (11 H, m, Ar + NH), 7.54 (1 H, br, NH), 7.68 (2 H, m, 2 x NH), 7.82 
(1 H, m, NH), 7.84 (2 H, m, 2 x NH), 7.90 (1 H, m, NH)
T.L.C. (C)Rf= 0.35 
MS (FAB+) 1149 (M + H)




amino)ethyl)amide hydrochloride (4.47 g, 4.6 mmol) was added to N,N-diisopropyl- 
ethylamine (2.72 g, 21.0 mmol) in CI^Clj (50 ml). N-(Phenylmethoxycarbonyl)sarcosine 
pentafluorophenyl ester (7.48 g, 13.8 mmol) and DMAP (20 mg) were added to the 
mixture and the resulting solution was stirred for 2 d. The solution was washed with cold 
10% aq. I^SC^ and with 10% aq. NajCC^. The solution was dried and the solvent was 
evaporated. Chromatography (CH2C12 / MeOH 2 0  : 1 then CH2C12 / MeOH 1 0  : 1 ) gave 
N-(N-(N-(N-(N-(phenylmethoxycarbonyl)sarcosyl)glycyl)phenylalanyl)leucyl)glycine N- 
(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide(3.50 g, 65%) as a pale cream 
foam.
xliv
*H NMR ((CD3)2SO) 20 °C (COSY 90)
8  0.82 (3 H, d, J  = 6.4 Hz, Leu-H3), 0.86 (3 H, d, J  = 6.4 Hz, Leu-H3), 2.49 (2 H, m, 
Leu p-H2), 1.61 ( 1  H, m, Leu y-H), 2.77 (1 H, m, Phe P-H2), 2.82 (3 H, s, Sar-H3), 2.86 
(3 H, s, Sar-H3), 3.03 (1 H, m, Phe p-H2), 3.11 (4 H, br, NCH2CH2N), 3.61-3.77 (4 H, 
m, 2  x Gly-Hj), 3.82 (2 H, s, Sar-H2), 3.87 (2 H, s, Sar-H2), 4.25 ( 1  H, m, Leu a-H),
4.53 ( 1  H, br, Phe a-H), 5.01 (2 H, s, Ar-CH2), 5.06 (2 H, s, Ar-CH2), 7.22 (5 H, m, 
Ar), 7.35 (5 H, m, Ar), 7.79 ( 1  H, m, NH), 8.06 ( 2  H, br, HNCH2CH2NH), 8 . 1 1  ( 1  H, m, 
Gly-NH), 8.16 (1 H, br, Gly-NH)
8  0.82 (3 H, d, J  = 6 . 4  Hz, Leu-H3), 0.86 (3 H, d, J  = 6.4 Hz, Leu-H3), 2.49 (2 H, m, 
Leu P-H2), 1.61 (1 H, m, Leu y-H), 2.77 (1 H, m, Phe P-H2), 2.85 (3 H, s, Sar-H3), 2.88 
(3 H, s, Sar-H3), 3.03 (1 H, m, Phe P-H2), 3.11 (4 H, br, NCH2CH2N), 3.61-3.77 (4 H, 
m, 2  x Gly-H2), 3.83 (2 H, s, Sar-H2), 3.88 (2 H, s, Sar-H2), 4.25 (1 H, m, Leu a-H),
4.53 (1 H, br, Phe a-H), 5.02 (2 H, s, Ar-CH2), 5.06 (2 H, s, Ar-CH2), 7.22 (5H, m, Ar), 
7.35 (5 H, m, Ar), 7.79 (1 H, m, NH), 8.06 (2 H, br, HNCH2CH2NH), 8.11 (1 H, m, 
Gly-NH), 8.16 ( 1  H, br, Gly-NH)
'H NMR ((CD3)2 SO) 80 °C
8  0.84 (3 H, d, J =  6.4 Hz, Leu-H3), 0.86 (3 H, d, 7  = 6.4 Hz, Leu-H3), 1.51 (2 H, m, 
Leu P-H2), 1.62 (1 H, m, Leu y-H), 2.82 (1 H, m, Phe P-H2), 2.89 (3 H, s, Sar-H3), 2.95 
(3 H, s, Sar-H3), 3.08 (1 H, m, Phe P-H2), 3.15 (4 H, br, NCH2CH2N), 3.63 (3 H, 
Gly-H2), 3.76 (1 H, m, Gly-H2), 3.83 (2 H, s, Sar-H2), 3.89 (2 H, s, Sar-H2), 4.25 (1 H, 
m, Leu a-H), 4.55 ( 1  H, m, Phe a-H), 5.06 (2 H, s, Ar-CH2), 7.22 (5 H, m, Ar), 7.33 
(5 H, m, Ar), 7.54 ( 2  H, br, HNCH2CH2NH), 7.68 (2 H, br, 2  x Gly-NH), 7 . 8 8  (2 H, m, 
Phe-NH + Leu-NH)
T.L.C. (C) Rf = 0.32
Acc. Mass 845.4216 (M + H) ( C ^ N .O , ,  requires 845.4198)
N^ljl-Dimethylethoxycarbonyl^N^^-methoxy-^oxohexytyglutamine penta
fluorophenyl ester (217)
DCC (4.72 g, 22.9 mmol) and pentafluorophenol (4.21 g, 22.9 mmol) were added to a 
stirred solution of Na-(l,l-dimethylethoxycarbonyl)-N5-(6 -methoxy-6 -oxohexyl)- 
glutamine (8.57 g, 22.9 mmol) in EtOAc (150 ml). The resulting suspension was stirred
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for 18 h and was then filtered. The filtrate was evaporated and the residue was re- 
dissolved in EtOAc and filtered. The solvent was evaporated to give Na-(l,l-dimethyl- 
ethoxycarbonyl)-N8-(6 -methoxy-6 -oxohexyl)glutamine pentafluorophenyl ester (12.37 g, 
quantitative) as a pale yellow wax.
*H NMR (CDCI3)
8  1.23 (2 H, m, NCHjCHjCHjCHjCHj), 1.36 (11 H, m, Bu-t + NCHjCHjCHjCHjCHj),
1.49 (2 H, m, NCHjCH^HjCHjCH:), 1.63 (2 H, m, Glu P-H2), 2.14 (2 H, m, Glu 
y-H2), 2.27 (2 H, t, J  = 7 3 Hz, NCHjCHjCHjCHjCHj), 3.04 (2 H, q, J  = 7 Hz, 
NCHjCH2CH2CH2CH2), 3.60 (3 H, s, OCHj), 3.88 (1 H, m, Glu a-H), 6.92 (1 H, d, J=
7.6 Hz, Glu-NH), 7.23 (10 H, m, Ar), 7.75 (1 H, t, J = 5.2 Hz, NHCH2CH2CH2).
19FNMR(CDC13)
8  -152.6 (2 F, d, J  = 20 Hz, 2,6-Ar), -158.7 (1 F, t, J  = 2 0  Hz, 4-Ar), -162.5 (2 F, t, 





Na-( 1,1 -Dimethylethoxycarbonyl)-N5-(6 -methoxy-6 -oxohexyl)glutamine pentafluoro­
phenyl ester (12.36 g, 22.9 mmol) was added to a stirred solution of N-(N-(N- 
glycylphenylalanyl)leucyl)glycine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)- 
amide hydrochloride (5.14 g, 7.6 mmol), N,N-diisopropylethylamine (2.17 g, 16.8 mmol) 
and DMAP (20 mg) in CH2CI2 (40 ml). After 18 h, dimethylformamide (20 ml) was added 
and stirring continued for 3 d. The solvent was evaporated and the residue was dissolved 
in EtOAc / MeOH (1:1). The solution was washed twice with cold 10% aq. H2S0 4, and 
twice with 10% aq. Na2C03. The solution was dried and the solvent was evaporated. 
Chromatography (CH2C12 / MeOH 2 0 : 1  then CH2C12 / MeOH 15:1) gave N-(N-(N-(N-
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solvent was evaporated and the residue was dissolved in EtOAc. The solution was 
filtered and the solvent was evaporated to give pentafluorophenyl 6 -(l,l-dimethylethoxy- 
carbonylamino)hexanoate (21.91 g, 98%) as a cream wax.
‘HNMR(CDC1j)
5 1.44 (11 H, m, Bu-t + NCH2CH2CH2CH2CH2), 1.54 (2 H, m, N O tQ iC H jC H jC H ^,
1.79 (2 H, m, NCHjCHjCHjCHjCHj), 2 . 6 8  ( 2  H, t, J =  7.3 Hz, NCH2CH2CH2CH2Cil2),
3.14 (2 H, m, NCHjCHjCHjCHjCHj), 4.58 (1 H, br, NH)
19FNMR(CDC13)
8  -153.3 (2 F, d, J  = 21.5 Hz, 2,6-Ar), -158.6 ( 1  F, t, J  = 18.1 Hz, 4-Ar), -162.8 ( 2  F, t, 





Pentafluorophenyl 6 -(l,l-dimethylethoxycarbonylamino)hexanoate (1.51 g, 4.79 mmol) 
was added to Na-(N-(phenylmethoxycarbonyl)sarcosyl)lysine N-(2-(N-(phenylmethoxy- 
carbonyl)sarcosylamino)ethyl)amide (1.9 g, 3.19 mmol), N,N-dimethylethylamine (1.12 g,
12.76 mmol) and DMAP in CH2CI2 (20 ml) and DMF (10 ml). The solution was stirred 
for 24 h and Pentafluorophenyl 6 -(l,l-dimethylethoxycarbonylamino)hexanoate (1.51 g,
4.79 mmol) was added. The solution was stirred for 3 d. The solvents were evaporated. 
Chromatography (CH2CI2 / MeOH 20:1) yielded N®-(6 -(l,l-dimethylethoxycarbonyl- 
amino)hexanoyl)-Na-(N-(phenylmethoxycarbonyl)sarcosyl)lysine N-(2-(N-(phenyl- 
methoxycarbonyl)sarcosylamino)ethyl)amide (2.18 g, 85%) as a buff*foam.
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(N®-( 1,1 -Dimethylethoxycarbonyl)-N5-(6 -methoxy-6 -oxohexyl)glutaminyl)glycyl)- 
phenylalanyl)leucyl)glycine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl) amide 
(6.41 g, 85%) as a buff foam.
' H  N M R  ( ( C D j ^ S O )  2 0 ° C  ( C O S Y  9 0 )
6  0.83 (3 H, d, J  = 6.4 Hz, Leu-CH3), 0.88 (3 H, d, J =  6.4 Hz, Leu-CHj), 1.23 (2 H, m, 
NCHjCHiCHjCHjCHj), 1.36 ( 1 1  H, m, Bu-t + NCHiCHjCHjCHjCHj), 1.49 (4 H, m, 
NCHjCH2CH2CH,CH2 + Leu P-H2), 1.57 ( 1  H, m, Leu y-H), 1.63 (2 H, m, Glu P-H2),
2.14 (2 H, m, Glu y-H2), 2.27 (2 H, t, J =  7.3 Hz, NCH2CH2CH2CH2CIL), 2.78 (1 H, m, 
Phe p-H2), 2.86 (3 IL s, Sar-Hj), 3.04 (2 H, q, J =  7 Hz, NCHjCHjCHjCHjCHj), 3.12 
(5 H, m, NCH2CH2N + Phe P-H2), 3.57 (3 H, s, OCHj), 3.60-3.69 (4 H., m, 2  x Gly-H2),
3.83 (2 H, s, Sar-H2), 3.88 (1 H, ra, Glu a-H), 4.25 (1 H, m, Leu a-H), 4.54 ( 1  H, br, 
Phe a-H), 5.03 (2 H, s, Ar-CH2), 6.92 (1 H, d, J  = 7.6 Hz, Glu-NH), 7.23 (10 H, m, Ar),
7.75 ( 1  H, t, J  = 5.2 Hz, NHCH2CH2CH2), 7.81 (1 H, br, NHCH2CH2NH), 7.99 (3 H, 
br, 2 x Gly-NH + NHCH2CH2NH), 8.05 (1 H, d, J =  8  Hz, Phe-NH), 8.18 ( 1  H, m, Leu- 
NH)
5 0.83 (3 H, d ,J =  6.4 Hz, Leu-CHj), 0.88 (3 H, d, 7  =6,4 Hz, Leu-CHj), 1.23 (2 H, m, 
NCH2CH2CH2CH2CH2), 1.36 (11 H, m, Bu-t + NCHjCHjCHjCHjCHj), 1.49 (4 H, m, 
NCH2CH2CH2CHjCH2 + Leu P-H2), 1.57 (1 H, m, Leu y-H), 1.63 (2 H, m, Ghi P-H2),
2.14 (2 H, m, Glu y-H2), 2.27 (2 H, t, J =  7.3 Hz, NCHjCHjC^CHjCHj), 2.78 (1 H, m, 
Phe P-Hj), 2.89 (3 H, s, Sar-H3), 3.04 (2 H, q, J =  7 Hz, NCHjCH2CH2CH2CH2), 3.12 
(5 H, m, NCH2CH2N + Phe P-H2), 3.57 (3 H, s, OCH3), 3.60-3.69 (4 H., m, 2  x Gly-H2),
3.84 (2 H, s, Sar-H2), 3.88 (1 H, m, Glu a-H), 4.25 (1 H, m, Leu a-H), 4.54 ( 1  H, br, 
Phe a-H), 5.07 (2 H, s, Ar-CH2), 6.92 (1 H, d ,J = 7  6 Hz Glu-NH), 7.23 (10 H, m, Ar),
7.75 (1 H, t, J =  5.2 Hz, NHCH2CH2CH2), 7.81 (1 H, br, NHCH2CH2NH), 7.99 (3 H, 
br, 2 x Gly-NH + NHCH2CH2NH), 8.05 (1 H, d, J  = 8  Hz, Phe-NH), 8.18 ( 1  H, m, Leu- 
NH)
'H NMR ((CD3)jSO) 80°C
8  0.86 (3 H, d, J  = 6 . 1  Hz, Leu-CH3), 0.90 (3 H, d, J=  6 . 1  Hz, Leu-CH3), 1.29 (2 H, m, 
NCHjCHjCIfcCHjCHj), 1.39 (11 H, m, Bu-t + NCHjCHjCHjCHjCHj), 1.53 (4 H, m, 
NCH2CH2CH2CHjCH2 + Leu P-H2), 1.63 (1 H, m, Leu y-H), 1.75 (2 H, m, Glu p-H2), 
2.13 (2 H, m, Glu y-H2), 2.28 (2 H, t, J =  7.3 Hz, NCH2CH2CH2CH2CHi), 2.85 (1 H, m, 
Phe P-H2), 2.90 (3 H, s, Sar-H3), 3.05 (2 H, q, J=  6 . 6  Hz, NCHjCH2CH2CH2CH2), 3.11 
(5 H, m, NCH2CH2N + Phe P-H2), 3.59 (3 H, s, OCH3), 3.68 (4 H., m, 2  x Gly-H2), 3.84 
(2 H, s, Sar-H2), 3.89 (1 H, m, Glu a-H), 4.26 (1 H, m, Leu a-H), 4.55 (1 H, br, Phe 
a-H), 5.07 (2 H, s, Ar-CH2), 6.57 (1 H, br, Glu-NH), 7.23 (10 H, m, Ar), 7.51 (1 H, m,
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NHCH2CH2CH2), 7.56 (1 H, br, NHCH2CH2NH), 7.69 (3 H, br, 2  x Gly-NH + 
NHCH2CH2NH), 7.78 (1 H, m, Phe-NH), 7.87 (1 H, m, Leu-NH)




Hydrogen chloride was bubbled through a solution of N-CN-^N-CN-^N^l,!- 
dimethylethoxycarbonyl)-N5-(6 -methoxy-6 -oxohexyl)glutaminyl)glycyl)phenylalanyl)- 
leucyl)glycine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (3.13 g,
3.15 mmol) in CH2C12 (20 ml) and MeOH (2 ml) for 30 min. The solvents and excess 
hydrogen chloride were evaporated to give N-(N-(N-(N-(N5-(6 -methoxy-6 - 
oxohexyl)glutaminyl)glycyl)phenylalanyl)leucyl)glycine N-(2-(N-(phenylmethoxy-
carbonyl)sarcosylamino)ethyl)amide (2.93 g, quantitative) as a beige foam.
'H NMR ((CD3)2SO) 20°C
8  0.83 (3 H, d, J  = 6 . 1  Hz, Leu-Hj), 0.88 (3 H, d, J =  6.1 Hz, Leu-H3), 1.23 (2 H, m, 
NCHjCHjCIfcCHjCHj), 1.35 (2 H, m, NCHjCHjCHjCHjCHj), 1.51 (2 H, m,
NCHjCHjCHjCHjCHj), 1.60 (3 H, m, Leu y-H + Leu P-H2), 1 . 6 8  ( 2  H, m, Glu P-H2),
2.20 (2 H, m, Glu y-H2), 2.27 (2 H, t, J =  7.3 Hz, NCH2CH2CH2CH2CHj), 2.79 (1 H, m, 
Phe P-H2), 2.85 (3 H, s, Sar-H3), 3.09 (7 H, br, NCH2CH2N + NCHjCHiCHjCHjCHj + 
Phe P-H2), 3.32 (1 H, m, Glu ot-H), 3.57 (3 H, s, OCH3), 3.65 (4 H, m, 2  x Gly-H2), 3.83 
(2 H, s, Sar-H2), 4.64 (1 H, m, Leu a-H), 4.93 (1 H, m, Phe a-H), 5.03 (2 H, s, Ar-CH2),
7.17 (1 H, m, NH), 7.27 (10 H, m, Ar), 7.91 (1 H, br, NH), 8.00 (1 H. m. NH), 8.17 (1
H, br, NH), 8.33 (5 H, br, NH3+ + 2  x NH), 8.72 (1 H, m, NH).
5 0.83 (3 H ,d ,J  = 6.1 Hz, Leu-H3), 0.88 (3 H, d, J  = 6.1 Hz, Leu-H3), 1.23 (2 H, m, 
NCHiCHjCHjCHjCHj), 1.35 (2 H, m, NCH2CH2CH2CH2CH2), 1.51 (2 H, m,
NCH2CH2CH2CH2CH2), 1.60 (3 H, m, Leu y-H + Leu P-H2), 1.68 (2 H, m, Glu P-H2),
2 . 2 0  ( 2  H, m, Glu y-H2), 2.27 (2 H ,t,7 =  7.3 Hz, NCH2CH2CH2CH2CH2), 2.79 ( 1  H, m, 
Phe P-H2), 2.89 (3 H, s, Sar-H3), 3.09 (7 H, br, NCH2CH2N + NCHjCHjCHjCHjCHj + 
Phe P-H2), 3.32 (1 H, m, Glu a-H), 3.57 (3 H, s, OCH3), 3.65 (4 H, m, 2 x Gly-H2), 3.85 
(2 H, s, Sar-H2), 4.64 (1 H, m, Leu a-H), 4.93 (1 H, m, Phe a-H), 5.07 (2 H, s, Ar-CH2),
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7.17 ( 1  H, m, NH), 7.27 ( 1 0  H, m, Ar), 7.91 ( 1  H, br, NH), 8.00 (1 H. m. NH), 8.17 (1 
H, br, NH), 8.33 (5 H, br, NHj+ + 2  x NH), 8.72 (1 H, m, NH).
‘H  N M R  ( ( C D j ^ S O )  8 0 ° C
8  0.84 (3 H, d, J =  6.4 Hz, Leu-H3), 0.88 ( 3  H, d ,7 =  6.4 Hz, Leu-H3), 1.27 (2 H, m, 
NCHjCHjCHjCHjCHj), 1.41 (2 H, m, NCHjCHjCHjCHjCHj), 1.55 (2 H, m, 
NCHjCHjCHjCHjCHj), 1.60 (3 H, m, Leu y-H + Leu P-H2), 1 . 6 8  (2 H, m, Glu P-H2),
2.26 (2 H, m, Glu y-H2), 2.48 (2 H, t, J =  7.3 Hz, NCHjCHjCHjCH^Hj), 2.88 (3 H, s, 
Sar-H3 + Phe P-H2), 3 .11 (2H, m, NCH2CH2CH2CH2CH2), 3 .18 (5 H, br, NCH2CH2N + 
Phe P-H2), 3.36 (1 H, m, Glu a-H), 3.58 (3 H, s, OCH3), 3.65 ( 4  H, m, 2  x Gly-H2), 3.85 
(2 H, s, Sar-H2), 4.64 (1 H, m, Leu a-H), 4.93 (1 H, m, Phe a-H), 5.06 (2 H, s, Ar-CH2),
7.17 ( 1  H, m, NH), 7.27 (10 H, m, Ar), 7.78 (3 H, br, 3  x NH), 8.10 ( 1  H. m, NH), 8.13 
(1 H, m, NH), 8.30 (3 H, br, NHj4), 8.72 (1 H, m, NH).




N-(Phenylmethoxycarbonyl)sarcosine pentafluorophenyl ester (7.23 g, 18.6 mmol) was 
added to a stirred solution of N-(N-(N-(N-(N5-(6 -methoxy-6 -oxohexyl)glutaminyl)- 
glycyl)phenylalanyl)leucyl)glycine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)- 
ethyl)amide hydrochloride (5.77 g, 6 . 2  mmol), N,N-diisopropylethylamine (3.20 g,
24.8 mmol) and DMAP (10 mg) in CH2CI2 (30 ml). After 18 h, dimethylformamide 
(20 ml) was added and stirring continued for 4d. The solvents were evaporated and the 
residue was dissolved in EtOAc / MeOH (1:1). The solution was washed with cold 10% 
aq. H2S0 4 and with 10% aq. Na2C03. The solution was dried and the solvent was 
evaporated. Chromatography (CH2CI2 / MeOH 20:1 then CH2CI2 / MeOH 15:1 then 
CH2CI2 / MeOH 10:1 ) gave N-(N-(N-(N-(N5-(6 -methoxy-6 -oxohexyl)-Na-(N-(phenyl- 
methoxycarbonyl)sarcosyl)glutaminyl)glycyl)phenylalanyl)leucyl)glycine N-(2-(N-
(phenylmethoxycarbonylsarcosyl)amino)ethyl)amide (3.19 g, 47%) as a pale yellow foam.
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'HNMR ((CDj)jSO) 20°C (COSY 90)
5 0.83 (3 H, d, J  = 6.4 Hz, Leu H3), 0.87 (3 H, d, J =  6.4 Hz, Leu H3), 1.22 ( 2  H, m, 
NCHjCHjCHjCHjCHj), 1.27 (2 H, m, NCHjCHjCHjCHjCHj), 1.49 (2 H, m, 
NCHjCHjCHjCHjCHj), 1.62 (3 H, m, Leu y-H + Leu p-H2), 1.69 (2 H, m, Glu P-H2),
2.08 ( 2  H, m, Glu y-H2), 2.27 (3 H, t, J =  7.3 Hz, NCH2CH2CH2CH2CH2>, 2.74 ( 1  H, m, 
Phe P-H2), 2.84 (2 H, s, Sar-H3), 2.89 (3 H, s, Sar-H3), 2.94 (3 H, m, Phe P-H2 + 
NCH2CH2CH2 CH2CH2), 3.12 (4 H, br, NCH2CH2N), 3.57 (3 H, s, OCH3), 3 . 6 6  (4 H, m, 
2 x Gly-H2), 3.84 (2 H, s, Sar-H2), 3.92 (2 H, s, Sar-H2), 4.26 (2 H, m, Leu a-H + Glu a  
-H), 4.53 (1 H, m, Phe a-H), 5.01 (2 H, s, Ar-CH2), 5.07 (2H, s, Ar-CH2), 7.29 (15 H, 
m, Ar), 7.78 (1 H, m, NHCH2CH2CH2), 7.83 (1 H, m, HNCH2CH2NH), 8.08 (2 H, m, 
HNCH2CH2NH_+ Gly-NH), 8.12 (1 H, m, Phe-NH), 8.32 (3 H, m, Leu-NH, Gly NH, 
Glu-NH)
8  0.83 (3 H, d, J =  6.4 Hz, Leu-H3), 0.87 (3 H, d, J =  6.4 Hz, Leu-H3), 1.22 (2 H, m, 
NCHjCHjCHjCHjCHj), 1.27 (2 H, m, NCH^HjCHjCH^Hj), 1.49 (2 H, m, 
NCHjCHjCHjCHjCHj), 1.62 (3 H, m, Leu y-H + Leu P-H2), 1.69 (2 H, m, Glu P-H2),
2.08 (2 H, m, Gluy-H2), 2.27 (3 H, t, J =  7.3 Hz, NCHjCHjCHjCHjCHj), 2.74 (1 H, m, 
Phe P-H2), 2.86 (2 H, s, Sar-H3), 2.87 (3 H, s, Sar-H3), 2.94 (3 H, m, Phe P-H2 + 
NCHiCHjCHjCHjCHj), 3.12 (4 H, br, NCH2CH2N), 3.57 (3 H, s, OCH3), 3.66 (4 H, m, 
2 x Gly-H2), 3.84 (2 H, s, Sar-H2), 3.92 (2 H, s, Sar-H2), 4.26 (2 H, m, Leu a-H + Glu a  
-H), 4.53 (1 H, m, Phe a-H), 5.03 (2 H, s, Ar-CH2), 5.04 (2 H, s, Ar-CH2), 7.29 (15 H, 
m, Ar), 7.78 (1 H, m, NHCH2CH2CH2), 7.83 (1 H, m, HNCH2CH2NH), 8.08 (2 H, m, 
HNCH2CH2NH + Gly-NH), 8.12 (1 H, m, Phe-NH), 8.32 (3 H, m, Leu-NH, Gly NH, 
Glu-NH)
‘H NMR ((CD3)2 SO) 80°C
6  0.84 (3 H, d, J  = 6.4 Hz, Leu-H3), 0.88 (3 H, d, J  = 6.4 Hz, Leu-H3), 1.26 (2 H, m, 
NCHjCHjCHjCHjCHj), 1.39 (2 H, m, NCHjCHjCHjCHjC^), 1.57 (2 H, m, 
NCH^HjCHjCHjCHj), 1.62 (3 H, m, Leu y-H + Leu P-H2), 1.75 (2 H, m, Glu p-H2),
2.12 (2 H, t, J =  7.6 Hz, Glu y-H2), 2.27 (2 H, t, J =  7.3 Hz, NCHjCHjCHjCHjCHj),
2.85 ( 1  H, m, Phe p-H2), 2.89 (3 H, s, Sar-H}), 3.09 (7 H, m, Phe P-H2 + 
NCH2CH2CH2CH2CH2 + NCH2CH2N), 3.58 (3 H, s, OCH3), 3.66 (4 H, m, 2  x Gly-H2),
3.85 (2 H, s, Sar-H2), 3.94 (2 H, br, Sar-H2), 4.24 (2 H, m, Leu a-H + Glu a-H), 4.54 (1 
H, m, Phe a-H), 5.05 (2 H, s, Ar-CH2), 5.07 (2 H, s, Ar-CH2), 7.28 (15 H, m, Ar), 7.48 
(1 H, m, NH), 7.58 (1 H, br, NH), 7.71 (2 H, m, 2 x NH), 7.84 (1 H, m, NH), 7.92 (3 H, 
m, 3 x NH), 8 . 0 1  ( 1  H, m, NH)
T.L.C. (C)Rf= 0.31 




N5-(6 -Methoxy-6 -oxohexyl)glutamine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)- 
ethyl)amide hydrochloride (5.92 g, 10.6 mmol) was added to a stirred solution of N -(l,l- 
dimethylethoxycarbonyl)glycine 2,4,5-trichlorophenyl ester (3.76 g, 10.6 mmol) in 
CH2CI2 (200 ml) containing N,N-diisopropylethylamine (4.11 g, 31.9 mmol) and DMAP 
(10 mg). The solution was stirred for 10 d. The solvent was evaporated and the residue 
was dissolved in EtOAc and then washed twice with cold 1 0 % aq. H jS O ^ d  twice with 
10% aq. Na2C0 3 . The solution was dried and the solvent was evaporated to give a pink 
oil. Trituration with Et2 0  yielded Na-(N-(l,l-dimethylethoxycarbonyl)glycyl)-N5-(6 - 
methoxy-6 -oxohexyl)glutaminyl N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)- 
amide (5 .32 g, 74%) as a buff solid. Mp 100-102°C
'H NMR ((CD3)2 SO) 20°C
5 1.22 (2 H, m, NCH2CHjCH2CH2CH2), 1.37 (11 H, m, Bu-t + NCH2CIfcCH2CH2CH2),
1.49 (2 H, m, NCH2CH2CH2CH2CH2), 1.72 (2 H, m, Glu P-H2), 2.05 (2 H, m, Glu y- 
H2), 2.24 (2 H, t, J =  7.3 Hz, NCH2CH2CH2CH2CH2), 2.86 (3 H, s, Sar-Hj), 3.10 (2 H, 
m, NCHiCHjCHjCHjCHj), 3.37 (4 H, br, NCH2CH2N), 3.44 (2 H, m, Gly-H2), 3.56 (3
H, s, OCHj), 3.82 (2 H, s, Sar-H2), 4.18 ( 1  H, m, Glu a-H), 5.04 (2 H, s, Ar-CH2), 7.01 
(1 H, m, NH), 7.36 (5 H, m, Ar), 7.76 ( 1  H, br, NH), 7.98 (3 H, br, 3 x NH)
‘H  N M R  ( ( C D j ^ S O )  8 0 ° C
8  1.25 (2 H, m, NCH2CH2CHjCH2CH2), 1.38 (11 H, m, Bu-t + NCHjCHiCHjCHjCHj),
I.51 (2 H, m, NCH2CH2CH2CH2CH2), 1.76 (2 H, m, Glu P-H2), 1.95 (2 H, nt, Glu 
y-H2), 2.08 (2 H, m, NOtCHjCHjCHjCHz), 2.88 (3 H, s, Sar-H3), 3.12 (2 H, q, 
J=  6.5 Hz, NCHjCHjCHjCH^H^, 3.25 (4 H, m, NCH2CH2N), 3.58 (5 H, m, Gly-H2 + 
OCHj), 3.83 (2 H, s, Sar-H2), 4.20 (1 H, m, Glu a-H), 5.06 (2 H, s, Ar-CH2), 6.62 (1 H, 
br, NH), 7.33 ( 6  H, m, Ar + NH), 7.46 ( 1  H, m, NH), 7.67 (2 H, br, 2  x NH).
T.L.C. (C )Rf= 0.56 




Hydrogen chloride was bubbled through a solution of Na-(N-(l,l-dimethylethoxy- 
carbonyl)glycyl)-Ns-(6 -methoxy-6 -oxohexyl)glutamine N-(2-(N-(phenylmethoxy-
carbonyl)sarcosylamino)ethyl)amide (3.86 g, 5.7 mmol) in tetrahydrofuran (100 ml) and 
MeOH (5 ml) for 30 min. The solvents and excess reagent were evaporated to give Na- 
glycyl-N5-(6 -methoxy-6 -oxohexyl)glutaminyl N-(2-(N-(phenylmethoxycarbonyl)sarcosyl- 
amino)ethyl)amide hydrochloride (3.49 g, quantitative) as a buff foam.
'HNMR((CD3)2SO)
5 1.22 (2 H, m, NCHjCHjCHjCHjCHj), 1.36 (2 H .n i, NCHjCHjCHjCHjCHj), 1.47 
(2H .ni, NCHjCHjCHjCHjCHj), 1.72 (2 H .n i, Glu P-H2), 1.92 (2 H, m, Glu y-H2),
2.09 (2 H, m, NCH2CH2CH2CH2CH2), 2.87 (3 H, s, Sar-H3), 3.02 (2 H, m, 
NCIfcCHjCHjCHjCHj), 3.16 (4 H, br, NCH2CH2N), 3.6 (2 H, m, Gly-H2), 3.84 (2 H, 
br, Sar-H2), 4.22 (1 H, m, Glu a-H), 5.03 (2 H, s, Ar-CH2), 7.26 (5 H, m, Ar), 7.89 ( 1  H, 
m, NH), 8.19 (3 H, br, NH3*), 8.67 (1 H, m, NH), 9.02 ( 1  H, br, NH)
8  1.22 (2 H, m, NCH2CH2CH2CH2CH2), 1.36 (2 H, m, NCHjCHjCHjCHjCHj), 1.47 
(2 H, m, NCHjCHjCHjCHjCHj), 1.72 (2 H, m, Glu p-H2), 1.92 (2 H, m, Glu y-H2),
2.09 (2 H, m, NCH2CH2CH2CH2CH2), 2.88 (3 H, s, Sar-H3), 3.02 (2 H, m, 
NCHjCHjCHjCHjCHj), 3.16 (4 H, br, NCH2CH2N), 3.6 (2 H, m, Gly-H2), 3.84 (2 H, 
br, Sar-H2), 4.22 (1 H, m, Glu a-H), 5.07 (2 H, s, Ar-CH2), 7.26 (5 H, m, Ar), 7.89 (1 H, 
m, NH), 8.19 (3 H, br, NHj4), 8.67 (1 H, m, NH), 9.02 (1 H, br, NH)




amino)ethyl)amide hydrochloride (6.3 g, 10.4 mmol) was added to N-(l,l-dimethyl- 
ethoxycarbonyl)glycine pentafluorophenyl ester (3.56 g, 10.4 mmol) and N,N-diiso- 
propylethylamine (4.05 g, 31.3 mmol) in CH2C12 (50 ml) and the solution was stirred for
lii
3d. The solution was washed twice with cold 10% aq. H2S04 and once with 10% aq. 
Na2C03. The solution was dried and the solvent was evaporated to give Na-(N-(1,1- 
dimethylethoxycarbonyl)gIycyl)-Ne-(2,2,2-trichloroethoxycarbonyl)lysine N-(2-(N- 
(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (6.89 g, 91%) as a pale brown foam
‘H NMR ((CD3)2 SO) 20°C
8  1.24 (2 H, m, Lys P,y,S-H2), 1.39 (11 H, m, Bu-t + Lys P,y,8 -H2), 1.62 (2 H, m, Lys 
P,y,6 -H2), 2.87 (3 H, s, Sar-H3), 3.00 (2 H, m, Lys e-H2), 3.11 (4 H, br, NCH2CH2N),
3.58 (2 H, br, Gly-H2), 3.84 (2 H, s, Sar-H2), 4.18 (1 H, m, Lys a-H), 4.78 (2 H, s, 
CH2CC13), 5.05 (2 H, s, Ar-CH2), 6.98 (1 H, m, NH), 7.37 (5 H, m, Ar), 7.68 (1 H, m, 
NH), 7.87 (1H, d, 7 =  8 . 6  Hz, Lys NH), 7.99 (2 H, br, 2 x NH)
8  1.24 (2 H, m, Lys P,y,8 -H2), 1.39 (11 H, m, Bu-t + Lys p,y,8 -H2), 1.62 (2 H, m, Lys 
P,y,8 -H2), 2.89 (3 H, s, Sar-H3), 3.00 (2 H, m, Lys e-H2), 3.11 (4 H, br, NCH2CH2N),
3.58 (2 H, br, Gly-H2), 3.84 (2 H, s, Sar-H2), 4.18 (1 H, m, Lys a-H), 4.78 (2 H, s, 
CH2CC13), 5.08 (2 H, s, Ar-CH2), 6.98 (1 H, m, NH), 7.37 (5 H, m, Ar), 7.68 ( 1  H, m, 
NH), 7.87 (1H, d, J=  8 . 6  Hz, Lys NH), 7.99 (2 H, br, 2 x NH)
T.L.C. (C) Rf = 0.42 
MS (FAB-) 625 (M - Boc)
Na-Glycyl-Ne-(2,2,2-trichIoroethoxycarbonyl)lysine N-(2-(N-(phenylmethoxy-
carbonyl)sarcosylamino)ethyl)amide hydrochloride (225)
Hydrogen chloride was bubbled through a solution of N“-(N-( 1, 1  -dimethylethoxy- 
carbonyl)glycyl-Ne-(2,2,2-trichloroethoxycarbonyl)lysine N-(2-(N-(phenylmethoxy- 
carbonyl)sarcosylamino)ethyl)amide (5.87 g, 8 . 1  mmol) in CH2C12 (50 ml) for 30 min. 
The solvent and excess hydrogen chloride were evaporated to give Na-glycyl-NE-(2,2,2- 
trichloroethoxycarbonyl)lysine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)- 
amide (5.27 g, 98%) as a buff foam.
liii
'H NMR ((CD3)2SO) 20°C
8  1.26 (2 H, m, Lys P,y,8 -H2), 1.41 (2 H, m, Lys P,y,8 -H2), 1.63 (2 H, m, Lys P,y,8 -H2),
2.86 (3 H, s, Sar-Hj), 2.99 (2 H, m, Lys 8 -H2), 3.11 (4 H, br, NCH2CH2N), 3.60 (2 H, m, 
Gly-H2), 3.84 (2 H, s, Sar-H2), 4.21 (1 H, m, Lys a-H2), 4.78 (2 H, s, CH2CC13), 5.04 
(2 H, s, Ar-CH2), 7.35 (5 H, m, Ar), 7.69 (1 H, m, NH), 8 . 1 1  (3 H, br, NH3+), 8.18 (2 H, 
br, 2 x NH), 8.61 (1 H, d , J=  7.6 Hz, Lys NH)
8  1.26 (2 H, m, Lys p,y,S-H2), 1.41 ( 2  H, m, Lys P,y,8 -H2), 1.63 (2 H, ra, Lys p,y,8 -H2),
2.89 (3 H, s, Sar-H3), 2.99 (2 H, m, Lys e-H2), 3.11 (4 H, br, NCH2CH2N), 3.60 (2 H, m, 
Gly-H2), 3.85 (2 H, s, Sar-H2), 4.21 (1 H, m, Lys a-H2), 4.78 (2 H, s, CH2CC13), 5.08 
(2 H, s, Ar-CH2), 7.35 (5 H, m, Ar), 7.69 (1 H, m, NH), 8.11 (3 H, br, NH3+), 8.18 (2 H, 
br, NH), 8.61 ( 1  H, d , J =  7.6 Hz, LysNH)
'H NMR ((CD3)2SO) 80°C
8  1.31 (2 H, m, Lys P,y,8 -H2), 1.45 (2 H, m, Lys p,y,8 -H2), 1.60 (2 H, m, Lys P,y,8 -H2),
2.89 (3 H, s, Sar-H3), 3.04 (2 H, m, Lys 8 -H2), 3.12 (4 H, br, NCH2CH2N), 3.59 (2 H, m, 
Gly-H2), 3.85 (2 H, s, Sar-H2), 4.21 (1 H, m, Lys ct-H2), 4.75 (2 H, s, CH2CC13), 5.07 
(2 H, s, Ar-CH2), 7.33 (5 H, br, Ar), 7.83 (1 H, m, NH), 7.92 (1 H, m, NH), 8.09 (3 H, 
br, NH34), 8.43 (1 H, d ,7 = 7  6 Hz, Lys NH).
T.L.C. (C) Rf= 0.12
N-(l,l-DimethyIethoxycarbonyl)leucine pentafluorophenyl ester (226)
N-(l,l-Dimethylethoxycarbonyl)leucine (63.56 g, 275 mmol) in EtOAc (200 ml) was 
cooled to 0°C. DCC (56.74 g, 275 mmol) and pentafluorophenol (50.62 g, 275 mmol) 
were added and the suspension was stirred for 24 h. The suspension was filtered and the 
solvent evaporated to give N-(l,l-dimethylethoxycarbonyl)leucine pentafluorophenyl 
ester (109 g, quantitative) as a cream wax.
liv
*H NMR (CDCb)
8  0.89 ( 6  H, d, 7 = 6.7 Hz, 2 x Leu-H3), 1.47 (9 H, s, Bu-t), 1.72 (1 H, m, Leu p-H2),
1.78 (2 H, m, Leu p-H2 + Leu y-H), 4.62 (1 H, m, Leu a-H), 4.95 (1 H, m, NH)
I9FNMR(CDC13)
8  -152.8 (2 F, d, 7  = 2 0  Hz, 2 ,6 -Ar), -158.1 ( 1  F, t, 7  = 2 0  Hz, 4-Ar), -162.8 (2 F, t, 
7 =  20 Hz, 3,5-Ar)





Na-Glycyl-Ne-(2,2,2-trichloroethoxycarbonyl)lysine N - ( 2  -(N -(phenylmethoxy carbonyl)- 
sarcosylamino)ethyl)amide (5.14 g, 7.8 mmol) was added to a stirred solution of N -(l,l- 
dimethylethoxycarbonyl)leucine pentafluorophenyl ester (3.89 g, 7.8 mmol), N,N-diiso- 
propylethylamine (3.01 g, 23.3 mmol) and DMAP (20 mg) in CH2C12 (50 ml) The 
mixture was stirred for 4 d, then washed twice with cold 1 0 % aq. H2S04, once with 10% 
aq. Na2C0 3 and once with brine. The solution was dried and the solvent was evaporated. 
Chromatography (CH2C12 / MeOH 30:1 increasing to CH2C12 / MeOH 1:1) gave N“-(N- 
(N-( 1,1 -dimethylethoxycarbonyl)leucyl)glycyl)-Ne-(2,2,2-trichloroethoxycarbonyl)lysine 
N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (5.53 g, 85%) as a 
colourless foam.
‘H NMR ((CD3)2 SO) 20°C
8  0.83 (3 H, d, J =  6.2 Hz, Leu-H3), 0.86 (3 H, d, J =  6.2 Hz, Leu-H3), 1.22-1.63 (18 H, 
m, Bu-t + Leu y-H + Leu p-H2 + Lys 3,y,8-H2), 2.86 (3 H, s, Sar-H3), 3.04 (2 H, q, 
7 = 6  9  Hz, Lys e-H2), 3.10 (4 H, br, NCH2CH2N), 3.72 (2 H, d, 7 =  5.1 Hz, Gly-H2),
3.82 (2 H, s, Sar-H2), 3.94 (1 H, m, Leu a-H), 4.14 (1 H, m, Lys a-H), 4.77 (2 H, s,
lv
CH2CC13), 5.04 (2 H, s, Ar-CH2), 6.98 ( 1  H, d, J=  8 . 1  Hz, NH), 7.36 (5 H, m, Ar), 7.64 
(1 H, t, J = 6.9 Hz, NH), 7.87 (1 H, d, J=  8 . 6  Hz, NH), 7.95 (3 H, br, 3 x NH)
5 0.83 (3 H, d, J =  6.2 Hz, Leu-H3), 0.86 (3 H, d, J =  6.2 Hz, Leu-H3), 1.22-1.63 (18 H, 
m, Bu-t + Leu y-H + Leu p-H2 + Lys P,y,6 -H2), 2.89 (3 H, s, Sar-H3), 3.04 (2 H, q, 
J = 6.9 Hz, Lys e-H2), 3.10 (4 H, br, NCH2CH2N), 3.72 (2 H, d, J  = 5.1 Hz, Gly-H2),
3.82 (2 H, s, Sar-H2), 3.94 (1 H, m, Leu a-H), 4.14 (1 H, m, Lys a-H), 4.77 (2 H, s, 
CH2CC13), 5.08 (2 H, s, Ar-CH2), 6.98 (1 H, d, J=  8.1 Hz, NH), 7.36 (5 H, m, Ar), 7.64 
(1 H, t, J = 6.9 Hz, NH), 7.87 (1 H, d, J = 8 . 6  Hz, NH), 7.95 (3 H, br, 3 x NH)
T.L.C. (C) Rf = 0.41 
MS (FAB+) 840 (M + H)
Na-(N-LeucyIglycyI)-NE-(2,2,2-trichIoroethoxycarbonyI)lysine N-(2-(N-(phenyl- 
methoxycarbonyl)sarcosylamino)ethyI)amide hydrochloride (228)
Hydrogen chloride was bubbled through a solution of N“-(N-(N-(l,l-dimethylethoxy- 
carbonyl)leucyl)glycyl)-NE-(2,2,2-trichloroethoxycarbonyl)lysine N-(2-(N-(phenyl- 
methoxycarbonyl)sarcosylamino)ethyl)amide (5.16 g, 6.15 mmol) in CH2C12 (50 ml) for 
30 min. MeOH (2 ml) was added and the solvents and excess hydrogen chloride were 
evaporated to give Na-(N-(leucylglycyl)-NE-(2,2,2-trichloroethoxycarbonyl)lysine N-(2- 
(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide hydrochloride (4.76 g, 
quantitative) as a colourless foam.
'H NMR ((CDa^SO) 20°C
8  0.89 ( 6  H, m, 2  x Leu-H3), 1.23 (2 H, br, Leu P-H2), 1.41 (2 H, m, Lys p,y,6 -H2), 1.61 
(5 H, m, Lys P,y,8 -H2 + Leu y-H), 2.86 (3 H, s, Sar-H3), 3.00 (2 H, m, Lys e-CH2), 3.13 
(4 H, br, NCH2CH2N), 3.84 (5 H, br, GIy-H2 + Sar-H2 + Leu a-H), 4.17 ( 1  H, m, Lys 
a-H), 4.78 (2 H, s, CH2CC13), 5.04 (2 H, s, Ar-H2), 7.37 (5 H, m, Ar), 7.67 (1 H, br, 
NH), 8.06 (1 H, br, NH), 8.13 (1 H, d, J = 7.6 Hz, NH), 8.25 (3 H, br, NHs*), 8.81 ( 1  H, 
m, NH)
8  0.89 ( 6  H, m, 2  x Leu-H3), 1.23 (2 H, br, Leu P-H2), 1.41 (2 H, m, Lys P,y,8 -H2), 1.61 
(5 H, m, Lys P,y,8 -H2 + Leu y-H), 2.89 (3 H, s, Sar-H3), 3.00 (2 H, m, Lys e-CH2), 3.13
lvi
(4 H, br, NCH2CH2N), 3.84 (5 H, br, Gly-H2 + Sar-H2 + Leu a-H), 4.17 (1 H, m, Lys 
a-H), 4.78 ( 2  H, s, CH2CC13), 5.08 ( 2  H, s, Ar-H2), 7.37 (5 H, m, Ar), 7.67 ( 1  H, br, 
NH), 8.06 (1 H, br, NH), 8.13 (1 H, d ,J=  7.6 Hz, NH), 8.25 (3 H, br, NHa^, 8.81 (1 H, 
m, NH)
1HNMR((CD3)2SO)80°C
8  0.91 ( 6  H, m, 2 x Leu-H3), 1.25 (2 H, br, Leu (3-H2), 1.43 (2 H, m, Lys P,y,8 -H2), 1.64 
(5 H, m, Lys P,y,8 -H2 + Leu y-H), 2.89 (3 H, s, Sar-H3), 3.00 (2 H, m, Lys e-CH2), 3.13 
(4 H, br, NCH2CH2N), 3.85 (5 H, br, Gly-H2 + Sar-H2 + Leu a-H), 4.19 (1 H, m, Lys 
a-H), 4.75 (2 H, s, CH2CC13), 5.06 (2 H, s, Ar-H2), 7.33 (5 H, br, Ar), 7.81 (1 H, br, 
NH), 7.89 (1 H, d, J = 8.2 Hz, NH), 8.22 (4 H, br, NH3+ + NH), 8 . 6 6  (1 H, t, J = 5.2 Hz, 
NH)
T.L.C. (C) Rf = 0.14 





carbonyl)sarcosylamino)ethyl)amide hydrochloride (4.68 g, 6.0 mmol) was added to a 
stirred solution of N-(l,l-dimethylethoxycarbonyl)phenylalanine pentafluorophenyl ester 
(2.60 g, 6.0 mmol), N,N-diisopropylethylamine (2.35 g, 18.1 mmol) and DMAP (20 mg) 
in CH2C12 (50 ml). The mixture was stirred for 24 h, then washed twice with cold 1 0 % 
aq. H2 S04, once with 10% aq. Na2C03 and once with brine. The solution was dried and 
the solvent was evaporated. Chromatography (CH2C12 / MeOH 30:1 then CH2C12 / 
MeOH 20:1) gave Na-(N-(N-(N-(l,l-dimethylethoxycarbonyl)phenylalanyl)leucyl)- 
glycyl)-NE-(2,2,2-trichloroethoxycarbonyl)lysine N-(2-(N-(phenylmethoxycarbonyl)- 
sarcosylamino)ethyl)amide (4.55 g, 77%) as a buff foam.
lvii
‘H NMR ((CD3)2SO) 20°C (COSY 90)
8  0.83 (3 H, d, J =  6.4 Hz, Leu-H3), 0.88 (3 H, d, J  = 6.4 Hz, Leu-Hj), 1.23 (1 H, br, 
Leu p-Hj), 1.29 (13 H, Bu-t + Lys P-H2 + Lys y-H2), 1.38 (2 H, m, Lys 8 -H2), 1.47 (1 H, 
m, Leu P-H2), 1.64 (1 H, m, Leu y-H), 2.73 ( 1  H, m, Phe P-H2), 2.86 (3 H, Sar-H3), 2.98 
(3 H, m, Lys e-H2 + Phe P-H2), 3.14 (4 H, br, NCH2CH2N), 3.72 (2 H, d, J =  5.7 Hz, 
Gly-H2), 3.88 (2 H, br, Sar-H2), 4.14 (2 H, m, Phe a-H + Lys a-H), 4.33 (1 H, m, Leu 
a-H), 4.74 (2 H, s, CH2CC13), 5.04 (2 H, s, Ar-CH2), 6.94 (1 H, A,J= 8.3 Hz, Phe-NH),
7.27 (10 H, m, Ar), 7.66 (1 H, t, J =  5.4 Hz, Lys e-NH)., 7.88 (1 H, d, J  = 7.8 Hz, Lys 
a-NH), 7.96 (3 H, m, Leu-NH + HNCH2CH2NH), 8.07 (1 H, br, Gly-NH)
8  0.83 (3 H, d, J  = 6.4 Hz, Leu-H3), 0.88 (3 H, d, J  = 6.4 Hz, Leu-H3), 1.23 (1 H, br, 
Leu P-H2), 1.29 (13 H, Bu-t + Lys P-H2 + Lys y-H2), 1.38 (2 H, m, Lys 8 -H2), 1.47 (1 H, 
m, Leu p-H2), 1.64 (1 H, m, Leu y-H), 2.73 (1 H, m, Phe p-H2), 2.89 (3 H, Sar-H3), 2.98 
(3 H, m, Lys e-H2 + Phe p-H2), 3.14 (4 H, br, NCH2CH2N), 3.72 (2 H, d, J  = 5.7 Hz, 
Gly-H2), 3.88 (2 H, br, Sar-H2), 4.14 (2 H, m, Phe a-H + Lys a-H), 4.33 (1 H, m, Leu 
a-H), 4.74 (2 H, s, CH2CC13), 5.08 (2 H, s, Ar-CH2), 6.94 ( 1  H, d , J=  8.3 Hz, Phe-NH),
7.27 (10 H, m, Ar), 7.66 (1 H, t , J =  5.4 Hz, Lys e-NH)., 7.88 ( 1  H, d, J  = 7.8 Hz, Lys 
a-NH), 7.96 (3 H, m, Leu-NH + HNCH2CH2NH), 8.07 (1 H, br, Gly-NH)
*H NMR ((CD3)2 SO) 80°C
8  0.85 (3 H, d, J  = 6.4 Hz, 1.30 (14 H, Bu-t + Lys P-H2 + Lys y-H2 + Leu P-H2), 1.44 
(2 H, m, Lys 8 -H2), 1.52 (1 H, m, Leu P-H2), 1.65 (1 H, m, Leu y-H), 2.78 (1 H, m, Phe 
P-H2), 2.88 (3 H, s, Sar-H3), 3.01 (3 H, Phe P-H2 + Lys e-H2), 3.14 (4 H, br, 
NCH2CH2N), 3.72 ( 2  H, d , J =  5.8 Hz, Gly-H2), 3.82 (2 H, s, Sar-H2), 4.19 ( 2  H, Phe 
a-H + Lys a-H), 4.31 (1 H, m, Leu a-H), 4.74 (2 H, s, CH2CC13), 5.06 (2 H, s, Ar-CH2),
7.28 (10 H, m, Ar), 7.58 (1 H, d, J =  7.9 Hz, NH), 7.65 (4 H, br, 4 x NH), 7.73 (1 H, d, 
J  =7.9 Hz, NH), 7.82 (1 H, t, J = 4.1 Hz, NH)
T.L.C. (C)Rf=0.54 
MS (FAB+) 987 (M + H)
Na-(N-(N-PhenylalanyIleucyl)gIycyl)-NE-(2,2,2-trichloroethoxycarbonyI)Iysine N-(2- 
(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide hydrochloride (230)
Hydrogen chloride was bubbled through a solution of N°-(N-(N-(N-( 1,1 -dimethylethoxy- 
carbonyl)phenylalanyl)leucyl)glycyl)-Ne-(2,2,2-trichloroethoxycarbonyl)lysine N-(2-(N-
lviii
(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (4.24 g, 4.3 mmol) in CH2C12 
(50 ml) for 30 min. MeOH (2 ml) was added and the solvents and excess hydrogen 
chloride were evaporated to give Na-(N-(N-phenylalanylleucyl)glycyl)-Ne-(2,2,2- 
trichloroethoxycarbonyl)lysine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)- 
amide (3.96 g, quantitative) as a buff foam.
‘H NMR ((CD3)jSO) 20°C
5 0.85 (3 H, d, J =  6.4 Hz, Leu-Hj), 0.88 (3 H, d , J =  6.4 Hz, Leu-H3), 1.23-1.64 (9 H, 
m, Leu y-H + Leu p-H2 + Lys P,y,8 -H2), 2.78 (1 H, m, Phe p-H2), 2 . 8 6  (3 H, s, Sar-Hj),
2.96 (3 H, m, Phe P-H2 + Lys e-H2), 3.12 (4 H, br, NCH2CH2N), 3.75 (2 H, m, Gly-H2),
3.84 (2 H, s, Sar-H2), 4.13 (2 H, m, Phe a-H + Lys a-H), 4.22 (1 H, m, Leu a-H), 4.77 
(2 H, s, CH2CC1j), 5.04 (2 H, s, Ar-H2), 7.28 (10 H, m, Ar), 7.68 (1 H, t, J  = 5.2 Hz, 
NH), 7.97 (1 H, m, NH), 8.07 (2 H, br, NH), 8.31 (4 H, br, NH3+ + NH), 8 . 8 6  (1 H, d, 
.7=7.9 Hz, NH)
8  0.85 (3 H, d, J  = 6.4 Hz, Leu-H3), 0.88 (3 H, d, J = 6.4 Hz, Leu-H3), 1.23-1.64 (9 H, 
m, Leu y-H + Leu p-H2 + Lys (3,y,5-H2), 2.78 (1 H, m, Phe p-H2), 2.89 (3 H, s, Sar-H3),
2.96 (3 H, m, Phe 0-H2 + Lys e-H2), 3.12 (4 H, br, NCH2CH2N), 3.75 (2 H, m, Gly-H2),
3.85 (2 H, s, Sar-H2), 4.13 (2 H, m, Phe a-H + Lys a-H), 4.22 (1 H, m, Leu a-H), 4.77 
(2 H, s, CH2CC13), 5.08 (2 H, s, Ar-H2), 7.28 ( 1 0  H, m, Ar), 7.68 ( 1  H, t, J =  5.2 Hz, 
NH), 7.97 (1 H, m, NH), 8.07 (2 H, br, NH), 8.31 (4 H, br, NH3+ + NH), 8 . 8 6  ( 1  H, d, 
J=  7.9 Hz, NH)
‘H NMR ((CD3)jSO) 80°C
8  0.85 (3 H, d, J  = 6 .1 Hz, Leu-H3), 0.88 (3 H, d, J  = 6 .1 Hz, Leu-H3), 1.24-1.73 (9 H, 
m, Leu y-H + Leu P-H2 + Lys P,y,8 -H2), 2.88 (3 H, s, Sar-H3), 3.03 (4 H, m , Phe P-H2 + 
Lys e-H2), 3.13 (4 H, br, NCH2CH2N), 3.74 (2 H, m, Gly-H2), 3.84 (2 H, s, Sar-H2),
4.15 (2 H, m, Phe a-H + Lys a-H), 4.26 ( 1  H, m, Leu a-H), 4.74 (2 H, s, CH2CC13),
5.06 (2 H, s, Ar-CH2), 7.28 (10 H, m, Ar), 7.68 (1 H, d , J=  7.9 Hz, NH), 7.82 (1 H, br, 
NH), 7.99 (1 H, t, J=  5.2 Hz, NH), 8.28 (4 H, br, NH3+ + NH), 8.71 ( 1  H, d, J =  7 . 9  Hz, 
NH)






(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide hydrochloride (3.75 g, 4.1 mmol) 
was added to a stirred solution of N-(l,l-dimethylethoxycarbonyl)glycine pentafluoro- 
phenyl ester (1.44 g, 4.1 mmol), N,N-diisopropylethylamine (1.58 g, 12.2 mmol) and 
DMAP (10 mg) in CH2CI2 (30 ml). The mixture was stirred for 12 d, then washed once 
with water, twice with cold 10% aq. H2S04, once with 1 0 % aq. Na2C0 3  and once with 
brine. The solution was dried and the solvent was evaporated to give Na-(N-(N-(N-(N- 
(1,1 -dimethylethoxycarbonyl)glycyl)phenylalanyl)leucyl)glycyl)-NE-(2,2,2-trichloro- 
ethoxycarbonyl)lysine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide 
(3.94 g, 93%) as a colourless foam.
'h  NMR ((CDj>2 SO) 20°C (COSY 90)
8  0.82 (3 H, d, J=  6.4 Hz, Leu-Hj), 0.87 (3 H, d, J =  6.4 Hz, Leu-Hj), 1.23-1.41 (13 H, 
m, Bu-t + Lys P,y-H2), 1.47 (4 H, m, Lys 8 -H2 + Leu P-H2), 1.59 ( 1  H, m, Leu y-H),
2.78 (1 H, m, Phe p-H2), 2.86 (3 H, s, Sar-H3), 3.01 (3 H, m, Phe p-H2 + Lys s-H2), 3.11 
(4 H, br, NCH2CH2N), 3.5 ( 2  H, m, Gly-H2), 3.73 (2 H, d, J  = 5.4 Hz, Gly-H2), 3.83 
(2 H, br, Sar-H2), 4.14 (1 H, m, Lys a-H), 4.28 (1 H, m, Leu a-H), 4.54 (1 H, m, Phe 
a-H), 4.77(2 H, s, CH2CC13), 5.04 (2 H, s, Ar-CH2), 6.93 ( 1  H, t , J =  5.9 Hz, Gly-NH),
7.27 (10 H, m, Ar), 7.66 (1 H, t, J = 5.4 Hz, Lys e-NH), 7.9 (4 H, br, Phe-NH + Lys-NH 
+ HNCH2CH2NH), 8.06 ( 1  H, br, Gly-NH), 8.16 ( 1  H, d ,J =  7.3 Hz, Leu-NH)
8  0.82 (3 H, d, 7 =  6.4 Hz, Leu-H3), 0.87 (3 H, d, J =  6.4 Hz, Leu-H3), 1.23-1.41 (13 H, 
m, Bu-t + Lys P,y-H2), 1.47 (4 H, m, Lys 8 -H2 + Leu P-H2), 1.59 (1 H, m, Leu y-H),
2.78 ( 1  H, m, Phe P-H2), 2.89 (3 H, s, Sar-H3), 3.01 (3 H, m, Phe p-H2 + Lys e-H2), 3.11 
(4 H, br, NCH2CH2N), 3.5 (2 H, m, Gly-H2), 3.73 (2 H, d, J  = 5.4 Hz, Gly-H2), 3.83 
(2 H, br, Sar-H2), 4.14 (1 H, m, Lys a-H), 4.28 (1 H, m, Leu a-H), 4.54 (1 H, m, Phe 
a-H), 4.77 (2 H, s, CH2CC13), 5.08 ( 2  H, s, Ar-CH2), 6.93 (1 H, t, J  = 5.9 Hz, Gly-NH),
7.27 (10 H, m, Ar), 7.66 (1 H, t, J = 5.4 Hz, Lys e-NH), 7.9 (4 H, br, Phe-NH + Lys-NH 
+ HNCH2CH2NH), 8.06 ( 1  H, br, Gly-NH), 8.16 (1 H, d, 7.3 Hz, Leu-NH)
lx
*H NMR ((CDj)2SO) 80°C
8  0.84 (3 H, d, J =  6.4 Hz, Leu-Hj), 0.87 (3 H, d, J  = 6.4 Hz, Leu-H3), 1.38 (18 H, m, 
Bu-t + Leu y-H + Leu p-H2 + Lys P,y,8 -H2), 2.84 ( 1  H, m, Phe (5-H2), 2.88 (3 H, s, 
Sar-Hj), 3.02 (3 H, m, Phe p-H2 + Lys e-H2), 3.14 (4 H, br, NCH2CH2N), 3.51 (2 H, m, 
Gly-H2), 3.72 (2 H, d, J  = 5.8 Hz, Gly-H2), 3.83 (2 H, s, Sar-H2), 4.16 (1 H, m, Lys 
a-H), 4.26 (1 H, m, Leu a-H), 4.55 (1 H, m, Phe a-H), 4.74 (2 H, s, CH2CC13), 5.06 
(2 H, s, Ar-CH2), 7.25 (10 H, m, Ar), 7.58 (1 H, d, J  = 7.9 Hz, NH), 7.65 (5 H, br, 5 x 
NH), 7.73 ( 1  H, t, J  = 5.5 Hz, NH), 7.85 (1 H, d , J - 7.9 Hz, NH)
T.L.C. (C) Rf = 0.40
Na-(N-(N-(N-GlycylphenylaIanyl)leucyl)glycyI)-Ne-(2,2,2-trichloroethoxycarboiiyI)- 
lysine N-(2-(N-(phenylmethoxycarbonyI)sarcosylamino)ethyI)amide hydrochloride 
(232)
Hydrogen chloride was bubbled through a solution of N°^N-(N-(N-(N-(l,l-dimethyl- 
ethoxycarbonyl)glycyl)phenylalanyl)leucyl)glycyl)-NE-(2,2,2-trichloroethoxycarbonyl)- 
lysine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (1.74 g, 1.67 mmol) 
in CH2C12 (30 ml) for 1 h. MeOH (1 ml) was added and the solvents and excess hydrogen 
chloride were evaporated to give Na-(N-(N-(N-glycylphenylalanyl)leucyl)glycyl-NE- 
(2,2,2-trichloroethoxycarbonyl)lysine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)- 
ethyl)amide hydrochloride (1.64 g, quantitative) as a colourless foam.
‘HNMR((CD3)2 SO)
8  0.83 (3 H, d,J= 6.0 Hz, Leu-H3), 0.88 (3 H ,d ,J =  6.0 Hz, Leu-H3), 1.23 (2 H, m, Lys 
P,y,S-H2), 1.39 (2 H, m, Lys P,y,8 -H2), 1.50-1.75 (5 H, m, Lys P,y,8 -H2 + Leu y-H + 
Leu P-H2), 2.77 ( 1  H, dd, J  = 13.5, 1 1 . 0  Hz, Phe P-H2), 2.85 (3 H, s, Sar-H3), 2.97 
(3 H, m, Phe P-H2 + Lys b-H2), 3.10 (4 H, br, NCH2CH2N), 3.40-3.65 (2 H, m, Gly-H2),
3.74 (2 H, br, Gly-H2), 3.83 (2 H, br, Sar-H2), 4.15 (1 H, m, a-H), 4.29 (lH .n i, a-H),
4.62 (1 H, m, a-H), 4.77 (2 H, s, CH2CC13), 5.03 (2 H, s, Ar-CH2), 7.18-7.40 (10 H, m, 
Ar + Phe-Ar), 7.68 (1 H, t, J  = 6 Hz, NH), 7.95 (1 H, d, J =  8  Hz, NH), 8.00-8.15 (5 H, 
br, NH3+ + 2 x NH), 8.44 ( 1  H, d, J =  7.9 Hz, NH), 8.70 (1 H, d,J= 7.9 Hz, NH)
lxi
6  0.83 (3 H, d, J = 6 . 0  Hz, Leu-H3), 0 . 8 8  (3 H, d, J=  6.0 Hz, Leu-H3), 1.23 (2 H, m, Lys 
P,y,8 -H 2), 1.39 (2 H, m, Lys p,y,8 -H 2), 1.50-1.75 (5 H, m, Lys P,y,8 -H2 + Leu y-H + 
Leu P-H2), 2.77 ( 1  H, dd, 13.5, 11.0 Hz, Phe p-H2), 2.88 (3 H, s, Sar-H3), 2.97 
(3 H, m, Phe p-H2 + Lys e-H2), 3.10 (4 H, br, NCH2CH2N), 3.40-3.65 (2 H, m, Gly-H2),
3.74 (2 H, br, Gly-H2), 3.83 (2 H, br, Sar-H2), 4.15 (1 H, m, a-H), 4.29 (1 H, m, a-H),
4.62 (1 H, m, a-H), 4.77 (2 H, s, CH2CC13), 5.07 (2 H, s, Ar-CH2), 7.18-7.40 (10 H, m, 
Ar + Phe-Ar), 7.68 (1 H, t , J =  6  Hz, NH), 7.95 (1 H, d, J=  8  Hz, NH), 8.00-8.15 (5 H, 
br, NH3+ + 2 x  NH), 8.44 (1 H, d, J=  7.9 Hz, NH), 8.70 (1 H, d, J =  7.9 Hz, NH)





N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide hydrochloride (6.77 g,
6.9 mmol) was added to N,N-diisopropylethylamine (2.94 g, 22.7 mmol) in CHjC^ 
(50 ml). N-(Phenylmethoxycarbonyl)sarcosine pentafluorophenyl ester (8.07 g,
20.7 mmol) and DMAP (10 mg) were added to the mixture and the resulting solution was 
stirred for 2 d. The solution was washed twice with cold 10% aq. HjSO*, twice with 10% 
aq. Na2C 0 3 and once with brine. The solution was dried and the solvent was evaporated. 
Chromatography (CH2C12 / MeOH 20:1) gave Na-(N-(N-(N-(N-(N-(phenylmethoxy- 
carbonyl)sarcosyl)glycyl)phenylalanyl)leucyl)glycyl)-Ne-(2,2,2-trichloroethoxy- 
carbonyl)lysine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (6.40 g, 
81%) as a pale yellow foam.
'H NMR ((CD3)2 SO) 20°C
8  0.85 (3 H, d, J=  6 .2 Hz, Leu-H3), 0.90 (3 H ,d ,J = 6  2  Hz, Leu-H3), 1.17 (2 H, m, Lys 
P,y,8 -H2), 1.41 (4 H, m, Lys P,y,8 -H2), 1.55 (3 H, m, Leu y-H + Leu p-H2), 2.6-2.75 
( 1  H, m, Phe P-H2), 2.77 (3 H, s, Sar-H3), 2.81 (3 H, s, Sar-H3), 2.93 (3 H, m, Lys e-H2 
+ Phe P-H2), 3.08 (4 H, br, NCH2CH2N), 3.62 (4 H, m, 2  x Gly-H2), 3.76 (2 H, br, 
Sar-H2), 3.81 (2 H, br, Sar-H2), 4.04 (1 H, m, a-H), 4.22 (1 H, m, a-H), 4.50 ( 1  H, m, 
a-H), 4.70 (2 H, s, CH2CC13), 4.95 (2 H, s, Ar-CH2), 5.00 (2 H, br, Ar-CH2), 7.24
lxii
(15 H, m, 2 x Ar + Phe-Ar), 7.61 (1 H, m, NH), 7.92 (5 H, m, 5 x NH), 8.08 (3 H, m, 3 
x NH)
5 0.85 (3 H, d, J=  6.2 Hz, Leu-H3), 0.90 (3 H, d, J=  6.2 Hz, Leu-H3), 1.17 (2 H, m, Lys 
P,y,8 -H2), 1.41 (4 H, m, Lys p,y,6 -H2), 1.55 (3 H, m, Leu y-H + Leu P-H2), 2.6-2.75 
(1 H, m, Phe P-H2), 2.79 (3 H, s, Sar-H3), 2.82 (3 H, s, Sar-H3), 2.93 (3 H, m, Lys e-H 2 
+ Phe p-H2), 3.08 (4 H, br, NCH2CH2N), 3.62 (4 H, m, 2  x Gly-H2), 3.76 (2 H, br, 
Sar-H2), 3.81 (2 H, br, Sar-H2), 4.04 (1 H, m, a-H), 4.22 (1 H, m, a-H), 4.50 (1 H, m, 
a-H), 4.70 (2 H, s, CH2CC13), 4.97 (2 H, s, Ar-CH2), 5.00 (2 H, br, Ar-CH2), 7.24 
(15 H, m, 2 x Ar + Phe-Ar), 7.61 (1 H, m, NH), 7.92 (5 H, m, 5 x NH), 8.08 (3 H, m, 3 
x NH).
T.L.C. (C) Rf = 0.42
Acc. Mass 1146.4133 (M + H) ( C ^ ^ C ^ N , ^  requires 1146.4111)
Na-(N-(N-(N-(N-(N“-( 1,1-Dimet hylethoxycarbo nyl)-N5-(6-meth oxy-6-oxohexy 1)- 
glutaminyI)glycyI)phenylalanyl)leucyl)glycyl)-Ne-(2,2,2-trichloroethoxycarbonyl)- 
lysine N-(2-(N-(phenylmethoxycarbonyl)sarcosy!amino)ethyl)amide (234)
Na-( 1,1 -Dimethylethoxycarbonyl)-N8-(6 -methoxy-6 -oxohexyl)glutamine pentafluoro- 
phenyl ester (8.67 g, 16.05 mmol) was added to a stirred solution of Na-(N-(N-(N- 
glycylphenylalanyl)leucyl)glycyl)-NE-(2,2,2-trichloroethoxycaibonyl)lysine N-(2*(N- 
(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide hydrochloride (5.25 g, 5.35 mmol), 
N,N-dimethylethylamine (1.87 g, 21.4 mmol) and DMAP ( 1 0  mg) in CH2C12 (40 ml) and 
dimethylformamide (10 ml). The solution was stirred for 4 d and then the solvent was 
evaporated. The residue was dissolved in EtOAc / MeOH (1:1), then washed with cold 
10% aq. H2S0 4, and with 10% aq. Na2C03 . The solution was dried and the solvent was 
evaporated. Chromatography (CH2C12 / MeOH 20:1 then CH2C12 / MeOH 15:1 then 
CH2Cl2/MeOH 1 0 : 1  ) gave Na-(N-(N-(N-(N-(Na-( 1,1-dimethylethoxycarbonyl)-N5-(6 - 
methoxy-6-oxohexyl)glutaminyl)glycyl)phenylalanyl)leucyl)glycyl)-Ne-(2,2,2-trichloro- 
ethoxycarbonyl)lysine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide 
(5.11 g, 73%) as a pale buff foam.
lxiii
*H NMR ((CD3)2SO) 20°C (COSY 90)
8  0.82 (3 H, d, J=  6.4 Hz, Leu-H3), 0.87 (3 H, d, J=  6.4 Hz, Leu-H3), 1.25 (4 H, m, Lys 
P,y,8 -H2 + NCH2CH2CH2CH2CH2), 1.37 (13 H, m, Bu-t + Lys P,y,8 -H2 + 
NCH2CH2CH2CH2CH2), 1.50 ( 6  H, m, Leu p-H2 + Lys P,y,8 -H2 +
NCH2CH2CH2CH2CH2), 1.62 (2 H, m, Leu y-H + Glu P-H), 1.83 (1 H , m, Glu P-H),
2.07 ( 2  H, t, J  = 7.8 Hz, Glu y-H2), 2.27 ( 2  H, t, J  = 7.3 Hz, NCH2CH2CH2CH2CH2),
2.76 (1 H, dd, J  = 15, 9 Hz, Phe P-H2), 2.86 (3 H, s, Sar-H3), 2.99 (5 H, m, 
NCH2CH2CH2CH2CH2 + Lys s-H2 + Phe p-H2), 3.11 (4 H, br, NCH2CH2N), 3.57 (3 H, 
s, OCH3), 3.64 (2 H, m, Gly-H2), 3 72 (2 H, d, J=  5.4 Hz, Gly-H2) 3.83 (2 H, s, Sar-H2),
3.88 (1 H, m, Leu a-H or Lys a-H), 4.16 (1 H, m. Leu a-H or Lys a-H), 4.23 (1 H, m, 
Glu a-H), 4.54 (1 H, m, Phe a-H), 4.77 ( 2  H, s, CH2CC13), 5.04 (2 H, s, Ar-CH2), 6.92 
(1 H, d, J  = 7 . 7  Hz, NH (couples to signal at 3.88)), 7.23 (5 H, m, Ar), 7.37 (5 H, m, 
Ar), 7.71 (1 H, t, J  = 5.9 Hz, NH (couples to signal at 2.99)), 7.76 ( 1  H, t, J =  5.4 Hz, 
NH (couples to signal at 2.99)), 7.86 (1 H, d ,J  = 7.8 Hz, NH (couples to signal at 4.16)),
7.92 (4 H, m, HNCH2CH2NH + 2 x Gly-NH), 8.03 (1 H, d, J =  8.3 Hz, Phe a-NH), 8.13 
(1 H, d, J=  7.8 Hz, Glu a-NH)
8  0.82 (3 H, d, J =  6.4 Hz, Leu-H3), 0.87 (3 H, d, J=  6.4 Hz, Leu-H3), 1.25 (4 H, m, Lys 
P,y,8 -H2 + NCH2CH2CH2CH2CH2), 1.37 (13 H, m, Bu-t + Lys P.y.S-Hj + 
NCH2CH2CH2CH2CH2), 1.50 ( 6  H, m, Leu P-H2 + Lys P,y,8 -H2 +
NCH2CH2CH2CH2CH2), 1.62 (2 H, m, Leu y-H + Glu P-H), 1.83 (1 H , m, Glu P-H),
2.07 (2 H, t, J  = 7.8 Hz, Glu y-H2), 2.27 ( 2  H, t, J  = 7.3 Hz, NCH2CH2CH2CH2CH2),
2.76 ( 1  H, dd, J  = 15, 9 Hz, Phe P-H2), 2.89 (3 H, s, Sar-H3), 2.99 (5 H, m, 
NCH2CH2CH2CH2CH2 + Lys e-H2 + Phe p-H2), 3.11 (4 H, br, NCH2CH2N), 3.57 (3 H, 
s, OCH3), 3.64 (2 H, m, Gly-H2), 3.72 (2 H, d, J=  5.4 Hz, Gly-Hj) 3.83 ( 2  H, s, Sar-H2),
3.88 (1 H, m, Leu a-H  or Lys a-H), 4.16 (1 H, m, Leu a-H or Lys a-H), 4.23 (1 H, m, 
Glu a-H), 4.54 (1 H, m, Phe a-H), 4.77 (2 H, s, CH2CC13), 5.08 (2 H, s, Ar-CH2), 6.92 
(1 H, d, J =  7.7 Hz, NH (couples to signal at 3.88)), 7.23 (5 H, m, Ar), 7.37 (5 H, m, 
Ar), 7.71 (1 H, t, J  = 5.9 Hz, NH (couples to signal at 2.99)), 7.76 (1 H, t, J  = 5.4 Hz, 
NH (couples to signal at 2.99)), 7.86 (1 H, d, J  = 7.8 Hz, NH (couples to signal at 4.16)),
7.92 (4 H, m, HNCH2CH2NH + 2  x Gly-NH), 8.03 (1 H, d, J  = 8.3 Hz, Phe a-NH), 8.13 
(1 H, d, J =  7.8 Hz, Glu a-NH)
‘H NMR ((CD3)2SO) 80°C
8  0.83 (3 H, d, J =  6.4 Hz, Leu-H3), 0.87 (3 H, d, J=  6.4 Hz, Leu-H3), 1.27 (4 H, m, Lys 
P,y,8 -H2 + NCH2CH2CH2CH2CH2), 1.38 (13 H, m, Bu-t + Lys P,y,8 -H2 + 
NCH2CH2CH2CH2CH2), 1.54 ( 6  H, m, Leu P-H2 + Lys p,y,8 -H2 +
NCH2CH2CH2CH2CH2), 1.65 ( 1  H, m, Leu y-H), 1.74 ( 1  H, m, Glu P-H), 1.87 ( 1  H, m, 
Glu p-H), 2.10 (2 H, t, J  = 7.6 Hz, Glu y-H2), 2.26 (2 H, t, J  = 7.3 Hz, 
NCH2CH2CH2CH2CH2), 2.82 ( 1  H, dd, J  = 14, 9 Hz, Phe P-H2), 2 . 8 8  (3 H, s, Sar-H3),
lxiv
3.05 (5 H, m, NCH2CH2CH2CH2CH2 + Lys e-H2 + Phe (LH2), 3.14 (4 H, br, 
NCH2CH2N), 3.58 (3 H, s, OCH3), 3.64 ( 2  H, m, Gly-H2), 3.72 (2 H, d, J  = 5.9 Hz, 
Gly-H2) 3.83 (2 H, s, Sar-H2), 3.94 (1 H, m, Leu a-H or Lys a-H), 4.16 (1 H, m, Leu 
a-H or Lys a-H), 4.24 (1 H, m, Glu a-H), 4.54 (1 H, m, Phe a-H), 4.74 (2 H, s, 
CH2CC13), 5.06 (2 H, s, Ar-CH2), 7.22 (5 H, m, Ar), 7.33 (5 H, m, Ar), 7.47 ( 1  H, t, 
J=  4.1 Hz, NH) 7.68 (3 H, m, 3 x NH), 7.81 (3 H, m, 3 x NH)




Hydrogen chloride was bubbled through a solution of Na-(N-(N-(N-(N-(Na-(l,l-di- 
methylethoxycarbonyl)-N5-(6 -methoxy-6 -oxohexyl)glutaminyl)glycyl)phenylalanyl)- 
leucyl)glycyl)-NE-(2,2,2-trichloroethoxycarbonyl)lysine N-(2-(N-(phenylmethoxy-
carbonyl)sarcosylamino)ethyl)amide (9.38 g, 7.2 mmol) in CH2C12 ( 2 0 0  ml) and MeOH 
(100 ml) for 40 min. The solvents and excess hydrogen chloride were evaporated to give 
Na-(N-(N-(N-(N-(Ns-(6 -methoxy-6 -oxohexyl)glutaminyl)glycyl)phenylalanyl)leucyl)- 
glycyl)-N6-(2,2,2-trichloroethoxycarbonyl)lysine N-(2-(N-(phenylmethoxycarbonyl)- 
sarcosylamino)ethyl)amide hydrochloride (8.93 g, quantitative) as a pale yellow foam.
'H NMR ((CD3)2SO) 80°C
8  0.82 (3 H, d, J=  6.4 Hz, Leu-H3), 0 . 8 8  (3 H, d, J  = 6 .4 Hz, Leu-H3), 1.28 (4 H, m, Lys 
P,y,8 -H2 + NCH2CH2CH2CH2CH2), 1.42 ( 6  H, m, Lys P,y,8 -H2 +
NCH2CH2CH2CH2CH2), 1.55 ( 6  H, m, Leu P-H2 + Lys p,y,8 -H2 +
NCH2CH2CH2CH2CH2), 1.61 ( 2  H, m, Leu y-H + Glu P-H2), 1.74 ( 1  H , m, Glu P-H2),
2.18 (2 H, m, Glu y-H2), 2.27 (2 H, t, J =  7.3 Hz, NCH2CH2CH2CH2CH2), 2.84 (1 H, m, 
Phe P-H2), 2 . 8 8  (3 H, s, Sar-H3), 3.04 (5 H, m, NCH2CH2CH2CH2CH2 + Lys e-H2 + Phe 
P-H2), 3.15 (4 H, br, NCH2CH2N), 3.58 (3 H, s, OCH3), 3.75 (4 H, m, 2  x Gly-H2), 3.90 
(2 H, s, Sar-H2), 4.15 (2 H, m, 2  x a-H), 4.28 (1 H, m, a-H), 4.55 (1 H, m, a-H), 4.74 
(2 H, s, CH2CC13), 5.06 (2 H, s, Ar-CH2), 7.23 (5 H, m, Ar), 7.33 (5 H, m, Ar), 7.67 (3 
H, br 3 x NH), 7.76 (1 H, br, NH), 7.84 (1 H, m, NH), 7.99 (1 H, d, J =  7.9 Hz, NH),
8.07 (1 H, d, J=  8.3 Hz, NH), 8.27 (4 H, m, NH3+ + NH), 8.55 ( 1  H, m, NH).
lxv
T.L.C. (C) Rf = 0.12 




N-(Phenylmethoxycarbonyl)sarcosine pentafluorophenyl ester (1.04 g, 2.7 mmol) was 
added to a stirred solution of Na-(N-(N-(N-(N-(N5-(6 -methoxy-6 -oxohexyl)glutaminyl)- 
glycyl)phenylalanyl)leucyl)glycyl)-Ne-(2,2,2-trichloroethoxycarbonyl)lysine N-(2-(N- 
(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide hydrochloride (2.84 g, 2.2 mmol), 
N,N-diisopropylethylamine (3.20 g, 24.8 mmol) and DMAP (10 mg) in CH2C12 (30 ml) 
and dimethylformamide (10 ml). After 18 h, a further portion of N-(phenylmethoxy- 
carbonyl)sarcosine pentafluorophenyl ester (1.04 g, 2.7 mmol) was added and stirring 
continued for 2 d. The solvents were evaporated and the residue was dissolved in EtOAc 
/ MeOH (1:1). The solution was washed with cold 10% aq. H2S0 4 and with 10% aq. 
Na2C03. The solution was dried and the solvent was evaporated. Chromatography 
(CH2C12 / MeOH 20:1 then CH2C12 / MeOH 15:1) gave N«-(N-(N-(N-(N-(N8-(6 - 
methoxy-6 -oxohexyl)-Na-(N-(phenylmethoxycarbonyl)sarcosyl)glutaminyl)glycyl)- 
phenylalanyl)leucyl)glycyl)-NE-(2,2,2-trichloroethoxycarbonyl)lysine N-(2-(N-(phenyl- 
methoxycarbonyl)sarcosylamino)ethyl)amide (1.25 g, 40%) as a cream solid. Mp 181- 
183°C
'H NMR ((CD^SO) 20°C (COSY 90)
8  0.83 (3 H, d, J =  6.4 Hz, Leu-H3), 0.86 (3 H, d, J=  6.4 Hz, Leu-H3), 1.22 (4 H, m, Lys 
P,y,8 -H2 + NCH2CH2CH2CH2CH2), 1.36 (4 H, m, Lys P,y,5-H2 +
NCH2CH2CH2CH2CH2), 1 48 (4 H, m, Lys P,y,8 -H2 + NCH2CH2CH2CH2CH2), 1.63 
(3 H, m, Leu P-H + Leu y-H2), 1.73 (1 H, m, Glu P-H2), 1.85 (1 H, m, Glu P-H2), 2.07 
( 2  H, m, Glu y-H2), 2.27 ( 2  H, t, J =  7.3 Hz, NCH2CH2CH2CH2CH2), 2.76 ( 2  H, m, Phe 
P-H2), 2.84 (3 H, s, Sar-H3), 2.87 (3 H, s, Sar-H3), 3.01 (4 H, m, NCH2CH2CH2CH2CH2 
+ Lys e-H2), 3.11 (4 H, br, NCH2CH2N), 3.56 (3 H, s, OCH3), 3.61 (1 H, m, Gly-H2),
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3.72 (3 H, m, Gly-H2), 3.82 (2 H, br, Sar-H2), 3.88 ( 2  H, s, Sar-H2), 4.13 ( 1  H, m, Leu 
a-H or Lys a-H or Glu a-H), 4.26 (2 H, m, Leu a-H or Lys a-H or Glu a-H), 4.53 
( 1  H, m, Phe a-H), 4.77 ( 2  H, s, CH2CC13), 5.04 (2 H, s, Ar-H2), 5.09 (2 H, s, Ar-H2),
7.30 (15 H, m, Ar + Phe-Ar), 7.67 (1 H, t, J  = 5.8 Hz, NH (couples to signal at 3.01)),
7.75 (1 H, m, NH (couples to signal at 3.01)), 7.89 (1 H, d, J  = 7.8 Hz, NH (couples to 
signal at 4.13)), 7.97 (2 H, br, HNCH2CH2NH), 8.05 (1 H, t , J  = 9.3 Hz, Phe NH), 8.16 
(4 H, m, 2 x Gly NH + 2 x NH (couples to signal at 4.26).
8  0.83 (3 H, i , J =  6.4 Hz, Leu-H3), 0 . 8 6  ( 3  H, d, J=  6.4 Hz, Leu-H3), 1.22 (4 H, m, Lys 
P,y,8 -H2 + NCH2CH2CH2CH2CH2), 1.36 (4 H, m, Lys P,y,8 -H2 +
NCH2CH2CH2CH2CH2), 1.48 (4 H, m, Lys p,y,8 -H2 + NCH2CH2CH2CH2CH2), 1.63 
(3 H, m, Leu P-H + Leu y-H2), 1.73 (1 H, m, Glu p-H2), 1.85 (1 H, m, Glu P-H2), 2.07 
(2 H, m, Glu y-H2), 2.27 (2 H, t, J =  7.3 Hz, NCH2CH2CH2CH2CH2), 2.76 (2 H, m, Phe 
P-H2), 2.86 (3 H, s, Sar-H3), 2.89 (3 H, s, Sar-H3), 3.01 (4 H, m, NClfcCHjCTLCHjCHj 
+ Lys e-H2), 3.11 (4 H, br, NCH2CH2N), 3.56 (3 H, s, OCH3), 3.61 (1 H, m, Gly-H2),
3.72 (3 H, m, Gly-H2), 3.82 (2 H, br, Sar-H2), 3.91 (2 H, s, Sar-H2), 4.13 (1 H, m, Leu 
a-H or Lys a-H or Glu a-H), 4.26 (2 H, m, Leu a-H or Lys a-H or Glu a-H), 4.53 
(1 H, m, Phe a-H), 4.77 (2 H, s, CH2CC13), 5.05 (2 H, s, Ar-H2), 5.08 (2 H, s, Ar-H2),
7.30 (15 H, m, Ar + Phe-Ar), 7.67 (1 H, t, J  = 5.8 Hz, NH (couples to signal at 3.01)),
7.75 ( 1  H, m, NH (couples to signal at 3.01)), 7.89 ( 1  H, d, J =  7.8 Hz, NH (couples to 
signal at 4.13)), 7.97 (2 H, br, HNCH2CH2NH), 8.05 (1 H, t, 7  = 9.3 Hz, Phe NH), 8.16 
(4 H, m, 2 x Gly NH + 2  x NH (couples to signal at 4.26)
' H  N M R  ( ( C D j ^ S O )  8 0 ° C
8  0.83 (3 H, d, J =  6.4 Hz, Leu-H3), 0.87 (3 H, d, J = 6.4 Hz, Leu-H3), 1.26 (4 H, m, Lys 
P,y,8 -H2 + NCHjCftdfcCftCHj), 1.42 (4 H, m, Lys P,y,S-H2 +
NCH2CH2CH2CH2CH2), 1.52 (4 H, m, Lys p,y,8 -H2 + NCH2CH2CH2CH2CH2), 1.64 
(3 H, m, Leu P-H + Leu y-H2), 1.77 (1 H, m, Glu P-H2), 1.91 ( 1  H, m, Glu P-H2), 2.10 
(2 H, t, J  = 7.6 Hz Glu y-H2), 2.26 (2 H, t, J  = 7.3 Hz, NOLCHjCftCHjCIi), 2.76 
(1 H, m, Phe P-H2), 2.87 (3 H, s, Sar-H3), 2.88 (3 H, s, Sar-H3), 3.05 (5 H, m, 
NCttCHjCHjCHjOL + Lys e-H2 + Phe P-H2), 3.14 (4 H, br, NCH2CH2N), 3.57 (3 H, 
s, OCH3), 3.71 (4 H, m, 2 x Gly-H2), 3.83 (2 H, br, Sar-H2), 3.92 (2 H, br, Sar-H2), 4.13 
(1 H, m, Leu a-H or Lys a-H or Glu a-H or Phe), 4.26 (2 H, m, Leu a-H or Lys a-H or 
Glu a-H or Phe), 4.53 (1 H, m, Leu a-H or Lys a-H or Glu a-H or Phe), 4.74 (2 H, s, 
CH2CCI3), 5.04 (2 H, s, Ar-H2), 5.06 (2 H, br, Ar-H2), 7.30 (15 H, m, Ar + Phe-Ar), 
7.46 (1 H, m, NH), 7.58 (1 H, d, J  = 7.9 Hz, NH), 7.66 (2 H, br, HNCH2CH2NH), 8.05 
(1 H, br, NH), 7.80 (3 H, m, 3 x NH), 7.89 (1 H, m, NH), 7.95 (1 H, d, J=  7.3 Hz, NH)
T.L.C. (C) Rf = 0.54




Zinc powder (4.34 g, 66.39 mmol) was added to a solution of Na-(N-(phenylmethoxy- 
carbonyl)sarcosyl)-NE-(2,2,2-trichloroethoxycarbonyl)lysine N-(2-(N-(phenylmethoxy- 
carbonyl)sarcosylamino)ethyl)amide) (1.25 g, 1.65 mmol) in 70% MeOH / water (10 ml) 
and boiled under reflux for 7 h. The mixture w7as filtered and the solvents were 
evaporated to give Na-(N-(phenylmethoxycarbonyl)sarcosyl)lysine N-(2-(N-(phenyl- 
methoxycarbonyl)sarcosylamino)ethyl)amide (953 mg, 97%) as a colourless glass.
1HNMR((CD3)2SO)20°C
8  1.23 (2 H, m, Lys p,y,8 -H2), 1.50 (2 H, m, Lys p,y,8 -H2), 1.62 (2 H, m, Lys P,y,8 -H2),
2.73 (2 H, m, Lys e-H2), 2.85 (2 H, s, Sar-H3), 2 . 8 6  (2 H, br, Sar-H3), 3.12 (4 H, br, 
NCH2CH2N), 3.84 (2 H, br, Sar-H2), 3.93 (2 H, br, Sar-H2), 4.20 (1 H, m, Lys a-H),
5.03 (2 H, s, Ar-CH2), 5.08 (2 H, s, Ar-CH2), 7.34 ( 1 0  H, m, 2 x Ar), 8.04-8.25 (4 H, m, 
4 x NH)
8  1.23 (2 H, m, Lys P,y,8 -H2), 1.50 (2 H, m, Lys P,y,8 -H2), 1.62 (2 H, m, Lys P,y,8 -H2),
2.73 (2 H, m, Lys e-H2), 2.86 (2 H, s, Sar-H3), 2.89 (2 H, br, Sar-H3), 3.12 (4 H, br, 
NCH2CH2N), 3.84 (2 H, br, Sar-H2), 3.93 (2 H, br, Sar-H2), 4.20 (1 H, m, Lys a-H),
5.04 (2 H, s, Ar-CH2), 5.08 (2 H, s, Ar-CH2), 7.34 (10 H, m, 2  x Ar), 8.04-8.25 (4 H, m, 
4 x NH).
T.L.C. (C)Rf= 0.15
Acc. Mass 599.3176 (M + H) (C30H43N6O7 requires 599.3193)
Pentafluorophenyl 6-(l,l-dimethylethoxycarbonylamino)hexanoate (244)
6 -(l,l-Dimethylethoxycarbonylamino)hexanoic acid (13.0 g, 56.3 mmol) in EtOAc ( 1 0 0  
ml) was cooled to 0°C. DCC ( 1 1 . 6  g, 56.3 mmol) and pentafluorophenol ( 1 0 . 3 5  g, 56.3 
mmol) were added and the suspension stirred for 24 h. The suspension was filtered. The
lxviii
1HNM R((CD3)2SO)
8  1 . 1 9  ( 4  H ,  m ,  L y s  P , y , 8 - H 2  +  N C H 2 C H 2 C H 2C H 2 C H 2) ,  1 . 3 6  ( 1 1  H ,  m ,  Bu-t +  L y s  
P , y , 8 - H 2  +  N C H j C I f c C H j C H i C H z ) ,  1 . 4 5  ( 4  H ,  m ,  L y s  P , y , 8 - H 2  +
N C f t C H j C H j C H j C H j ) ,  2 . 0 1  ( 2  H ,  m ,  N C H 2 C H 2 C H 2 C H 2 C H 2 ) ,  2 . 8 5  ( 3  H ,  s ,  S a r - H 3) ,
2 . 8 8  (3 H, br, Sar-H3), 2.96 (4 H, m, Lys e-H 2 + NdfcCHjOfeCHzCHj), 3. 1 1  (4 H, br, 
NCH2CH2N), 3.83 (2 H, br, Sar-H2), 3.91 (2 H, br, Sar-H2), 4.13 (1 H, m, Lys a-H),
5.02 (2 H, s, Ar-CH2), 5.07 (2 H, br, Ar-CH2), 6.78 (1 H, m, NH), 7.36 (10 H, 2 x Ar),
7.73 (1 H, m, NH), 7.96 (3 H, br, 3 x NH)
8  1 . 1 9  (4 H ,  m, L y s  P , y , 8 - H 2  +  N C H j C H j C H j O f e O f e ) ,  1 . 3 6  ( 1 1  H ,  m, Bu-t +  L y s  
P , y , 8 - H 2  +  N C H 2C H 2C H 2 C H 2 C H 2) ,  1 . 4 5  (4 H ,  m, L y s  P , y , 8 - H 2  +
N C H j C H i C H i C H j C H j ) ,  2 . 0 1  ( 2  H ,  r a ,  N C H j C H j C H j C H j C f c L ) ,  2 . 8 6  ( 3  H ,  s ,  S a r - H 3) ,
2.88 (3 H, br, Sar-H3), 2.96 (4 H, m ,  L y s  e-H2 + N C H j C H j C H j C H z C H j ) ,  3.11 (4 H, br, 
NCH2CH2N), 3.83 (2 H, br, Sar-H2), 3.91 (2 H, br, Sar-H2), 4.13 (1 H, m ,  L y s  a-H),
5.04 (2 H, s ,  Ar-CH2), 5.07 (2 H, br, Ar-CH2), 6.78 (1 H, m ,  NH), 7.36 (10 H, 2 x  Ar),
7 . 7 3  ( 1  H ,  m ,  N H ) ,  7 . 9 6  ( 3  H ,  br, 3  x  N H )
T.L.C. (C) Rf= 0.41 
MS (FAB+) 712 (M - Boc)
Ne-(6-Aminoheianoyl)-N'x-(N-(phenylmetboxycarbonyl)sarcosyl)Iysine N-(2-(N- 
(phenylmethoxycarbonyl)sarcosyIamino)ethyI)amide hydrochloride (246)
N*-(6 -( 1,1 -Dimethylethoxycarbonylamino)hexanoyl)-Na-(N-(phenylmethoxycarbonyl)- 
sarcosyl)lysine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (2.18 g,
2.7 mmol) in CH2CI2 (20 ml) and MeOH (5 ml) was treated with hydrogen chloride for 
30 min. The solvents and excess reagent were evaporated to give N*-(6 -aminohexanoyl)- 
Na-(N-(phenylmethoxycarbonyl)sarcosyl)lysine N-(2-(N-(phenylmethoxycarbonyl)- 
sarcosylamino)ethyl)amide hydrochloride (1.93 g, 96%) as a pale foam.






(520 mg, 0.67 mmol) was added to N*-(6 -aminohexanoyl)-Na-(N-(phenylmethoxy- 
carbonyl)sarcosyl)lysine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide 
hydrochloride (385 mg, 0.53 mmol), N,N-diisopropylethylamine (205 mg, 1.59 mmol) 
and DMAP (10 mg) in C H C I 3  (20 ml). The solution was stirred for 24 h and the solvents 
were evaporated. Chromatography ( C H C I 3  then C H C I 3  / MeOH 80: 1 then C H C I 3  /  
MeOH 40. 1 then C H C I 3  / MeOH 20: 1) yielded Na-(N-(phenylmethoxycarbonyl)- 
sarcosyl)-N8-(6-(N1-(4-( 10,15,20-triphenyl-2 l//,23//-porphin-5-yl)phenyl)ureido)- 
hexanoyl)lysine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (593 mg, 
82%) as a purple glass.
*H NMR ( C D C I 3 )
6  -2.78 (2 H, s, 21,25-H2), 1.2-1.7 (12 H, m, Lys fry^-H* + NCHiOkCIfcCHzCHj),
2.12 (2 H, br, NCH2CH2CH2CH2CH2), 2.93 (3 H, s, Sar-H3), 2.99 (3 H, s, Sar-H3), 3.0-
3.3 ( 8  H, m, Lys e-H2 + NCH2CH2CH2CH2CH2 + NCH2CH2N), 3.77 (2 H, m, Sar-H2),
3.86 (2 H, m, Sar-H2), 4.36 (1 H, m, Lys a-H), 5.06 (2 H, s, Ar-CH2), 5.07 (2 H, s, Ar- 
CH2), 5.75 (1 H, br, NH), 5.83 (1 H, br, NH), 6.39 (1 H, br, NH), 6.57 (1 H, br, NH), 
6.94 (1 H, br, NH), 7.24 (10 H, br, 2 x Ar), 7.37 (1 H, br, NH)
6  -2.78 (2 H, s, 2/,23-H2), 1.2-1.7 (12 H, m, Lys 0,y,8-H6 + N C H z C H j C H j C & C H j ) ,
2.12 (2 H, br, NCH2CH2CH2CH2CH2), 2.99 (3 H, s, Sar-H3), 3.00 (3 H, s, Sar-H3), 
3 0-3.3 ( 8  H, m, Lys e-H2 + NCH2CH2CH2CH2CH2 + NCH2CH2N), 3.77 (2 H, m, Sar- 
H2), 3.86 (2 H, m, Sar-H2), 4.36 (1 H, m, Lys a-H), 5.07 ( 4  H, s, 2  x Ar-CH2), 5.75 (1 
H, br, NH), 5.83 (1 H, br, NH), 6.39 (1 H, br, NH), 6.57 (1 H, br, NH), 6.94 (1 H, br, 
NH), 7.24 (10 H, br, 2 x Ar), 7.37 (1 H, br, NH)




Zinc powder (5.5 g, 86.5 mmol) was added to N-(N-(N-(N-(Na-(N-(phenylmethoxy- 
carbonyl)sarcosyl)-Ne-(2,2,2-trichloroethoxycarbonyl)lysyl)glycyl)phenylalanyl)leucyl)- 
glycine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (2.50 g, 2.58 mmol) 
in 70% MeOH / water (20 ml) and the mixture boiled under reflux for 18 h. The mixture 
was filtered and the solvents evaporated to yield N-(N-(N-(N-(N“-(N-(phenylmethoxy- 
carbonyl)sarcosyl)lysyl)glycyl)phenylalanyl)leucyl)glycine N-(2-(N-(phenylmethoxy- 
carbonyl)sarcosylamino)ethyl)amide (2.04 g 94%) as a white foam.
‘H NMR ((CD3)2SO) 20°C
8  0.83 (3 H, A, J=  6.2 Hz, Leu-H3), 0.87 (3 H, d, J  = 6.2 Hz, Leu-H3), 1.25 (2 H, m, 
Lys P,y,8 -H2), 1.52 (5 H, m, Leu P-H2 + Leu y-H + Lys P,y,6 -H 2), 1.61 (2 H, m, Lys 
p,y,8 -H 2), 2.69 (2 H, m, Phe P-H2), 2.83 (3 H, s, Sar-H3), 2.86 (3 H, s, Sar-H3), 3.05 
(2 H, m, Lys e-H2), 3.12 (4 H, br, NCH2CH2N), 3.63 ( 4  H, m, 2 x Gly-H2), 3.83 (2 H, 
br, Sar-H2), 3.91 (2 H, br, Sar-H2), 4.25 ( 2  H, m, 2  x a-H), 4.54 ( 1  H, m, a-H), 5.01 
(2 H, s, Ar-H2), 5.03 (2 H, s, Ar-H2), 7.35 (15 H, m, Ar + Phe-Ar), 7.83 ( 1  H, br, NH),
8.10 (3 H, br, 3 x NH), 8.25 (4 H, m, 4 x NH)
8  0.83 (3 H, d, J  = 6.2 Hz, Leu-H3), 0.87 (3 H, d, J =  6.2 Hz, Leu-H3), 1.25 (2 H, m, 
Lys P,y,8 -H2), 1.52 (5 H, m, Leu P-H2 + Leu y-H + Lys P,y,8 -H 2), 1.61 (2 H, m, Lys 
P,y,8 -H 2), 2.69 ( 2  H, m, Phe P-H2), 2.85 (3 H, s, Sar-H3), 2.88 (3 H, s, Sar-H3), 3.05 
(2 H, m, Lys e-H2), 3.12 (4 H, br, NCH2CH2N), 3.63 ( 4  H, m, 2  x Gly-H2), 3.83 (2 H, 
br, Sar-H2), 3.91 (2 H, br, Sar-H2), 4.25 ( 2  H, m, 2  x a-H), 4.54 ( 1  H, m, a-H), 5.03 
(2 H, s, Ar-H2), 5.07 (2 H, s, Ar-H2), 7.35 (15 H, m, Ar + Phe-Ar), 7.83 (1 H, br, NH),
8.10 (3 H, br, 3 x NH), 8.25 (4 H, m, 4 x NH)
T.L.C. (C)Rf= 0.18





Pentafluorophenyl 6 -(l,l-dimethylethoxycarbonylamino)hexanoate (2.6 g, 6.57 mmol) 
was added to N-^-CN-^-CNT1 -(N-(phenylmethoxycarbonyl)sarcosyl)lysyl)glycyl)phenyl- 
alanyl)leucyl)glycine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide 
(2.15 g, 2.19 mmol), N,N-diisopropylethylamine (850 mg, 6.56 mmol) and DMAP 
(20 mg) in CH2C12 (20 ml) and DMF (10 ml). The solution was stirred for 5 d. The 
solvents were evaporated. Chromatography (CH2C12 / MeOH 20:1) gave N-(N-(N-(N- 
(N®-(6 -( 1,1 -dimethylethoxycarbonylaminoJhexanoyO-N^-(N-(phenylmethoxycarbonyl)- 
sarcosyl)lysyl)glycyl)phenylalanyl)leucyl)glycine N-(2-(N-(phenylmethoxycarbonyl)- 
sarcosylamino)ethyl)amide (1.43 g, 55%) as a pale yellow glass.
'H NMR ((CD3)2SO) 20°C
S 0.82 (3 H, d, J =  6 . 2  Hz, Leu-H3), 0.87 (3 H, d, J  = 6.2 Hz, Leu-H3), 1 .2-1.7 (24 H, m, 
Bu-t + Leu p-H2  + Leu y-H + Lys P,y, 6  + NCH2CH2CH2CH2CH2), 2.01 (2 H, m, 
NCHjCHtCHjCHjCfcb), 2.76-3.04 (2 H, m, Phe p-H2), 2.83 (2 H, s, Sar-H3), 2.86 (2 H, 
br, Sar-H3), 3.17 ( 8  H, m, NCH2CH2CH2CH2CH2 + Lys e-H2 + NCH2CH2N), 3.59 (4 H, 
m, 2 x Gly-H2), 3.84 (2 H, br, Sar-H2), 3.91 (2 H, br, Sar-H2), 4.24 (2 H, m, 2  x a-H ),
4.53 (1 H, m, a-H), 5.01 (2 H, br, Ar-CH2), 5.03 (2 H, s, Ar-CH2), 6.76 (1 H, m, NH),
7.30 (15 H, m, 2 x Ar + Phe-Ar), 7.75 (1 H, m, NH), 7.84 (1 H, m, NH), 8.04 (2 H, m, 2 
x NH), 8.20 (3 H, m, 3 x NH), 8.97 (1 H, m, NH)
5 0.82 (3 H, d, J =  6.2 Hz, Leu-H3), 0.87 (3 H, d, J  = 6.2 Hz, Leu-H3), 1.2-1.7 (24 H, m, 
Bu-t + Leu P-H2 + Leu y-H + Lys P,y, 8  + NCH2CH2CH2CH2CH2), 2.01 (2 H, m, 
NCHjCftCHjCHjCHj), 2.76-3.04 (2 H, m, Phe P-H2), 2.86 (2 H, s, Sar-H3), 2.88 (2 H, 
br, Sar-H3), 3.17 ( 8  H, m, NCH2CH2CH2CH2CH2 + Lys e-H2 + NCH2CH2N), 3.59 (4 H, 
m, 2  x Gly-H2), 3.84 (2 H, br, Sar-H2), 3.91 (2 H, br, Sar-H2), 4.24 ( 2  H, m, 2  x a-H),
4.53 (1 H, m, a-H), 5.03 (2 H, br, Ar-CH2), 5.07 (2 H, s, Ar-CH2), 6.76 (1 H, m, NH),
7.30 (15 H, m, 2 x Ar + Phe-Ar), 7.75 (1 H, m, NH), 7.84 (1 H, m, NH), 8.04 (2 H, ra, 2 






Hydrogen chloride was bubbled through N-(N-(N-(N-(N€-(6 -( 1,1 -dimethylethoxy- 
carbonylamino)hexanoyl)-Na-(N-(phenylmethoxycarbonyl)sarcosyl)lysyl)glycyl)phenyl- 
alanyl)Ieucyl)glycine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide
(1.40 g, 1.17 mmol) in CH2C12 (30 ml) for 35 min. MeOH (5 ml) was added and the 
solvents and excess reagent were evaporated to give N-(N-(N-(N-(N®-(6 -amino- 
hexanoyO-bT-^-fchenylmethoxycarbonytysarcosyOlysytyglycylJphenylalanytyleucyl)- 
glycine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide hydrochloride 
(1.33 g, quantitative) as a white foam.
This material was carried forward without characterisation.




(2.54 g, 3.26 mmol) was added to N-(N-(N-(N-(Na-(N-(phenylmethoxycarbonyl)- 
sarcosyl)lysyl)glycyl)phenylalanyl)leucyl)glycine N-(2-(N-(phenylmethoxycarbonyl)- 
sarcosylamino)ethyl)amide (2.04 g, 2.07 mmol), N,N-diisopropylethylamine (1.34 g, 
10.35 mmol), DMAP (20 mg) in CHC13 (30 ml) and DMF (10 ml). The solution was 
stirred for 24 h and the solvents were then evaporated. Chromatography (CHC13 / MeOH 
80:1 then CHC13 / MeOH 40:1 then CHC13 / MeOH 20:1 then CHC13 / MeOH 10:1) 
yielded N-(N-(N-(N-(Na-(N-(phenylmethoxycarbonyl)sarcosyl)-N€-(4-( 10,15,20-tri-
phenyl-21//,23//-porphin-5-yl)phenylaminocarbonyl)lysyl)glycyl)phenylalanyl)leucyl)- 




8  -2.90 (2 H, s, 2/,25H), 0.83 (3 H, d, J =  6.3 Hz, Leu-H3), 0.88 (3 H, d, J =  6.3 Hz, 
Leu-H3), 1.2-1. 8  (9 H, m, Lys (3,y,8-H2 + Leu y-H + Leu p-H2), 2.79 (1 H, m, Phe 
p-H2), 2.82 (3 H, s, Sar-H3), 2.86 (3 H, br, Sar-H3), 3.16 (7 H, br, NCH2CH2N + Lys 
e-H2 + Phe P-H2), 3.68 (4 H, m, 2 x Gly-H2), 3.82 (2 H, br, Sar-H2), 3.98 (2 H, br, 
Sar-H2), 4.32 (2 H, m, 2 x a-H), 4.59 (1 H, m, a-H), 5.00 (2 H, s, Ar-CH2), 5.04 (2 H, 
s, Ar-CH2), 6.35 (1 H, br, NH), 7.29 (15 H, m, 2 x Ar + Phe-Ar), 7.84 (11 H, m, 3 x Ph
3,4,5-H3 + disubstituted aromatic 2,6-H2), 8.07 (2 H, d, J=  8.2 Hz, disubstituted 
aromatic 3,5-H2), 8.19 (11 H, m, 3 x Ph 2,6-H2 + 5  x NH), 8.75-9.00 (11 H, m,
2,3,7,8,12,13,17,18-^ + 3 x NH)
8  -2.90 (2 H, s, 27,23H), 0.83 (3 H, d, J  = 6.3 Hz, Leu-H3), 0.88 (3 H, d, J  = 6.3 Hz, 
Leu-H3), 1.2-1. 8  (9 H, m, Lys P,y,8 -H 2 + Leu y-H + Leu P-H2), 2.79 (1 H, m, Phe 
P-H2), 2.86 (3 H, s, Sar-H3), 2.89 (3 H, br, Sar-H3), 3.16 (7 H, br, NCH2CH2N + Lys 
e-H2 + Phe P-H2), 3 . 6 8  ( 4  H, m, 2  x Gly-H2), 3.82 (2 H, br, Sar-H2), 3.98 (2 H, br, 
Sar-H2), 4.32 (2 H, m, 2 x a-H), 4.59 (1 H, m, a-H), 5.04 (4 H, s, 2 x Ar-CH2), 6.35 
(1 H, br, NH), 7.29 (15 H, m, 2 x Ar + Phe-Ar), 7.84 (11 H, m, 3 x Ph 3,4,5-H3 + 
^substituted aromatic 2,6-H2), 8.07 (2 H, d, J ~  8.2 Hz, disubstituted aromatic 3,5-H2), 
8.19 (11 H, m, 3 x Ph 2,6-H2 + 5 x NH), 8.75-9.00 (11 H, m, 2,3,7,8,12,13,17,18-Hs + 3 
x NH)
T.L.C. (C) Rf = 0.42 





(1.41 g, 1.81 mmol) was added to N-(N-(N-(N-(N€-(6 -aminohexanoyl)-Na-(N-(phenyl- 
methoxycarbonyl)sarcosyl)lysyl)glycyl)phenylalanyl)leucyl)glycine N-(2-(N-(phenyl- 
methoxycarbonyl)sarcosylamino)ethyl)amide hydrochloride (1.28 g, 1.13 mmol), N,N- 
diisopropylethylamine (730 mg, 5.66 mmol) and DMAP (10 mg) in CHC13 (20 ml) and 
DMF (10 ml). The solution was stirred for 48 h and the solvents were evaporated. 
Chromatography (a) (CHC13 / MeOH 1 0 0 : 1  then CHC13 / MeOH 80:1 then CHC13 /
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MeOH 60:1 then CHC13 / MeOH 1:1) and (b) ( CHC13 / MeOH 9:1) yielded N-(N-(N- 
(N-(Na-(N-(phenylmethoxycarbonyl)sarcosyl)-Ne-(6-(N'-(4-( 10,15,20-triphenyl- 
21//,23//-porphin-5-yl)phenyl)ureido)hexanoyl)lysyl)glycyl)phenylalanyl)leucyl)glycine 
N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (1.25 g, 64%) as a purple 
glass.
*H NMR ((CD3)2SO) 20°C
8  -2.9 (2 H, s, 21,23H), 0.82 (3 H, d, J=  6.2 Hz, Leu-H3), 0.87 (3 H, d , J=  6.2 Hz, Leu- 
H3), 1 .2 -1 . 6  (15 H, m, Leu P-H2 + Leu y-H + Lys P,y,S + NCH2CH2CH2CH2CH2), 2 . 1 0  
(2 H, m, NCH2CH2CH2CH2CH2), 2.78 (1 H, m, Phe P-H2), 2.84 (2 H, s, Sar-H3), 2.85 (2 
H, s, Sar-H3), 3 .12 (9 H, m, NCH2CH2CH2CH2CH2 + Lys 8 -H2 + NCH2CH2N + Phe P- 
H2), 3.55-3.78 (4 H, m, 2  x Gly-H2), 3.82 (2 H, br, Sar-H2), 3.91 (2 H, br, Sar-H2), 4.24 
( 2  H, m, 2  x a-H), 4.55 (1 H, m, a-H), 5.01 (2 H, br, Ar-CH2), 5.05 ( 2  H, s, Ar-CH2),
7.29 (15 H, m, 2 x Ar + Phe-Ar), 7.82 (11 H, m, 3 x Ph 3,4,5-H3 + disubstituted 
aromatic 2,6-H2), 8.06 (2 H, d, J -  8.4 Hz, disubstituted aromatic 3 ,5 -H2), 8.23 (11 H, 
m, 3  x Ph2,6-H2 + 5  x NH), 8.80-9.00 (11 H, m, 2,3,7,8,]2,13,17,J8-Ht + 3  x NH)
8  -2.9 (2 H, s, 21,23H), 0.82 (3 H, d, J  = 6.2 Hz, Leu-H3), 0.87 (3 H, d, J  = 6.2 Hz, 
Leu-H3), 1.2-1.6 (15 H, m, Leu p-H2 + Leu y-H + Lys P,y, 8  + NCH2CH2CH2CH2CH2),
2 . 1 0  (2 H, m, NCH2CH2CH2CH2CH2), 2.78 ( 1  H, m, Phe P-H2), 2.85 (2 H, s, Sar-H3),
2.87 (2 H, s, Sar-H3), 3.12 (9 H, m, NCH2CH2CH2CH2CH2 + Lys e-H2 + NCH2CH2N + 
Phe P-H2), 3.55-3.78 (4 H, m, 2  x Gly-H2), 3.82 ( 2  H, br, Sar-H2), 3.91 ( 2  H, br, 
Sar-Hj), 4.24 (2 H, m, 2  x a-H), 4.55 ( 1  H, m, a-H), 5.01 (2 H, br, Ar-CH2), 5.05 (2 H, 
s, Ar-CH2), 7.29 (15 H, m, 2  x Ar + Phe-Ar), 7.82 (11 H, m, 3 x Ph 3,4,5-H3 + 
disubstituted aromatic 2,6-H2), 8.06 ( 2  H, d, J  = 8.4 Hz, disubstituted aromatic 3,5-H2), 
8.23 (11 H, m, 3 x Ph2,6-H2 + 5 x M l), 8.80-9.00 (11 H, m, 2,3,7,8,12,13,17,18-H8 + 3 
x NH)
T.L.C. (C)Rf=0.48 




Zinc powder (6.5 g, 99.4 mmol) was added to Na-(N-(N-(N-(N-(N-(phenylmethoxy- 
carbonyl)sarcosyl)glycyl)phenylalanyl)leucyl)glycyl)-NE-(2,2,2-trichloroethoxycarbonyl)- 
lysine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (3.04 g, 2.68 mmol) 
in 70% MeOH / water (20 ml). The mixture was boiled under reflux for 24 h and was 
then filtered. The solvents were evaporated to give Na-(N-(N-(N-(N-(N-(phenylmethoxy- 
carbonyl)sarcosyl)glycyl)phenylalanyl)leucyl)glycyl)lysine N-(2-(N-(phenylmethoxy- 
carbonyl)sarcosylamino)ethyl)amide (2.50 g, 95%) as a cream foam.
‘H NMR ((CD3)2SO) 20°C
8  0.82 (3 H, d , J  = 6.2 Hz, Leu-H3), 0.86 (3 H, d, J  = 6.2 Hz, Leu-Hj), 1 .29 (2 H, m, Lys 
p,y,S-H2), 1.52 (5 H, m, Leu P-H2 + Leu y-H + Lys P,y,8 -H 2), 1.64 (2 H, m, Lys 
P,y,5-H2), 2.72 (2 H, m, Lys e-H2), 2.78 (1 H, m, Phe p-H2), 2.83 (3 H, s, Sar-H3), 2.87 
(3 H, s, Sar-H3), 3.02 (1 H, br, Phe p-H2), 3.10 (4 H, br, NCH2CH2N), 3.61 (2 H, m, 
Gly-H2), 3.73 (2 H, m, Gly-H2), 3.73 (2 H, br, Sar-H2), 3.88 (2 H, br, Sar-H2), 4.15 (1 H, 
m, a-H), 4.24 (1 H, m, a-H), 4.53 (1 H, m, a-H), 5.01 (2 H, s, Ar-H2), 5.07 (2 H, br, 
Ar-H2), 7.30 (15 H, m, Ar + Phe-Ar), 8.03 (4 H, br, 4 x NH), 8.20 (4 H, m, 4 x NH)
8  0.82 (3 H, d, J  = 6.2 Hz, Leu-H3), 0.86 (3 H, d, J  = 6.2 Hz, Leu-H3), 1.29 (2 H, m, Lys 
P,y,8 -H 2), 1.52 (5 H, m, Leu P-H2 + Leu y-H + Lys P,y,8 -H 2), 1.64 ( 2  H, m, Lys 
P,y,8 -H 2), 2.72 (2 H, m, Lys e-H2), 2.78 ( 1  H, m, Phe P-H2), 2.85 (3 H, s, Sar-H3), 2.88 
(3 H, s, Sar-H3), 3.02 (1 H, br, Phe P-H2), 3.10 (4 H, br, NCH2CH2N), 3.61 (2 H, m, 
Gly-H2), 3.73 (2 H, m, Gly-H2), 3.73 (2 H, br, Sar-H2), 3.88 (2 H, br, Sar-H2), 4.15 (1 H, 
m, a-H), 4.24 (1 H, m, a-H), 4.53 (1 H, m, a-H), 5.03 (2 H, s, Ar-H2), 5.07 (2 H, br, 






Pentafluorophenyl 6 -(l,l-dimethylethoxycarbonylamino)hexanoate (2.90 g, 7.2 mmol) 
was added to Na-(N-(N-(N-(N-(N-(phenylmethoxycarbonyl)sarcosyl)glycyl)phenyl- 
alanyl)leucyl)glycyl)lysine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide 
(2.41 g, 2.45 mmol), N,N-diisopropylethylamine (950 mg, 7.2 mmol) and DMAP 
(20 mg) in CH2CI2 (20 ml) and DMF (10 ml). The solution was stirred for 5 d and the 
solvents were evaporated. Chromatography (CH2C12 / MeOH 2 0 :1 ) yielded N®-(6 -(l,l- 
dimethylethoxycarbonylamino)hexanoyl)-Na-(N-(N-(N-(N‘(N-(phenylmethoxycarbonyl)- 
sarcosyl)glycyl)phenylalanyl)leucyl)glycyl)lysine N-(2-(N-(phenylmethoxycarbonyl)-
sarcosylamino)ethyl)amide (1.35 g, 51%) as a cream foam.
‘H NMR ((CD3)2 SO) 20°C
8  0.82 (3 H, d, J  = 6.4 Hz, Leu-H3), 0.87 (3 H, d, J  = 6.4 Hz, Leu-H3), 1.21 (4 H, m, 
Lys P,y,8 -H2 + NCH2CH2CH2CH2CH2), 1.36 (13 H, m, Bu-t + Lys P,y,8 -H2 + 
NCH2CH2CH2CH2CH2), 1.47 (4 H, m, Lys p,y,8 -H2 + NCHjCHjOfeCIfcCHj), 1.63 
(3 H, m, Leu y-H + Leu P-H2), 2 . 0 0  (2 H, t, J  = 7.3 Hz, NCH2CH2CH2CH2CH2>, 2.76 
(2 H, m, Phe P-H2), 2.83 (3 H, s, Sar-H3), 2.86 (3 H, s, Sar-H3), 2.99 (4 H, m, Lys e-H2 
+ NCH2CH2CH2CH2CH2), 3.10 (4 H, br, NCH2CH2N), 3.62 (2 H, m, Gly-H2), 3.73 
(2H, m, Gly-H2), 3.82 (2 H, br, Sar-H2), 3.88 (2 H, br, Sar-H2), 4.12 (1 H, m, a-H),
4.22 (1 H, m, a-H), 4.53 ( 1  H, m, a-H), 5.02 ( 2  H, s, Ar-H2), 5.07 (2 H, br, Ar-H2), 6.76 
(1 H, m, NH), 7.30 (15 H, m, Ar + Phe-Ar), 7.72 (1 H, m, NH), 7.80 (1 H, br, NH), 7.98
(3 H, br, 3 x NH), 8.14 (3 H, m, 3  x NH)
8  0.82 (3 H, d, J  = 6.4 Hz, Leu-H3), 0.87 (3 H, d, J  = 6.4 Hz, Leu-H3), 1.21 (4 H, m, 
Lys p,y,8 -H2 + NCH2CH2CH2CH2CH2), 1.36 (13 H, m, Bu-t + Lys P,y,8 -H2 + 
NCH2CH2CH2CH2CH2), 1.47 (4 H, m, Lys P,y,8 -H2  + NCHjCHzOfcCtfcCHj), 1.63 
(3 H, m, Leu y-H + Leu P-H2), 2.00 (2 H, t,J =  7.3 Hz, NCHjCHjCHjCftClt), 2.76 
(2 H, m, Phe P-H2), 2.85 (3 H, s, Sar-H3), 2.87 (3 H, s, Sar-H3), 2.99 (4 H, m, Lys s-H2 
+ NClfcCHiCHiCHiCHJ, 3.10 (4 H, br, NCH2CH2N), 3.62 (2 H, m, Gly-H2), 3.73 
(2 H, m, Gly-H2), 3.82 (2 H, br, Sar-H2), 3.88 (2 H, br, Sar-H2), 4.12 (1 H, m, a-H),
4.22 ( 1  H, m, a-H), 4.53 (1 H, m, a-H), 5.03 (2 H, s, Ar-H2), 5.07 (2 H, br, Ar-H2), 6.76 
(1 H, m, NH), 7.30 (15 H, m, Ar + Phe-Ar), 7.72 (1 H, m, NH), 7.80 ( 1  H, br, NH), 7.98
(3 H, br, 3 x NH), 8.14 (3 H, m, 3 x NH).
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N8-(6 -( 1,1 -Dimethylethoxycarbonylamino)hexanoyl)-Na-(N-(N-(N-(N-(N-(phenyl- 
methoxycarbonyl)sarcosyl)glycyl)phenylalanyl)leucyl)glycyl)lysine N-(2-(N-(phenyl- 
methoxycarbonyl)sarcosylamino)ethyl)amide (1.35g, 1.13 mmol) in CH2C12 (30 ml) was 
treated with hydrogen chloride for 40 min. Methanol (5 ml) was added and the solvents 
and excess reagent evaporated to give N®-(6 -aminohexanoyl)-Na-(N-(N-(N-(N-(N- 
(phenylmethoxycarbonyl)sarcosyl)glycyl)phenylalanyl)leucyl)glycyl)lysine N-(2-(N- 
(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide hydrochloride (1.28 g, quantitative) 
as an off white foam.





(2.14 g, 2.74 mmol) was added to -(6 -( 1 ,1  -dimethylethoxycarbonylamino)hexanoyl)-
N** -(N-(N-(N-(N-(N-(phenylmethoxycarbonyl)sarcosyl)glycyl)phenylalanyl)leucyl)- 
glycyl)lysine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (1.71 g, 
1.74 mmol), N,N-diisopropylethylamine (1.13 g, 8.70 mmol) and DMAP (20 mg) in 
CHCI3 (30 ml) and DMF (10 ml). The solution was stirred for 24 h. The solvents were 
evaporated. Chromatography (CHC13 then CHC13 / MeOH 60 : 1 then CHC13 / MeOH 




carbonyl)sarcosylamino)ethyl)amide (2.37 g, 84%) as a purple glass.
1HNMR((CD3)2SO)
8  -2.90 ( 2  H, s, 21,23-H), 0.84 (3 H, d, J=  6.3 Hz, Leu-H3), 0 . 8 8  (3 H, d, J=  6.3 Hz, 
Leu-H3), 1.18-1.80 (9 H, m, Lys P,y,8 -H2 + Leu y-H + Leu P-H2), 2.72 (1 H, m, Phe 
p-H2), 2.83 (3 H, s, Sar-H3), 2.87 (3 H, s, Sar-H3), 3.16 (7 H, m, NCH2CH2N + Phe 
P-H2 + Lys e-H2), 3.55-3.72 (4 H, m, 2  x Gly-H2), 3.86 (2 H, s, Sar-H2), 3.87 (2 H, br, 
Sar-H2), 4.25 ( 2  H, m, 2  x a-H), 4.58 (1 H, m, a-H), 5.00 (2 H, s, Ar-CH2), 5.04 (2 H, 
br, Ar-CH2), 6.36 (1 H, t , J=  6  Hz, NH), 7.28 (15 H, m, 2 x Ar + Phe-Ar), 7.84 (11 H, 3 
x Ph 3,4,5-H3 + disubstituted aromatic 2,6-H2), 7.95-8.25 ( 1 1  H, m, 3 x Ph 2,6-H2 + 
disubstituted aromatic 3,5-H2 + 5 x NH), 8 .8-9.0 (11 H, m, 2,3,7,8,12,13,17,7£-H8 + 3 x 
NH)
8  -2.90 (2 H, s, 21,23-H), 0.84 (3 H, d, J=  6.3 Hz, Leu-H3), 0.88 (3 H, d, J=  6.3 Hz, 
Leu-H3), 1.18-1.80 (9 H, m, Lys P,y,8 -H2 + Leu y-H + Leu p-H2), 2.72 (1 H, m, Phe 
P-H2), 2.86 (3 H, s, Sar-H3), 2.90 (3 H, s, Sar-H3), 3.16 (7 H, m, NCH2CH2N + Phe 
p-H2 + Lys s-H 2), 3.55-3.72 (4 H, m, 2  x Gly-H2), 3.86 (2 H, s, Sar-H2), 3.87 (2 H, br, 
Sar-H2), 4.25 ( 2  H, m, 2  x a-H), 4.58 (1 H, m, a-H), 5.04 (2 H, s, Ar-CH2), 5.06 (2 H, 
br, Ar-CH2), 6.36 (1 H, t, J = 6  Hz, NH), 7.28 (15 H, m, 2 x Ar + Phe-Ar), 7.84 (11 H, 3 
x Ph 3,4,5-H3 + disubstituted aromatic 2,6-H2), 7.95-8.25 (11 H, m, 3 x Ph 2,6-H2 + 
disubstituted aromatic 3,5-H2 + 5 x NH), 8 .8-9.0 (11 H, m, 2,3,7,8,12,13,17,18-Hg + 3  x 
NH)
T.L.C. (C) Rf = 0.48 





(1.36 g, 1.74 mmol) was added to N®-(6 -aminohexanoyl)-Na-(N-(N-(N-(N-(N-(phenyl- 
methoxycarbonyl)sarcosyl)glycyl)phenylalanyl)leucyl)glycyl)lysine N-(2-(N-(phenyl- 
methoxycarbonyl)sarcosylamino)ethyl)amide hydrochloride (1.23 g, 1.09 mmol), N,N-
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diisopropylethylamine (704 mg, 5.45 mmol) and DMAP (10 mg) in CHC13 (30 ml) and 
DMF (10 ml). The solution was stirred for 48 h, then the solvents were evaporated. 
Chromatography (a) (CHC13 / MeOH 80 : 1 then CHC13 / MeOH 60 : 1 then CHC13 / 
MeOH 40 : 1 then CHC13 / MeOH 30:1 then CHC13 / MeOH 25:1 then CHC13 / MeOH 
15:1 then CHC13 / MeOH 12 : 1 then CHC13 / MeOH 10 : 1 then CHC13 / MeOH 1 : 1 ) 
and (b) (CHC13 / MeOH 9 : 1 )  gave Na-(N-(N-(N-(N-(N-(phenylmethoxycarbonyl)- 
sarcosyl)glycyl)phenylalanyl)leucyl)glycyl)-N€-(6-(N1-(4-(l 0,15,20-triphenyl-21/7,23/7- 
porphin-5-yl)phenyl)ureido)hexanoyl)lysine N-(2-(N-phenylmethoxycarbonyl)sarcosyl- 
amino)ethyl)amide (1.52 g, 80%) as a purple glass.
'H NMR ((CD^SO) 20°C
5 -2.91 (2 H, s, 21,23-H), 0.83 (3 H, d, J  = 6.2 Hz, Leu-H3), 0.86 (3 H, d, J  = 6.2 Hz, 
Leu-H3), 1.35-160 (11 H, m, 2 x Lys P,y,8 -H2 + NCHjCtfcCHjCHjCHj + Leu y-H + 
Leu p-H2), 2.10 (2 H. m, NCHjC^CHjCHjClfc), 2.80 (1 H, m, Phe P-H2), 2.82 (3 H, s, 
Sar-H3), 2.85 (3 H, s, Sar-H3), 3.00-3.10 (9 H, m, Lys e-H 2 + NCH2CH2CH2CH2CH2 + 
NCH2CH2N + Phe P-H2), 3.55-3.75 (4 H, m, 2 x Gly-H2), 3.83 (2 H, br, Sar-H2), 3.87 (2 
H, br, Sar-H2), 4.18 (1 H, m, a-H), 4.22 (1 H, m, a-H), 4.59 (1 H, m, a-H), 5.00 (2 H, s, 
Ar-H2), 5.02 (2 H, br, Ar-H2), 6.36 (1 H, t, J=  6  Hz, NH), 7.28 (15 H, m, 2 x Ar + Phe- 
Ar), 7.83 (11 H, 3 x Ph 3,4,5-H3 + disubstituted aromatic 2,6-H2), 7.96-8.24 (11 H, m, 3 
x Ph 2,6-H2 + disubstituted aromatic 3,5-H2 + 5 x NH), 8.75-9.0 (11 H, m, 
2,3,7,8,12,13,17,75-Hg + 3 x NH)
6  -2.91 (2 H, s, 2/,25-H), 0.83 (3 H, d, J  = 6.2 Hz, Leu-H3), 0.86 (3 H, d, J  = 6.2 Hz, 
Leu-H3), 1.35-160 (11 H, m, 2 x Lys P,y,6 -H2 + NCHzCHzCHjCILCHz + Leu y-H + 
Leu p-H2), 2 . 1 0  ( 2  H. m, NCH2CH2CH2CH2CH2), 2.80 ( 1  H, m, Phe P-H2), 2.85 (3 H, s, 
Sar-H3), 2.87 (3 H, s, Sar-H3), 3.00-3.10 (9 H, m, Lys e-H 2 + NCH2CH2CH2CH2CH2 + 
NCH2CH2N + Phe P-H2), 3.55-3.75 (4 H, m, 2 x Gly-H2), 3.83 (2 H, br, Sar-H2), 3.87 (2 
H, br, Sar-H2), 4.18 (1 H, m, a-H), 4.22 (1 H, m, a-H), 4.59 (1 H, m, a-H), 5.02 (2 H, s, 
Ar-H2), 5.05 (2 H, br, Ar-H2), 6.36 (1 H, t, J=  6  Hz, NH), 7.28 (15 H, m, 2 x Ar + Phe- 
Ar), 7.83 (11 H, 3 x  Ph 3,4,5-H3 + disubstituted aromatic 2,6-H2), 7.96-8.24 (11 H, m, 3 
x Ph 2,6-H2 + disubstituted aromatic 3,5-H2 + 5  x NH), 8.75-9.0 (11 H, m,
2,3,7,8,12,13,17,18-Hs + 3 x NH)
T.L.C. (C) Rf = 0.42 





Zinc powder (4.5 g, 6 8 . 8  mmol) was added to a suspension of Na-(N-(N-(N-(N-(Na-(N- 
(phenylmethoxycarbonyl)sarcosyl)-N5-(6 -methoxy-6 -oxohexyl)glutaminyl)glycyl)phenyl- 
alanyl)leucyl)glycyl)-Ns-(2,2,2-trichloroethoxycarbonyl)lysine N-(2-(N-(phenylmethoxy- 
carbonyl)sarcosylamino)ethyl)amide (2.5 g, 1.78 mmol) in 70% MeOH / water (20 ml). 
The mixture was boiled under reflux for 26 h. The mixture was filtered and the solvents 
were evaporated to give Na-(N-(N-(N-(N-(Na-(N-(phenylmethoxycarbonyl)sarcosyl)-N5- 
(6 -methoxy-6 -oxohexyl)glutaminyl)glycyl)phenylalanyl)leucyl)glycyl)lysine N-(2-(N- 
(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (1.98 g, 89%) as a pale foam.
NMR ((CD3)2SO) 20°C
6  0.82 (3 H, d, J=  6.2 Hz, Leu-H3), 0.86 (3 H, d, J = 6.2 Hz, Leu-H3), 1.24 (4 H, m, Lys 
P,y,5-H2 + NCH2CH2CH2CH2CH2), 1.33 (4 H, m, Lys p,y,5-H2 +
NCH2CH2CH2CH2CH2), 1.49 (4 H, m, Lys P,y,8 -H2 + NCH2CH2CH2CH2CH2), 1.63 
(3 H, m, Leu P-H2 + Leu y-H + Glu P-H2), 2.06 (2 H, m, Glu y-H2), 2.27 (2 H, t, 
J = 7.3 Hz, NCH2CH2CH2CH2CH2), 2.74 (2 H, m, Phe P-H2), 2.83 (3 H, s, Sar-H3), 2.86 
(3 H, br, Sar-H3), 3.00 (4 H, m, NCH2CH2CH2CH2CH2 + Lys e-H2), 3.11 (4 H, br, 
NCH2CH2N), 3.57 (3 H, s, OCH3), 3.63 (1 H, m, Gly-H2), 3.72 (3 H, m, Gly-H2), 3.83 
(2 H, br, Sar-H2), 3.91 (2 H, br, Sar-H2), 4.21 (3 H, m, 3 x  a-H), 4.51 (1 H, m, a-H), 
5.01 (2 H, s, Ar-H2), 5.04 (2 H, br, Ar-H2), 7.30 (15 H, m, 2 x  Ar + Phe-Ar), 7.77 (1 H, 
br, NH), 8.01 (5 H, m, 5 x  NH), 8.19 (4 H, m, 4 x  NH).
6  0.82 (3 H, d, 6.2 Hz, Leu-H3), 0.86 (3 H, d, J =  6.2 Hz, Leu-H3), 1.24 (4 H, m, Lys 
P,y,8 -H2 + NCH2CH2CH2CH2CH2), 1.33 (4 H, m, Lys p,y,6 -H2 +
NCH2CH2CH2CH2CH2), 1.49 (4 H, m, Lys p,y,8 -H2 + NCH2CH2CH2CH2CH2), 1.63 
(3 H, m, Leu p-H2 + Leu y-H + Glu P-H2), 2.06 (2 H, m, Glu y-H2), 2.27 (2 H, t, 
J =  7.3 Hz, NCH2CH2CH2CH2CH2), 2.74 (2 H, m, Phe P-H2), 2.86 (3 H, s, Sar-H3), 2.89 
(3 H, br, Sar-H3), 3.00 (4 H, m, NCH2CH2CH2CH2CH2 + Lys s-H2), 3 .11 (4 H, br, 
NCH2CH2N), 3.57 (3 H, s, OCH3), 3.63 (1 H, m, Gly-H2), 3.72 (3 H, m, Gly-H2), 3.83 
(2 H, br, Sar-H2), 3.91 (2 H, br, Sar-H2), 4.21 (3 H, m, 3 x  a-H), 4.51 (1 H, m, a-H),
5.04 (2 H, s, Ar-H2), 5.08 (2 H, br, Ar-H2), 7.30 (15 H, m, 2 x  Ar + Phe-Ar), 7.77 (1 H, 
br, NH), 8.01 (5 H, m, 5 x  NH), 8.19 (4 H, m, 4 x  NH).
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Pentafluorophenyl 6 -(l,l-dimethylethoxycarbonylamino)hexanoate (896 mg, 2.27 mmol) 
was added to Na-(N-(N-(N-(N-(Na-(N-(phenylmethoxycarbonyl)sarcosyl)-N5-(6 - 
methoxy-6 -oxohexyl)glutaminyl)glycyl)phenylalanyl)leucyl)glycyl)lysine N-(2-(N-
(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (1.89 g, 1.51 mmol), N,N- 
dimethylethylamine (530 mg, 6.08 mmol) and DMAP (10 mg) in CH2C12 (15 ml) and 
DMF (15 ml). The solution was stirred for 24 h then pentafluorophenyl 6 -( 1,1- 
dimethylethoxycarbonylamino)hexanoate (896 mg, 2.27 mmol) was added. Stirring was 
continued for 3d and the solvents were evaporated. Chromatography (CH2C12 / MeOH 
20:1 then MeOH) yielded N€-(6 -(l,l-dimethylethoxycarbonylamino)hexanoyl)-Na-(N-(N- 
(^(^(^(N-fchenylmethoxycarbonytysarcosyO-N^O-methoxy-O-oxohexyl)- 
glutaminyl)glycyl)phenylalanyl)leucyl)glycyl)lysine N-(2-(N-(phenylmethoxycarbonyl)- 
sarcosylamino)ethyl)amide (1.95 g, 89%) as a buff foam.
'H NMR ((CD3)2SO) 20°C
8  0.82 (3 H, d, . /=  6.1 Hz, Leu-H3), 0.86 (3 H, d , J =  6 . 1  Hz, Leu-H3), 1.22 ( 6  H, m, 
Lys P,y,8 -H2 + 2  x NCHiCHjCIfcCHiCHj), 1.36 (17 H, m, Bu-t + Leu P-H2 + Lys 
P,T,8 -H2 + 2  x  NCH2CH2CH2CH2CH2), 1.50 ( 6  H, m, Lys P,y,8 -H2 + 2 x  
NCHjCHjCHiCIfcCHj), 1.59-1.92 (3 H, m, Leu y-H + Glu P-H2), 2.04 (4 H, m, Glu 
y-H2 + NCH^^CHiCHjCHj), 2.27 (2 H. t. J =  7.3 Hz, NCHjCHzCHjCHjCHj), 2.76-
3.18 (18 H, m, Sar-H3 + Phe P-H2 + Lys e-H2 + NCH2CH2N + 2  x  
NCH2CH2CH2CH2CH2), 3.57 (3 H, s, OCH3), 3.65 (4 H, m, 2 x  Gly-H2), 3.84 (2 H, br, 
Sar-H2), 3.92 (2 H, br, Sar-H2), 4 . 2 0  (3H, m, 3  x  a-H), 4.49 (1 H, m, 1 x  a-H), 5.01 
(2 H, s, Ar-H2), 5.07 (2 H, s, Ar-H2), 6.78 (1 H, t, J  = 6.7 Hz, NH), 7.22 (5 H, m, Ar),
7.36 (10 H, m, Ar), 7.78 (1 H, d, J =  6 . 7  Hz, NH), 7.91 ( 1  H, d, J =  7 . 8  Hz, NH), 8.02 
(4 H, m, 4  x NH), 8.19 (4H, m, 4 x NH)
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8  0.82 (3 H, d, 7  = 6.1 Hz, Leu-H3), 0.86 (3 H, d, 7  = 6.1 Hz, Leu-H3), 1.22 ( 6  H, m, 
Lys p,y,8 -H2 + 2 x NCH2CH2CH2CH2CH2), 1.36 (17 H, m, Bu-t + Leu p-H2 + Lys 
p,y,8 -H2 + 2  x  NCH2CH2CH2CH2CH2), 1.50 ( 6  H, m, Lys P,y,8 -H2 + 2  x  
NCH2CH2CH2CH2CH2), 1.59-1.92 (3 H, m, Leu y-H + Glu P-H2), 2.04 (4 H, m, Glu 
y-H2 + NCH2CH2CH2CH2CH2), 2.27 (2 H, t, 7  = 7.3 Hz, NCH2CH2CH2CH2CH2), 2.76-
3.18 (18 H, m, Sar-H3 + Phe p-H2 + Lys e-H2 + NCH2CH2N + 2  x  
NCH2CH2CH2CH2CH2), 3.57 (3 H, s, OCH3), 3.65 ( 4  H, m, 2  x  Gly-H2), 3.84 (2 H, br, 
Sar-H2), 3.92 (2 H, br, Sar-H2), 4.20 (3H, m, 3 x  a-H), 4.49 ( 1  H, m, 1 x  a-H), 5.04 
(2 H, s, Ar-H2), 5.05 (2 H, s, Ar-H2), 6.78 (1 H, t, 7  = 6.7 Hz, NH), 7.22 (5 H, m, Ar),
7.36 (10 H, m, Ar), 7.78 (1 H, d, 7  = 6.7 Hz, NH), 7.91 (1 H, d, 7  = 7.8 Hz, NH), 8.02 
(4 H, m, 4 x NH), 8  .19 (4 H, m, 4 x NH)
'H NMR ((CD3)2SO) 80°C (COSY 90)
8  0.82 (3 H, d, 7  = 6.1 Hz, Leu-H3), 0.86 (3 H, d, 7 = 6  1 Hz, Leu-H3), 1.21 ( 6  H, m, 
Lys P,y,8 -H2 + 2  x  NCH2CH2CH2CH2CH2), 1.36 (17 H, m, Bu-t + Leu P-H2 + Lys 
P,y,8 -H2 + 2  x  NCH2CH2CH2CH2CH2), 1.49 ( 6  H, m, Lys P,y,8 -H2 + 2  x  
NCH2CH2CH2CH2CH2), 1.59 (1 H, m, Leu y-H), 1.76 ( 1  H, m, Glu P-H2), 1.89 ( 1  H, m, 
Glu P-H2), 2.02 (2 H, t, 7 =  6.9 Hz, NCH2CH2CH2CH2CH2), 2.10 ( 2  H, t, 7 =  5.2 Hz, 
Glu y-H2), 2.29 ( 2  H, t, 7 =  6.9 Hz, NCH2CH2CH2CH2CH2), 2.78 (4 H, m, Phe p-H2 + 
Sar-H3), 3.02 (7 H, m, Phe p-H2 + Lys e-H2 + 2 x  NCH2CH2CH2CH2CH2), 3.14 (4 H, br, 
NCH2CH2N), 3.57 (3 H, s, OCH3), 3.69 (4 H, m, 2 x  Gly-H2), 3.81 (2 H, s, Sar-H2),
3.89 (2 H, s, Sar-H2), 4.18 (1 H, m, 1 x  a-H), 4.22 ( 2  H, m, 2  x  a-H), 4.52 (1 H, m, Phe 
a-H), 5.04 (2 H, s, Ar-H2), 5.07 (2 H, s, Ar-H2), 7.22 (5 H, m, Ar), 7.32 (10 H, m, Ar), 
7.41 (1 H, br, NCHjCHjCHzCHjCHj), 7.46 ( 1  H, m, NClfcCHjCHjCHjCHz), 7.59 (1 H, 
d, 7 =  8  Hz, NH (couples to signal at 4.18)), 7.68 (3 H, br, NHCH2CH2NH + NH), 7.75 
(1 H, m, Gly-NH), 7.82 (1 H, m, Phe-NH), 7.84 (1 H, m, NH (couples to signal at 4.22)),
7.87 (1 H, m, Gly-NH), 8.00 (1 H, m, NH (couples to signal at 4.22))
T.L.C. (C) Rf = 0.30





Hydrogen chloride was passed through N®-(6 -(l,l-dimethylethoxycarbonylainino)- 
hexanoyl)-Na-(N-(N-(N-(N-(Na-(N-(phenylmethoxycarbonyl)sarcosyl)-N5-(6 -methoxy-6 - 
oxohexyl)glutaminyl)glycyl)phenylalanyl)leucyl)glycyl)lysine N-(2-(N-(phenylmethoxy- 
carbonyl)sarcosylamino)ethyl)amide (1.92 g, 1.32 mmol) in CH2C12 ( 2 0  ml) and MeOH 
(5 ml) for 40 min. The solvents and excess reagent were evaporated to give N*-(6 -amino- 
hexanoyl)-Na-(N-(N-(N-(N-(Na-(N-(phenylmethoxycarbonyl)sarcosyl)-N5-(6 -methoxy-6 - 
oxohexyl)glutaminyl)glycyl)phenylalanyl)leucyl)glycyl)lysine N-(2-(N-(phenylmethoxy- 
carbonyl)sarcosylamino)ethyl)amide hydrochloride (1.84g, quantitative).






(1.51 g, 1.94 mmol) was added to N®-(6 -aminohexanoyl)-Na-(N-(N-(N-(N-(Na-(N- 
(phenylmethoxycarbonyl)sarcosyl)-N8-(6 -methoxy-6 -oxohexyl)glutaminyl)glycyl)phenyl- 
alanyl)leucyl)glycyl)lysine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide 
hydrochloride (1.80 g, 1.29 mmol), N,N-dimethylethylamine (560 mg, 6.45 mmol), and 
DMAP (20 mg) in CHCI3 (10 ml) and DMF (20 ml). The solution was stirred for 48 h. 
The solvents were evaporated. Chromatography (CHC13 / MeOH 20 : 1) gave N“-(N-(N- 
(N-(N-(Na-(N-(phenylmethoxycarbonyl)sarcosyl)-N6-(6 -methoxy-6 -oxohexyl)- 
glutaminyl)glycyl)phenylalanyl)leucyl)glycyl)-N€-(6-(N'-(4-( 10,15,20-triphenyl-2 IHJ23H- 
porphin-5-yl)phenyl)ureido)hexanoyl)lysine N-(2-(N-(phenylmethoxycarbonyl)sarcosyl- 
amino)ethyl)amide hydrochloride (2.19 g, 85%) as a purple glass.
'HNMR ((CDj)2SO)
8  -2.95 (2 H, s, 21,23V), 0.78 ( 3  H, d, J  = 5.9 Hz, Leu-Hs), 0.83 (3 H, d, J  = 5.9 Hz, 
Leu-H3), 1.18 ( 6  H, m, Lys P,r,8 -H2 + 2  x NCHjCHjCHjCHzCHj), 1.30 ( 6  H, m, Lys
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P,y,8 -H2 + 2 x  NCH2CH2CH2CH2CH2), 1.46 ( 6  H, m, Lys P,y,8 -H2 + 2 x  
NCH2CH2CH2CH2CH2), 1.55-1.95 (5 H, m, Leu y-H + Leu p-H2 + Glu p-H2), 2.04 (4 H, 
m, Glu y-H2 + NCH2CH2CH2CH2CH2), 2.21 (2 H, m, NCH2CH2CH2CH2CH2), 2.76-3.18 
(18 H, m, Sar-H3 + Phe P-H2 + Lys e-H2 + NCH2CH2N + 2 x  NCH2CH2CH2CH2CH2),
3.52 (3 H, s, OCH3), 3.59-3.78 ( 4  H, m, 2  x Gly-H2), 3.79 (2 H, br, Sar-H2), 3.84 (2 H, 
br, Sar-H2), 4.22 (3H, m, 3 x  a-H), 4.51 (1 H, m, 1 x  a-H), 4.97 (2 H, s, Ar-H2), 4.99 
(2 H, s, Ar-H2), 6.35 ( l H , t , 7 = 6  Hz, NH), 7.28 (15 H, 2 x  Ar + Phe-Ar), 7.78 (9 H, m, 
3 x Ph 3,4,5-H3), 8.0-8.1 ( 8  H, m, disubstituted aromatic 2,6-H2 + 6  x NH), 8.18 (11 H, 
m, 3 x  Ph 2,6-H2 + disubstituted aromatic 3,5-H2 + 3 x  NH), 8.75-8.95 ( 8  H, m,
2.3.7.8.12.13.17.18-H8)
8  -2.95 (2 H, s, 2/,23H), 0.78 (3 H, d, J  = 5.9 Hz, Leu-H3), 0.83 (3 H, d, J  = 5.9 Hz, 
Leu-H3), 1.18 ( 6  H, m, Lys p,y,8 -H2 + 2  x  NCH2CH2CILCH2CH2), 1.30 ( 6  H, m, Lys 
P,y,8 -H2 + 2  x  NCH2CH2CH2CH2CH2), 1.46 ( 6  H, m, Lys p,y,8 -H2 + 2 x  
NCH2CH2CH2CH2CH2), 1.55-1.95 (5 H, m, Leu y-H + Leu P-H2 + Glu P-H2), 2.04 (4 H, 
m, Glu y-H2 + NCH2CH2CH2CH2CH2), 2.21 (2 H, m, NCH2CH2CH2CH2CH2), 2.76-3.18 
(18 H, m, Sar-H3 + Phe P-H2 + Lys e-H2 + NCH2CH2N + 2  x  NCH2CH2CH2CH2CH2),
3.52 (3 H, s, OCH3), 3.59-3.78 ( 4  H, m, 2  x Gly-H2), 3.79 (2 H, br, Sar-H2), 3.84 (2 H, 
br, Sar-H2), 4.22 (3H, m, 3 x  a-H), 4.51 ( 1  H, m, 1 x  a-H), 4.99 (2 H, s, Ar-H2), 5.02 
(2 H, s, Ar-H2), 6.35 (1 H, t, J=  6  Hz, NH), 7.28 (15 H, 2 x  Ar + Phe-Ar), 7.78 (9 H, m, 
3 x  Ph 3,4,5-H3), 8.0-8.1 ( 8  H, m, disubstituted aromatic 2,6-H2 + 6  x  NH), 8.18 (11 H, 
m, 3 x Ph 2,6-H2 + disubstituted aromatic 3,5-H2 + 3  x NH), 8.75-8.95 ( 8  H, m,
2.3.7.8.12.13.17.18-H8)
T.L.C. (C) Rf = 0.34 
MS (FAB+) 1998 (M + H)
N5-(6-Hydrazino-6-oxohexyl)-Na-(N-(phenylmethoxycarbonyl)sarcosyl)gIutamine 
N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (264)
Hydrazine hydrate (0.4 ml, 7.19 mmol) was added to N^b-methoxy-b-oxohexylJ-N^fN- 
(phenylmethoxycarbonyl)sarcosyl)glutamine N-(2-(N-(phenylmethoxycarbonyl)sarcosyl- 
amino)ethyl)amide (512 mg, 0.71 mmol) in MeOH (5 ml). The solution was heated at 40° 
C for 14 h. The solvent and excess reagent were evaporated to reveal N5-(6 -hydrazino-6 - 
oxohexyl)-Na-(N-(phenylmethoxycarbonyl)sarcosyl)glutamine N-(2-(N-(phenylmethoxy- 




8  1.19 (2 H, m, NCH2CH2CH2CH2CH2), 1.35 (2 H, m, NCH2CH2CH2CH2CH2), 1.44 
(2 H, m, NCHjCHjCHjCItCH^, 1.73 ( 1  H, m, Glu p-H2), 1.84 ( 1  H, m, Glu P-H2),
1.98 (2 H, t, J =  7.3 Hz, NCHjCHjCHjCHjCHj), 2.04 (2 H, m, Glu y-H2), 2.85 (2 H, s, 
Sar-Hj), 2.88 (2 H, s, Sar-Hj), 2.99 (2 H, m, NCHjCHjC^C^CHj), 3.12 (4 H, br, 
NCH2CH2N), 3.83 (2 H, s, Sar-H2), 3.91 (2 H, s, Sar-H2), 4.19 (1 H, m, Glu a-H), 5.04 
( 2  H, s, Ar-CH2), 5.08 ( 2  H, s, Ar-CH2), 7.36 ( 1 0  H, m, Ar), 7.78 ( 1  H, br, NH), 8 . 0 1  
(1 H, br, NH), 8.04 (1 H, br, NH), 8.17 (1 H, m, NH), 8.92 (1 H, s, NH2NH)
8  1.19 ( 2  H, m, NCHjCHjCHjCHjCHj), 1.35 ( 2  H, m, NCHjCHiCHjCHjCHj), 1.44 
(2H, m, NCHjCHjCHjCHjCHj), 1.73 ( 1  H, m, Glu P-H2), 1.84 (1 H, m, Glu P-H2),
1.98 (2 H, t, J=  7.3 Hz, NCH^HjCHjCHjCHj), 2  04 (2 H, m, Glu y-H2), 2.84 (2 H, s, 
Sar-Hj), 2.88 (2 H, s, Sar-H3), 2.99 (2 H, m, NCHjCHjCHjCHjC^), 3.12 (4 H, br, 
NCH2CH2N), 3.83 (2 H, s, Sar-H2), 3.93 (2 H, s, Sar-H2), 4.19 ( 1  H, m, Glu a-H), 5.03 
(2 H, s, Ar-CH2), 5.08 (2 H, s, Ar-CH2), 7.36 (10 H, m, Ar), 7.78 (1 H, br, NH), 8 . 0 1  
(1 H, br, NH), 8.04 (1 H, br, NH), 8.17 (1 H, m, NH), 8.92 (1 H, s, NH2NH)
T.L.C. (C)Rf= 0.18
MS (FAB+) 727 (M + H)




4M Hydrogen chloride in dioxane (0.62 ml) was added to N5-(6 -hydrazino-6 -oxohexyl)- 
N“-(N-(phenylmethoxycarbonyl)sarcosyl)glutamine N-(2-(N-(phenylmethoxycarbonyl)- 
sarcosylamino)ethyl)amide (500 mg, 0.69 mmol) in DMF (2 ml). The solution was cooled 
to -20°C and /-butyl nitrite (0.074 ml) was added. The solution was stirred for 50 min 
and then cooled to -60°C. N,N-diisopropylethylamine (0.48 ml, 4 eq.) was added and the 
solution was allowed to warm to -30°C. 4-( 10,15,20-Triphenyl-2l//,23//-porphin-5-yl)- 
benzeneamine (1.28 g, 2.07 mmol) and DMAP (5 mg) in CHC13 (20 ml) were added to 
the solution. The solution was stirred at room temperature for 24 h. The solvents were
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evaporated. Chromatography (hexane / EtOH 1:1) gave N5-(6-oxo-6-(4-(l 0,15,20- 
triphenyl-21//,23//-porphin-5-yl)phenylamino)hexyl)-Na-(N-(phenylmethoxycarbonyl)- 
sarcosyl)glutamine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide
(332 mg, 37%) as a purple glass.
‘H NMR (CDC13)
8  -2.75 (2 H, 21,23-H2), 0.89 (2 H, m, NCHjCHjCHjCHjCHj), 1.25-1.65 ( 6  H, m, 
NCH2CH2CH2CH2CH2 + Glu p-Hj), 1 .9-2.4 (4 H, Glu y-H2  + NCHjCHjCHjCHjCHj),
3.0-3.1 ( 8  H, m, NCH2CH2 CH2CH2CH2 + 2 x Sar-H3), 3.35 (4 H, br, NCH2CH2N),
3.85-4.05 ( 4  H, m, 2  x Sar-H2), 4.42 (1 H, m, Glu a-H), 5.13 (4 H, br, 2 x Ar-CH2), 
7.25-7.33 (13 H, m, 3  x NH + 2  x Ar-H5), 7.70-7.76 (11 H, m, 3 x Ph 3,4,5-Hj + 
disubstituted aromatic 2,6-H2), 7.96 (2 H, m, 2 x NH), 8.12 (2H, d, J=  8.2 Hz, 
disubstituted aromatic 3,5-H2), 8.17-8.23 (6 H, m, 3 x Ph 2,6-H2), 8.85 ( 8  H, br, 
porphyrin 2,3,7,8,12,13,17,7£-H8).
T.L.C. (C) Rf = 0.43
N6-(6-Oxo-6-(2-oxo-2-(4-( 10,15,20-tripheny 1-21//,23/7-porph in-5-yl)pheny lamino)- 
ethylamino)hexyI)-Na-(N-(phenylmethoxycarbonyI)sarcosyl)glutamine N-(2-(N- 
(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (271)
4M Hydrogen chloride in dioxane (1.86 ml) was added to a solution of N5-(6 -hydrazino-
6 -oxohexyl)-Na-(N-(phenylmethoxycarbonyl)sarcosyl)glutamine N-(2-(N-(phenyl-
methoxycarbonyl)sarcosylamino)ethyl)amide (1.50 g, 2.07 mmol) in DMF (3 ml). The 
solution was taken to -20°C and /-butyl nitrite (0.23 ml) was added. The solution was 
stirred for 3 h and then taken to -60°C. N,N-Dimethylethylamine (1.06 g, 8.27 mmol) 
was added and the solution warmed to -30°C. 5-(4-(Glycylamino)phenyl)-l0,15,20- 
triphenyl-2l//-23//-porphine trihydrochloride (2.30 g, 2.9 mmol) and N,N-dimethylethyl- 
amine ( 1 . 1 2  g, 8.7 mmol) were added and the solution warmed to room temperature. The 
solution was stirred for 24 h. The solvents were evaporated. Chromatography (CHC13 / 
MeOH 20 : 1) gave N5-(6-oxo-6-(2-oxo-2-(4-( 10,15,20-triphenyl-2 l//,23//-porphin-5-
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yl)phenylamino)ethylamino)hexyl)-Na-(N-(phenylmethoxycarbonyl)sarcosyI)glutamine N- 
(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (1.93 g, 76%) as a deep 
purple glass.
'H NMR (CDCIj)
8  -2.75 (2 H, 2I,23~H2), 0.89 (2 H, m, NCHjCHjCHjCHjCHj), 1.25-1.65 ( 6  H, m, 
NCH2CH2CH2CH2CH2 + Glu P-H2), 1.9-2.4 (4 H, Glu y-H2 + NCH2CH2CH2CH2CH2),
3.0-3.1  ( 8  H, m, NCH2CH2CH2CH2CH2 + 2  x Sar-Hj), 3.35 (4 H, br, NCH2CH2N),
3.85-4.05 (4 H, m, 2 x Sar-H2), 4.15-4.25 (2 H, m, Gly-H2), 4.42 (1 H, m, Glu a-H),
5.13 (4 H, br, 2  x Ar-CH2), 7.25-7.33 (1 4 H ,m ,4 x N H  + 2 x Ar-H5), 7.70-7.76 (11 H, 
m, 3 x Ph 3,4,5-H3 + disubstituted aromatic 2,6-H2), 7.96 (2 H, m, 2  x NH), 8.12 (2 H, 
d, J — 8.2 Hz, disubstituted aromatic 3,5-H2), 8.17-8.23 (6 H, m, 3 x Ph 2 ,6 -H2), 8.84 
( 8  H, br, porphyrin 2,3,7,8,12,13,17,18-H8).
T.L.C. (C) Rf = 0.35
Acc. Mass (FAB+) 1381.6184 (M + H) (C81H81N12O10 requires 1381.6199).
N-(N-(N-(N-(N6-(6 -Hydrazino-6 -oxohexyl)-Na-(N-(phenylmethoxycarbonyl)- 
sarcosyl)glutaminyl)glycyl)phenyIalanyl)Ieucyl)glycine N-(2-(N-(phenylmethoxy- 
carbonyl)sarcosylamino)ethyl)amide (272)
Hydrazine hydrate (0.52 ml, 9.3 mmol) was added to N-(N-(N-(N-(N6-(6 -methoxy-6 - 
oxohexyl)-Na-(N-(phenylmethoxycarbonyl)sarcosyl)glutaminyl)glycyl)phenylalanyl)- 
leucyl)glycine N-(2-(N-(phenylmethoxycarbonylsarcosylamino)ethyl)amide ( 1 . 0 0  g, 
0.91 mmol) in MeOH (15 ml). The solution was heated at 45°C for 48 h. The solvent and 
excess reagent were evaporated to yield N-(N-(N-(N-(N5-(6 -hydrazino-6 -oxohexyl)-Na- 
(N-(phenylmethoxycarbonyl)sarcosyl)glutaminyl)glycyl)phenylalanyl)leucyl)glycine N-(2- 




8  0.81 (3 H, d, J  = 6.4 Hz, Leu-Hj), 0.86 (3 H, d, J =  6.4 Hz, Leu-H3), 1.05 (2 H, m, 
NCHjCHjQfcCHjCHj), 1 2 2  ( 2  H, m, NCHjCHjCHjCHjCHj), 1.36 ( 2  H, m, 
NCHjCHjCHjCHjCHj), 1.48 (2 H, m, Leu P-H2), 1.60 (1 H, m, Leu y-H), 1.71-1.87 
(2 H, m, Glu P-H2), 1.97 (2 H, t , J=  7.3 Hz, NCH2CH2CH2CH2CH!), 2.06 (2 H, m, Glu 
y-H2), 2.77(1 H, m, Phe P-H2), 2.84 (3 H, s, Sar-H3), 2.87 (3 H, s, Sar-H3), 2.96 (3 H, m, 
Phe P-H2 + NCH2CH2CH2CH2CH2 + 3.10 (4 H, br. NCH2CH2N), 3.52-3.69 (4 H, m, 2  x 
Gly a-H), 3.82 (2 H, br, Sar-H2), 3.90 (2 H, br, Sar-H2), 4.23 ( 2  H, m, Leu a-H + Glu 
a-H), 4.49 (1 H, m, Phe a-H), 4.98 (2 H, s, Ar-CH2), 5.06 (2 H, s, Ar-CH2), 7.28 (15 H, 
m, 3  x Ar), 7.76 ( 1  H, d, J  =4.9 Hz, NH), 7.84 (1 H, br, NH), 8.03 (2 H, br, 2 x NH),
8.07 (1 H, m, NH), 8.22 (3 H, m, 3 x NH) 8.91 (1 H, s, NHNH2)
8  0.81 (3 H, d, J  = 6.4 Hz, Leu-H3), 0.86 (3 H, d, J =  6.4 Hz, Leu-H3), 1.05 (2 H, m, 
NCH2CH2CHjCH2CH2), 1.22 (2 H, m, NCH2CH2CIiCH 2CH2), 1.36 (2 H, m, 
NCH2CH2CH2CH2CH2), 1.48 (2 H, m, Leu P-H2), 1.60 (1 H, m, Leu y-H), 1.71-1.87 
(2 H, m, Glu P-H2), 1.97 (2 H, t, J=  7.3 Hz, NCH2CH2CH2CH2CHi), 2.06 (2 H, m, Glu 
y-H2), 2.77(1 H, m, Phe P-H2), 2.82 (3 H, s, Sar-H3), 2.85 (3 H, s, Sar-H3), 2.96 (3 H, m, 
Phe P-H2 + NCHjCH^H^HjCHj + 3.10 (4 H, br. NCH2CH2N), 3.52-3.69 (4 H, m, 2  x 
Gly a-H), 3.82 (2 H, br, Sar-H2), 3.90 (2 H, br, Sar-H2), 4.23 (2 H, m, Leu a-H + Glu 
a-H), 4.49 (1 H, m, Phe a-H), 5.01 (2 H, s, Ar-CH2), 5.03 (2 H, s, Ar-CH2), 7.28 (15 H, 
m, 3 x Ar), 7.76 (1 H, d, J =  4.9 Hz, NH), 7.84 (1 H, br, NH), 8.03 (2 H, br, 2 x NH),
8.07 (1 H, m, NH), 8.22 (3 H, m, 3 x NH) 8.91 (1 H, s, NHNH2)
T.L.C. (C)Rf= 0.12 





4M Hydrogen chloride in dioxane (0.75 ml) was added to N-(N-(N-(N-(N5-(6 -hydrazino-
6 -oxohexyl)-Na-(N-(phenylmethoxycarbonyl)sarcosyl)glutaminyl)glycyl)phenylalanyl)- 
leucyl)glycine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (913 mg, 
0.83 mmol) in DMF (3 ml). The solution was taken to -20°C and /-butyl nitrite 
(0.090 ml) was added. The solution was stirred for 3 h and then taken to -60°C. N,N-Di- 
methylethylamine (290 mg, 3.3 mmol) was added and the solution allowed to warm to
xc
-3 0°C. 5-(4-(Glycylamino)phenyl)-10,15,20-triphenyl-2 l//-23//-porphine trihydro­
chloride (880 mg, 1.14 mmol), N,N-dimethylethylamine (396 g, 4.56 mmol) and DMAP 
( 1 0  mg) in CHCI3 (20 ml) were added. The solution was stirred for 48 h. The solvents 
were evaporated. Chromatography (a) (CHCI3 / MeOH 20:1) and (b) CHCI3 / MeOH 
10:1) gave N-(N-(N-(N-(N8-(6-oxo-6-(2-oxo-2-(4-(10,15,20-triphenyl-21H,23H- 
porphin-5-yl)phenylamino)ethylamino)hexyl)-Na-(N-(phenylmethoxycarbonyl)sarcosyl)- 
glutaminyl)glycyl)phenylalanyl)leucyl)glycine N-(2-(N-(phenylmethoxycarbonyl)-
sarcosylamino)ethyl)amide (1.21 g, 83%) as a purple glass.
'HNMR((CD3)2 SO)
8  -2.95 (2 H, s, 2/,23-H2), 0.79 (3 H, d, J  = 6 . 3  Hz, Leu-Hj), 0.84 (3 H, d, J  = 6.3 Hz, 
Leu-Hj), 1.2-1. 6  ( 6  H, m, NCHjCHjCHjCHjCHj), 1.65-1.90 (5 H, m, Leu P-H2 + Leu 
y-H + Glu P-H2), 2.06 (2 H, m, Glu y-H2), 2.20 (2 H, m, N C H jC H iO iO ^C Ii), 2.75 
(1 H, m, Phe P-H2), 2.81 (3 H, s, Sar-H3), 2.87 (3 H, s, Sar-Hj), 2.98 (3 H, m, Phe p-H2 
+ NCHiCH2CH2CH2CH2) 3.09 (4 H, br. NCH2CH2N), 3.55-3.78 (4 H, m, 2  x  Gly a-H),
3.80 (2 H, br, Sar-H2), 3.88 (2 H, br, Sar-H2), 4.01 (1 H, m, a-H), 4.22(1 H, m, a-H),
4.50 (1 H, m, a-H), 4.98 (2 H, s, Ar-CH2), 5.02 (2 H, s, Ar-CH2), 7.28 (15 H, m, 3 x  
Ar), 7.82 (9 H, m, 3 x Ph 3,4,5-H3), 8.02 (2 H, d, J  -  8 . 6  Hz, disubstituted aromatic-H2),
8.14 (2 H, d, J=  8 . 6  Hz, disubstituted aromatic-H2), 8.18-8.22 ( 6  H, m, 3 x Ph 2,6-H2),
8.80 ( 6  H, br, porphyrin 2,3,7,8,12,13,17,18-lU)
8  -2.95 (2 H, s, 2/,23-H2), 0.79 (3 H, d, J=  6.3 Hz, Leu-H3), 0.84 (3 H, d, J  = 6.3 Hz, 
Leu-H3), 1.2-1. 6  ( 6  H, m, NCH^HjCHjCHjCH^, 1.65-1.90 (5 H, m, Leu p-H2 + Leu 
y-H + Glu p-H2), 2.06 (2 H, m, Glu y-H2), 2.20 (2 H, m, NCH2CH2CH2CH2CH2), 2.75 
(1 H, m, Phe P-H2), 2.83 (3 H, s, Sar-H3), 2.89 (3 H, s, Sar-H3), 2.98 (3 H, m, Phe P-H2 
+ NCH2CH2CH2CH2CH2) 3.09 (4 H, br. NCH2CH2N), 3.55-3.78 (4 H, m, 2  x  Gly a-H),
3.80 (2 H, br, Sar-H2), 3.88 (2 H, br, Sar-H2), 4.01 (1 H, m, a-H), 4.22(1 H, m, a-H),
4.50 (1 H, m, a-H), 5.02 (2 H, s, Ar-CH2), 5.04 (2 H, s, Ar-CH2), 7.28 (15 H, m, 3 x  
Ar), 7.82 (9 H, m, 3 x  Ph 3,4,5-H3), 8.02 (2 H, d, J  = 8 . 6  Hz, disubstituted aromatic-H2),
8.14 (2 H, d, J=  8 . 6  Hz, disubstituted aromatic-H2), 8.18-8.22 ( 6  H, m, 3 x Ph 2,6-H2),
8.80 ( 6  H, br, porphyrin 2,3,7,8,12,13,17, /^-FL)
T.L.C. (C) Rf = 0.36 





Hydrazine hydrate (0.4 ml, 6.43 mmol) was added to Na-(N-(N-(N-(N8-(6 -methoxy-6 - 
oxyhexyl)-Na-(N-(phenylmethoxycarbonyl)sarcosyl)glutaminyl)glycyl)phenylalanyl)- 
leucyl)glycine Ne-(2,2,2-trichloroethoxycarbonyl)lysine N-(2 -(N-(phenylmethoxy- 
carbonyl)sarcosylamino)ethyl)amide (890 mg, 0.63 mmol) in MeOH (10 ml). The 
solution was heated at 40°C for 24 h. Hydrazine hydrate (0.4 ml, 6.43 mmol) was added 
and heating continued at 55°C for 48 h. The solvent was evaporated to reveal Na-(N-(N- 
(N-(N6-(6 -hydrazino-6 -oxohexyl)-Na-(N-(phenylmethoxycarbonyl)sarcosyl)glutaminyl)- 
glycyl)phenylalanyl)leucyl)glycine Ne-(2,2,2-trichloroethoxycarbonyl)lysine N-(2-(N- 
(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (890 mg, quantitative) as a cream 
solid. Mp 185-190°C
'HNMR((CD 3)2S0)
8  0.82 (3 H, d, J=  6.4 Hz, Leu-H3), 0.87 (3 H, d, J=  6.4 Hz, Leu-H3), 1.21 (4 H, m, Lys 
P,y,8 -H2 + NCH2CH2CH2CH2CH2), 1.37 (4 H, m, Lys P,y,8 -H2 +
NCH2CH2CH2CH2CH2), 1.49 (4 H, m, Lys p,y,5-H2 + NCH2CH2CH2CH2CH2), 1.56-
1.85 (3 H, m, Leu P-H + Leu y-H2), 1.86-2.15 (4 H, m, Glu P-H2 + Glu y-H2), 1.98 (2 H, 
t, J =  7.7 Hz, NCH2CH2CH2CH2CH2), 2.78 (1 H, m, Phe P-H2), 2.84 (3 H, s, Sar-H3),
2.87 (3 H, s, Sar-H3), 2.99 (5 H, m, NQfcCHzOfcCHjOfe + Lys e-H2 + Phe P-H2), 3.11 
(4 H, br, NCH2CH2N), 3.45 (2 H, m, Gly-H2), 3.71 (2 H, m, Gly-H2), 3.83 (2 H, br, 
Sar-H2), 3.91 (2 H, br, Sar-H2), 4.15 (1 H, m, a-H), 4.26 (2 H, m, 2  x a-H), 4.53 (1 H, 
m, a-H), 4.77 (2 H, s, CH2CC13), 5 . 0 1  (2 H, s, Ar-CH2), 5.03 (2 H, s, Ar-CH2), 7.30 
(15 H, m, 2 x Ar + Phe-Ar), 7.68 (1 H, m, NH), 7.77 (1 H, m, NH), 7.94 (5 H, m, 5  x 
NH), 8.18 (3 H, m, 3 x NH), 8.92 (1 H, s, NHNH2).
8  0.82 (3 H, d, J  = 6.4 Hz, Leu-H3), 0.87 (3 H, d, J=  6.4 Hz, Leu-H3), 1.21 (4 H, m, Lys 
P,y,8 -H2 + NCH2CH2CH2CH2CH2), 1.37 (4 H, m, Lys P,y,8 -H2 +
NCH2CH2CH2CH2CH2), 1.49 (4 H, m, Lys P,y,8 -H2 + NCH2CH2CH2CH2CH2), 1.56-
1.85 (3 H, m, Leu P-H + Leu y-H2), 1.86-2.15 (4 H,m, Glu P-H2 +Glu y-H2), 1.98 (2 H, 
t, J  = 7.7 Hz, NCH2CH2CH2CH2CH2), 2.78 ( 1  H, m, Phe p-H2), 2 . 8 6  (3 H, s, Sar-H3),
2.88 (3 H, s, Sar-H3), 2.99 (5 H, m, NCH2CH2CH2CH2CH2 + Lys e-H2 + Phe P-H2), 3.11 
(4 H, br, NCH2CH2N), 3.45 (2 H, m, Gly-H2), 3.71 (2 H, m, Gly-H2), 3.83 (2 H, br,
Sar-H2), 3.91 (2 H, br, Sar-H2), 4.15 (1 H, m, a-H), 4.26 ( 2  H, m, 2  x a-H), 4.53 (1 H, 
m, a-H), 4.77 (2 H, s, CH2CC13), 5.03 (2 H, s, Ar-CH2), 5.07 (2 H, s, Ar-CH2), 7.30 
(15 H, m, 2 x Ar + Phe-Ar), 7.68 (1 H, m, NH), 7.77 (1 H, m, NH), 7.94 ( 5  H, m, 5 x 
NH), 8.18 (3 H, m, 3 x NH), 8.92 (1 H, s, NHNH2).





4M Hydrogen chloride in dioxane (0.53 ml) was added to Na-(N-(N-(N-(N5-(6 - 
hydrazino-6 -oxohexyl)-Na-(N-(phenylmethoxycarbonyl)sarcosyl)glutaminyl)glycyl)- 
phenylalanyl)leucyl)glycine Ne-(2,2,2-trichloroethoxycarbonyl)lysine N-(2-(N-(phenyl- 
methoxycarbonyl)sarcosylamino)ethyl)amide (839 mg, 0.59 mmol) in DMF (2 ml). The 
solution was cooled to -20°C and /-butyl nitrite (0.064 ml) was added. The solution was 
stirred for 6 h then cooled to -60°C. N,N-Dimethylethylamine (205 mg, 2.36 mmol) was 
added and the solution allowed to warm to -30°C. 5-(4-(Glycylamino)phenyl)-l0,15,20- 
triphenyl-217/-23//-porphine trihydrochloride (0.63 g, 0.81 mmol), N,N-dimethyl- 
ethylamine (205 mg, 2.36 mmol) and DMAP (10 mg) in CHCI3 (20 ml) were added and 
the solution stirred for 48 h. The solvents were evaporated. Chromatography (CHCI3 / 
MeOH 20:1) gave Na-(N-(N-(N-(N6-(6-oxo-6-(2-oxo-2-(4-(10,15,20-triphenyl- 
21//,23//-porphin-5-yl)phenylamino)ethylamino)hexyl)-Na-(N-(phenylmethoxycarbonyl)- 
sarcosyl)glutaminyl)glycyl)phenylalanyl)leucyl)glycine Ns-(2,2,2-trichloroethoxy-
carbonyl)lysine N-(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide ( 1 . 0 0  g, 
83%) as a purple glass.
'H NMR ((CD3)2SO) 20°C
8  -2.94 (2 H, s, 21,23-H2), 0.83 (3 H, d, J  = 7.3 Hz, Leu-H3), 0 . 8 8  (3 H, br, Leu-H3),
1.18 ( 6  H, m, Lys P,y,8 -H2 + 2 x NCHiCHjCHjCHiCHj), 1 .37 ( 6  H, m, Lys P,y,5-H2 +
xciii
NCH2CH2CH2CH2CH2)( 1.49 (4 H, m, Lys P,y,5-H2 + NCHjCHjCHjCHjCft), 1.50-
1.90 (7 H, m, Leu 0-H2 + Leu y-H + Glu P-H2 + Glu y-H2) 2.05 (2 H, m, 
NCH2CH2CH2CH2CH2), 2.76-2.91 ( 8  H, m, Phe p-H2 + 2  x Sar-Hj), 3.08 (4 H, m, 
NCH2CH2CH2CH2CH2 + Lys e-H2), 3.10 (4 H, br, NCH2CH2N), 3.69 ( 4  H, m, 2  x 
Gly-H2), 3.81 (2 H, br, Sar-H2), 3.89 (2 H, br, Sar-H2), 4.18 ( 3  H, m, 3  x a-H), 4.50 
(1 H, m, a-H), 4.74 (2 H, s, CH2CC13), 5.01 (2 H, br, Ar-CH2), 5.05 (2 H, br, Ar-CH2),
7.30 (15 H, m, 2 x Ar + Phe-Ar), 7.70-7.76 (11 H, m, 3 x Ph 3,4,5-Hj + disubstituted 
aromatic 2,6-H2), 7.96 (2 H, m, 2 x NH), 8.12 (2 H, d, J=  8.2 Hz, disubstituted aromatic
3,5-H2), 8.17-8.23 (12 H, m, 6  x NH + 3 x Ph 2,6-H2), 8.84 (12 H, br, 4 x NH + 
porphyrin 2,3,7,8,I2,13,J7,18-HS).
T.L.C. (C) Rf = 0.33 
MS (FAB+) 2059 (M + H)
N-(Phenylmethoxycarbonyl)sarcosine N-(l-methylethyl)amide (278)
N-(l-methylethyl)amine (1.82g, 30.8 mmol) was added dropwise to a stirred solution of 
N-(phenylmethoxycarbonyl)sarcosine pentafluorophenyl ester (4.0 g, 10.3 mmol) in 
CHjClj (20 ml). After 2 h, the solution was washed with water, twice with 10% aq. 
H2S04 and twice with 10% aq. Na,CO, The solution was dried and the solvent was 
evaporated to give N-(phenylmethoxycarbonyl)sarcosine N-(l-methylethyl)amide (2.5 g, 
92%) as an oflf-white solid. Mp 91 - 93°C.
!H NMR (CDCI3)
6  1.10 ( 6  H, br, (CHj^CH), 3.01 (3 H, s, Sar-H3), 3.89 (2 H, s, Sar-H2), 4.05 (1 H, m, 
(CH3)2CH), 5.16 (2 H, s, Ar-CH2), 5.7 (1 H, m, NH), 7.36 (5 H, br, Ar)
T.L.C. (C) Rf = 0.61
Sarcosine N-(l-methylethyI)amide hydrobromide (279)
N-(Phenylmethoxycarbonyl)sarcosine N-( 1 -methylethyl)amide (1.0 g, 3.8 mmol) was 
dissolved in a 30% solution of HBr in acetic acid (5.1 g, 18.9 mmol). After 1 h, the
xciv
reaction was quenched by addition of dry Et20  (75 ml). The mixture was allowed to 
stand at 4°C for 1 h. The precipitate was then collected by filtration to give sarcosine N- 
(l-methylethyl)amide hydrobromide (680 mg, 85%) as a buff solid. Mp 148 - 150°C.
'h NMR(CDC13)
8  1.17 ( 6  H, d, 7 = 6 .6  Hz, (CHj)2CH), 2.65 (3 H, t, 7  = 5.3 Hz, Sar-H3), 3.70 (2 H, t, 




2-(Phenoxymethyl)oxirane (284 mg, 1.9 mmol) was added to a solution of sarcosine N- 
(l-methylethyl)amide hydrobromide (400 mg, 1.9 mmol) and N,N-diisopropylethylamine 
(269 mg, 2.1 mmol) in ethanol and the resulting solution was stirred for 3 d. The solvent 
was evaporated and the residue was dissolved in C H ^  .The solution was washed with 
water and was then dried. The solvent was evaporated to give N-(2-hydroxy-3-phenoxy- 
propyl)sarcosine N-(l-methylethyl)amide (430 mg, 90%) as a yellow oil.
‘HNMR(CDC13)
8  1.16 ( 6  H, d, 7 =  6.7 Hz, (CHj)2CH), 2.40 (3 H, s, Sar-H3), 2.55 ( 1  H, dd, 7  = 1 2 .8 ,
3.3 Hz, NCHjCH), 2.67 (1 H, dd, 7  = 12.8, 9.2 Hz, NCHjCH), 3.89 (1 H, dd, 7  = 9.5,
6.4 Hz, OCHjCH), 3.99 (1 H, dd, 7  = 9.5, 4.0 Hz, OCHjCH), 4.07 (1 H, m, 
CH2CHCH2), 4.12 ( 1  H, m, (CH3)2CH), 6.89 (2 H, t, 7 =  7.9 Hz, Ar-2,6), 6.98 (1 H, t, 
7=  7.3 Hz, Ar-4), 7.29 (2 H, m, Ar-3,5)
T.L.C. (C) Rf=0.55 




N-(Phenylmethoxycaibonyl)sarcosine 2,4,5-trichlorophenyl ester (10.56 g, 26.25 mmol) 
was added to 4,9-dioxadodecane-1,12-diamine (2.14 g, 10.5 mmol), N,N-diisopropyl- 
ethylamine (2.98 g, 23.1 mmol) and DMAP (20 mg) in CH2CI2 (40 ml). The solution was 
stirred for 4 d. The solution was washed with 1 0 % aq. H2SO4 and with 1 0 % aq. Na2C0 3 . 
The solution was dried and the solvent was evaporated. Chromatography (CH2CI2 then 
CH2CI2 / MeOH 40:1) yielded N-(phenylmethoxycarbonyl)sarcosine N-(12-((N-phenyl- 
methoxycarbonyl)sarcosylamino)-4,9-dioxa-l,12-dodecanyl)amide (5.00 g, 78%) as a 
cream wax.
'H NMR (CDCIj)
8  1.56 (4 H, s, OCHjCHjCHjCHjO), 2.99 (3 H, s, Sar-H3), 3.37 ( 8  H, m, 2 x 
CHjCHiOCHj), 3.44 (4 H, br, 2 x CHjCHjOCHj), 5.14 (4 H, s, Sar-H2), 6.54 (2 H , br, 
2 x NH), 7.34 ( 1 0  H, br, Ar)
T.L.C. (C)Rf= 0.56 
MS (FAB+) 615 (M + H)
N-(Phenylmethoxycarbonyl)sarcosine N-(9-((N-phenylmethoxycarbonyl)sarcosyl- 
amino)nonyI)amide (286)
N-(Phenylmethoxycarbonyl)sarcosine 2,4,5-trichlorophenyl ester (6.33 g, 15.75 mmol) 
was added to nonane-1,9-diamine (l.OOg, 6.30 mmol), N,N-diisopropylethylamine 
(814 mg, 13.86 mmol) and DMAP ( 1 0  mg) in CHC12 (50 ml). The solution was stirred 
for 7 d. The solution was washed with 1 0 % aq. H2 S04 and with 10% aq. Na2C0 3 . The 
solution was dried and the solvent was evaporated. Chromatography (CH2C12 / MeOH 
40: 1) gave N-(phenylmethoxycarbonyl)sarcosine N-(9-((N-phenylmethoxycarbonyl)- 
sarcosylamino)nonyl)amide (3.25 g, 91%) as a white solid. Mp 80-83°C.
xcvi
’H NMR (CDC1,)
5 1.25 (10 H, s, NCH2CH2(CH2)5CH2CH2N)> 1.43 (4 H, br, NCH2CHj(CH2)5. 
CHjCHjN), 3.01 ( 6  H, s, 2 x Sar-Hj), 3.22 (4 H, m, NCHjCH^CH^sCHjOyNT), 3.91 
(4H, s, 2 x Sar-H2), 5 .16 (3 H, s, Ar-CH2), 5.85 (1 H, br, NH), 6.10 ( 1  H, br, NH), 7.35 
(10 H, s, Ar)
T.L.C. (C) Rf = 0.55
Sarcosine N-(9-(sarcosyIamino)nonyl)amide (287)
10% Palladium on charcoal (450 mg) was added to a solution of N-(phenylmethoxy- 
carbonyl)sarcosine N-(9-((N-phenylmethoxycarbonyl)sarcosylamino)nonyl)amide (2.26 g,
3.98 mmol) in MeOH (30 ml). The mixture was treated with hydrogen for 2 d and then 
filtered through Celite®. The solvent and MeOH washings were evaporated to give 
sarcosine N-(9-(sarcosylamino)nonyl)amide (1.19 g, 99%) as a white wax.
‘H NMR (CDClj)
8 1 . 2 3  ( 1 0  H ,  s ,  N C H j C H j C C H ^ C H j C H j N ) ,  1 . 3 8  ( 4  H ,  br, N C H 2C H 2 ( C H 2) 5.  
C H i C H 2N ) ,  2 . 2 2  ( 6  H ,  s ,  2  x S a r - H 3) ,  2 . 9 8  ( 4  H ,  s ,  2  x S a r - H 2) ,  3 . 0 5  ( 4  H ,  q, J  = 6 . 2  
H z ,  N C H 2C H 2( C H 2) 5C H 2C H 2N ) ,  7 . 7 4  ( 2  H ,  br, 2  x  N H )
T.L.C. (C)Rf=0.14
l,14-Bis(oiiranylmethoxy)-3,6,9,12-tetraoxatetradecane (289)
Tetrabutylammonium hydroxide (40% w/v in water, 162 mg, 0.25 mmol) was added to a 
mixture of chloromethyloxirane (6.75 g, 75 mmol), NaOH (3.0 g, 7 mmol) and water 
(0.3 ml). Penta(ethylene glycol) (3,6,9,12-tetraoxatetradecane-l,14-diol) (2.98 g, 
12.5 mmol) was added dropwise to this stirred solution. The solution was heated at 40°C 
for 40 min. The suspension was then filtered and the organic layer was diluted with 
CHjC^.The solution was dried and the solvents were evaporated to give 1,14- 




8  2.62 (2 H, dd, J  = 5.1, 2.8 Hz, 2  x oxirane 3-H), 2.80 (2 H, t,J =  4.2 Hz, 2  x oxirane 
3-H), 3.17 (2 H, m, 2  x oxirane 2-H), 3.42 (2 H, dd, J  = 11.5, 5.7 Hz, 2 x OCHz- 
oxirane), 3.66 (20 H, 5 x 0CH2CH20), 3.81 (2 H, dd, J  = 11.5, 2.9 Hz, 2 x OCfcb- 
oxirane)
PEG-400 bis(oxiranylmethyl ether) (291)
Method 1
PEG-400 (5.00 g, 12.5 mmol) was added dropwise to a stirred solution of chloromethyl- 
oxirane (6.75 g, 75 mmol), NaOH (3.00 g, 7.5 mmol), tetrabutylammonium hydroxide 
(40% in water, 0.162 g) and water (0.3 ml). The suspension was heated at 65°C for 2 h. 
The cooled suspension was filtered and the solids were washed with CH2CI2 . The 
combined filtrate and washings were dried and the solvent was evaporated to afford 
PEG-400 bis(oxiranylmethyl ether) (4.24 g, 6 8 %)
‘H NMR (CDClj)
8  2.59 ( 2  H, dd, J  = 5.1, 2.4 Hz, 2  x oxirane 3-H), 2.78 (2 H, t, J  = 5.0 Hz, 2 x oxirane 
3-H), 3.15 ( 2  H, m, 2  x oxirane 2-H), 3.40 (2 H, dd, J  = 11.7, 5.8 Hz, 2 x OClfc- 
oxirane), 3.66 (35 H, 9 x 0CH2CH20), 3.78 (2 H, dd, J  = 11.5, 2 . 9  Hz, 2  x OClfc- 
oxirane)
PEG-400 bis(oxiranylmethyl ether) (291)
Method 2
PEG-400 (5.00 g, 12.5 mmol) was added dropwise to a stirred solution of chloromethyl- 
oxirane (6.75 g, 75 mmol), NaOH (3.00 g, 7.5 mmol) and water (0.3 ml). The suspension 
was heated at 65°C for 2 h. The cooled suspension was filtered and the solids were 
washed with CH2CI2 . The combined filtrate and washings were dried and the solvent was 
evaporated to afford PEG-400 bis(oxiranylmethyl ether) (4.49 g, 71%). This material was 
spectroscopically identical to the material prepared by Method 1.
xcviii
Macrocyde derived from sarcosine N-(9-(sarcosyIamino)nonyI)amide and PEG-400 
bis(oxiranylmethyl ether) (292)
Sarcosine N-(9-(sarcosylamino)nonyl)amide (500 mg, 1.66 mmol) and PEG-400 
bis(oxiranylmethyl ether) (806 mg, 1 . 6 6  mmol) were heated at reflux in ethanol ( 1 0  ml) 
for 15 h. The solution was allowed to cool and the solvent was evaporated to give the 
macrocycle (1.30 g, 99%).
*H NMR (CDC13)
6  1.29 (10 H, s, NCH2CH2(CH2)5CH2CH2N), 1.49 (4 H, br, NCH2CH2(CH2)5. 
CH2CH2N), 2.34 ( 6  H, s, 2  x Sar-H3), 2.42 (2 H, dd, J = 13, 4 Hz, 2 x NCH2CHOH),
2.50 (2 H, dd, J = 13, 8  Hz, 2 x NCH2CHOH), 3.05 (2 H, d, J = 16 Hz, Sar-H2), 3.10 (2 
H, d, J = 16 Hz, Sar-H2), 3.23 (4H, q ,J - 7 Hz, NCHjCH^CH^CHzCHjN), 3.35-3.55 
(4 H, m, 2 x OCHhCHOH), 3.62 (35 H, br, 9 x 0CH2CH20), 3.91 (2 H, m, 2 x CHOH), 
7.45 (2 H, br, NH)
MS (electrospray +) 915 (M + H, (CH2CH20)n), 871 (M + H, (CH2CH2O)i0), 827 
(M + H, (CH2CH20 )9), 783 (M + H, (CH2CH20 )8), 739 (M + H, (CH2CH20 )7), 695 
(M + H, (CH2CH20 )6), 651 (M + H, (CH2CH20 )5)
PEG-1500 bis(oxirany!methyl ether) (294)
PEG-1500 (20.0 g, 13.3 mmol) was added dropwise to a stirred solution of chloro- 
methyloxirane (14.37 g, 160 mmol), NaOH (3.20 g, 8.0 mmol) and water (0.31 ml). The 
suspension was heated at 65°C for 3 h. The cooled suspension was filtered and the solids 
were washed with CH2C12. The combined filtrate and washings were dried and the solvent 
was evaporated to afford PEG-1500 bis(oxiranylmethyl ether) (16.33 g, 76%).
'HNMRftCDjkSO)
5 2.52 (2 H, dd, J  -  5.1, 2.7 Hz, 2 x oxirane 3-H), 2.71 ( 2 H , t , 7  = 5.0 Hz, 2 x oxirane
3-H), 3.08 (2 H, m, 2 x oxirane 2-H), 3.24 (2 H, dd, J  = 11.5, 5.1 Hz, 2 x OCKb- 
oxirane), 3.66 (135 H, 34 x 0CH2CH20), 3.69 (2 H, dd, 7 =  11.5, 2.6 Hz, 2  x OCHz- 
oxirane).
xcix
Gel Perm eation  C hrom atography : C om pound 292
Analysis performed by Dr G Price, School o f  Chemistry, University o f  Bath
Param eters
Bruker LC21/41 GPC System
THF eluent 1 ml min'1
‘PL G el’ (Polymer Laboratories Ltd) 60 cm mixed bed column
75 pi o f  0.01%  solution injection volume
SUMMARY REPORT Date : 30/08/94 Time : 08:03
Chromatoqram PH-C19 Sample Id. :
Baseline Mode T rapezoida1
Baseline drawn from 15.50 to 19.95 (min)
Integration from 15.58 to 19.93 (min)
Total Area 8.0522E+05 Mr. data points : 522





Polydispers.it-' (D) I . 298
Results calculated using calibration Mode : Mar-row Standard
Data handling file MATT Mark- Houwinfc onstants :
Calibration file 8-94 K = 1.000000 a = 0 .00
Fit Type Cubic Ret. qf Ref- -"eak : 0 .00
Cost1 1 r i on ts Ret. Window Peak : 0 .00
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(2-(N-(phenylmethoxycarbonyl)sarcosylamino)ethyl)amide (500 mg, 0.59 mmol) was 
heated to 60°C in MeOH (30 ml). Palladium on charcoal (67 mg) was added to the 
stirred solution and the reaction mixture treated with hydrogen. After 30 h, the 
suspension was filtered and the solvent was evaporated from the filtrate to give N-(N-(N- 
(N-sarcosylglycyl)phenylalanyl)leucyl)glycineN-(2-(N-sarcosylamino)ethyl)amide 
(332 mg, 98%) as a colourless oil.
'H NMR ((CD^SO) 20°C
8 0.93 (3 H, d. J =  6.2 Hz, Leu-H3), 0.99 (3 H, d, J=  6.2 Hz, Leu-Hj), 1.55 (3 H, m, 
Leu y-H + Leu P-H2), 2.97 (1 H, m, Phe P-H2), 3 .11 (1 H, m, Phe P-H2), 3.16 (6 H, s, 2 
x Sar-H3), 3.27 (4 H, br, NCH2CH2N), 3.48 (4 H, br, 2 x Sar-H2), 3.68-3.85 (4 H, m, 2 
x Gly-H2), 4.28 (1 H, m, a-H), 4.62 (1 H, br, a-H), 7.34 (10 H, m, Ar), 7.86 (1 H, m, 
NH), 8.03 (1 H, m, NH), 8.16 (2 H, m, NH), 8.23 (1 H, m, NH), 8.34 (1 H, m, NH)
*H NMR ((CD3)2SO) 80°C
8 0.85 (3 H, d, J  = 6.4 Hz, Leu-Hj), 0.89 (3 H, d, J  = 6.2 Hz, Leu-Hj), 1.43 (1 H, m, 
Leu y-H), 1.53 (2 H, m, Leu P-H2), 2.86 (2 H, m, Phe P-H2), 3.05 (3 H, s, Sar-H3), 3.08 
(3 H, s, Sar-H3), 3.19 (4 H, br, NCH2CH2N), 3.57-3.82 (8 H, m, 2 x Sar-H2 + 2 x 
Gly-H2), 4.25 (1 H, m, a-H), 4.55 (1 H, br, a-H), 7.22 (10 H, m, Ar), 7.55 (1 H, br, 
NH), 7.69 (2 H, br, NH), 7.87 (3 H, br, NH).
T.L.C. (C) Rf = 0.05
Polymerisation of N-(N-(N-(N-sarcosyl)glycyl)phenylalanyl)leucyl)glycine N-(2-(N— 
sarcosylamino)ethyl)amide and PEG-1500 bis(oxiranylmethyl ether) (296)
N-(N-(N-(N-sarcosyl)glycyl)phenylalanyl)leucyl)glycine N-(2-(N-sarcosylamino)ethyl)- 
amide (120 mg, 0.21 mmol), and PEG-1500 bis(oxiranylmethyl ether) (312 mg, 
0.21 mmol) were heated at reflux in ethanol (5 ml) for 48 h. The solution was allowed to
cool and the solvent was evaporated to give a colourless gum. Samples of the crude 
product were taken for GPC analysis.
Na-Sarcosyl-Ns-(6-(N,-(4-(10,15,20-triphenyl-21//,23iy-porphin-5-yl)phenyl)- 




amino)ethyl)amide (150 mg, 0.11 mmol) was dissolved in acetic acid (2 ml). HBr in 
acetic acid (30%) (1 ml) was added and the solution was stirred for 45 min. The salt was 
precipitated by addition of ether (20 ml). The solid was washed four times with ether and 
was then collected by filtration. The solid was dried under reduced pressure in the 
presence of NaOH to give Na-sarcosyl-Ne-(6-(N,-(4-( 10,15,20-triphenyl-2\H,23H- 
porphin-5-yl)phenyl)ureido)hexanoyl)lysine N-(2-(N-sarcosylamino)ethyl)amide tetra­
hydrobromide (151 mg, 97%) as a dark green glass.
'HNMR((CDj)2SO)
8 -0.60 (2 H, br, 21,22,22,24-H2), -0.38 (2 H, br, 21,22,22,24-H2), 1.2-1.8 (12 H, m, Lys 
P.y.S-Hj + NCHjCHjCiLCHjCHj), 2.12 (2 H, m, NCHjCHjCHjCHjCHj), 2.56 (6 H, 
m, 2 x Sar-Hj), 3.05 (2 H, m, NCH2CH2CH2CH2CH2) 3.19 (6 H, Lys s-H2 + 
NCH2CH2N), 3.70 (2 H, t , J=  5.5 Hz, Sar-H2), 3.78 (2 H, m, Sar-H2), 4.24 (1 H, m, Lys 
a-H), 7.80 (11 H, m, 3 x Ph 3,4,5-H3 + disubstituted aromatic), 8.05-8.30 (15 H, br, 
disubstituted aromatic 2,3,5,6-Ri + 3 x Ph 2,6-H2, + 5 x NH), 8.59 (1 H, br, NH), 8.6- 
8.9 (12 H, br, 2,3,7,8,12,13,17,18-YU + 2 x NH;,*)
UV (MeOH + N,N-diisopropylethylamine) X 406 (Soret), 512, 549, 590, 645
Polymerisation of N“-(N-sarcosyl)-Ne-(6-(N,-(4-(10,15,20-triphenyl-21/f,23//- 
porphin-5-yl)phenyl)ureido)hexanoyl)Iysine N-(2-(N-sarcosylamino)ethyI)amide 
and PEG-1500 bis(oxiranylmethyl ether) (298)
N“-(N-sarcosyl)-Ns-(6-(N’-(4-( 10,15,20-triphenyl-21 //,23//-porphin-5 -yl)phenyl)ureido)- 
hexanoyl)lysine N-(2-(N-sarcosylamino)ethyl)amide tetrahydrobromide (100 mg, 
0.08 mmol), K2CO3 (0.35 mmol) PEG-1500 bis(oxiranylmethyl ether) (105 mg, 
0.07 mmol) were heated at reflux in ethanol (5 ml) for 48 h. The suspension was allowed 
to cool and was then filtered. The solvent was evaporated from the filtrate and washings 
to give a purple gum. Samples of the crude product were taken for GPC analysis.
*HNMR(CDC13)




Na-Sarcosyl-N*-(6-(N’-(4-( 10,15,20-triphenyl-2 l//,23//-porphin-5-yl)phenyl)ureido)- 
hexanoyl)lysine N-(2-(N-sarcosylamino)ethyl)amide tetrahydrobromide ( 1 0 0  mg, 
0.08 mmol) was dissolved in an excess of conc. aq. HC1 to form the hydrochloride salt. 
The solvent and excess reagent were evaporated and the residue was dissolved in DMF 
(10 ml). Manganese (II) chloride (10 mg, 0.08 mmol) was added and the suspension was 
heated at reflux for 24 h. A further portion of manganese (II) chloride was added (10 mg,
0.08 mmol) and heating continued. After a further 24 h, the suspension was filtered and 
the solvent was evaporated. The residue was dissolved in CHCI3 . The solution was 
washed with water and with aq. Na2CC>3 and was then dried. The solvent was evaporated 
to give iS'-chloro-(5-(4-(N,-(6-oxo-6-( 1 -oxo-2-(sarcosylamino)-1 -(2-(sarcosylamino)-
ethylamino)hexylamino)hexyl)ureido)phenyl)-10,15,20-triphenylporphinato)manganese 
(ID) (51 mg, 57%) as a dark green-brown gum.




Ns-(6-Oxo-6-(2-oxo-2-(4-( 10,15,20-triphenyl-2 l//,23//-porphin-5-yl)phenylamino)ethyl- 
amino)hexyl)-Na-(N-(phenylmethoxycarbonyl)sarcosyl)glutamine N-(2-(N-(phenyl- 
methoxycarbonyl)sarcosylamino)ethyl)amide (300 mg, 0.22 mmol) was dissolved in 
acetic acid (4 ml) and 30% HBr in acetic acid (2 ml). The solution was stirred for 1 h. 
Ether (40 ml) was added and the salt precipitated. The salt was washed four times with 
ether (40 ml), collected by filtration and then dried under reduced pressure in the 
presence of NaOH to give N5-(6-oxo-6-(2-oxo-2-(4-( 10,15,20-triphenyl-2\H,23H- 
porphin-5-yl)phenylamino)ethylamino)hexyl)-Na-(N-sarcosyl)glutamine N-(2-(N-
sarcosylamino)ethyl)amide tetrahydrobromide (260 mg, 94%) as a dark green glass.
'H NMR ((CD3)2SO)
8 -0.30 (2 H, br, 21,22,23,24-H2), -0.26 (2 H, br, 21,22,23,24-H2), 1.34 (2 H, m, 
NCH2CH2CH2CH2CH2), 1.45 (2 H, m, NCH2ClfcCH2CH2CH2), 1.58 (2 H, 
NCH2CH2CH2CH2CH2), 1.70-1.95 (2 H, m, Glu P-H2), 2.12 (2 H, m, Glu y-H2), 2.25 
(2H .ni, NCHjCHjCHjCHjCIi), 2.57 (6 H, t, J=  5.3 Hz, 2 x Sar-Hj), 3.06 (2 H, m, 
NCHjCHjCHjCHjCHj), 3.18 (4 H, br, NCH2CH2N), 3.7-4.02 (6 H, m, 2 x Sar-H2 + 
Gly-H2), 4.24 (1 H, m, Glu a-H), 7.82 (11 H, m, 3 x Ph 3,4,5-H3 + disubstituted 
aromatic), 8.00-8.35 (15 H, br, disubstituted aromatic 2,3,5,6-H4 +3 x Ph 2,6-H2, + 5 x  
NH), 8.51 (1 H, br, NH), 8 6-8.9 (12 H, br, 2,3,7,8,12,13,17, 18-Ha + 2 x NH2+)





N5-(6-Oxo-6-(2-oxo-2-(4-( 10,15,20-triphenyl-2 l//,23//-porphin-5-yl)phenylamino)ethyl- 
amino)hexyl)-Na-(N-sarcosyl)glutamine N-(2-(N-sarcosylamino)ethyl)amide tetrahydro­
bromide (277 mg, 0.22 mmol) and manganese (II) chloride (275 mg, 2.2 mmol) were 
heated at reflux in DMF for 2 h. The suspension was cooled and then filtered. The solvent 
was evaporated from the filtrate and the residue redissolved in CHCb. The solution was 
washed with Na2C0 3  and then dried. The solvent was evaporated to give 5-chloro-(5-(4- 
((N-(6-( 1 -oxo-2-(sarcosylamino)-1 -(2-(sarcosylamino)ethylamino)pentanoylamino)- 
hexanoyl)glycyl)amino)phenyl)-10,15,20-triphenylporphinato)manganese (IE) (190 mg, 
72%) as an dark green-brown glass.
UV (MeOH) X 467 (Soret), 564, 598
cv
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4 - N i t r o p h e n y l  A / - l 4 - ( 1 0 , 1 5 . 2 0 - t r i p h e n y l p o r p h y r i n - 5 - y l ) p h e n y l ] c a r b a m a t e  a n d
5 - ( 4 - ( / V - g l y c y l a m i n o ) p h e n y l ) - 1 0 , 1 5 , 2 0 - t r i p h e n y l p o r p h y r i n  h a v e  b e e n  s y n t h e s i s e d  f r o m  a  r e a d i l y  p r e p a r e d  
m o n o f u n c t i o n a l i s e d  p o r p h y r i n ;  t h e y  c o u p l e  e f f i c i e n t l y  w i t h  t h e  s i d e - c h a i n s  o f  e x t e n d e d  l y s y l  a n d  g l u t a m y l  p e p t i d e  
d e r i v a t i v e s ,  r e s p e c t i v e l y .
P o r p h y r i n s  a l o n e  o r  l i n k e d  t o  p o l y m e r s  a n d  o t h e r  t a r g e t i n g  
m o i e t i e s  h a v e  i m p o r t a n t  r o l e s  i n  d i a g n o s i s  a n d  t h e r a p y  o f  
c a n c e r .  F o r  e x a m p l e ,  t h e  s o - c a l l e d  ‘ h a e m a t o p o r p h y r i n  d e r i v a ­
t i v e '  a n d  o t h e r  p o r p h y r i n s  a c t  a s  p h o t o s e n s i t i s e r s  f o r  c o n v e r s i o n  
o f  t r i p l e t  o x y g e n  t o  s i n g l e t  o x y g e n  i n  p h o t o d y n a m i c  t h e r a p y 1 
a n d  p o r p h y r i n s  a r e  k n o w n  t o  a c c u m u l a t e  s e l e c t i v e l y  i n  s o m e  
t y p e s  o f  t u m o u r  t i s s u e . 2  l e a d i n g  t o  p r o s p e c t s  o f  t h e i r  u s e  a s  
t a r g e t t i n g  g r o u p s .  P o r p h y r i n a t o m a n g a n e s e  c o m p l e x e s  a r e  u s e d  
a s  c o n t r a s t - e n h a n c i n g  a g e n t s  i n  m a g n e t i c  r e s o n a n c e  i m a g i n g  
( M R I ) ,  o w i n g  t o  t h e i r  h i g h  m o l a r  r e l a x i v i t i e s  i n  a q u e o u s  
s o l u t i o n . 3  A t t a c h m e n t  o f  m e t a l l o p o r p h y r i n  a n d  o t h e r  a g e n t s  t o  a  
s o l u b l e  p o l y m e r  e n h a n c e s  m o l a r  r e l a x i v i t y  a n d  t h u s  e f f e c t i v e ­
n e s s  a s  a  M R I  c o n t r a s t  a g e n t . 4
S i g n i f i c a n t  d i f f i c u l t y  i n  p r e p a r i n g  m o n o - f u n c t i o n a l i s e d  p o r ­
p h y r i n s  i n  a  c o n t r o l l e d  m a n n e r  i s  c a u s e d  b y  t h e  f a c t  t h a t  t h e  
m o s t  r e a d i l y  a v a i l a b l e  n a t u r a l l y - o c c u r r i n g  p o r p h y r i n s ,  s u c h  a s  
p r o t o p o r p h y r i n  I X  a n d  m e s o p o r p h y r i n  I I ,  c a r r y  m o r e  t h a n  o n e  
i d e n t i c a l  e l e c t r o p h i l i c  o r  n u c l e o p h i l i c  f u n c t i o n a l  g r o u p .  T h e  
c l a s s i c a l  A d l e r - R o t h e m u n d 5  p r o c e d u r e  f o r  s y n t h e s i s  o f  meso- 
t e t r a a r y l p o r p h y r i n s  f r o m  a r y l a l d e h y d e s  a n d  p y r r o l e  p r o c e e d s  i n  
< 2 0 %  y i e l d  a n d  m o n o - A r - f u n c t i o n a l i s e d  p o r p h y r i n s  a r e  o n l y  
o b t a i n e d  i n  v e r y  l o w  y i e l d s  b y  s e p a r a t i o n  o f  s t a t i s t i c a l  m i x t u r e s  
o f  p o r p h y r i n s  f o r m e d  f r o m  m i x t u r e s  o f  a l d e h y d e s , 6  w h e r e a s  t h e  
r e c e n t l y - r e p o r t e d  H e c k  c o u p l i n g 7  n e e d s  s e v e r a l  s y n t h e t i c  s t e p s  
t o  p r e p a r e  t h e  s t a r t i n g  5 , 1 5 - d i p h e n y l - 1 0 - i o d o p o r p h y r i n  T o
o b v i a t e  t h e s e  p r o b l e m s  o f  s y n t h e s i s  o f  m o n o - A r - s u b s t i t u t e d  
t e t r a p h e n y l p o r p h y n n s ,  K r u p e r  et al*  d e v e l o p e d  a n  e f f i c i e n t  
m o n o n i t r a t i o n  a n d  s u b s e q u e n t  r e d u c t i o n  o f  t h e  r e a d i l y - a v a i l a b l e  
m c j o - t e t r a p h e n v l p o r p h y r i n .  W e  n o w  r e p o r t  o u r  e x p l o i t a t i o n  o f  
t h i s  w e a k l y  n u c l e o p h i l i c  a m i n e  i n  g e n e r a t i n g  r e a c t i v e  e l e c t r o ­
p h i l i c  a n d  n u c l e o p h i l i c  m o n o f u n c t i o n a l  p o r p h y r i n s  f o r  a t t a c h ­
m e n t  t o  s i d e - c h a i n  e x t e n d e d  a . o j - b i s ( m e t h y l a m i n o )  p e p t i d e s .  
P o l y m e r s  d e r i v e d  f r o m  t h e  l a t t e r  w i l l  b e  o f  u s e  i n  M R I .
a , u } - B i s [ b e n z y l o x y c a r b o n y l ( m e i h y l ) a m i n o ]  p e p t i d e s  w i t h  
c a r b o x y l i c  a c i d  d e r i v a t i v e s  a n d  p r i m a r y  a m i n e s  i n  s i d e - c h a i n s  
o f  t h e  s a m e  l e n g t h  w e r e  b u i l t  u p  a s  s h o w n  i n  S c h e m e  1 .  N- 
( B e n z y l o x c a r b o n y l ) s a r c o s i n e  l 9  w a s  c o n v e r t e d  t o  i t s  p e n t a -  
f i u o r o p h e n y l  ( P F P )  a c t i v e  e s t e r  2 t  a n d  t h i s  w a s  a d d e d  t o  a  
2 0 - f o l d  e x c e s s  o f  e t h a n e - 1 , 2 - d i a m i n e  t o  s e t  u p  t h e  p r o t e c t e d  
s a r c o s i n e  a m i n o e i h y l a m i d e  3 t  a s  t h e  s e q u e n c e  i n v e r t i n g  u n i t  f o r  
t h e  C - t e r m i n i  o f  t h e  p e p t i d e s .
O r t h o g o n a l  p r o t e c t i o n  o f  t h e  a -  a n d  e - a m i n e s  o f  L - l y s i n e  4  
w a s  r e q u i r e d  f o r  e l a b o r a t i o n  o f  t h e  p e p t i d e  c h a i n  a n d  o f  t h e  s i d e -  
c h a i n .  T h i s  w a s  a c h i e v e d  b y  c o m p l e x a t i o n  w i t h  c o p p e r f u ) .  
s e l e c t i v e  a c y l a t i o n  o f  t h e  e - a m i n e  w i t h  2 , 2 , 2 - t r i c h l o r o e t h y l  
c h l o r o f o r m a t e ,  d e c o m p l e x a t i o n  a n d  a c y l a t i o n  o f  t h e  a - a m i n e  
w i t h  d i - r m - b u t y l  d i c a r b o n a t e  i n  a  t w o - p h a s e  s y s t e m ,  i n  a  
m o d i f i c a t i o n  o f  t h e  m e t h o d  o f  Y a j i m a  et al.'° T h e  r e s u l t i n g  
B o c L y s ( T r o c ) O H  5 t  w a s  c o n v e n e d  t o  t h e  P F P  a c t i v e  e s t e r  6 , t  
p r i o r  t o  c o u p l i n g  w i t h  3  t o  a f f o r d  t h e  f u l l y  o n h o g o n a l l y
tn
ZMeN COR
1 R = OH
2 R = OCcFs
3 R = NHCH2CH2NH2
NHR'
r 2h n  c o r 3
,—  4 R ' = R2 = H, R3 = OH 
p r r  5 R ' = Troc R2 = Boc. R3 : 





I—  7 R’ = Troc, R2 = Boc 
r r  8 R1 = Troc. R2 = H-HCI '
' 9 R ’ = Troc. R2 = ZMeNCH2CO
~ r  10 R’ = H. R2 = ZMeNCH2CO 
L I  11 R’ = CO(CH2)sNHBoc, R2 = ZMeNCH2CO 
LI 12 R’ = CO(CH2)5NH2-HCI, R2 = ZMeNCH2CO
COR’
BocHN COR2
r—  13 R ’ = OCeFj. R2 = OBn 
 ----  14 R ' = NH(CH2)sC 0 2Me. R2 = OBn
15 R ’ = NH(CH2)s . R2 = OH





17 R’ = OMe. R2 = Boc
18 R’ = OMe. R2 = H-HCI
19 R1 = OMe. R2 = ZMeNCH2CO
20 R’ = NHNH2. R2 = ZMeNCH2CO
21 R> = N3. R2 = ZM eN CH ^O
Scheme 1 Synthesis of extended sequence-inverted pepudes 12 and 21. Troc = 2.2.2-inchloroethoxycarbonyl Reagents and conditions:tt i. C6FsOH. DCC. 
EtOAc. 0 °C, 20 h, 90-95%; li. H2NCH2CH2NH2 (20 x excess). CH2CI2. 3 h. 82%. ii.. CuCOj. H:0. reflux. 3 h. then TrocCI. Na2CO,. H,0. 0 °C. 20 h; 
iv, Na*, EDTA2-. H20 . refiux. 2 h; v. BocjO. Et,N. H20 , dioxan. 3 d. 58% from 4; vi. 3. Pr2 NEt. CH2CI2. 85%. v„. HC1. CH2C12. 1 h. quant.; viii. 2. Pr j^NEi. 
DMAP. CHjCU. 4 d. 87%, ix. Zn. MeOH. reflux. 5 h. 83%; x. BocNH(CH2)5C02C*F5. Pr,NEi DMAP. CH2CI2. 6 d. 55%. xi. H2N(CH2)sC 02Me HCI, 
Pr2NEt. DMAP. C H jC Ij. 7 d. 89%; xii. H2. Pd/C. teirahydrofuran. 3 h. quant; xiii. NjK, H20 . MeOH. 40 °C. 8 h. quant; xiv. Bu'ONO. DMF. THF. dioxan. 
HCI. —20 °C. 50 min. then Pr2NEt. —60 °C (this solution was taken forward for reaction with 27. Scheme 2).
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p r o t e c t e d  i n v c n e d - s e q u e n c c  p e p t i d e  7 . t  T h e  p e p t i d e  c h a i n  w a s  
c o m p l e t e d  b y  a c i d i c  r e m o v a l  o f  t h e  B o c  g r o u p ,  g i v i n g  t h e  s a l t  
8 . t  a n d  a c y l a t i o n  w i t h  o n e  f u r t h e r  e q u i v a l e n t  o f  2 .  W i t h  t h e  
i n v e r t e d  s e q u e n c e  o f  t h e  p e p t i d e  n o w  c o m p l e t e ,  a t t e n t i o n  w a s  
t u r n e d  t o  e x t e n s i o n  o f  t h e  l e n g t h  o f  t h e  s i d e - c h a i n  o f  9  +  T h e  e -  
a n t i n e  1 0 +  w a s  r e v e a l e d  b y  s e l e c t i v e  r e d u c t i v e  r e m o v a l  o f  t h e  
T r o c  g r o u p  ( z i n c  d u s t  i n  m e t h a n o l ) .  A c y l a t i o n  w i t h  p e n t a -  
f l u o r o p h e n y l  b - f / m - b u t o x y c a r b o n y l a m i n o j h e x a n o a l e 1 1 g a v e  
t h e  o r t h o g o n a l l y  p r o t e c t e d  p e p t i d e  d e r i v a t i v e  1 1 . 1  D e p r o t e c t i o n  
( H C I )  a f f o r d e d  t h e  t a r g e t  i n v e n e d - s e q u e n c e  p e p t i d e  1 2 +  w i t h  
t h e  e x t e n d e d  p r i m a r y  a m i n e  s i d e - c h a i n  f o r  c o u p l i n g  w i t h  a n  
a p p r o p r i a t e  m o n o f u n c t i o n a l  p o r p h y r i n  e l e c t r o p h i l e .
I n  t h e  a s s e m b l y  o f  a  c o r r e s p o n d i n g  i n v e n e d - s e q u e n c e  
p e p t i d e  w i t h  a n  e x t e n d e d  a c t i v a t e d  c a r b o x y l i c  a c i d  s i d e - c h a i n ,  
t h e  e x t e n s i o n  w a s  p e r f o r m e d  p r i o r  t o  c o n s t r u c t i o n  o f  t h e  p e p t i d e  
t o  a v o i d  p r o b l e m s  o f  f o r m a t i o n  o f  p y r o g l u t a m a t e s .  A c y l a t i o n  o f  
t h e  s p a c e r  u n i t ,  m e t h y l  6 - a m i n o h c x a n o a t e ,  w i t h  B o c  g l u t a m i c  
a c i d  a - b e n z y l  e s t e r  ' / - P F P  e s t e r  I 3 1 3  g a v e  t h e  e x t e n d e d  
d e r i v a t i v e  1 4  +  T h e  o - c a r b o x y i i c  a c i d  1 5 +  w a s  r e v e a l e d  b y  
s e l e c t i v e  h y d r o g e n o l y s i s  o f  t h e  b e n z y l  e s t e r .  I n  a  s e r i e s  o f  s t e p s  
s i m i l a r  t o  t h o s e  u s e d  f o r  b u i l d i n g  t h e  i n v e n e d - s e q u e n c e  l y s i n e  
p e p t i d e ,  t h i s  c a r b o x y l i c  a c i d  w a s  a c t i v a t e d  a s  t h e  P F P  e s t e r  1 6 +  
a n d  c o u p l e d  w i t h  t h e  s e q u e n c e - i n v e r t i n g  u n i t  3  t o  a f f o r d  1 7 . +  
A g a i n ,  s e l e c t i v e  a c i d o l y t i c  d e p r o t e c t i o n  r e v e a l e d  t h e  G l u  o r -  
a m i n e  1 8  C o u p l i n g  w i t h  3  a f f o r d e d  t h e  t a r g e t  i n v e n e d -
s e q u e n c e  p e p t i d e  1 9 +  w i t h  t h e  e x t e n d e d  c a r b o x y l i c  a c i d  s i d e -  
c h a i n  p r o t e c t e d  a s  t h e  m e t h y l  e s t e r .  T h i s  e s t e r  r e s i s t e d  s e l e c t i v e  
h y d r o l y s i s  u n d e r  b o t h  b a s i c  a n d  a c i d i c  c o n d i t i o n s  b u t  s u c ­
c u m b e d  t o  h y d r a z i n o l y s i s ,  g i v i n g  t h e  h y d r a z i d e  2 0  +  F r o m  t h i s ,  
t h e  a c y l  a z i d e  2 1  +  +  w a s  f o r m e d  b y  r e a c t i o n  w i t h  r e / 7 - b u t y l  
n i t r i t e  u n d e r  a c i d i c  c o n d i t i o n s ,  o t h e r  n i t r o s a t i n g  a g e n t s  (e.g. 
s o d i u m  n i t r i t e )  b e i n g  c i t h e r  i n e f f i c i e n t  o r  d e s t r u c t i v e .  T h i s  
p r o v i d e s  a n  a c t i v e  a c y l a i i n g  f u n c t i o n  f o r  r e a c t i o n  w i t h  a n  
a p p r o p r i a t e  p o r p h y r i n  n u c l e o p h i l e
T h e  m o n o a m i n o p h e n y l p o r p h y r i n  2 4  w a s  p r e p a r e d  i n  4 6 %  
o v e r a l l  y i e l d  i n  t w o  s t e p s  f r o m  m e s o - t e t r a p h e n y l p o r p h y r i n  2 2 ,  
i n  a  m o d i f i c a t i o n  o f  ( h e  m e t h o d  o f  K r u p e r  era/  ( S c h e m e  2 ) . 8  
T h e  c o r r e s p o n d i n g  i s o c y a n a t e  w o u l d  r e p r e s e n t  a  p o t e n t  e l e c t r o ­
p h i l e  f o r  r e a c t i o n  w i t h  t h e  e x t e n d e d  l y s i n e  d e r i v a t i v e  1 2  b u t  2 4  
r e a c t e d  s l o w l y  w i t h  p h o s g e n e ,  g i v i n g  m a i n l y  t h e  c o r r e s p o n d i n g  
A f A — b i s r i e i r a p h e n y l p o r p h y r i n y O u r e a .  H o w e v e r ,  t h e  a m i n e  2 4  
w a s  a c y l a t e d  s m o o i h l y §  b y  4 - m t r o p h e n y l  c h l o r o f o r m a t e ,  g i v i n g  
t h e  c a r b a m a t e  2 5 ,  a  s y n t h o n  f o r  t h e  r e q u i r e d  i s o c y a n a t e  
T r e a t m e n t  o f  2 5  u n d e r  m i l d l y  b a s i c  c o n d i t i o n s  g e n e r a t e d  t h e  
i s o c y a n a t e  w h i c h  c o u p l e d  in suu§ w i t h  t h e  e x t e n d e d  l y s i n e  
d e r i v a t i v e  1 2 ,  g i v i n g  t h e  p r o t e c t e d  p o r p h y r i n v l  p e p t i d e  d e r i v a ­
t i v e  2 8 ^ j  i n  g o o d  y i e l d .
T h e  a r y l a m i n e  2 4  w a s  f o u n d  t o  b e  a  r e m a r k a b l y  w e a k  
n u c l e o p h i l e ,  r e a c t i n g  w i t h  s u c c i n i c  a n h y d r i d e  o n l y  a f t e r  a  
p r o l o n g e d  p e r i o d  a t  e l e v a t e d  t e m p e r a t u r e  a n d  n o t  r e a c t i n g  w i t h
A n h N -
- P h







22 R = H
23 R = N 0 2
24 R = NH2
25 R = NHCC^CfiHUNO? p
26 R = NHCOCH2NHBoc
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Scheme 2 Activation of teiraphenylporphyrinamine 24 as an clecirophilc and as a nucleophile, coupling with extended sequence-inverted peptides 12 and 
21. Reagents and conditions :tt i. fuming HNO,. CHCI,. 5 h. 55%. ii. SnCI>. cone aq HCI. 80 °C. 2 h. 84%; tii. 4-mtrophenyl chloroformate. PrsNEt. CHCI,. 
20 h. then chromatography. 67%; iv. BocGlyOQF,. PCjNEi. DMAP. CHCU. 46 h. 95%. v. HCI. C H jC Ij. I h. quam; vi. Pr-jNEi DMAP CHvCri 20h 82% 
vii; PrsNEt DMAP. CHCI,. 2 h. 58%
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p e p i i d e  a c t i v e  e s t e r s  o r  w i t h  t h e  a c y l  a z i d e  2 1  M u c h  g r e a t e r  
n u c l e o p h i l i c i t y  i s  r e q u i r e d  f o r  e f f i c i e n t  c o u p l i n g  w i t h  p e p i i d e  
d e r i v a t i v e s  u n d e r  m i l d  c o n d i t i o n s .  T o  i n t r o d u c e  a  p r i m a r y  
a l i p h a t i c  a m i n e  a s  a  m o r e  p o t e n t  n u c l e o p h i l e ,  t h e  a r y l a m i n e  w a s  
a c y l a t e d  b y  t r e a t m e n t | |  w i t h  a  t w o  f o l d  e x c e s s  o f  t h e  P F P  a c t i v e  
e s t e r  o f  N - B o c - g l y c i n e  a t  4 0  ° C ,  f o r m i n g  2 6 .  T h e  p r i m a r y  
a l i p h a t i c  a m i n e  2 7  w a s  r e v e a l e d  b y  d e p r o t e c t i o n | |  w i t h  h y d r o g e n  
c h l o r i d e .  T h i s  m o r e  r e a c t i v e  n u c l e o p h i l e  t h e n  c o u p l e d  e f f i  
c i e n l l y | |  w i t h  t h e  e x t e n d e d  p e p t i d e  d e r i v a t i v e  a c y l  a z i d e  2 1 .  
g i v i n g  t h e  p o r p h y r i n y l  p e p t i d e  d e r i v a t i v e  2 9 . * *
T h e  m o n o a m i n o t e t r a p h e n y l p o r p h y r i n  2 4  i s  t h u s  d e m o n ­
s t r a t e d  t o  b e  a  r e a d i l y  a c c e s s i b l e  m o n o f u n c t i o n a l i s e d  p o r p h y r i n  
w h i c h  c a n  b e  c o n v e r t e d  s t r a i g h t f o r w a r d l y  i n t o  a  r e a c t i v e  
e l e c t r o p h i l e  a n d  a  r e a c t i v e  u n h i n d e r e d  n u c l e o p h i l e  w h i c h  
s h o u l d  h a v e  g e n e r a l  u t i l i t y  i n  c o n t r o l l e d  a t t a c h m e n t  o f  p o r p h y ­
r i n s  t o  p e p t i d e s ,  p o l y m e r s  a n d  o t h e r  m o l e c u l e s .
W e  t h a n k  M r  R .  R .  H a r t e l l  a n d  M r  D .  W o o d  ( U n i v e r s i t y  o f  
B a t h )  f o i  N M R  s p e c t r a .  D r  J .  A .  B a l l a n t i n e  a n d  t h e  E P S R C  
M a s s  S p e c t r o m e t r y  C e n t r e  ( U n i v e r s i t y  C o l l e g e .  S w a n s e a )  f o r  
h i g h  r e s o l u t i o n  m a s s  s p e c t r a  a n d  S a n o f i  W i n t h r o p  P h a r  
m a c e u t i c a l s  f o r  f i n a n c i a l  s u p p o r t .  S .  E .  M .  h o l d s  a  U n i v e r s i t y  o f  
B a t h  R e s e a r c h  B u r s a r y .
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Footnotes
t All novel compounds were charactensed by 'H NMR and by FAB MS and 
were shown to be pure by TLC. Target compounds and major intermediates 
were also charactensed by high resolution FAB MS. 
i Acyl azide 21 was prepared and used without punfication. to avoid 
Curtius rearrangement.
§ M ethod: Compound 24 (5.70 g,9.25 mmol) was stirred with 4-nurophenvl 
chloroformate (1.86 g. 9.25 mmol) and PryNEi (1.19 g. 9.25 mmol) in 
CHCI 3 (50 cmJ) for 20 h. Chromatography gave 25 (4.85 g. 67*51) as a purple 
glass. Compound 12 (385 mg, 530 pmol) and 25 (520 mg. 670 pmol) were 
stirred with PrsNEt (205 mg. 1.6 mmol) and DMAP (10 mg) in CH2CI2 (10 
cm3) for 20 h Chromatography gave 28 (593 mg. 82%) as a purple glass 
) Spectroscopic data for 28 6 (CDCIj) -2.78 (2 H. s, porphynn 21. 23-H2).
I 2-17(10 H. m. Lys p. Y-H4 + NCH2CW2a y ;Ctf2CH2CO). 2 12 (2 H. br 
CHjCtf jCO). 2.93 (3 H, s. NCH}), 2.99 (3 H. s. NCHj). 3.0-3 3 (8 H. Lys 
e-H: + NC/fjCHjCHj + NCHjCHjN). 3.77 (2 H. m. Sar-H2). 3 86 (2 H. m. 
Sar'-Hj), 4.36 (I H. m. Lys a-H). 5.06 (3 H. s) and 5.07 (I H. s ) ( 2 x  
PhCHjO). 5.75 (1 H. br, NH). 5.83 (1 H. br. NH). 6.39 (I H. br. NH). 6.57 
(1 H, br. NH). 6.94(1 H. br. NH), 7.24 (10 H. br s. 2 x benzvloxy Ph-Hs). 
7.37 (1 H. br. NH). 7.69 (11 H, m, 3 X porphynn-Ph 3.4.5-H3 + porphynn 
QFLN 2,6-Hj), 8.06 (2 H. d. J 8 4 Hz. porphynn-C«H4N 3.5-H2). 8.15 (6 
H, m, 3 x porphynn-Ph 2.6-H2), 8 79 (2 H. d J 4.7 Hz. porphynn 3,7-H2). 
8.82 (4 H. s. porphynn 12.13.17.18-FL). 8 87 (2 H. d, J 5 1 Hz. porphyrin 
2.8-H2); ml: (FAB) 1367 6384 (M + H) (Cg,Ht>NpO, requires 
1367.6406).
|| Method Compound 24 (5.00 g. 8 16 mmol) was slirrcd with Boc 
GIvOC^F,(5.58 g 16 3 mmol). PrsNEt (2.32 g. I8.0mmol)and DMAP(5() 
mg) in CHCI* (100 cm') for 46 h ai 40 °C Chromatography gave 26 (6 00 
g. 95%) as a purple glass This compound (2.24 g. 2.9 mmol) was treated 
with excess HCI in CH2CU (100 cm3) for 1 h The solvent and excess 
reagent were evaporated to give 27 (2.10 g. quantitative). rerr-Butyl nitrite 
(0 22 cm3) in THF (1.75 cm’) was added to 21 (1.50 mg. 2.07 mmol) in 
DMF (3.0 cm3) and HCI in 1.4-dioxan (4 0 mol dm-'. I 86 cm3) at -20  °C 
The mixture was stirred for 2 h PrsNEt (1.06 g) was added at —60 °C. 
followed by 27 (2 09 g. 2.9 mmol) and Pr'2NEt (1.12 g. 18.7 mmol) in 
CHCIj (30 cm3) The mixture was stirred for 2 h Chromatography gave 29 
(1.64 g. 58%) as a purple glass
** Spectroscopic data for 29. 6t< (CDCI3) -2.75 (2 H. porphyrin 21.23-H2). 
0 89 (2 H. m. NCH2CH;C/y2CH2CH:CO). 1 25-1.65 (6 H m. 
NCH-.CWiCH2C/f2CHjCO - Glu p-H2). 1.9-2.4 (4 H. Glu y-H: + 
CHrCHjC/ACO). 3.0-3 I (S H. in. NCH2CH2CH2 + 2 x NCHj).3 35(4 H. 
br. NCH'Cl-LN). 3.85-4.05(4 H. 111. 2 x Sar-H2). 4 15-4.25 (2 H. nt. Gly 
Hj). 4.42 (1 H. m. Glu a-H). 5 13 (4 H.brs. 2 x PhCH,0). 7.25-7.33 (14 
H m. 4 x NH + 2 x bcnzylosv Ph-Hj). 7.70-7.76 ( 11 H. nt. 3 x porphyrin 
Ph 3 4.5 H, + porphyrin-CfrHjN 2.6-H:). 7 96(2 H. m. 2 /  NH). 8 12(2 H. 
d.7 8.2 Hz. porphyrin-CftHjN 3.5-H2). 8 17-8.23 (6 H. m. 3 x porphvrin-Ph 
2.6-Hii. 8.84 (8 H. br s. porphyrin 2.3.7.8.12.13.17.18-H*); tw : (FAB) 
1381 6184 (M + H) (Cg|H8|Ni;Oio requires 1381.6199)
“  Reactions took place at ambient temperature, unless otherwise stated
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